/*! For license information please see main.1cbe0146.js.LICENSE.txt */
!function(){var e={76:function(e,t,n){"use strict";n.d(t,{Z:function(){return ae}});var r=function(){function e(e){var t=this;this._insertTag=function(e){var n;n=0===t.tags.length?t.insertionPoint?t.insertionPoint.nextSibling:t.prepend?t.container.firstChild:t.before:t.tags[t.tags.length-1].nextSibling,t.container.insertBefore(e,n),t.tags.push(e)},this.isSpeedy=void 0===e.speedy||e.speedy,this.tags=[],this.ctr=0,this.nonce=e.nonce,this.key=e.key,this.container=e.container,this.prepend=e.prepend,this.insertionPoint=e.insertionPoint,this.before=null}var t=e.prototype;return t.hydrate=function(e){e.forEach(this._insertTag)},t.insert=function(e){this.ctr%(this.isSpeedy?65e3:1)===0&&this._insertTag(function(e){var t=document.createElement("style");return t.setAttribute("data-emotion",e.key),void 0!==e.nonce&&t.setAttribute("nonce",e.nonce),t.appendChild(document.createTextNode("")),t.setAttribute("data-s",""),t}(this));var t=this.tags[this.tags.length-1];if(this.isSpeedy){var n=function(e){if(e.sheet)return e.sheet;for(var t=0;t<document.styleSheets.length;t++)if(document.styleSheets[t].ownerNode===e)return document.styleSheets[t]}(t);try{n.insertRule(e,n.cssRules.length)}catch(r){0}}else t.appendChild(document.createTextNode(e));this.ctr++},t.flush=function(){this.tags.forEach((function(e){return e.parentNode&&e.parentNode.removeChild(e)})),this.tags=[],this.ctr=0},e}(),a=Math.abs,o=String.fromCharCode,i=Object.assign;function s(e){return e.trim()}function l(e,t,n){return e.replace(t,n)}function u(e,t){return e.indexOf(t)}function c(e,t){return 0|e.charCodeAt(t)}function d(e,t,n){return e.slice(t,n)}function f(e){return e.length}function p(e){return e.length}function m(e,t){return t.push(e),e}var h=1,v=1,b=0,y=0,g=0,_="";function w(e,t,n,r,a,o,i){return{value:e,root:t,parent:n,type:r,props:a,children:o,line:h,column:v,length:i,return:""}}function S(e,t){return i(w("",null,null,"",null,null,0),e,{length:-e.length},t)}function C(){return g=y>0?c(_,--y):0,v--,10===g&&(v=1,h--),g}function k(){return g=y<b?c(_,y++):0,v++,10===g&&(v=1,h++),g}function T(){return c(_,y)}function x(){return y}function E(e,t){return d(_,e,t)}function P(e){switch(e){case 0:case 9:case 10:case 13:case 32:return 5;case 33:case 43:case 44:case 47:case 62:case 64:case 126:case 59:case 123:case 125:return 4;case 58:return 3;case 34:case 39:case 40:case 91:return 2;case 41:case 93:return 1}return 0}function A(e){return h=v=1,b=f(_=e),y=0,[]}function R(e){return _="",e}function F(e){return s(E(y-1,M(91===e?e+2:40===e?e+1:e)))}function O(e){for(;(g=T())&&g<33;)k();return P(e)>2||P(g)>3?"":" "}function N(e,t){for(;--t&&k()&&!(g<48||g>102||g>57&&g<65||g>70&&g<97););return E(e,x()+(t<6&&32==T()&&32==k()))}function M(e){for(;k();)switch(g){case e:return y;case 34:case 39:34!==e&&39!==e&&M(g);break;case 40:41===e&&M(e);break;case 92:k()}return y}function I(e,t){for(;k()&&e+g!==57&&(e+g!==84||47!==T()););return"/*"+E(t,y-1)+"*"+o(47===e?e:k())}function z(e){for(;!P(T());)k();return E(e,y)}var L="-ms-",D="-moz-",j="-webkit-",Z="comm",B="rule",W="decl",U="@keyframes";function V(e,t){for(var n="",r=p(e),a=0;a<r;a++)n+=t(e[a],a,e,t)||"";return n}function G(e,t,n,r){switch(e.type){case"@import":case W:return e.return=e.return||e.value;case Z:return"";case U:return e.return=e.value+"{"+V(e.children,r)+"}";case B:e.value=e.props.join(",")}return f(n=V(e.children,r))?e.return=e.value+"{"+n+"}":""}function H(e,t){switch(function(e,t){return(((t<<2^c(e,0))<<2^c(e,1))<<2^c(e,2))<<2^c(e,3)}(e,t)){case 5103:return j+"print-"+e+e;case 5737:case 4201:case 3177:case 3433:case 1641:case 4457:case 2921:case 5572:case 6356:case 5844:case 3191:case 6645:case 3005:case 6391:case 5879:case 5623:case 6135:case 4599:case 4855:case 4215:case 6389:case 5109:case 5365:case 5621:case 3829:return j+e+e;case 5349:case 4246:case 4810:case 6968:case 2756:return j+e+D+e+L+e+e;case 6828:case 4268:return j+e+L+e+e;case 6165:return j+e+L+"flex-"+e+e;case 5187:return j+e+l(e,/(\w+).+(:[^]+)/,"-webkit-box-$1$2-ms-flex-$1$2")+e;case 5443:return j+e+L+"flex-item-"+l(e,/flex-|-self/,"")+e;case 4675:return j+e+L+"flex-line-pack"+l(e,/align-content|flex-|-self/,"")+e;case 5548:return j+e+L+l(e,"shrink","negative")+e;case 5292:return j+e+L+l(e,"basis","preferred-size")+e;case 6060:return j+"box-"+l(e,"-grow","")+j+e+L+l(e,"grow","positive")+e;case 4554:return j+l(e,/([^-])(transform)/g,"$1-webkit-$2")+e;case 6187:return l(l(l(e,/(zoom-|grab)/,j+"$1"),/(image-set)/,j+"$1"),e,"")+e;case 5495:case 3959:return l(e,/(image-set\([^]*)/,j+"$1$`$1");case 4968:return l(l(e,/(.+:)(flex-)?(.*)/,"-webkit-box-pack:$3-ms-flex-pack:$3"),/s.+-b[^;]+/,"justify")+j+e+e;case 4095:case 3583:case 4068:case 2532:return l(e,/(.+)-inline(.+)/,j+"$1$2")+e;case 8116:case 7059:case 5753:case 5535:case 5445:case 5701:case 4933:case 4677:case 5533:case 5789:case 5021:case 4765:if(f(e)-1-t>6)switch(c(e,t+1)){case 109:if(45!==c(e,t+4))break;case 102:return l(e,/(.+:)(.+)-([^]+)/,"$1-webkit-$2-$3$1"+D+(108==c(e,t+3)?"$3":"$2-$3"))+e;case 115:return~u(e,"stretch")?H(l(e,"stretch","fill-available"),t)+e:e}break;case 4949:if(115!==c(e,t+1))break;case 6444:switch(c(e,f(e)-3-(~u(e,"!important")&&10))){case 107:return l(e,":",":"+j)+e;case 101:return l(e,/(.+:)([^;!]+)(;|!.+)?/,"$1"+j+(45===c(e,14)?"inline-":"")+"box$3$1"+j+"$2$3$1"+L+"$2box$3")+e}break;case 5936:switch(c(e,t+11)){case 114:return j+e+L+l(e,/[svh]\w+-[tblr]{2}/,"tb")+e;case 108:return j+e+L+l(e,/[svh]\w+-[tblr]{2}/,"tb-rl")+e;case 45:return j+e+L+l(e,/[svh]\w+-[tblr]{2}/,"lr")+e}return j+e+L+e+e}return e}function $(e){return R(J("",null,null,null,[""],e=A(e),0,[0],e))}function J(e,t,n,r,a,i,s,c,d){for(var p=0,h=0,v=s,b=0,y=0,g=0,_=1,w=1,S=1,E=0,P="",A=a,R=i,M=r,L=P;w;)switch(g=E,E=k()){case 40:if(108!=g&&58==L.charCodeAt(v-1)){-1!=u(L+=l(F(E),"&","&\f"),"&\f")&&(S=-1);break}case 34:case 39:case 91:L+=F(E);break;case 9:case 10:case 13:case 32:L+=O(g);break;case 92:L+=N(x()-1,7);continue;case 47:switch(T()){case 42:case 47:m(K(I(k(),x()),t,n),d);break;default:L+="/"}break;case 123*_:c[p++]=f(L)*S;case 125*_:case 59:case 0:switch(E){case 0:case 125:w=0;case 59+h:y>0&&f(L)-v&&m(y>32?Q(L+";",r,n,v-1):Q(l(L," ","")+";",r,n,v-2),d);break;case 59:L+=";";default:if(m(M=q(L,t,n,p,h,a,c,P,A=[],R=[],v),i),123===E)if(0===h)J(L,t,M,M,A,i,v,c,R);else switch(b){case 100:case 109:case 115:J(e,M,M,r&&m(q(e,M,M,0,0,a,c,P,a,A=[],v),R),a,R,v,c,r?A:R);break;default:J(L,M,M,M,[""],R,0,c,R)}}p=h=y=0,_=S=1,P=L="",v=s;break;case 58:v=1+f(L),y=g;default:if(_<1)if(123==E)--_;else if(125==E&&0==_++&&125==C())continue;switch(L+=o(E),E*_){case 38:S=h>0?1:(L+="\f",-1);break;case 44:c[p++]=(f(L)-1)*S,S=1;break;case 64:45===T()&&(L+=F(k())),b=T(),h=v=f(P=L+=z(x())),E++;break;case 45:45===g&&2==f(L)&&(_=0)}}return i}function q(e,t,n,r,o,i,u,c,f,m,h){for(var v=o-1,b=0===o?i:[""],y=p(b),g=0,_=0,S=0;g<r;++g)for(var C=0,k=d(e,v+1,v=a(_=u[g])),T=e;C<y;++C)(T=s(_>0?b[C]+" "+k:l(k,/&\f/g,b[C])))&&(f[S++]=T);return w(e,t,n,0===o?B:c,f,m,h)}function K(e,t,n){return w(e,t,n,Z,o(g),d(e,2,-2),0)}function Q(e,t,n,r){return w(e,t,n,W,d(e,0,r),d(e,r+1,-1),r)}var Y=function(e,t,n){for(var r=0,a=0;r=a,a=T(),38===r&&12===a&&(t[n]=1),!P(a);)k();return E(e,y)},X=function(e,t){return R(function(e,t){var n=-1,r=44;do{switch(P(r)){case 0:38===r&&12===T()&&(t[n]=1),e[n]+=Y(y-1,t,n);break;case 2:e[n]+=F(r);break;case 4:if(44===r){e[++n]=58===T()?"&\f":"",t[n]=e[n].length;break}default:e[n]+=o(r)}}while(r=k());return e}(A(e),t))},ee=new WeakMap,te=function(e){if("rule"===e.type&&e.parent&&!(e.length<1)){for(var t=e.value,n=e.parent,r=e.column===n.column&&e.line===n.line;"rule"!==n.type;)if(!(n=n.parent))return;if((1!==e.props.length||58===t.charCodeAt(0)||ee.get(n))&&!r){ee.set(e,!0);for(var a=[],o=X(t,a),i=n.props,s=0,l=0;s<o.length;s++)for(var u=0;u<i.length;u++,l++)e.props[l]=a[s]?o[s].replace(/&\f/g,i[u]):i[u]+" "+o[s]}}},ne=function(e){if("decl"===e.type){var t=e.value;108===t.charCodeAt(0)&&98===t.charCodeAt(2)&&(e.return="",e.value="")}},re=[function(e,t,n,r){if(e.length>-1&&!e.return)switch(e.type){case W:e.return=H(e.value,e.length);break;case U:return V([S(e,{value:l(e.value,"@","@"+j)})],r);case B:if(e.length)return function(e,t){return e.map(t).join("")}(e.props,(function(t){switch(function(e,t){return(e=t.exec(e))?e[0]:e}(t,/(::plac\w+|:read-\w+)/)){case":read-only":case":read-write":return V([S(e,{props:[l(t,/:(read-\w+)/,":-moz-$1")]})],r);case"::placeholder":return V([S(e,{props:[l(t,/:(plac\w+)/,":-webkit-input-$1")]}),S(e,{props:[l(t,/:(plac\w+)/,":-moz-$1")]}),S(e,{props:[l(t,/:(plac\w+)/,L+"input-$1")]})],r)}return""}))}}],ae=function(e){var t=e.key;if("css"===t){var n=document.querySelectorAll("style[data-emotion]:not([data-s])");Array.prototype.forEach.call(n,(function(e){-1!==e.getAttribute("data-emotion").indexOf(" ")&&(document.head.appendChild(e),e.setAttribute("data-s",""))}))}var a=e.stylisPlugins||re;var o,i,s={},l=[];o=e.container||document.head,Array.prototype.forEach.call(document.querySelectorAll('style[data-emotion^="'+t+' "]'),(function(e){for(var t=e.getAttribute("data-emotion").split(" "),n=1;n<t.length;n++)s[t[n]]=!0;l.push(e)}));var u,c,d=[G,(c=function(e){u.insert(e)},function(e){e.root||(e=e.return)&&c(e)})],f=function(e){var t=p(e);return function(n,r,a,o){for(var i="",s=0;s<t;s++)i+=e[s](n,r,a,o)||"";return i}}([te,ne].concat(a,d));i=function(e,t,n,r){u=n,V($(e?e+"{"+t.styles+"}":t.styles),f),r&&(m.inserted[t.name]=!0)};var m={key:t,sheet:new r({key:t,container:o,nonce:e.nonce,speedy:e.speedy,prepend:e.prepend,insertionPoint:e.insertionPoint}),nonce:e.nonce,inserted:s,registered:{},insert:i};return m.sheet.hydrate(l),m}},9797:function(e,t){"use strict";t.Z=function(e){var t=Object.create(null);return function(n){return void 0===t[n]&&(t[n]=e(n)),t[n]}}},9886:function(e,t,n){"use strict";n.d(t,{T:function(){return s},w:function(){return i}});var r=n(2791),a=n(76),o=(n(9140),n(2561),(0,r.createContext)("undefined"!==typeof HTMLElement?(0,a.Z)({key:"css"}):null));o.Provider;var i=function(e){return(0,r.forwardRef)((function(t,n){var a=(0,r.useContext)(o);return e(t,a,n)}))},s=(0,r.createContext)({})},9140:function(e,t,n){"use strict";n.d(t,{O:function(){return h}});var r=function(e){for(var t,n=0,r=0,a=e.length;a>=4;++r,a-=4)t=1540483477*(65535&(t=255&e.charCodeAt(r)|(255&e.charCodeAt(++r))<<8|(255&e.charCodeAt(++r))<<16|(255&e.charCodeAt(++r))<<24))+(59797*(t>>>16)<<16),n=1540483477*(65535&(t^=t>>>24))+(59797*(t>>>16)<<16)^1540483477*(65535&n)+(59797*(n>>>16)<<16);switch(a){case 3:n^=(255&e.charCodeAt(r+2))<<16;case 2:n^=(255&e.charCodeAt(r+1))<<8;case 1:n=1540483477*(65535&(n^=255&e.charCodeAt(r)))+(59797*(n>>>16)<<16)}return(((n=1540483477*(65535&(n^=n>>>13))+(59797*(n>>>16)<<16))^n>>>15)>>>0).toString(36)},a={animationIterationCount:1,borderImageOutset:1,borderImageSlice:1,borderImageWidth:1,boxFlex:1,boxFlexGroup:1,boxOrdinalGroup:1,columnCount:1,columns:1,flex:1,flexGrow:1,flexPositive:1,flexShrink:1,flexNegative:1,flexOrder:1,gridRow:1,gridRowEnd:1,gridRowSpan:1,gridRowStart:1,gridColumn:1,gridColumnEnd:1,gridColumnSpan:1,gridColumnStart:1,msGridRow:1,msGridRowSpan:1,msGridColumn:1,msGridColumnSpan:1,fontWeight:1,lineHeight:1,opacity:1,order:1,orphans:1,tabSize:1,widows:1,zIndex:1,zoom:1,WebkitLineClamp:1,fillOpacity:1,floodOpacity:1,stopOpacity:1,strokeDasharray:1,strokeDashoffset:1,strokeMiterlimit:1,strokeOpacity:1,strokeWidth:1},o=n(9797),i=/[A-Z]|^ms/g,s=/_EMO_([^_]+?)_([^]*?)_EMO_/g,l=function(e){return 45===e.charCodeAt(1)},u=function(e){return null!=e&&"boolean"!==typeof e},c=(0,o.Z)((function(e){return l(e)?e:e.replace(i,"-$&").toLowerCase()})),d=function(e,t){switch(e){case"animation":case"animationName":if("string"===typeof t)return t.replace(s,(function(e,t,n){return p={name:t,styles:n,next:p},t}))}return 1===a[e]||l(e)||"number"!==typeof t||0===t?t:t+"px"};function f(e,t,n){if(null==n)return"";if(void 0!==n.__emotion_styles)return n;switch(typeof n){case"boolean":return"";case"object":if(1===n.anim)return p={name:n.name,styles:n.styles,next:p},n.name;if(void 0!==n.styles){var r=n.next;if(void 0!==r)for(;void 0!==r;)p={name:r.name,styles:r.styles,next:p},r=r.next;return n.styles+";"}return function(e,t,n){var r="";if(Array.isArray(n))for(var a=0;a<n.length;a++)r+=f(e,t,n[a])+";";else for(var o in n){var i=n[o];if("object"!==typeof i)null!=t&&void 0!==t[i]?r+=o+"{"+t[i]+"}":u(i)&&(r+=c(o)+":"+d(o,i)+";");else if(!Array.isArray(i)||"string"!==typeof i[0]||null!=t&&void 0!==t[i[0]]){var s=f(e,t,i);switch(o){case"animation":case"animationName":r+=c(o)+":"+s+";";break;default:r+=o+"{"+s+"}"}}else for(var l=0;l<i.length;l++)u(i[l])&&(r+=c(o)+":"+d(o,i[l])+";")}return r}(e,t,n);case"function":if(void 0!==e){var a=p,o=n(e);return p=a,f(e,t,o)}}if(null==t)return n;var i=t[n];return void 0!==i?i:n}var p,m=/label:\s*([^\s;\n{]+)\s*(;|$)/g;var h=function(e,t,n){if(1===e.length&&"object"===typeof e[0]&&null!==e[0]&&void 0!==e[0].styles)return e[0];var a=!0,o="";p=void 0;var i=e[0];null==i||void 0===i.raw?(a=!1,o+=f(n,t,i)):o+=i[0];for(var s=1;s<e.length;s++)o+=f(n,t,e[s]),a&&(o+=i[s]);m.lastIndex=0;for(var l,u="";null!==(l=m.exec(o));)u+="-"+l[1];return{name:r(o)+u,styles:o,next:p}}},2561:function(e,t,n){"use strict";var r;n.d(t,{L:function(){return i},j:function(){return s}});var a=n(2791),o=!!(r||(r=n.t(a,2))).useInsertionEffect&&(r||(r=n.t(a,2))).useInsertionEffect,i=o||function(e){return e()},s=o||a.useLayoutEffect},5438:function(e,t,n){"use strict";n.d(t,{My:function(){return o},fp:function(){return r},hC:function(){return a}});function r(e,t,n){var r="";return n.split(" ").forEach((function(n){void 0!==e[n]?t.push(e[n]+";"):r+=n+" "})),r}var a=function(e,t,n){var r=e.key+"-"+t.name;!1===n&&void 0===e.registered[r]&&(e.registered[r]=t.styles)},o=function(e,t,n){a(e,t,n);var r=e.key+"-"+t.name;if(void 0===e.inserted[t.name]){var o=t;do{e.insert(t===o?"."+r:"",o,e.sheet,!0);o=o.next}while(void 0!==o)}}},2156:function(e,t,n){"use strict";var r=n(4836);t.Z=void 0;var a=r(n(5649)),o=n(184),i=(0,a.default)((0,o.jsx)("path",{d:"M15.41 7.41 14 6l-6 6 6 6 1.41-1.41L10.83 12z"}),"NavigateBefore");t.Z=i},5129:function(e,t,n){"use strict";var r=n(4836);t.Z=void 0;var a=r(n(5649)),o=n(184),i=(0,a.default)((0,o.jsx)("path",{d:"M10 6 8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z"}),"NavigateNext");t.Z=i},5649:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0}),Object.defineProperty(t,"default",{enumerable:!0,get:function(){return r.createSvgIcon}});var r=n(3111)},4360:function(e,t,n){"use strict";n.d(t,{Z:function(){return j}});var r=n(7462),a=n(3366),o=n(6189),i=n(2466),s=n(5080),l=n(4942);function u(e,t){var n;return(0,r.Z)({toolbar:(n={minHeight:56},(0,l.Z)(n,e.up("xs"),{"@media (orientation: landscape)":{minHeight:48}}),(0,l.Z)(n,e.up("sm"),{minHeight:64}),n)},t)}var c=n(2065),d={black:"#000",white:"#fff"},f={50:"#fafafa",100:"#f5f5f5",200:"#eeeeee",300:"#e0e0e0",400:"#bdbdbd",500:"#9e9e9e",600:"#757575",700:"#616161",800:"#424242",900:"#212121",A100:"#f5f5f5",A200:"#eeeeee",A400:"#bdbdbd",A700:"#616161"},p={50:"#f3e5f5",100:"#e1bee7",200:"#ce93d8",300:"#ba68c8",400:"#ab47bc",500:"#9c27b0",600:"#8e24aa",700:"#7b1fa2",800:"#6a1b9a",900:"#4a148c",A100:"#ea80fc",A200:"#e040fb",A400:"#d500f9",A700:"#aa00ff"},m={50:"#ffebee",100:"#ffcdd2",200:"#ef9a9a",300:"#e57373",400:"#ef5350",500:"#f44336",600:"#e53935",700:"#d32f2f",800:"#c62828",900:"#b71c1c",A100:"#ff8a80",A200:"#ff5252",A400:"#ff1744",A700:"#d50000"},h={50:"#fff3e0",100:"#ffe0b2",200:"#ffcc80",300:"#ffb74d",400:"#ffa726",500:"#ff9800",600:"#fb8c00",700:"#f57c00",800:"#ef6c00",900:"#e65100",A100:"#ffd180",A200:"#ffab40",A400:"#ff9100",A700:"#ff6d00"},v={50:"#e3f2fd",100:"#bbdefb",200:"#90caf9",300:"#64b5f6",400:"#42a5f5",500:"#2196f3",600:"#1e88e5",700:"#1976d2",800:"#1565c0",900:"#0d47a1",A100:"#82b1ff",A200:"#448aff",A400:"#2979ff",A700:"#2962ff"},b={50:"#e1f5fe",100:"#b3e5fc",200:"#81d4fa",300:"#4fc3f7",400:"#29b6f6",500:"#03a9f4",600:"#039be5",700:"#0288d1",800:"#0277bd",900:"#01579b",A100:"#80d8ff",A200:"#40c4ff",A400:"#00b0ff",A700:"#0091ea"},y={50:"#e8f5e9",100:"#c8e6c9",200:"#a5d6a7",300:"#81c784",400:"#66bb6a",500:"#4caf50",600:"#43a047",700:"#388e3c",800:"#2e7d32",900:"#1b5e20",A100:"#b9f6ca",A200:"#69f0ae",A400:"#00e676",A700:"#00c853"},g=["mode","contrastThreshold","tonalOffset"],_={text:{primary:"rgba(0, 0, 0, 0.87)",secondary:"rgba(0, 0, 0, 0.6)",disabled:"rgba(0, 0, 0, 0.38)"},divider:"rgba(0, 0, 0, 0.12)",background:{paper:d.white,default:d.white},action:{active:"rgba(0, 0, 0, 0.54)",hover:"rgba(0, 0, 0, 0.04)",hoverOpacity:.04,selected:"rgba(0, 0, 0, 0.08)",selectedOpacity:.08,disabled:"rgba(0, 0, 0, 0.26)",disabledBackground:"rgba(0, 0, 0, 0.12)",disabledOpacity:.38,focus:"rgba(0, 0, 0, 0.12)",focusOpacity:.12,activatedOpacity:.12}},w={text:{primary:d.white,secondary:"rgba(255, 255, 255, 0.7)",disabled:"rgba(255, 255, 255, 0.5)",icon:"rgba(255, 255, 255, 0.5)"},divider:"rgba(255, 255, 255, 0.12)",background:{paper:"#121212",default:"#121212"},action:{active:d.white,hover:"rgba(255, 255, 255, 0.08)",hoverOpacity:.08,selected:"rgba(255, 255, 255, 0.16)",selectedOpacity:.16,disabled:"rgba(255, 255, 255, 0.3)",disabledBackground:"rgba(255, 255, 255, 0.12)",disabledOpacity:.38,focus:"rgba(255, 255, 255, 0.12)",focusOpacity:.12,activatedOpacity:.24}};function S(e,t,n,r){var a=r.light||r,o=r.dark||1.5*r;e[t]||(e.hasOwnProperty(n)?e[t]=e[n]:"light"===t?e.light=(0,c.$n)(e.main,a):"dark"===t&&(e.dark=(0,c._j)(e.main,o)))}function C(e){var t=e.mode,n=void 0===t?"light":t,s=e.contrastThreshold,l=void 0===s?3:s,u=e.tonalOffset,C=void 0===u?.2:u,k=(0,a.Z)(e,g),T=e.primary||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:v[200],light:v[50],dark:v[400]}:{main:v[700],light:v[400],dark:v[800]}}(n),x=e.secondary||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:p[200],light:p[50],dark:p[400]}:{main:p[500],light:p[300],dark:p[700]}}(n),E=e.error||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:m[500],light:m[300],dark:m[700]}:{main:m[700],light:m[400],dark:m[800]}}(n),P=e.info||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:b[400],light:b[300],dark:b[700]}:{main:b[700],light:b[500],dark:b[900]}}(n),A=e.success||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:y[400],light:y[300],dark:y[700]}:{main:y[800],light:y[500],dark:y[900]}}(n),R=e.warning||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:h[400],light:h[300],dark:h[700]}:{main:"#ed6c02",light:h[500],dark:h[900]}}(n);function F(e){return(0,c.mi)(e,w.text.primary)>=l?w.text.primary:_.text.primary}var O=function(e){var t=e.color,n=e.name,a=e.mainShade,i=void 0===a?500:a,s=e.lightShade,l=void 0===s?300:s,u=e.darkShade,c=void 0===u?700:u;if(!(t=(0,r.Z)({},t)).main&&t[i]&&(t.main=t[i]),!t.hasOwnProperty("main"))throw new Error((0,o.Z)(11,n?" (".concat(n,")"):"",i));if("string"!==typeof t.main)throw new Error((0,o.Z)(12,n?" (".concat(n,")"):"",JSON.stringify(t.main)));return S(t,"light",l,C),S(t,"dark",c,C),t.contrastText||(t.contrastText=F(t.main)),t},N={dark:w,light:_};return(0,i.Z)((0,r.Z)({common:(0,r.Z)({},d),mode:n,primary:O({color:T,name:"primary"}),secondary:O({color:x,name:"secondary",mainShade:"A400",lightShade:"A200",darkShade:"A700"}),error:O({color:E,name:"error"}),warning:O({color:R,name:"warning"}),info:O({color:P,name:"info"}),success:O({color:A,name:"success"}),grey:f,contrastThreshold:l,getContrastText:F,augmentColor:O,tonalOffset:C},N[n]),k)}var k=["fontFamily","fontSize","fontWeightLight","fontWeightRegular","fontWeightMedium","fontWeightBold","htmlFontSize","allVariants","pxToRem"];var T={textTransform:"uppercase"},x='"Roboto", "Helvetica", "Arial", sans-serif';function E(e,t){var n="function"===typeof t?t(e):t,o=n.fontFamily,s=void 0===o?x:o,l=n.fontSize,u=void 0===l?14:l,c=n.fontWeightLight,d=void 0===c?300:c,f=n.fontWeightRegular,p=void 0===f?400:f,m=n.fontWeightMedium,h=void 0===m?500:m,v=n.fontWeightBold,b=void 0===v?700:v,y=n.htmlFontSize,g=void 0===y?16:y,_=n.allVariants,w=n.pxToRem,S=(0,a.Z)(n,k);var C=u/14,E=w||function(e){return"".concat(e/g*C,"rem")},P=function(e,t,n,a,o){return(0,r.Z)({fontFamily:s,fontWeight:e,fontSize:E(t),lineHeight:n},s===x?{letterSpacing:"".concat((i=a/t,Math.round(1e5*i)/1e5),"em")}:{},o,_);var i},A={h1:P(d,96,1.167,-1.5),h2:P(d,60,1.2,-.5),h3:P(p,48,1.167,0),h4:P(p,34,1.235,.25),h5:P(p,24,1.334,0),h6:P(h,20,1.6,.15),subtitle1:P(p,16,1.75,.15),subtitle2:P(h,14,1.57,.1),body1:P(p,16,1.5,.15),body2:P(p,14,1.43,.15),button:P(h,14,1.75,.4,T),caption:P(p,12,1.66,.4),overline:P(p,12,2.66,1,T)};return(0,i.Z)((0,r.Z)({htmlFontSize:g,pxToRem:E,fontFamily:s,fontSize:u,fontWeightLight:d,fontWeightRegular:p,fontWeightMedium:h,fontWeightBold:b},A),S,{clone:!1})}function P(){return["".concat(arguments.length<=0?void 0:arguments[0],"px ").concat(arguments.length<=1?void 0:arguments[1],"px ").concat(arguments.length<=2?void 0:arguments[2],"px ").concat(arguments.length<=3?void 0:arguments[3],"px rgba(0,0,0,").concat(.2,")"),"".concat(arguments.length<=4?void 0:arguments[4],"px ").concat(arguments.length<=5?void 0:arguments[5],"px ").concat(arguments.length<=6?void 0:arguments[6],"px ").concat(arguments.length<=7?void 0:arguments[7],"px rgba(0,0,0,").concat(.14,")"),"".concat(arguments.length<=8?void 0:arguments[8],"px ").concat(arguments.length<=9?void 0:arguments[9],"px ").concat(arguments.length<=10?void 0:arguments[10],"px ").concat(arguments.length<=11?void 0:arguments[11],"px rgba(0,0,0,").concat(.12,")")].join(",")}var A=["none",P(0,2,1,-1,0,1,1,0,0,1,3,0),P(0,3,1,-2,0,2,2,0,0,1,5,0),P(0,3,3,-2,0,3,4,0,0,1,8,0),P(0,2,4,-1,0,4,5,0,0,1,10,0),P(0,3,5,-1,0,5,8,0,0,1,14,0),P(0,3,5,-1,0,6,10,0,0,1,18,0),P(0,4,5,-2,0,7,10,1,0,2,16,1),P(0,5,5,-3,0,8,10,1,0,3,14,2),P(0,5,6,-3,0,9,12,1,0,3,16,2),P(0,6,6,-3,0,10,14,1,0,4,18,3),P(0,6,7,-4,0,11,15,1,0,4,20,3),P(0,7,8,-4,0,12,17,2,0,5,22,4),P(0,7,8,-4,0,13,19,2,0,5,24,4),P(0,7,9,-4,0,14,21,2,0,5,26,4),P(0,8,9,-5,0,15,22,2,0,6,28,5),P(0,8,10,-5,0,16,24,2,0,6,30,5),P(0,8,11,-5,0,17,26,2,0,6,32,5),P(0,9,11,-5,0,18,28,2,0,7,34,6),P(0,9,12,-6,0,19,29,2,0,7,36,6),P(0,10,13,-6,0,20,31,3,0,8,38,7),P(0,10,13,-6,0,21,33,3,0,8,40,7),P(0,10,14,-6,0,22,35,3,0,8,42,7),P(0,11,14,-7,0,23,36,3,0,9,44,8),P(0,11,15,-7,0,24,38,3,0,9,46,8)],R=["duration","easing","delay"],F={easeInOut:"cubic-bezier(0.4, 0, 0.2, 1)",easeOut:"cubic-bezier(0.0, 0, 0.2, 1)",easeIn:"cubic-bezier(0.4, 0, 1, 1)",sharp:"cubic-bezier(0.4, 0, 0.6, 1)"},O={shortest:150,shorter:200,short:250,standard:300,complex:375,enteringScreen:225,leavingScreen:195};function N(e){return"".concat(Math.round(e),"ms")}function M(e){if(!e)return 0;var t=e/36;return Math.round(10*(4+15*Math.pow(t,.25)+t/5))}function I(e){var t=(0,r.Z)({},F,e.easing),n=(0,r.Z)({},O,e.duration);return(0,r.Z)({getAutoHeightDuration:M,create:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:["all"],r=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},o=r.duration,i=void 0===o?n.standard:o,s=r.easing,l=void 0===s?t.easeInOut:s,u=r.delay,c=void 0===u?0:u;(0,a.Z)(r,R);return(Array.isArray(e)?e:[e]).map((function(e){return"".concat(e," ").concat("string"===typeof i?i:N(i)," ").concat(l," ").concat("string"===typeof c?c:N(c))})).join(",")}},e,{easing:t,duration:n})}var z={mobileStepper:1e3,fab:1050,speedDial:1050,appBar:1100,drawer:1200,modal:1300,snackbar:1400,tooltip:1500},L=["breakpoints","mixins","spacing","palette","transitions","typography","shape"];function D(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.mixins,n=void 0===t?{}:t,l=e.palette,c=void 0===l?{}:l,d=e.transitions,f=void 0===d?{}:d,p=e.typography,m=void 0===p?{}:p,h=(0,a.Z)(e,L);if(e.vars)throw new Error((0,o.Z)(18));var v=C(c),b=(0,s.Z)(e),y=(0,i.Z)(b,{mixins:u(b.breakpoints,n),palette:v,shadows:A.slice(),typography:E(v,m),transitions:I(f),zIndex:(0,r.Z)({},z)});y=(0,i.Z)(y,h);for(var g=arguments.length,_=new Array(g>1?g-1:0),w=1;w<g;w++)_[w-1]=arguments[w];return y=_.reduce((function(e,t){return(0,i.Z)(e,t)}),y)}var j=D},4205:function(e,t,n){"use strict";var r=(0,n(4360).Z)();t.Z=r},277:function(e,t,n){"use strict";var r=n(4046),a=n(4205),o=(0,r.ZP)({defaultTheme:a.Z,rootShouldForwardProp:function(e){return(0,r.x9)(e)&&"classes"!==e}});t.ZP=o},5513:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(8691),a=n(4205);function o(e){var t=e.props,n=e.name;return(0,r.Z)({props:t,name:n,defaultTheme:a.Z})}},9853:function(e,t,n){"use strict";var r=n(7312);t.Z=r.Z},3111:function(e,t,n){"use strict";n.r(t),n.d(t,{capitalize:function(){return a.Z},createChainedFunction:function(){return o},createSvgIcon:function(){return w},debounce:function(){return S},deprecatedPropType:function(){return C},isMuiElement:function(){return k},ownerDocument:function(){return x},ownerWindow:function(){return E},requirePropFactory:function(){return P},setRef:function(){return A},unstable_ClassNameGenerator:function(){return Z},unstable_useEnhancedEffect:function(){return R},unstable_useId:function(){return M},unsupportedProp:function(){return I},useControlled:function(){return z},useEventCallback:function(){return L.Z},useForkRef:function(){return D.Z},useIsFocusVisible:function(){return j.Z}});var r=n(5902),a=n(9853);var o=function(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];return t.reduce((function(e,t){return null==t?e:function(){for(var n=arguments.length,r=new Array(n),a=0;a<n;a++)r[a]=arguments[a];e.apply(this,r),t.apply(this,r)}}),(function(){}))},i=n(7462),s=n(2791),l=n.t(s,2),u=n(3366),c=n(8182),d=n(4419),f=n(5513),p=n(277),m=n(1217);function h(e){return(0,m.Z)("MuiSvgIcon",e)}(0,n(5878).Z)("MuiSvgIcon",["root","colorPrimary","colorSecondary","colorAction","colorError","colorDisabled","fontSizeInherit","fontSizeSmall","fontSizeMedium","fontSizeLarge"]);var v=n(184),b=["children","className","color","component","fontSize","htmlColor","inheritViewBox","titleAccess","viewBox"],y=(0,p.ZP)("svg",{name:"MuiSvgIcon",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,"inherit"!==n.color&&t["color".concat((0,a.Z)(n.color))],t["fontSize".concat((0,a.Z)(n.fontSize))]]}})((function(e){var t,n,r,a,o,i,s,l,u,c,d,f,p,m,h,v,b,y=e.theme,g=e.ownerState;return{userSelect:"none",width:"1em",height:"1em",display:"inline-block",fill:"currentColor",flexShrink:0,transition:null==(t=y.transitions)||null==(n=t.create)?void 0:n.call(t,"fill",{duration:null==(r=y.transitions)||null==(a=r.duration)?void 0:a.shorter}),fontSize:{inherit:"inherit",small:(null==(o=y.typography)||null==(i=o.pxToRem)?void 0:i.call(o,20))||"1.25rem",medium:(null==(s=y.typography)||null==(l=s.pxToRem)?void 0:l.call(s,24))||"1.5rem",large:(null==(u=y.typography)||null==(c=u.pxToRem)?void 0:c.call(u,35))||"2.1875rem"}[g.fontSize],color:null!=(d=null==(f=(y.vars||y).palette)||null==(p=f[g.color])?void 0:p.main)?d:{action:null==(m=(y.vars||y).palette)||null==(h=m.action)?void 0:h.active,disabled:null==(v=(y.vars||y).palette)||null==(b=v.action)?void 0:b.disabled,inherit:void 0}[g.color]}})),g=s.forwardRef((function(e,t){var n=(0,f.Z)({props:e,name:"MuiSvgIcon"}),r=n.children,o=n.className,s=n.color,l=void 0===s?"inherit":s,p=n.component,m=void 0===p?"svg":p,g=n.fontSize,_=void 0===g?"medium":g,w=n.htmlColor,S=n.inheritViewBox,C=void 0!==S&&S,k=n.titleAccess,T=n.viewBox,x=void 0===T?"0 0 24 24":T,E=(0,u.Z)(n,b),P=(0,i.Z)({},n,{color:l,component:m,fontSize:_,instanceFontSize:e.fontSize,inheritViewBox:C,viewBox:x}),A={};C||(A.viewBox=x);var R=function(e){var t=e.color,n=e.fontSize,r=e.classes,o={root:["root","inherit"!==t&&"color".concat((0,a.Z)(t)),"fontSize".concat((0,a.Z)(n))]};return(0,d.Z)(o,h,r)}(P);return(0,v.jsxs)(y,(0,i.Z)({as:m,className:(0,c.Z)(R.root,o),focusable:"false",color:w,"aria-hidden":!k||void 0,role:k?"img":void 0,ref:t},A,E,{ownerState:P,children:[r,k?(0,v.jsx)("title",{children:k}):null]}))}));g.muiName="SvgIcon";var _=g;function w(e,t){var n=function(n,r){return(0,v.jsx)(_,(0,i.Z)({"data-testid":"".concat(t,"Icon"),ref:r},n,{children:e}))};return n.muiName=_.muiName,s.memo(s.forwardRef(n))}var S=function(e){var t,n=arguments.length>1&&void 0!==arguments[1]?arguments[1]:166;function r(){for(var r=this,a=arguments.length,o=new Array(a),i=0;i<a;i++)o[i]=arguments[i];var s=function(){e.apply(r,o)};clearTimeout(t),t=setTimeout(s,n)}return r.clear=function(){clearTimeout(t)},r};var C=function(e,t){return function(){return null}};var k=function(e,t){return s.isValidElement(e)&&-1!==t.indexOf(e.type.muiName)};function T(e){return e&&e.ownerDocument||document}var x=T;var E=function(e){return T(e).defaultView||window};var P=function(e,t){return function(){return null}},A=n(2971).Z,R=n(5721).Z,F=n(885),O=0;var N=l.useId;var M=function(e){if(void 0!==N){var t=N();return null!=e?e:t}return function(e){var t=s.useState(e),n=(0,F.Z)(t,2),r=n[0],a=n[1],o=e||r;return s.useEffect((function(){null==r&&a("mui-".concat(O+=1))}),[r]),o}(e)};var I=function(e,t,n,r,a){return null};var z=function(e){var t=e.controlled,n=e.default,r=(e.name,e.state,s.useRef(void 0!==t).current),a=s.useState(n),o=(0,F.Z)(a,2),i=o[0],l=o[1];return[r?t:i,s.useCallback((function(e){r||l(e)}),[])]},L=n(6702),D=n(792),j=n(2763),Z={configure:function(e){console.warn(["MUI: `ClassNameGenerator` import from `@mui/material/utils` is outdated and might cause unexpected issues.","","You should use `import { unstable_ClassNameGenerator } from '@mui/material/className'` instead","","The detail of the issue: https://github.com/mui/material-ui/issues/30011#issuecomment-1024993401","","The updated documentation: https://mui.com/guides/classname-generator/"].join("\n")),r.Z.configure(e)}}},6702:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(2791),a=n(5721);var o=function(e){var t=r.useRef(e);return(0,a.Z)((function(){t.current=e})),r.useCallback((function(){return t.current.apply(void 0,arguments)}),[])}},792:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(2791),a=n(2971);var o=function(e,t){return r.useMemo((function(){return null==e&&null==t?null:function(n){(0,a.Z)(e,n),(0,a.Z)(t,n)}}),[e,t])}},2763:function(e,t,n){"use strict";n.d(t,{Z:function(){return f}});var r,a=n(2791),o=!0,i=!1,s={text:!0,search:!0,url:!0,tel:!0,email:!0,password:!0,number:!0,date:!0,month:!0,week:!0,time:!0,datetime:!0,"datetime-local":!0};function l(e){e.metaKey||e.altKey||e.ctrlKey||(o=!0)}function u(){o=!1}function c(){"hidden"===this.visibilityState&&i&&(o=!0)}function d(e){var t=e.target;try{return t.matches(":focus-visible")}catch(n){}return o||function(e){var t=e.type,n=e.tagName;return!("INPUT"!==n||!s[t]||e.readOnly)||"TEXTAREA"===n&&!e.readOnly||!!e.isContentEditable}(t)}var f=function(){var e=a.useCallback((function(e){var t;null!=e&&((t=e.ownerDocument).addEventListener("keydown",l,!0),t.addEventListener("mousedown",u,!0),t.addEventListener("pointerdown",u,!0),t.addEventListener("touchstart",u,!0),t.addEventListener("visibilitychange",c,!0))}),[]),t=a.useRef(!1);return{isFocusVisibleRef:t,onFocus:function(e){return!!d(e)&&(t.current=!0,!0)},onBlur:function(){return!!t.current&&(i=!0,window.clearTimeout(r),r=window.setTimeout((function(){i=!1}),100),t.current=!1,!0)},ref:e}}},2421:function(e,t,n){"use strict";n.d(t,{ZP:function(){return _},Co:function(){return w}});var r=n(2791),a=n(7462),o=n(9797),i=/^((children|dangerouslySetInnerHTML|key|ref|autoFocus|defaultValue|defaultChecked|innerHTML|suppressContentEditableWarning|suppressHydrationWarning|valueLink|abbr|accept|acceptCharset|accessKey|action|allow|allowUserMedia|allowPaymentRequest|allowFullScreen|allowTransparency|alt|async|autoComplete|autoPlay|capture|cellPadding|cellSpacing|challenge|charSet|checked|cite|classID|className|cols|colSpan|content|contentEditable|contextMenu|controls|controlsList|coords|crossOrigin|data|dateTime|decoding|default|defer|dir|disabled|disablePictureInPicture|download|draggable|encType|enterKeyHint|form|formAction|formEncType|formMethod|formNoValidate|formTarget|frameBorder|headers|height|hidden|high|href|hrefLang|htmlFor|httpEquiv|id|inputMode|integrity|is|keyParams|keyType|kind|label|lang|list|loading|loop|low|marginHeight|marginWidth|max|maxLength|media|mediaGroup|method|min|minLength|multiple|muted|name|nonce|noValidate|open|optimum|pattern|placeholder|playsInline|poster|preload|profile|radioGroup|readOnly|referrerPolicy|rel|required|reversed|role|rows|rowSpan|sandbox|scope|scoped|scrolling|seamless|selected|shape|size|sizes|slot|span|spellCheck|src|srcDoc|srcLang|srcSet|start|step|style|summary|tabIndex|target|title|translate|type|useMap|value|width|wmode|wrap|about|datatype|inlist|prefix|property|resource|typeof|vocab|autoCapitalize|autoCorrect|autoSave|color|incremental|fallback|inert|itemProp|itemScope|itemType|itemID|itemRef|on|option|results|security|unselectable|accentHeight|accumulate|additive|alignmentBaseline|allowReorder|alphabetic|amplitude|arabicForm|ascent|attributeName|attributeType|autoReverse|azimuth|baseFrequency|baselineShift|baseProfile|bbox|begin|bias|by|calcMode|capHeight|clip|clipPathUnits|clipPath|clipRule|colorInterpolation|colorInterpolationFilters|colorProfile|colorRendering|contentScriptType|contentStyleType|cursor|cx|cy|d|decelerate|descent|diffuseConstant|direction|display|divisor|dominantBaseline|dur|dx|dy|edgeMode|elevation|enableBackground|end|exponent|externalResourcesRequired|fill|fillOpacity|fillRule|filter|filterRes|filterUnits|floodColor|floodOpacity|focusable|fontFamily|fontSize|fontSizeAdjust|fontStretch|fontStyle|fontVariant|fontWeight|format|from|fr|fx|fy|g1|g2|glyphName|glyphOrientationHorizontal|glyphOrientationVertical|glyphRef|gradientTransform|gradientUnits|hanging|horizAdvX|horizOriginX|ideographic|imageRendering|in|in2|intercept|k|k1|k2|k3|k4|kernelMatrix|kernelUnitLength|kerning|keyPoints|keySplines|keyTimes|lengthAdjust|letterSpacing|lightingColor|limitingConeAngle|local|markerEnd|markerMid|markerStart|markerHeight|markerUnits|markerWidth|mask|maskContentUnits|maskUnits|mathematical|mode|numOctaves|offset|opacity|operator|order|orient|orientation|origin|overflow|overlinePosition|overlineThickness|panose1|paintOrder|pathLength|patternContentUnits|patternTransform|patternUnits|pointerEvents|points|pointsAtX|pointsAtY|pointsAtZ|preserveAlpha|preserveAspectRatio|primitiveUnits|r|radius|refX|refY|renderingIntent|repeatCount|repeatDur|requiredExtensions|requiredFeatures|restart|result|rotate|rx|ry|scale|seed|shapeRendering|slope|spacing|specularConstant|specularExponent|speed|spreadMethod|startOffset|stdDeviation|stemh|stemv|stitchTiles|stopColor|stopOpacity|strikethroughPosition|strikethroughThickness|string|stroke|strokeDasharray|strokeDashoffset|strokeLinecap|strokeLinejoin|strokeMiterlimit|strokeOpacity|strokeWidth|surfaceScale|systemLanguage|tableValues|targetX|targetY|textAnchor|textDecoration|textRendering|textLength|to|transform|u1|u2|underlinePosition|underlineThickness|unicode|unicodeBidi|unicodeRange|unitsPerEm|vAlphabetic|vHanging|vIdeographic|vMathematical|values|vectorEffect|version|vertAdvY|vertOriginX|vertOriginY|viewBox|viewTarget|visibility|widths|wordSpacing|writingMode|x|xHeight|x1|x2|xChannelSelector|xlinkActuate|xlinkArcrole|xlinkHref|xlinkRole|xlinkShow|xlinkTitle|xlinkType|xmlBase|xmlns|xmlnsXlink|xmlLang|xmlSpace|y|y1|y2|yChannelSelector|z|zoomAndPan|for|class|autofocus)|(([Dd][Aa][Tt][Aa]|[Aa][Rr][Ii][Aa]|x)-.*))$/,s=(0,o.Z)((function(e){return i.test(e)||111===e.charCodeAt(0)&&110===e.charCodeAt(1)&&e.charCodeAt(2)<91})),l=n(9886),u=n(5438),c=n(9140),d=n(2561),f=s,p=function(e){return"theme"!==e},m=function(e){return"string"===typeof e&&e.charCodeAt(0)>96?f:p},h=function(e,t,n){var r;if(t){var a=t.shouldForwardProp;r=e.__emotion_forwardProp&&a?function(t){return e.__emotion_forwardProp(t)&&a(t)}:a}return"function"!==typeof r&&n&&(r=e.__emotion_forwardProp),r},v=function(e){var t=e.cache,n=e.serialized,r=e.isStringTag;(0,u.hC)(t,n,r);(0,d.L)((function(){return(0,u.My)(t,n,r)}));return null},b=function e(t,n){var o,i,s=t.__emotion_real===t,d=s&&t.__emotion_base||t;void 0!==n&&(o=n.label,i=n.target);var f=h(t,n,s),p=f||m(d),b=!p("as");return function(){var y=arguments,g=s&&void 0!==t.__emotion_styles?t.__emotion_styles.slice(0):[];if(void 0!==o&&g.push("label:"+o+";"),null==y[0]||void 0===y[0].raw)g.push.apply(g,y);else{0,g.push(y[0][0]);for(var _=y.length,w=1;w<_;w++)g.push(y[w],y[0][w])}var S=(0,l.w)((function(e,t,n){var a=b&&e.as||d,o="",s=[],h=e;if(null==e.theme){for(var y in h={},e)h[y]=e[y];h.theme=(0,r.useContext)(l.T)}"string"===typeof e.className?o=(0,u.fp)(t.registered,s,e.className):null!=e.className&&(o=e.className+" ");var _=(0,c.O)(g.concat(s),t.registered,h);o+=t.key+"-"+_.name,void 0!==i&&(o+=" "+i);var w=b&&void 0===f?m(a):p,S={};for(var C in e)b&&"as"===C||w(C)&&(S[C]=e[C]);return S.className=o,S.ref=n,(0,r.createElement)(r.Fragment,null,(0,r.createElement)(v,{cache:t,serialized:_,isStringTag:"string"===typeof a}),(0,r.createElement)(a,S))}));return S.displayName=void 0!==o?o:"Styled("+("string"===typeof d?d:d.displayName||d.name||"Component")+")",S.defaultProps=t.defaultProps,S.__emotion_real=S,S.__emotion_base=d,S.__emotion_styles=g,S.__emotion_forwardProp=f,Object.defineProperty(S,"toString",{value:function(){return"."+i}}),S.withComponent=function(t,r){return e(t,(0,a.Z)({},n,r,{shouldForwardProp:h(S,r,!0)})).apply(void 0,g)},S}},y=b.bind();["a","abbr","address","area","article","aside","audio","b","base","bdi","bdo","big","blockquote","body","br","button","canvas","caption","cite","code","col","colgroup","data","datalist","dd","del","details","dfn","dialog","div","dl","dt","em","embed","fieldset","figcaption","figure","footer","form","h1","h2","h3","h4","h5","h6","head","header","hgroup","hr","html","i","iframe","img","input","ins","kbd","keygen","label","legend","li","link","main","map","mark","marquee","menu","menuitem","meta","meter","nav","noscript","object","ol","optgroup","option","output","p","param","picture","pre","progress","q","rp","rt","ruby","s","samp","script","section","select","small","source","span","strong","style","sub","summary","sup","table","tbody","td","textarea","tfoot","th","thead","time","title","tr","track","u","ul","var","video","wbr","circle","clipPath","defs","ellipse","foreignObject","g","image","line","linearGradient","mask","path","pattern","polygon","polyline","radialGradient","rect","stop","svg","text","tspan"].forEach((function(e){y[e]=y(e)}));var g=y;function _(e,t){return g(e,t)}var w=function(e,t){Array.isArray(e.__emotion_styles)&&(e.__emotion_styles=t(e.__emotion_styles))}},1184:function(e,t,n){"use strict";n.d(t,{L7:function(){return l},P$:function(){return c},VO:function(){return a},W8:function(){return s},dt:function(){return u},k9:function(){return i}});var r=n(2466),a={xs:0,sm:600,md:900,lg:1200,xl:1536},o={keys:["xs","sm","md","lg","xl"],up:function(e){return"@media (min-width:".concat(a[e],"px)")}};function i(e,t,n){var r=e.theme||{};if(Array.isArray(t)){var i=r.breakpoints||o;return t.reduce((function(e,r,a){return e[i.up(i.keys[a])]=n(t[a]),e}),{})}if("object"===typeof t){var s=r.breakpoints||o;return Object.keys(t).reduce((function(e,r){if(-1!==Object.keys(s.values||a).indexOf(r)){e[s.up(r)]=n(t[r],r)}else{var o=r;e[o]=t[o]}return e}),{})}return n(t)}function s(){var e,t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},n=null==(e=t.keys)?void 0:e.reduce((function(e,n){return e[t.up(n)]={},e}),{});return n||{}}function l(e,t){return e.reduce((function(e,t){var n=e[t];return(!n||0===Object.keys(n).length)&&delete e[t],e}),t)}function u(e){for(var t=s(e),n=arguments.length,a=new Array(n>1?n-1:0),o=1;o<n;o++)a[o-1]=arguments[o];var i=[t].concat(a).reduce((function(e,t){return(0,r.Z)(e,t)}),{});return l(Object.keys(t),i)}function c(e){var t,n=e.values,r=e.breakpoints,a=e.base||function(e,t){if("object"!==typeof e)return{};var n={},r=Object.keys(t);return Array.isArray(e)?r.forEach((function(t,r){r<e.length&&(n[t]=!0)})):r.forEach((function(t){null!=e[t]&&(n[t]=!0)})),n}(n,r),o=Object.keys(a);return 0===o.length?n:o.reduce((function(e,r,a){return Array.isArray(n)?(e[r]=null!=n[a]?n[a]:n[t],t=a):"object"===typeof n?(e[r]=null!=n[r]?n[r]:n[t],t=r):e[r]=n,e}),{})}},2065:function(e,t,n){"use strict";n.d(t,{$n:function(){return d},Fq:function(){return u},_j:function(){return c},mi:function(){return l}});var r=n(6189);function a(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:0,n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:1;return Math.min(Math.max(t,e),n)}function o(e){if(e.type)return e;if("#"===e.charAt(0))return o(function(e){e=e.slice(1);var t=new RegExp(".{1,".concat(e.length>=6?2:1,"}"),"g"),n=e.match(t);return n&&1===n[0].length&&(n=n.map((function(e){return e+e}))),n?"rgb".concat(4===n.length?"a":"","(").concat(n.map((function(e,t){return t<3?parseInt(e,16):Math.round(parseInt(e,16)/255*1e3)/1e3})).join(", "),")"):""}(e));var t=e.indexOf("("),n=e.substring(0,t);if(-1===["rgb","rgba","hsl","hsla","color"].indexOf(n))throw new Error((0,r.Z)(9,e));var a,i=e.substring(t+1,e.length-1);if("color"===n){if(a=(i=i.split(" ")).shift(),4===i.length&&"/"===i[3].charAt(0)&&(i[3]=i[3].slice(1)),-1===["srgb","display-p3","a98-rgb","prophoto-rgb","rec-2020"].indexOf(a))throw new Error((0,r.Z)(10,a))}else i=i.split(",");return{type:n,values:i=i.map((function(e){return parseFloat(e)})),colorSpace:a}}function i(e){var t=e.type,n=e.colorSpace,r=e.values;return-1!==t.indexOf("rgb")?r=r.map((function(e,t){return t<3?parseInt(e,10):e})):-1!==t.indexOf("hsl")&&(r[1]="".concat(r[1],"%"),r[2]="".concat(r[2],"%")),r=-1!==t.indexOf("color")?"".concat(n," ").concat(r.join(" ")):"".concat(r.join(", ")),"".concat(t,"(").concat(r,")")}function s(e){var t="hsl"===(e=o(e)).type||"hsla"===e.type?o(function(e){var t=(e=o(e)).values,n=t[0],r=t[1]/100,a=t[2]/100,s=r*Math.min(a,1-a),l=function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(e+n/30)%12;return a-s*Math.max(Math.min(t-3,9-t,1),-1)},u="rgb",c=[Math.round(255*l(0)),Math.round(255*l(8)),Math.round(255*l(4))];return"hsla"===e.type&&(u+="a",c.push(t[3])),i({type:u,values:c})}(e)).values:e.values;return t=t.map((function(t){return"color"!==e.type&&(t/=255),t<=.03928?t/12.92:Math.pow((t+.055)/1.055,2.4)})),Number((.2126*t[0]+.7152*t[1]+.0722*t[2]).toFixed(3))}function l(e,t){var n=s(e),r=s(t);return(Math.max(n,r)+.05)/(Math.min(n,r)+.05)}function u(e,t){return e=o(e),t=a(t),"rgb"!==e.type&&"hsl"!==e.type||(e.type+="a"),"color"===e.type?e.values[3]="/".concat(t):e.values[3]=t,i(e)}function c(e,t){if(e=o(e),t=a(t),-1!==e.type.indexOf("hsl"))e.values[2]*=1-t;else if(-1!==e.type.indexOf("rgb")||-1!==e.type.indexOf("color"))for(var n=0;n<3;n+=1)e.values[n]*=1-t;return i(e)}function d(e,t){if(e=o(e),t=a(t),-1!==e.type.indexOf("hsl"))e.values[2]+=(100-e.values[2])*t;else if(-1!==e.type.indexOf("rgb"))for(var n=0;n<3;n+=1)e.values[n]+=(255-e.values[n])*t;else if(-1!==e.type.indexOf("color"))for(var r=0;r<3;r+=1)e.values[r]+=(1-e.values[r])*t;return i(e)}},4046:function(e,t,n){"use strict";n.d(t,{ZP:function(){return k},x9:function(){return S}});var r=n(2982),a=n(885),o=n(3366),i=n(7462),s=n(2421),l=n(5080),u=n(7312),c=["variant"];function d(e){return 0===e.length}function f(e){var t=e.variant,n=(0,o.Z)(e,c),r=t||"";return Object.keys(n).sort().forEach((function(t){r+="color"===t?d(r)?e[t]:(0,u.Z)(e[t]):"".concat(d(r)?t:(0,u.Z)(t)).concat((0,u.Z)(e[t].toString()))})),r}var p=n(104),m=["name","slot","skipVariantsResolver","skipSx","overridesResolver"],h=["theme"],v=["theme"];function b(e){return 0===Object.keys(e).length}function y(e){return"string"===typeof e&&e.charCodeAt(0)>96}var g=function(e,t){return t.components&&t.components[e]&&t.components[e].styleOverrides?t.components[e].styleOverrides:null},_=function(e,t){var n=[];t&&t.components&&t.components[e]&&t.components[e].variants&&(n=t.components[e].variants);var r={};return n.forEach((function(e){var t=f(e.props);r[t]=e.style})),r},w=function(e,t,n,r){var a,o,i=e.ownerState,s=void 0===i?{}:i,l=[],u=null==n||null==(a=n.components)||null==(o=a[r])?void 0:o.variants;return u&&u.forEach((function(n){var r=!0;Object.keys(n.props).forEach((function(t){s[t]!==n.props[t]&&e[t]!==n.props[t]&&(r=!1)})),r&&l.push(t[f(n.props)])})),l};function S(e){return"ownerState"!==e&&"theme"!==e&&"sx"!==e&&"as"!==e}var C=(0,l.Z)();function k(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.defaultTheme,n=void 0===t?C:t,l=e.rootShouldForwardProp,u=void 0===l?S:l,c=e.slotShouldForwardProp,d=void 0===c?S:c,f=e.styleFunctionSx,k=void 0===f?p.Z:f,T=function(e){var t=b(e.theme)?n:e.theme;return k((0,i.Z)({},e,{theme:t}))};return T.__mui_systemSx=!0,function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{};(0,s.Co)(e,(function(e){return e.filter((function(e){return!(null!=e&&e.__mui_systemSx)}))}));var l,c=t.name,f=t.slot,p=t.skipVariantsResolver,C=t.skipSx,k=t.overridesResolver,x=(0,o.Z)(t,m),E=void 0!==p?p:f&&"Root"!==f||!1,P=C||!1;var A=S;"Root"===f?A=u:f?A=d:y(e)&&(A=void 0);var R=(0,s.ZP)(e,(0,i.Z)({shouldForwardProp:A,label:l},x)),F=function(e){for(var t=arguments.length,s=new Array(t>1?t-1:0),l=1;l<t;l++)s[l-1]=arguments[l];var u=s?s.map((function(e){return"function"===typeof e&&e.__emotion_real!==e?function(t){var r=t.theme,a=(0,o.Z)(t,h);return e((0,i.Z)({theme:b(r)?n:r},a))}:e})):[],d=e;c&&k&&u.push((function(e){var t=b(e.theme)?n:e.theme,r=g(c,t);if(r){var o={};return Object.entries(r).forEach((function(n){var r=(0,a.Z)(n,2),s=r[0],l=r[1];o[s]="function"===typeof l?l((0,i.Z)({},e,{theme:t})):l})),k(e,o)}return null})),c&&!E&&u.push((function(e){var t=b(e.theme)?n:e.theme;return w(e,_(c,t),t,c)})),P||u.push(T);var f=u.length-s.length;if(Array.isArray(e)&&f>0){var p=new Array(f).fill("");(d=[].concat((0,r.Z)(e),(0,r.Z)(p))).raw=[].concat((0,r.Z)(e.raw),(0,r.Z)(p))}else"function"===typeof e&&e.__emotion_real!==e&&(d=function(t){var r=t.theme,a=(0,o.Z)(t,v);return e((0,i.Z)({theme:b(r)?n:r},a))});var m=R.apply(void 0,[d].concat((0,r.Z)(u)));return m};return R.withConfig&&(F.withConfig=R.withConfig),F}}},5080:function(e,t,n){"use strict";n.d(t,{Z:function(){return p}});var r=n(7462),a=n(3366),o=n(2466),i=n(4942),s=["values","unit","step"];function l(e){var t=e.values,n=void 0===t?{xs:0,sm:600,md:900,lg:1200,xl:1536}:t,o=e.unit,l=void 0===o?"px":o,u=e.step,c=void 0===u?5:u,d=(0,a.Z)(e,s),f=function(e){var t=Object.keys(e).map((function(t){return{key:t,val:e[t]}}))||[];return t.sort((function(e,t){return e.val-t.val})),t.reduce((function(e,t){return(0,r.Z)({},e,(0,i.Z)({},t.key,t.val))}),{})}(n),p=Object.keys(f);function m(e){var t="number"===typeof n[e]?n[e]:e;return"@media (min-width:".concat(t).concat(l,")")}function h(e){var t="number"===typeof n[e]?n[e]:e;return"@media (max-width:".concat(t-c/100).concat(l,")")}function v(e,t){var r=p.indexOf(t);return"@media (min-width:".concat("number"===typeof n[e]?n[e]:e).concat(l,") and ")+"(max-width:".concat((-1!==r&&"number"===typeof n[p[r]]?n[p[r]]:t)-c/100).concat(l,")")}return(0,r.Z)({keys:p,values:f,up:m,down:h,between:v,only:function(e){return p.indexOf(e)+1<p.length?v(e,p[p.indexOf(e)+1]):m(e)},not:function(e){var t=p.indexOf(e);return 0===t?m(p[1]):t===p.length-1?h(p[t]):v(e,p[p.indexOf(e)+1]).replace("@media","@media not all and")},unit:l},d)}var u={borderRadius:4},c=n(5682);function d(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:8;if(e.mui)return e;var t=(0,c.hB)({spacing:e}),n=function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=0===n.length?[1]:n;return a.map((function(e){var n=t(e);return"number"===typeof n?"".concat(n,"px"):n})).join(" ")};return n.mui=!0,n}var f=["breakpoints","palette","spacing","shape"];var p=function(){for(var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.breakpoints,n=void 0===t?{}:t,i=e.palette,s=void 0===i?{}:i,c=e.spacing,p=e.shape,m=void 0===p?{}:p,h=(0,a.Z)(e,f),v=l(n),b=d(c),y=(0,o.Z)({breakpoints:v,direction:"ltr",components:{},palette:(0,r.Z)({mode:"light"},s),spacing:b,shape:(0,r.Z)({},u,m)},h),g=arguments.length,_=new Array(g>1?g-1:0),w=1;w<g;w++)_[w-1]=arguments[w];return y=_.reduce((function(e,t){return(0,o.Z)(e,t)}),y)}},114:function(e,t,n){"use strict";n.d(t,{Gc:function(){return q},G$:function(){return J}});var r=n(8529),a=n(8247);var o=function(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];var r=t.reduce((function(e,t){return t.filterProps.forEach((function(n){e[n]=t})),e}),{}),o=function(e){return Object.keys(e).reduce((function(t,n){return r[n]?(0,a.Z)(t,r[n](e)):t}),{})};return o.propTypes={},o.filterProps=t.reduce((function(e,t){return e.concat(t.filterProps)}),[]),o},i=n(5682),s=n(1184);function l(e){return"number"!==typeof e?e:"".concat(e,"px solid")}var u=(0,r.Z)({prop:"border",themeKey:"borders",transform:l}),c=(0,r.Z)({prop:"borderTop",themeKey:"borders",transform:l}),d=(0,r.Z)({prop:"borderRight",themeKey:"borders",transform:l}),f=(0,r.Z)({prop:"borderBottom",themeKey:"borders",transform:l}),p=(0,r.Z)({prop:"borderLeft",themeKey:"borders",transform:l}),m=(0,r.Z)({prop:"borderColor",themeKey:"palette"}),h=(0,r.Z)({prop:"borderTopColor",themeKey:"palette"}),v=(0,r.Z)({prop:"borderRightColor",themeKey:"palette"}),b=(0,r.Z)({prop:"borderBottomColor",themeKey:"palette"}),y=(0,r.Z)({prop:"borderLeftColor",themeKey:"palette"}),g=function(e){if(void 0!==e.borderRadius&&null!==e.borderRadius){var t=(0,i.eI)(e.theme,"shape.borderRadius",4,"borderRadius");return(0,s.k9)(e,e.borderRadius,(function(e){return{borderRadius:(0,i.NA)(t,e)}}))}return null};g.propTypes={},g.filterProps=["borderRadius"];var _=o(u,c,d,f,p,m,h,v,b,y,g),w=o((0,r.Z)({prop:"displayPrint",cssProperty:!1,transform:function(e){return{"@media print":{display:e}}}}),(0,r.Z)({prop:"display"}),(0,r.Z)({prop:"overflow"}),(0,r.Z)({prop:"textOverflow"}),(0,r.Z)({prop:"visibility"}),(0,r.Z)({prop:"whiteSpace"})),S=o((0,r.Z)({prop:"flexBasis"}),(0,r.Z)({prop:"flexDirection"}),(0,r.Z)({prop:"flexWrap"}),(0,r.Z)({prop:"justifyContent"}),(0,r.Z)({prop:"alignItems"}),(0,r.Z)({prop:"alignContent"}),(0,r.Z)({prop:"order"}),(0,r.Z)({prop:"flex"}),(0,r.Z)({prop:"flexGrow"}),(0,r.Z)({prop:"flexShrink"}),(0,r.Z)({prop:"alignSelf"}),(0,r.Z)({prop:"justifyItems"}),(0,r.Z)({prop:"justifySelf"})),C=function(e){if(void 0!==e.gap&&null!==e.gap){var t=(0,i.eI)(e.theme,"spacing",8,"gap");return(0,s.k9)(e,e.gap,(function(e){return{gap:(0,i.NA)(t,e)}}))}return null};C.propTypes={},C.filterProps=["gap"];var k=function(e){if(void 0!==e.columnGap&&null!==e.columnGap){var t=(0,i.eI)(e.theme,"spacing",8,"columnGap");return(0,s.k9)(e,e.columnGap,(function(e){return{columnGap:(0,i.NA)(t,e)}}))}return null};k.propTypes={},k.filterProps=["columnGap"];var T=function(e){if(void 0!==e.rowGap&&null!==e.rowGap){var t=(0,i.eI)(e.theme,"spacing",8,"rowGap");return(0,s.k9)(e,e.rowGap,(function(e){return{rowGap:(0,i.NA)(t,e)}}))}return null};T.propTypes={},T.filterProps=["rowGap"];var x=o(C,k,T,(0,r.Z)({prop:"gridColumn"}),(0,r.Z)({prop:"gridRow"}),(0,r.Z)({prop:"gridAutoFlow"}),(0,r.Z)({prop:"gridAutoColumns"}),(0,r.Z)({prop:"gridAutoRows"}),(0,r.Z)({prop:"gridTemplateColumns"}),(0,r.Z)({prop:"gridTemplateRows"}),(0,r.Z)({prop:"gridTemplateAreas"}),(0,r.Z)({prop:"gridArea"})),E=o((0,r.Z)({prop:"position"}),(0,r.Z)({prop:"zIndex",themeKey:"zIndex"}),(0,r.Z)({prop:"top"}),(0,r.Z)({prop:"right"}),(0,r.Z)({prop:"bottom"}),(0,r.Z)({prop:"left"})),P=o((0,r.Z)({prop:"color",themeKey:"palette"}),(0,r.Z)({prop:"bgcolor",cssProperty:"backgroundColor",themeKey:"palette"}),(0,r.Z)({prop:"backgroundColor",themeKey:"palette"})),A=(0,r.Z)({prop:"boxShadow",themeKey:"shadows"});function R(e){return e<=1&&0!==e?"".concat(100*e,"%"):e}var F=(0,r.Z)({prop:"width",transform:R}),O=function(e){if(void 0!==e.maxWidth&&null!==e.maxWidth){return(0,s.k9)(e,e.maxWidth,(function(t){var n,r,a;return{maxWidth:(null==(n=e.theme)||null==(r=n.breakpoints)||null==(a=r.values)?void 0:a[t])||s.VO[t]||R(t)}}))}return null};O.filterProps=["maxWidth"];var N=(0,r.Z)({prop:"minWidth",transform:R}),M=(0,r.Z)({prop:"height",transform:R}),I=(0,r.Z)({prop:"maxHeight",transform:R}),z=(0,r.Z)({prop:"minHeight",transform:R}),L=((0,r.Z)({prop:"size",cssProperty:"width",transform:R}),(0,r.Z)({prop:"size",cssProperty:"height",transform:R}),o(F,O,N,M,I,z,(0,r.Z)({prop:"boxSizing"}))),D=(0,r.Z)({prop:"fontFamily",themeKey:"typography"}),j=(0,r.Z)({prop:"fontSize",themeKey:"typography"}),Z=(0,r.Z)({prop:"fontStyle",themeKey:"typography"}),B=(0,r.Z)({prop:"fontWeight",themeKey:"typography"}),W=(0,r.Z)({prop:"letterSpacing"}),U=(0,r.Z)({prop:"textTransform"}),V=(0,r.Z)({prop:"lineHeight"}),G=(0,r.Z)({prop:"textAlign"}),H=o((0,r.Z)({prop:"typography",cssProperty:!1,themeKey:"typography"}),D,j,Z,B,W,V,G,U),$={borders:_.filterProps,display:w.filterProps,flexbox:S.filterProps,grid:x.filterProps,positions:E.filterProps,palette:P.filterProps,shadows:A.filterProps,sizing:L.filterProps,spacing:i.ZP.filterProps,typography:H.filterProps},J={borders:_,display:w,flexbox:S,grid:x,positions:E,palette:P,shadows:A,sizing:L,spacing:i.ZP,typography:H},q=Object.keys($).reduce((function(e,t){return $[t].forEach((function(n){e[n]=J[t]})),e}),{})},8247:function(e,t,n){"use strict";var r=n(2466);t.Z=function(e,t){return t?(0,r.Z)(e,t,{clone:!1}):e}},5682:function(e,t,n){"use strict";n.d(t,{hB:function(){return h},eI:function(){return m},ZP:function(){return S},NA:function(){return v}});var r=n(885),a=n(1184),o=n(8529),i=n(8247);var s={m:"margin",p:"padding"},l={t:"Top",r:"Right",b:"Bottom",l:"Left",x:["Left","Right"],y:["Top","Bottom"]},u={marginX:"mx",marginY:"my",paddingX:"px",paddingY:"py"},c=function(e){var t={};return function(n){return void 0===t[n]&&(t[n]=e(n)),t[n]}}((function(e){if(e.length>2){if(!u[e])return[e];e=u[e]}var t=e.split(""),n=(0,r.Z)(t,2),a=n[0],o=n[1],i=s[a],c=l[o]||"";return Array.isArray(c)?c.map((function(e){return i+e})):[i+c]})),d=["m","mt","mr","mb","ml","mx","my","margin","marginTop","marginRight","marginBottom","marginLeft","marginX","marginY","marginInline","marginInlineStart","marginInlineEnd","marginBlock","marginBlockStart","marginBlockEnd"],f=["p","pt","pr","pb","pl","px","py","padding","paddingTop","paddingRight","paddingBottom","paddingLeft","paddingX","paddingY","paddingInline","paddingInlineStart","paddingInlineEnd","paddingBlock","paddingBlockStart","paddingBlockEnd"],p=[].concat(d,f);function m(e,t,n,r){var a,i=null!=(a=(0,o.D)(e,t,!1))?a:n;return"number"===typeof i?function(e){return"string"===typeof e?e:i*e}:Array.isArray(i)?function(e){return"string"===typeof e?e:i[e]}:"function"===typeof i?i:function(){}}function h(e){return m(e,"spacing",8)}function v(e,t){if("string"===typeof t||null==t)return t;var n=e(Math.abs(t));return t>=0?n:"number"===typeof n?-n:"-".concat(n)}function b(e,t,n,r){if(-1===t.indexOf(n))return null;var o=function(e,t){return function(n){return e.reduce((function(e,r){return e[r]=v(t,n),e}),{})}}(c(n),r),i=e[n];return(0,a.k9)(e,i,o)}function y(e,t){var n=h(e.theme);return Object.keys(e).map((function(r){return b(e,t,r,n)})).reduce(i.Z,{})}function g(e){return y(e,d)}function _(e){return y(e,f)}function w(e){return y(e,p)}g.propTypes={},g.filterProps=d,_.propTypes={},_.filterProps=f,w.propTypes={},w.filterProps=p;var S=w},8529:function(e,t,n){"use strict";n.d(t,{D:function(){return i}});var r=n(4942),a=n(7312),o=n(1184);function i(e,t){var n=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(!t||"string"!==typeof t)return null;if(e&&e.vars&&n){var r="vars.".concat(t).split(".").reduce((function(e,t){return e&&e[t]?e[t]:null}),e);if(null!=r)return r}return t.split(".").reduce((function(e,t){return e&&null!=e[t]?e[t]:null}),e)}function s(e,t,n){var r,a=arguments.length>3&&void 0!==arguments[3]?arguments[3]:n;return r="function"===typeof e?e(n):Array.isArray(e)?e[n]||a:i(e,n)||a,t&&(r=t(r)),r}t.Z=function(e){var t=e.prop,n=e.cssProperty,l=void 0===n?e.prop:n,u=e.themeKey,c=e.transform,d=function(e){if(null==e[t])return null;var n=e[t],d=i(e.theme,u)||{};return(0,o.k9)(e,n,(function(e){var n=s(d,c,e);return e===n&&"string"===typeof e&&(n=s(d,c,"".concat(t).concat("default"===e?"":(0,a.Z)(e)),e)),!1===l?n:(0,r.Z)({},l,n)}))};return d.propTypes={},d.filterProps=[t],d}},104:function(e,t,n){"use strict";var r=n(4942),a=n(8247),o=n(114),i=n(1184);function s(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];var r=t.reduce((function(e,t){return e.concat(Object.keys(t))}),[]),a=new Set(r);return t.every((function(e){return a.size===Object.keys(e).length}))}function l(e,t){return"function"===typeof e?e(t):e}var u=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:o.G$,t=Object.keys(e).reduce((function(t,n){return e[n].filterProps.forEach((function(r){t[r]=e[n]})),t}),{});function n(e,n,a){var o,i=(o={},(0,r.Z)(o,e,n),(0,r.Z)(o,"theme",a),o),s=t[e];return s?s(i):(0,r.Z)({},e,n)}function u(e){var o=e||{},c=o.sx,d=o.theme,f=void 0===d?{}:d;if(!c)return null;function p(e){var o=e;if("function"===typeof e)o=e(f);else if("object"!==typeof e)return e;if(!o)return null;var c=(0,i.W8)(f.breakpoints),d=Object.keys(c),p=c;return Object.keys(o).forEach((function(e){var c=l(o[e],f);if(null!==c&&void 0!==c)if("object"===typeof c)if(t[e])p=(0,a.Z)(p,n(e,c,f));else{var d=(0,i.k9)({theme:f},c,(function(t){return(0,r.Z)({},e,t)}));s(d,c)?p[e]=u({sx:c,theme:f}):p=(0,a.Z)(p,d)}else p=(0,a.Z)(p,n(e,c,f))})),(0,i.L7)(d,p)}return Array.isArray(c)?c.map(p):p(c)}return u}();u.filterProps=["sx"],t.Z=u},886:function(e,t,n){"use strict";n.d(t,{Z:function(){return c}});var r=n(5080),a=n(2791);var o=a.createContext(null);function i(){return a.useContext(o)}function s(e){return 0===Object.keys(e).length}var l=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:null,t=i();return!t||s(t)?e:t},u=(0,r.Z)();var c=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:u;return l(e)}},8691:function(e,t,n){"use strict";n.d(t,{Z:function(){return i}});var r=n(7462);function a(e){var t=e.theme,n=e.name,a=e.props;return t&&t.components&&t.components[n]&&t.components[n].defaultProps?function(e,t){var n=(0,r.Z)({},t);return Object.keys(e).forEach((function(t){void 0===n[t]&&(n[t]=e[t])})),n}(t.components[n].defaultProps,a):a}var o=n(886);function i(e){var t=e.props,n=e.name,r=e.defaultTheme;return a({theme:(0,o.Z)(r),name:n,props:t})}},5902:function(e,t){"use strict";var n=function(e){return e},r=function(){var e=n;return{configure:function(t){e=t},generate:function(t){return e(t)},reset:function(){e=n}}}();t.Z=r},7312:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(6189);function a(e){if("string"!==typeof e)throw new Error((0,r.Z)(7));return e.charAt(0).toUpperCase()+e.slice(1)}},4419:function(e,t,n){"use strict";function r(e,t,n){var r={};return Object.keys(e).forEach((function(a){r[a]=e[a].reduce((function(e,r){return r&&(e.push(t(r)),n&&n[r]&&e.push(n[r])),e}),[]).join(" ")})),r}n.d(t,{Z:function(){return r}})},2466:function(e,t,n){"use strict";n.d(t,{P:function(){return a},Z:function(){return o}});var r=n(7462);function a(e){return null!==e&&"object"===typeof e&&e.constructor===Object}function o(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{clone:!0},i=n.clone?(0,r.Z)({},e):e;return a(e)&&a(t)&&Object.keys(t).forEach((function(r){"__proto__"!==r&&(a(t[r])&&r in e&&a(e[r])?i[r]=o(e[r],t[r],n):i[r]=t[r])})),i}},6189:function(e,t,n){"use strict";function r(e){for(var t="https://mui.com/production-error/?code="+e,n=1;n<arguments.length;n+=1)t+="&args[]="+encodeURIComponent(arguments[n]);return"Minified MUI error #"+e+"; visit "+t+" for the full message."}n.d(t,{Z:function(){return r}})},1217:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(5902),a={active:"active",checked:"checked",completed:"completed",disabled:"disabled",error:"error",expanded:"expanded",focused:"focused",focusVisible:"focusVisible",required:"required",selected:"selected"};function o(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:"Mui",o=a[t];return o?"".concat(n,"-").concat(o):"".concat(r.Z.generate(e),"-").concat(t)}},5878:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(1217);function a(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:"Mui",a={};return t.forEach((function(t){a[t]=(0,r.Z)(e,t,n)})),a}},2971:function(e,t,n){"use strict";function r(e,t){"function"===typeof e?e(t):e&&(e.current=t)}n.d(t,{Z:function(){return r}})},5721:function(e,t,n){"use strict";var r=n(2791),a="undefined"!==typeof window?r.useLayoutEffect:r.useEffect;t.Z=a},1694:function(e,t){var n;!function(){"use strict";var r={}.hasOwnProperty;function a(){for(var e=[],t=0;t<arguments.length;t++){var n=arguments[t];if(n){var o=typeof n;if("string"===o||"number"===o)e.push(n);else if(Array.isArray(n)){if(n.length){var i=a.apply(null,n);i&&e.push(i)}}else if("object"===o){if(n.toString!==Object.prototype.toString&&!n.toString.toString().includes("[native code]")){e.push(n.toString());continue}for(var s in n)r.call(n,s)&&n[s]&&e.push(s)}}}return e.join(" ")}e.exports?(a.default=a,e.exports=a):void 0===(n=function(){return a}.apply(t,[]))||(e.exports=n)}()},8182:function(e,t,n){"use strict";function r(e){var t,n,a="";if("string"==typeof e||"number"==typeof e)a+=e;else if("object"==typeof e)if(Array.isArray(e))for(t=0;t<e.length;t++)e[t]&&(n=r(e[t]))&&(a&&(a+=" "),a+=n);else for(t in e)e[t]&&(a&&(a+=" "),a+=t);return a}t.Z=function(){for(var e,t,n=0,a="";n<arguments.length;)(e=arguments[n++])&&(t=r(e))&&(a&&(a+=" "),a+=t);return a}},4173:function(e,t){!function(e){"use strict";function t(){}function n(e,t,n,r,a){for(var o=0,i=t.length,s=0,l=0;o<i;o++){var u=t[o];if(u.removed){if(u.value=e.join(r.slice(l,l+u.count)),l+=u.count,o&&t[o-1].added){var c=t[o-1];t[o-1]=t[o],t[o]=c}}else{if(!u.added&&a){var d=n.slice(s,s+u.count);d=d.map((function(e,t){var n=r[l+t];return n.length>e.length?n:e})),u.value=e.join(d)}else u.value=e.join(n.slice(s,s+u.count));s+=u.count,u.added||(l+=u.count)}}var f=t[i-1];return i>1&&"string"===typeof f.value&&(f.added||f.removed)&&e.equals("",f.value)&&(t[i-2].value+=f.value,t.pop()),t}function r(e){return{newPos:e.newPos,components:e.components.slice(0)}}t.prototype={diff:function(e,t){var a=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{},o=a.callback;"function"===typeof a&&(o=a,a={}),this.options=a;var i=this;function s(e){return o?(setTimeout((function(){o(void 0,e)}),0),!0):e}e=this.castInput(e),t=this.castInput(t),e=this.removeEmpty(this.tokenize(e));var l=(t=this.removeEmpty(this.tokenize(t))).length,u=e.length,c=1,d=l+u,f=[{newPos:-1,components:[]}],p=this.extractCommon(f[0],t,e,0);if(f[0].newPos+1>=l&&p+1>=u)return s([{value:this.join(t),count:t.length}]);function m(){for(var a=-1*c;a<=c;a+=2){var o=void 0,d=f[a-1],p=f[a+1],m=(p?p.newPos:0)-a;d&&(f[a-1]=void 0);var h=d&&d.newPos+1<l,v=p&&0<=m&&m<u;if(h||v){if(!h||v&&d.newPos<p.newPos?(o=r(p),i.pushComponent(o.components,void 0,!0)):((o=d).newPos++,i.pushComponent(o.components,!0,void 0)),m=i.extractCommon(o,t,e,a),o.newPos+1>=l&&m+1>=u)return s(n(i,o.components,t,e,i.useLongestToken));f[a]=o}else f[a]=void 0}c++}if(o)!function e(){setTimeout((function(){if(c>d)return o();m()||e()}),0)}();else for(;c<=d;){var h=m();if(h)return h}},pushComponent:function(e,t,n){var r=e[e.length-1];r&&r.added===t&&r.removed===n?e[e.length-1]={count:r.count+1,added:t,removed:n}:e.push({count:1,added:t,removed:n})},extractCommon:function(e,t,n,r){for(var a=t.length,o=n.length,i=e.newPos,s=i-r,l=0;i+1<a&&s+1<o&&this.equals(t[i+1],n[s+1]);)i++,s++,l++;return l&&e.components.push({count:l}),e.newPos=i,s},equals:function(e,t){return this.options.comparator?this.options.comparator(e,t):e===t||this.options.ignoreCase&&e.toLowerCase()===t.toLowerCase()},removeEmpty:function(e){for(var t=[],n=0;n<e.length;n++)e[n]&&t.push(e[n]);return t},castInput:function(e){return e},tokenize:function(e){return e.split("")},join:function(e){return e.join("")}};var a=new t;function o(e,t,n){return a.diff(e,t,n)}function i(e,t){if("function"===typeof e)t.callback=e;else if(e)for(var n in e)e.hasOwnProperty(n)&&(t[n]=e[n]);return t}var s=/^[A-Za-z\xC0-\u02C6\u02C8-\u02D7\u02DE-\u02FF\u1E00-\u1EFF]+$/,l=/\S/,u=new t;function c(e,t,n){return n=i(n,{ignoreWhitespace:!0}),u.diff(e,t,n)}function d(e,t,n){return u.diff(e,t,n)}u.equals=function(e,t){return this.options.ignoreCase&&(e=e.toLowerCase(),t=t.toLowerCase()),e===t||this.options.ignoreWhitespace&&!l.test(e)&&!l.test(t)},u.tokenize=function(e){for(var t=e.split(/(\s+|[()[\]{}'"]|\b)/),n=0;n<t.length-1;n++)!t[n+1]&&t[n+2]&&s.test(t[n])&&s.test(t[n+2])&&(t[n]+=t[n+2],t.splice(n+1,2),n--);return t};var f=new t;function p(e,t,n){return f.diff(e,t,n)}function m(e,t,n){var r=i(n,{ignoreWhitespace:!0});return f.diff(e,t,r)}f.tokenize=function(e){var t=[],n=e.split(/(\n|\r\n)/);n[n.length-1]||n.pop();for(var r=0;r<n.length;r++){var a=n[r];r%2&&!this.options.newlineIsToken?t[t.length-1]+=a:(this.options.ignoreWhitespace&&(a=a.trim()),t.push(a))}return t};var h=new t;function v(e,t,n){return h.diff(e,t,n)}h.tokenize=function(e){return e.split(/(\S.+?[.!?])(?=\s+|$)/)};var b=new t;function y(e,t,n){return b.diff(e,t,n)}function g(e){return g="function"===typeof Symbol&&"symbol"===typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"===typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e},g(e)}function _(e){return w(e)||S(e)||C()}function w(e){if(Array.isArray(e)){for(var t=0,n=new Array(e.length);t<e.length;t++)n[t]=e[t];return n}}function S(e){if(Symbol.iterator in Object(e)||"[object Arguments]"===Object.prototype.toString.call(e))return Array.from(e)}function C(){throw new TypeError("Invalid attempt to spread non-iterable instance")}b.tokenize=function(e){return e.split(/([{}:;,]|\s+)/)};var k=Object.prototype.toString,T=new t;function x(e,t,n){return T.diff(e,t,n)}function E(e,t,n,r,a){var o,i;for(t=t||[],n=n||[],r&&(e=r(a,e)),o=0;o<t.length;o+=1)if(t[o]===e)return n[o];if("[object Array]"===k.call(e)){for(t.push(e),i=new Array(e.length),n.push(i),o=0;o<e.length;o+=1)i[o]=E(e[o],t,n,r,a);return t.pop(),n.pop(),i}if(e&&e.toJSON&&(e=e.toJSON()),"object"===g(e)&&null!==e){t.push(e),i={},n.push(i);var s,l=[];for(s in e)e.hasOwnProperty(s)&&l.push(s);for(l.sort(),o=0;o<l.length;o+=1)i[s=l[o]]=E(e[s],t,n,r,s);t.pop(),n.pop()}else i=e;return i}T.useLongestToken=!0,T.tokenize=f.tokenize,T.castInput=function(e){var t=this.options,n=t.undefinedReplacement,r=t.stringifyReplacer,a=void 0===r?function(e,t){return"undefined"===typeof t?n:t}:r;return"string"===typeof e?e:JSON.stringify(E(e,null,null,a),a,"  ")},T.equals=function(e,n){return t.prototype.equals.call(T,e.replace(/,([\r\n])/g,"$1"),n.replace(/,([\r\n])/g,"$1"))};var P=new t;function A(e,t,n){return P.diff(e,t,n)}function R(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},n=e.split(/\r\n|[\n\v\f\r\x85]/),r=e.match(/\r\n|[\n\v\f\r\x85]/g)||[],a=[],o=0;function i(){var e={};for(a.push(e);o<n.length;){var r=n[o];if(/^(\-\-\-|\+\+\+|@@)\s/.test(r))break;var i=/^(?:Index:|diff(?: -r \w+)+)\s+(.+?)\s*$/.exec(r);i&&(e.index=i[1]),o++}for(s(e),s(e),e.hunks=[];o<n.length;){var u=n[o];if(/^(Index:|diff|\-\-\-|\+\+\+)\s/.test(u))break;if(/^@@/.test(u))e.hunks.push(l());else{if(u&&t.strict)throw new Error("Unknown line "+(o+1)+" "+JSON.stringify(u));o++}}}function s(e){var t=/^(---|\+\+\+)\s+(.*)$/.exec(n[o]);if(t){var r="---"===t[1]?"old":"new",a=t[2].split("\t",2),i=a[0].replace(/\\\\/g,"\\");/^".*"$/.test(i)&&(i=i.substr(1,i.length-2)),e[r+"FileName"]=i,e[r+"Header"]=(a[1]||"").trim(),o++}}function l(){for(var e=o,a=n[o++].split(/@@ -(\d+)(?:,(\d+))? \+(\d+)(?:,(\d+))? @@/),i={oldStart:+a[1],oldLines:+a[2]||1,newStart:+a[3],newLines:+a[4]||1,lines:[],linedelimiters:[]},s=0,l=0;o<n.length&&!(0===n[o].indexOf("--- ")&&o+2<n.length&&0===n[o+1].indexOf("+++ ")&&0===n[o+2].indexOf("@@"));o++){var u=0==n[o].length&&o!=n.length-1?" ":n[o][0];if("+"!==u&&"-"!==u&&" "!==u&&"\\"!==u)break;i.lines.push(n[o]),i.linedelimiters.push(r[o]||"\n"),"+"===u?s++:"-"===u?l++:" "===u&&(s++,l++)}if(s||1!==i.newLines||(i.newLines=0),l||1!==i.oldLines||(i.oldLines=0),t.strict){if(s!==i.newLines)throw new Error("Added line count did not match for hunk at line "+(e+1));if(l!==i.oldLines)throw new Error("Removed line count did not match for hunk at line "+(e+1))}return i}for(;o<n.length;)i();return a}function F(e,t,n){var r=!0,a=!1,o=!1,i=1;return function s(){if(r&&!o){if(a?i++:r=!1,e+i<=n)return i;o=!0}if(!a)return o||(r=!0),t<=e-i?-i++:(a=!0,s())}}function O(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};if("string"===typeof t&&(t=R(t)),Array.isArray(t)){if(t.length>1)throw new Error("applyPatch only works with a single input.");t=t[0]}var r,a,o=e.split(/\r\n|[\n\v\f\r\x85]/),i=e.match(/\r\n|[\n\v\f\r\x85]/g)||[],s=t.hunks,l=n.compareLine||function(e,t,n,r){return t===r},u=0,c=n.fuzzFactor||0,d=0,f=0;function p(e,t){for(var n=0;n<e.lines.length;n++){var r=e.lines[n],a=r.length>0?r[0]:" ",i=r.length>0?r.substr(1):r;if(" "===a||"-"===a){if(!l(t+1,o[t],a,i)&&++u>c)return!1;t++}}return!0}for(var m=0;m<s.length;m++){for(var h=s[m],v=o.length-h.oldLines,b=0,y=f+h.oldStart-1,g=F(y,d,v);void 0!==b;b=g())if(p(h,y+b)){h.offset=f+=b;break}if(void 0===b)return!1;d=h.offset+h.oldStart+h.oldLines}for(var _=0,w=0;w<s.length;w++){var S=s[w],C=S.oldStart+S.offset+_-1;_+=S.newLines-S.oldLines,C<0&&(C=0);for(var k=0;k<S.lines.length;k++){var T=S.lines[k],x=T.length>0?T[0]:" ",E=T.length>0?T.substr(1):T,P=S.linedelimiters[k];if(" "===x)C++;else if("-"===x)o.splice(C,1),i.splice(C,1);else if("+"===x)o.splice(C,0,E),i.splice(C,0,P),C++;else if("\\"===x){var A=S.lines[k-1]?S.lines[k-1][0]:null;"+"===A?r=!0:"-"===A&&(a=!0)}}}if(r)for(;!o[o.length-1];)o.pop(),i.pop();else a&&(o.push(""),i.push("\n"));for(var O=0;O<o.length-1;O++)o[O]=o[O]+i[O];return o.join("")}function N(e,t){"string"===typeof e&&(e=R(e));var n=0;function r(){var a=e[n++];if(!a)return t.complete();t.loadFile(a,(function(e,n){if(e)return t.complete(e);var o=O(n,a,t);t.patched(a,o,(function(e){if(e)return t.complete(e);r()}))}))}r()}function M(e,t,n,r,a,o,i){i||(i={}),"undefined"===typeof i.context&&(i.context=4);var s=p(n,r,i);function l(e){return e.map((function(e){return" "+e}))}s.push({value:"",lines:[]});for(var u=[],c=0,d=0,f=[],m=1,h=1,v=function(e){var t=s[e],a=t.lines||t.value.replace(/\n$/,"").split("\n");if(t.lines=a,t.added||t.removed){var o;if(!c){var p=s[e-1];c=m,d=h,p&&(f=i.context>0?l(p.lines.slice(-i.context)):[],c-=f.length,d-=f.length)}(o=f).push.apply(o,_(a.map((function(e){return(t.added?"+":"-")+e})))),t.added?h+=a.length:m+=a.length}else{if(c)if(a.length<=2*i.context&&e<s.length-2){var v;(v=f).push.apply(v,_(l(a)))}else{var b,y=Math.min(a.length,i.context);(b=f).push.apply(b,_(l(a.slice(0,y))));var g={oldStart:c,oldLines:m-c+y,newStart:d,newLines:h-d+y,lines:f};if(e>=s.length-2&&a.length<=i.context){var w=/\n$/.test(n),S=/\n$/.test(r),C=0==a.length&&f.length>g.oldLines;!w&&C&&f.splice(g.oldLines,0,"\\ No newline at end of file"),(w||C)&&S||f.push("\\ No newline at end of file")}u.push(g),c=0,d=0,f=[]}m+=a.length,h+=a.length}},b=0;b<s.length;b++)v(b);return{oldFileName:e,newFileName:t,oldHeader:a,newHeader:o,hunks:u}}function I(e,t,n,r,a,o,i){var s=M(e,t,n,r,a,o,i),l=[];e==t&&l.push("Index: "+e),l.push("==================================================================="),l.push("--- "+s.oldFileName+("undefined"===typeof s.oldHeader?"":"\t"+s.oldHeader)),l.push("+++ "+s.newFileName+("undefined"===typeof s.newHeader?"":"\t"+s.newHeader));for(var u=0;u<s.hunks.length;u++){var c=s.hunks[u];l.push("@@ -"+c.oldStart+","+c.oldLines+" +"+c.newStart+","+c.newLines+" @@"),l.push.apply(l,c.lines)}return l.join("\n")+"\n"}function z(e,t,n,r,a,o){return I(e,e,t,n,r,a,o)}function L(e,t){return e.length===t.length&&D(e,t)}function D(e,t){if(t.length>e.length)return!1;for(var n=0;n<t.length;n++)if(t[n]!==e[n])return!1;return!0}function j(e){var t=ne(e.lines),n=t.oldLines,r=t.newLines;void 0!==n?e.oldLines=n:delete e.oldLines,void 0!==r?e.newLines=r:delete e.newLines}function Z(e,t,n){e=B(e,n),t=B(t,n);var r={};(e.index||t.index)&&(r.index=e.index||t.index),(e.newFileName||t.newFileName)&&(W(e)?W(t)?(r.oldFileName=U(r,e.oldFileName,t.oldFileName),r.newFileName=U(r,e.newFileName,t.newFileName),r.oldHeader=U(r,e.oldHeader,t.oldHeader),r.newHeader=U(r,e.newHeader,t.newHeader)):(r.oldFileName=e.oldFileName,r.newFileName=e.newFileName,r.oldHeader=e.oldHeader,r.newHeader=e.newHeader):(r.oldFileName=t.oldFileName||e.oldFileName,r.newFileName=t.newFileName||e.newFileName,r.oldHeader=t.oldHeader||e.oldHeader,r.newHeader=t.newHeader||e.newHeader)),r.hunks=[];for(var a=0,o=0,i=0,s=0;a<e.hunks.length||o<t.hunks.length;){var l=e.hunks[a]||{oldStart:1/0},u=t.hunks[o]||{oldStart:1/0};if(V(l,u))r.hunks.push(G(l,i)),a++,s+=l.newLines-l.oldLines;else if(V(u,l))r.hunks.push(G(u,s)),o++,i+=u.newLines-u.oldLines;else{var c={oldStart:Math.min(l.oldStart,u.oldStart),oldLines:0,newStart:Math.min(l.newStart+i,u.oldStart+s),newLines:0,lines:[]};H(c,l.oldStart,l.lines,u.oldStart,u.lines),o++,a++,r.hunks.push(c)}}return r}function B(e,t){if("string"===typeof e){if(/^@@/m.test(e)||/^Index:/m.test(e))return R(e)[0];if(!t)throw new Error("Must provide a base reference or pass in a patch");return M(void 0,void 0,t,e)}return e}function W(e){return e.newFileName&&e.newFileName!==e.oldFileName}function U(e,t,n){return t===n?t:(e.conflict=!0,{mine:t,theirs:n})}function V(e,t){return e.oldStart<t.oldStart&&e.oldStart+e.oldLines<t.oldStart}function G(e,t){return{oldStart:e.oldStart,oldLines:e.oldLines,newStart:e.newStart+t,newLines:e.newLines,lines:e.lines}}function H(e,t,n,r,a){var o={offset:t,lines:n,index:0},i={offset:r,lines:a,index:0};for(K(e,o,i),K(e,i,o);o.index<o.lines.length&&i.index<i.lines.length;){var s=o.lines[o.index],l=i.lines[i.index];if("-"!==s[0]&&"+"!==s[0]||"-"!==l[0]&&"+"!==l[0])if("+"===s[0]&&" "===l[0]){var u;(u=e.lines).push.apply(u,_(Y(o)))}else if("+"===l[0]&&" "===s[0]){var c;(c=e.lines).push.apply(c,_(Y(i)))}else"-"===s[0]&&" "===l[0]?J(e,o,i):"-"===l[0]&&" "===s[0]?J(e,i,o,!0):s===l?(e.lines.push(s),o.index++,i.index++):q(e,Y(o),Y(i));else $(e,o,i)}Q(e,o),Q(e,i),j(e)}function $(e,t,n){var r=Y(t),a=Y(n);if(ee(r)&&ee(a)){var o,i;if(D(r,a)&&te(n,r,r.length-a.length))return void(o=e.lines).push.apply(o,_(r));if(D(a,r)&&te(t,a,a.length-r.length))return void(i=e.lines).push.apply(i,_(a))}else if(L(r,a)){var s;return void(s=e.lines).push.apply(s,_(r))}q(e,r,a)}function J(e,t,n,r){var a,o=Y(t),i=X(n,o);i.merged?(a=e.lines).push.apply(a,_(i.merged)):q(e,r?i:o,r?o:i)}function q(e,t,n){e.conflict=!0,e.lines.push({conflict:!0,mine:t,theirs:n})}function K(e,t,n){for(;t.offset<n.offset&&t.index<t.lines.length;){var r=t.lines[t.index++];e.lines.push(r),t.offset++}}function Q(e,t){for(;t.index<t.lines.length;){var n=t.lines[t.index++];e.lines.push(n)}}function Y(e){for(var t=[],n=e.lines[e.index][0];e.index<e.lines.length;){var r=e.lines[e.index];if("-"===n&&"+"===r[0]&&(n="+"),n!==r[0])break;t.push(r),e.index++}return t}function X(e,t){for(var n=[],r=[],a=0,o=!1,i=!1;a<t.length&&e.index<e.lines.length;){var s=e.lines[e.index],l=t[a];if("+"===l[0])break;if(o=o||" "!==s[0],r.push(l),a++,"+"===s[0])for(i=!0;"+"===s[0];)n.push(s),s=e.lines[++e.index];l.substr(1)===s.substr(1)?(n.push(s),e.index++):i=!0}if("+"===(t[a]||"")[0]&&o&&(i=!0),i)return n;for(;a<t.length;)r.push(t[a++]);return{merged:r,changes:n}}function ee(e){return e.reduce((function(e,t){return e&&"-"===t[0]}),!0)}function te(e,t,n){for(var r=0;r<n;r++){var a=t[t.length-n+r].substr(1);if(e.lines[e.index+r]!==" "+a)return!1}return e.index+=n,!0}function ne(e){var t=0,n=0;return e.forEach((function(e){if("string"!==typeof e){var r=ne(e.mine),a=ne(e.theirs);void 0!==t&&(r.oldLines===a.oldLines?t+=r.oldLines:t=void 0),void 0!==n&&(r.newLines===a.newLines?n+=r.newLines:n=void 0)}else void 0===n||"+"!==e[0]&&" "!==e[0]||n++,void 0===t||"-"!==e[0]&&" "!==e[0]||t++})),{oldLines:t,newLines:n}}function re(e){for(var t,n,r=[],a=0;a<e.length;a++)n=(t=e[a]).added?1:t.removed?-1:0,r.push([n,t.value]);return r}function ae(e){for(var t=[],n=0;n<e.length;n++){var r=e[n];r.added?t.push("<ins>"):r.removed&&t.push("<del>"),t.push(oe(r.value)),r.added?t.push("</ins>"):r.removed&&t.push("</del>")}return t.join("")}function oe(e){var t=e;return t=(t=(t=(t=t.replace(/&/g,"&amp;")).replace(/</g,"&lt;")).replace(/>/g,"&gt;")).replace(/"/g,"&quot;")}P.tokenize=function(e){return e.slice()},P.join=P.removeEmpty=function(e){return e},e.Diff=t,e.diffChars=o,e.diffWords=c,e.diffWordsWithSpace=d,e.diffLines=p,e.diffTrimmedLines=m,e.diffSentences=v,e.diffCss=y,e.diffJson=x,e.diffArrays=A,e.structuredPatch=M,e.createTwoFilesPatch=I,e.createPatch=z,e.applyPatch=O,e.applyPatches=N,e.parsePatch=R,e.merge=Z,e.convertChangesToDMP=re,e.convertChangesToXML=ae,e.canonicalize=E,Object.defineProperty(e,"__esModule",{value:!0})}(t)},6025:function(e,t,n){"use strict";n.r(t),n.d(t,{cache:function(){return j},css:function(){return L},cx:function(){return O},flush:function(){return R},getRegisteredStyles:function(){return M},hydrate:function(){return F},injectGlobal:function(){return I},keyframes:function(){return z},merge:function(){return N},sheet:function(){return D}});var r=function(){function e(e){this.isSpeedy=void 0===e.speedy||e.speedy,this.tags=[],this.ctr=0,this.nonce=e.nonce,this.key=e.key,this.container=e.container,this.before=null}var t=e.prototype;return t.insert=function(e){if(this.ctr%(this.isSpeedy?65e3:1)===0){var t,n=function(e){var t=document.createElement("style");return t.setAttribute("data-emotion",e.key),void 0!==e.nonce&&t.setAttribute("nonce",e.nonce),t.appendChild(document.createTextNode("")),t}(this);t=0===this.tags.length?this.before:this.tags[this.tags.length-1].nextSibling,this.container.insertBefore(n,t),this.tags.push(n)}var r=this.tags[this.tags.length-1];if(this.isSpeedy){var a=function(e){if(e.sheet)return e.sheet;for(var t=0;t<document.styleSheets.length;t++)if(document.styleSheets[t].ownerNode===e)return document.styleSheets[t]}(r);try{var o=105===e.charCodeAt(1)&&64===e.charCodeAt(0);a.insertRule(e,o?0:a.cssRules.length)}catch(i){0}}else r.appendChild(document.createTextNode(e));this.ctr++},t.flush=function(){this.tags.forEach((function(e){return e.parentNode.removeChild(e)})),this.tags=[],this.ctr=0},e}();var a=function(e){function t(e,r,l,u,f){for(var p,m,h,v,_,S=0,C=0,k=0,T=0,x=0,O=0,M=h=p=0,z=0,L=0,D=0,j=0,Z=l.length,B=Z-1,W="",U="",V="",G="";z<Z;){if(m=l.charCodeAt(z),z===B&&0!==C+T+k+S&&(0!==C&&(m=47===C?10:47),T=k=S=0,Z++,B++),0===C+T+k+S){if(z===B&&(0<L&&(W=W.replace(d,"")),0<W.trim().length)){switch(m){case 32:case 9:case 59:case 13:case 10:break;default:W+=l.charAt(z)}m=59}switch(m){case 123:for(p=(W=W.trim()).charCodeAt(0),h=1,j=++z;z<Z;){switch(m=l.charCodeAt(z)){case 123:h++;break;case 125:h--;break;case 47:switch(m=l.charCodeAt(z+1)){case 42:case 47:e:{for(M=z+1;M<B;++M)switch(l.charCodeAt(M)){case 47:if(42===m&&42===l.charCodeAt(M-1)&&z+2!==M){z=M+1;break e}break;case 10:if(47===m){z=M+1;break e}}z=M}}break;case 91:m++;case 40:m++;case 34:case 39:for(;z++<B&&l.charCodeAt(z)!==m;);}if(0===h)break;z++}if(h=l.substring(j,z),0===p&&(p=(W=W.replace(c,"").trim()).charCodeAt(0)),64===p){switch(0<L&&(W=W.replace(d,"")),m=W.charCodeAt(1)){case 100:case 109:case 115:case 45:L=r;break;default:L=F}if(j=(h=t(r,L,h,m,f+1)).length,0<N&&(_=s(3,h,L=n(F,W,D),r,P,E,j,m,f,u),W=L.join(""),void 0!==_&&0===(j=(h=_.trim()).length)&&(m=0,h="")),0<j)switch(m){case 115:W=W.replace(w,i);case 100:case 109:case 45:h=W+"{"+h+"}";break;case 107:h=(W=W.replace(b,"$1 $2"))+"{"+h+"}",h=1===R||2===R&&o("@"+h,3)?"@-webkit-"+h+"@"+h:"@"+h;break;default:h=W+h,112===u&&(U+=h,h="")}else h=""}else h=t(r,n(r,W,D),h,u,f+1);V+=h,h=D=L=M=p=0,W="",m=l.charCodeAt(++z);break;case 125:case 59:if(1<(j=(W=(0<L?W.replace(d,""):W).trim()).length))switch(0===M&&(p=W.charCodeAt(0),45===p||96<p&&123>p)&&(j=(W=W.replace(" ",":")).length),0<N&&void 0!==(_=s(1,W,r,e,P,E,U.length,u,f,u))&&0===(j=(W=_.trim()).length)&&(W="\0\0"),p=W.charCodeAt(0),m=W.charCodeAt(1),p){case 0:break;case 64:if(105===m||99===m){G+=W+l.charAt(z);break}default:58!==W.charCodeAt(j-1)&&(U+=a(W,p,m,W.charCodeAt(2)))}D=L=M=p=0,W="",m=l.charCodeAt(++z)}}switch(m){case 13:case 10:47===C?C=0:0===1+p&&107!==u&&0<W.length&&(L=1,W+="\0"),0<N*I&&s(0,W,r,e,P,E,U.length,u,f,u),E=1,P++;break;case 59:case 125:if(0===C+T+k+S){E++;break}default:switch(E++,v=l.charAt(z),m){case 9:case 32:if(0===T+S+C)switch(x){case 44:case 58:case 9:case 32:v="";break;default:32!==m&&(v=" ")}break;case 0:v="\\0";break;case 12:v="\\f";break;case 11:v="\\v";break;case 38:0===T+C+S&&(L=D=1,v="\f"+v);break;case 108:if(0===T+C+S+A&&0<M)switch(z-M){case 2:112===x&&58===l.charCodeAt(z-3)&&(A=x);case 8:111===O&&(A=O)}break;case 58:0===T+C+S&&(M=z);break;case 44:0===C+k+T+S&&(L=1,v+="\r");break;case 34:case 39:0===C&&(T=T===m?0:0===T?m:T);break;case 91:0===T+C+k&&S++;break;case 93:0===T+C+k&&S--;break;case 41:0===T+C+S&&k--;break;case 40:if(0===T+C+S){if(0===p)if(2*x+3*O===533);else p=1;k++}break;case 64:0===C+k+T+S+M+h&&(h=1);break;case 42:case 47:if(!(0<T+S+k))switch(C){case 0:switch(2*m+3*l.charCodeAt(z+1)){case 235:C=47;break;case 220:j=z,C=42}break;case 42:47===m&&42===x&&j+2!==z&&(33===l.charCodeAt(j+2)&&(U+=l.substring(j,z+1)),v="",C=0)}}0===C&&(W+=v)}O=x,x=m,z++}if(0<(j=U.length)){if(L=r,0<N&&(void 0!==(_=s(2,U,L,e,P,E,j,u,f,u))&&0===(U=_).length))return G+U+V;if(U=L.join(",")+"{"+U+"}",0!==R*A){switch(2!==R||o(U,2)||(A=0),A){case 111:U=U.replace(g,":-moz-$1")+U;break;case 112:U=U.replace(y,"::-webkit-input-$1")+U.replace(y,"::-moz-$1")+U.replace(y,":-ms-input-$1")+U}A=0}}return G+U+V}function n(e,t,n){var a=t.trim().split(h);t=a;var o=a.length,i=e.length;switch(i){case 0:case 1:var s=0;for(e=0===i?"":e[0]+" ";s<o;++s)t[s]=r(e,t[s],n).trim();break;default:var l=s=0;for(t=[];s<o;++s)for(var u=0;u<i;++u)t[l++]=r(e[u]+" ",a[s],n).trim()}return t}function r(e,t,n){var r=t.charCodeAt(0);switch(33>r&&(r=(t=t.trim()).charCodeAt(0)),r){case 38:return t.replace(v,"$1"+e.trim());case 58:return e.trim()+t.replace(v,"$1"+e.trim());default:if(0<1*n&&0<t.indexOf("\f"))return t.replace(v,(58===e.charCodeAt(0)?"":"$1")+e.trim())}return e+t}function a(e,t,n,r){var i=e+";",s=2*t+3*n+4*r;if(944===s){e=i.indexOf(":",9)+1;var l=i.substring(e,i.length-1).trim();return l=i.substring(0,e).trim()+l+";",1===R||2===R&&o(l,1)?"-webkit-"+l+l:l}if(0===R||2===R&&!o(i,1))return i;switch(s){case 1015:return 97===i.charCodeAt(10)?"-webkit-"+i+i:i;case 951:return 116===i.charCodeAt(3)?"-webkit-"+i+i:i;case 963:return 110===i.charCodeAt(5)?"-webkit-"+i+i:i;case 1009:if(100!==i.charCodeAt(4))break;case 969:case 942:return"-webkit-"+i+i;case 978:return"-webkit-"+i+"-moz-"+i+i;case 1019:case 983:return"-webkit-"+i+"-moz-"+i+"-ms-"+i+i;case 883:if(45===i.charCodeAt(8))return"-webkit-"+i+i;if(0<i.indexOf("image-set(",11))return i.replace(x,"$1-webkit-$2")+i;break;case 932:if(45===i.charCodeAt(4))switch(i.charCodeAt(5)){case 103:return"-webkit-box-"+i.replace("-grow","")+"-webkit-"+i+"-ms-"+i.replace("grow","positive")+i;case 115:return"-webkit-"+i+"-ms-"+i.replace("shrink","negative")+i;case 98:return"-webkit-"+i+"-ms-"+i.replace("basis","preferred-size")+i}return"-webkit-"+i+"-ms-"+i+i;case 964:return"-webkit-"+i+"-ms-flex-"+i+i;case 1023:if(99!==i.charCodeAt(8))break;return"-webkit-box-pack"+(l=i.substring(i.indexOf(":",15)).replace("flex-","").replace("space-between","justify"))+"-webkit-"+i+"-ms-flex-pack"+l+i;case 1005:return p.test(i)?i.replace(f,":-webkit-")+i.replace(f,":-moz-")+i:i;case 1e3:switch(t=(l=i.substring(13).trim()).indexOf("-")+1,l.charCodeAt(0)+l.charCodeAt(t)){case 226:l=i.replace(_,"tb");break;case 232:l=i.replace(_,"tb-rl");break;case 220:l=i.replace(_,"lr");break;default:return i}return"-webkit-"+i+"-ms-"+l+i;case 1017:if(-1===i.indexOf("sticky",9))break;case 975:switch(t=(i=e).length-10,s=(l=(33===i.charCodeAt(t)?i.substring(0,t):i).substring(e.indexOf(":",7)+1).trim()).charCodeAt(0)+(0|l.charCodeAt(7))){case 203:if(111>l.charCodeAt(8))break;case 115:i=i.replace(l,"-webkit-"+l)+";"+i;break;case 207:case 102:i=i.replace(l,"-webkit-"+(102<s?"inline-":"")+"box")+";"+i.replace(l,"-webkit-"+l)+";"+i.replace(l,"-ms-"+l+"box")+";"+i}return i+";";case 938:if(45===i.charCodeAt(5))switch(i.charCodeAt(6)){case 105:return l=i.replace("-items",""),"-webkit-"+i+"-webkit-box-"+l+"-ms-flex-"+l+i;case 115:return"-webkit-"+i+"-ms-flex-item-"+i.replace(C,"")+i;default:return"-webkit-"+i+"-ms-flex-line-pack"+i.replace("align-content","").replace(C,"")+i}break;case 973:case 989:if(45!==i.charCodeAt(3)||122===i.charCodeAt(4))break;case 931:case 953:if(!0===T.test(e))return 115===(l=e.substring(e.indexOf(":")+1)).charCodeAt(0)?a(e.replace("stretch","fill-available"),t,n,r).replace(":fill-available",":stretch"):i.replace(l,"-webkit-"+l)+i.replace(l,"-moz-"+l.replace("fill-",""))+i;break;case 962:if(i="-webkit-"+i+(102===i.charCodeAt(5)?"-ms-"+i:"")+i,211===n+r&&105===i.charCodeAt(13)&&0<i.indexOf("transform",10))return i.substring(0,i.indexOf(";",27)+1).replace(m,"$1-webkit-$2")+i}return i}function o(e,t){var n=e.indexOf(1===t?":":"{"),r=e.substring(0,3!==t?n:10);return n=e.substring(n+1,e.length-1),M(2!==t?r:r.replace(k,"$1"),n,t)}function i(e,t){var n=a(t,t.charCodeAt(0),t.charCodeAt(1),t.charCodeAt(2));return n!==t+";"?n.replace(S," or ($1)").substring(4):"("+t+")"}function s(e,t,n,r,a,o,i,s,l,c){for(var d,f=0,p=t;f<N;++f)switch(d=O[f].call(u,e,p,n,r,a,o,i,s,l,c)){case void 0:case!1:case!0:case null:break;default:p=d}if(p!==t)return p}function l(e){return void 0!==(e=e.prefix)&&(M=null,e?"function"!==typeof e?R=1:(R=2,M=e):R=0),l}function u(e,n){var r=e;if(33>r.charCodeAt(0)&&(r=r.trim()),r=[r],0<N){var a=s(-1,n,r,r,P,E,0,0,0,0);void 0!==a&&"string"===typeof a&&(n=a)}var o=t(F,r,n,0,0);return 0<N&&(void 0!==(a=s(-2,o,r,r,P,E,o.length,0,0,0))&&(o=a)),"",A=0,E=P=1,o}var c=/^\0+/g,d=/[\0\r\f]/g,f=/: */g,p=/zoo|gra/,m=/([,: ])(transform)/g,h=/,\r+?/g,v=/([\t\r\n ])*\f?&/g,b=/@(k\w+)\s*(\S*)\s*/,y=/::(place)/g,g=/:(read-only)/g,_=/[svh]\w+-[tblr]{2}/,w=/\(\s*(.*)\s*\)/g,S=/([\s\S]*?);/g,C=/-self|flex-/g,k=/[^]*?(:[rp][el]a[\w-]+)[^]*/,T=/stretch|:\s*\w+\-(?:conte|avail)/,x=/([^-])(image-set\()/,E=1,P=1,A=0,R=1,F=[],O=[],N=0,M=null,I=0;return u.use=function e(t){switch(t){case void 0:case null:N=O.length=0;break;default:if("function"===typeof t)O[N++]=t;else if("object"===typeof t)for(var n=0,r=t.length;n<r;++n)e(t[n]);else I=0|!!t}return e},u.set=l,void 0!==e&&l(e),u},o="/*|*/";function i(e){e&&s.current.insert(e+"}")}var s={current:null},l=function(e,t,n,r,a,l,u,c,d,f){switch(e){case 1:switch(t.charCodeAt(0)){case 64:return s.current.insert(t+";"),"";case 108:if(98===t.charCodeAt(2))return""}break;case 2:if(0===c)return t+o;break;case 3:switch(c){case 102:case 112:return s.current.insert(n[0]+t),"";default:return t+(0===f?o:"")}case-2:t.split("/*|*/}").forEach(i)}},u=function(e){void 0===e&&(e={});var t,n=e.key||"css";void 0!==e.prefix&&(t={prefix:e.prefix});var o=new a(t);var i,u={};i=e.container||document.head;var c,d=document.querySelectorAll("style[data-emotion-"+n+"]");Array.prototype.forEach.call(d,(function(e){e.getAttribute("data-emotion-"+n).split(" ").forEach((function(e){u[e]=!0})),e.parentNode!==i&&i.appendChild(e)})),o.use(e.stylisPlugins)(l),c=function(e,t,n,r){var a=t.name;s.current=n,o(e,t.styles),r&&(f.inserted[a]=!0)};var f={key:n,sheet:new r({key:n,container:i,nonce:e.nonce,speedy:e.speedy}),nonce:e.nonce,inserted:u,registered:{},insert:c};return f};var c=function(e){for(var t,n=0,r=0,a=e.length;a>=4;++r,a-=4)t=1540483477*(65535&(t=255&e.charCodeAt(r)|(255&e.charCodeAt(++r))<<8|(255&e.charCodeAt(++r))<<16|(255&e.charCodeAt(++r))<<24))+(59797*(t>>>16)<<16),n=1540483477*(65535&(t^=t>>>24))+(59797*(t>>>16)<<16)^1540483477*(65535&n)+(59797*(n>>>16)<<16);switch(a){case 3:n^=(255&e.charCodeAt(r+2))<<16;case 2:n^=(255&e.charCodeAt(r+1))<<8;case 1:n=1540483477*(65535&(n^=255&e.charCodeAt(r)))+(59797*(n>>>16)<<16)}return(((n=1540483477*(65535&(n^=n>>>13))+(59797*(n>>>16)<<16))^n>>>15)>>>0).toString(36)},d={animationIterationCount:1,borderImageOutset:1,borderImageSlice:1,borderImageWidth:1,boxFlex:1,boxFlexGroup:1,boxOrdinalGroup:1,columnCount:1,columns:1,flex:1,flexGrow:1,flexPositive:1,flexShrink:1,flexNegative:1,flexOrder:1,gridRow:1,gridRowEnd:1,gridRowSpan:1,gridRowStart:1,gridColumn:1,gridColumnEnd:1,gridColumnSpan:1,gridColumnStart:1,msGridRow:1,msGridRowSpan:1,msGridColumn:1,msGridColumnSpan:1,fontWeight:1,lineHeight:1,opacity:1,order:1,orphans:1,tabSize:1,widows:1,zIndex:1,zoom:1,WebkitLineClamp:1,fillOpacity:1,floodOpacity:1,stopOpacity:1,strokeDasharray:1,strokeDashoffset:1,strokeMiterlimit:1,strokeOpacity:1,strokeWidth:1};var f=function(e){var t={};return function(n){return void 0===t[n]&&(t[n]=e(n)),t[n]}},p=/[A-Z]|^ms/g,m=/_EMO_([^_]+?)_([^]*?)_EMO_/g,h=function(e){return 45===e.charCodeAt(1)},v=function(e){return null!=e&&"boolean"!==typeof e},b=f((function(e){return h(e)?e:e.replace(p,"-$&").toLowerCase()})),y=function(e,t){switch(e){case"animation":case"animationName":if("string"===typeof t)return t.replace(m,(function(e,t,n){return _={name:t,styles:n,next:_},t}))}return 1===d[e]||h(e)||"number"!==typeof t||0===t?t:t+"px"};function g(e,t,n,r){if(null==n)return"";if(void 0!==n.__emotion_styles)return n;switch(typeof n){case"boolean":return"";case"object":if(1===n.anim)return _={name:n.name,styles:n.styles,next:_},n.name;if(void 0!==n.styles){var a=n.next;if(void 0!==a)for(;void 0!==a;)_={name:a.name,styles:a.styles,next:_},a=a.next;return n.styles+";"}return function(e,t,n){var r="";if(Array.isArray(n))for(var a=0;a<n.length;a++)r+=g(e,t,n[a],!1);else for(var o in n){var i=n[o];if("object"!==typeof i)null!=t&&void 0!==t[i]?r+=o+"{"+t[i]+"}":v(i)&&(r+=b(o)+":"+y(o,i)+";");else if(!Array.isArray(i)||"string"!==typeof i[0]||null!=t&&void 0!==t[i[0]]){var s=g(e,t,i,!1);switch(o){case"animation":case"animationName":r+=b(o)+":"+s+";";break;default:r+=o+"{"+s+"}"}}else for(var l=0;l<i.length;l++)v(i[l])&&(r+=b(o)+":"+y(o,i[l])+";")}return r}(e,t,n);case"function":if(void 0!==e){var o=_,i=n(e);return _=o,g(e,t,i,r)}}if(null==t)return n;var s=t[n];return void 0===s||r?n:s}var _,w=/label:\s*([^\s;\n{]+)\s*;/g;var S=function(e,t,n){if(1===e.length&&"object"===typeof e[0]&&null!==e[0]&&void 0!==e[0].styles)return e[0];var r=!0,a="";_=void 0;var o=e[0];null==o||void 0===o.raw?(r=!1,a+=g(n,t,o,!1)):a+=o[0];for(var i=1;i<e.length;i++)a+=g(n,t,e[i],46===a.charCodeAt(a.length-1)),r&&(a+=o[i]);w.lastIndex=0;for(var s,l="";null!==(s=w.exec(a));)l+="-"+s[1];return{name:c(a)+l,styles:a,next:_}};function C(e,t,n){var r="";return n.split(" ").forEach((function(n){void 0!==e[n]?t.push(e[n]):r+=n+" "})),r}var k=function(e,t,n){var r=e.key+"-"+t.name;if(!1===n&&void 0===e.registered[r]&&(e.registered[r]=t.styles),void 0===e.inserted[t.name]){var a=t;do{e.insert("."+r,a,e.sheet,!0);a=a.next}while(void 0!==a)}};function T(e,t){if(void 0===e.inserted[t.name])return e.insert("",t,e.sheet,!0)}function x(e,t,n){var r=[],a=C(e,r,n);return r.length<2?n:a+t(r)}var E=function e(t){for(var n="",r=0;r<t.length;r++){var a=t[r];if(null!=a){var o=void 0;switch(typeof a){case"boolean":break;case"object":if(Array.isArray(a))o=e(a);else for(var i in o="",a)a[i]&&i&&(o&&(o+=" "),o+=i);break;default:o=a}o&&(n&&(n+=" "),n+=o)}}return n},P=function(e){var t=u(e);t.sheet.speedy=function(e){this.isSpeedy=e},t.compat=!0;var n=function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=S(n,t.registered,void 0);return k(t,a,!1),t.key+"-"+a.name};return{css:n,cx:function(){for(var e=arguments.length,r=new Array(e),a=0;a<e;a++)r[a]=arguments[a];return x(t.registered,n,E(r))},injectGlobal:function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=S(n,t.registered);T(t,a)},keyframes:function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=S(n,t.registered),o="animation-"+a.name;return T(t,{name:a.name,styles:"@keyframes "+o+"{"+a.styles+"}"}),o},hydrate:function(e){e.forEach((function(e){t.inserted[e]=!0}))},flush:function(){t.registered={},t.inserted={},t.sheet.flush()},sheet:t.sheet,cache:t,getRegisteredStyles:C.bind(null,t.registered),merge:x.bind(null,t.registered,n)}},A=P(),R=A.flush,F=A.hydrate,O=A.cx,N=A.merge,M=A.getRegisteredStyles,I=A.injectGlobal,z=A.keyframes,L=A.css,D=A.sheet,j=A.cache},2110:function(e,t,n){"use strict";var r=n(8309),a={childContextTypes:!0,contextType:!0,contextTypes:!0,defaultProps:!0,displayName:!0,getDefaultProps:!0,getDerivedStateFromError:!0,getDerivedStateFromProps:!0,mixins:!0,propTypes:!0,type:!0},o={name:!0,length:!0,prototype:!0,caller:!0,callee:!0,arguments:!0,arity:!0},i={$$typeof:!0,compare:!0,defaultProps:!0,displayName:!0,propTypes:!0,type:!0},s={};function l(e){return r.isMemo(e)?i:s[e.$$typeof]||a}s[r.ForwardRef]={$$typeof:!0,render:!0,defaultProps:!0,displayName:!0,propTypes:!0},s[r.Memo]=i;var u=Object.defineProperty,c=Object.getOwnPropertyNames,d=Object.getOwnPropertySymbols,f=Object.getOwnPropertyDescriptor,p=Object.getPrototypeOf,m=Object.prototype;e.exports=function e(t,n,r){if("string"!==typeof n){if(m){var a=p(n);a&&a!==m&&e(t,a,r)}var i=c(n);d&&(i=i.concat(d(n)));for(var s=l(t),h=l(n),v=0;v<i.length;++v){var b=i[v];if(!o[b]&&(!r||!r[b])&&(!h||!h[b])&&(!s||!s[b])){var y=f(n,b);try{u(t,b,y)}catch(g){}}}}return t}},746:function(e,t){"use strict";var n="function"===typeof Symbol&&Symbol.for,r=n?Symbol.for("react.element"):60103,a=n?Symbol.for("react.portal"):60106,o=n?Symbol.for("react.fragment"):60107,i=n?Symbol.for("react.strict_mode"):60108,s=n?Symbol.for("react.profiler"):60114,l=n?Symbol.for("react.provider"):60109,u=n?Symbol.for("react.context"):60110,c=n?Symbol.for("react.async_mode"):60111,d=n?Symbol.for("react.concurrent_mode"):60111,f=n?Symbol.for("react.forward_ref"):60112,p=n?Symbol.for("react.suspense"):60113,m=n?Symbol.for("react.suspense_list"):60120,h=n?Symbol.for("react.memo"):60115,v=n?Symbol.for("react.lazy"):60116,b=n?Symbol.for("react.block"):60121,y=n?Symbol.for("react.fundamental"):60117,g=n?Symbol.for("react.responder"):60118,_=n?Symbol.for("react.scope"):60119;function w(e){if("object"===typeof e&&null!==e){var t=e.$$typeof;switch(t){case r:switch(e=e.type){case c:case d:case o:case s:case i:case p:return e;default:switch(e=e&&e.$$typeof){case u:case f:case v:case h:case l:return e;default:return t}}case a:return t}}}function S(e){return w(e)===d}t.AsyncMode=c,t.ConcurrentMode=d,t.ContextConsumer=u,t.ContextProvider=l,t.Element=r,t.ForwardRef=f,t.Fragment=o,t.Lazy=v,t.Memo=h,t.Portal=a,t.Profiler=s,t.StrictMode=i,t.Suspense=p,t.isAsyncMode=function(e){return S(e)||w(e)===c},t.isConcurrentMode=S,t.isContextConsumer=function(e){return w(e)===u},t.isContextProvider=function(e){return w(e)===l},t.isElement=function(e){return"object"===typeof e&&null!==e&&e.$$typeof===r},t.isForwardRef=function(e){return w(e)===f},t.isFragment=function(e){return w(e)===o},t.isLazy=function(e){return w(e)===v},t.isMemo=function(e){return w(e)===h},t.isPortal=function(e){return w(e)===a},t.isProfiler=function(e){return w(e)===s},t.isStrictMode=function(e){return w(e)===i},t.isSuspense=function(e){return w(e)===p},t.isValidElementType=function(e){return"string"===typeof e||"function"===typeof e||e===o||e===d||e===s||e===i||e===p||e===m||"object"===typeof e&&null!==e&&(e.$$typeof===v||e.$$typeof===h||e.$$typeof===l||e.$$typeof===u||e.$$typeof===f||e.$$typeof===y||e.$$typeof===g||e.$$typeof===_||e.$$typeof===b)},t.typeOf=w},8309:function(e,t,n){"use strict";e.exports=n(746)},5781:function(e,t,n){"use strict";n.r(t);var r=Number.isNaN||function(e){return"number"===typeof e&&e!==e};function a(e,t){if(e.length!==t.length)return!1;for(var n=0;n<e.length;n++)if(a=e[n],o=t[n],!(a===o||r(a)&&r(o)))return!1;var a,o;return!0}t.default=function(e,t){var n;void 0===t&&(t=a);var r,o=[],i=!1;return function(){for(var a=[],s=0;s<arguments.length;s++)a[s]=arguments[s];return i&&n===this&&t(a,o)||(r=e.apply(this,a),i=!0,n=this,o=a),r}}},888:function(e,t,n){"use strict";var r=n(9047);function a(){}function o(){}o.resetWarningCache=a,e.exports=function(){function e(e,t,n,a,o,i){if(i!==r){var s=new Error("Calling PropTypes validators directly is not supported by the `prop-types` package. Use PropTypes.checkPropTypes() to call them. Read more at http://fb.me/use-check-prop-types");throw s.name="Invariant Violation",s}}function t(){return e}e.isRequired=e;var n={array:e,bigint:e,bool:e,func:e,number:e,object:e,string:e,symbol:e,any:e,arrayOf:t,element:e,elementType:e,instanceOf:t,node:e,objectOf:t,oneOf:t,oneOfType:t,shape:t,exact:t,checkPropTypes:o,resetWarningCache:a};return n.PropTypes=n,n}},2007:function(e,t,n){e.exports=n(888)()},9047:function(e){"use strict";e.exports="SECRET_DO_NOT_PASS_THIS_OR_YOU_WILL_BE_FIRED"},8472:function(e,t,n){n(3561)},8015:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0});var r,a=function(){function e(e,t){for(var n=0;n<t.length;n++){var r=t[n];r.enumerable=r.enumerable||!1,r.configurable=!0,"value"in r&&(r.writable=!0),Object.defineProperty(e,r.key,r)}}return function(t,n,r){return n&&e(t.prototype,n),r&&e(t,r),t}}(),o=n(2791),i=(r=o)&&r.__esModule?r:{default:r},s=n(1509),l=n(8333);var u=function(e){function t(e){!function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}(this,t);var n=function(e,t){if(!e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return!t||"object"!==typeof t&&"function"!==typeof t?e:t}(this,(t.__proto__||Object.getPrototypeOf(t)).call(this,e));return n.state={},n}return function(e,t){if("function"!==typeof t&&null!==t)throw new TypeError("Super expression must either be null or a function, not "+typeof t);e.prototype=Object.create(t&&t.prototype,{constructor:{value:e,enumerable:!1,writable:!0,configurable:!0}}),t&&(Object.setPrototypeOf?Object.setPrototypeOf(e,t):e.__proto__=t)}(t,e),a(t,[{key:"buildURI",value:function(){return s.buildURI.apply(void 0,arguments)}},{key:"componentDidMount",value:function(){var e=this.props,t=e.data,n=e.headers,r=e.separator,a=e.enclosingCharacter,o=e.uFEFF,i=e.target,s=e.specs,l=e.replace;this.state.page=window.open(this.buildURI(t,o,n,r,a),i,s,l)}},{key:"getWindow",value:function(){return this.state.page}},{key:"render",value:function(){return null}}]),t}(i.default.Component);u.defaultProps=Object.assign(l.defaultProps,{target:"_blank"}),u.propTypes=l.propTypes,t.default=u},9088:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0});var r,a=Object.assign||function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e},o=function(){function e(e,t){for(var n=0;n<t.length;n++){var r=t[n];r.enumerable=r.enumerable||!1,r.configurable=!0,"value"in r&&(r.writable=!0),Object.defineProperty(e,r.key,r)}}return function(t,n,r){return n&&e(t.prototype,n),r&&e(t,r),t}}(),i=n(2791),s=(r=i)&&r.__esModule?r:{default:r},l=n(1509),u=n(8333);var c=function(e){function t(e){!function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}(this,t);var n=function(e,t){if(!e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return!t||"object"!==typeof t&&"function"!==typeof t?e:t}(this,(t.__proto__||Object.getPrototypeOf(t)).call(this,e));return n.buildURI=n.buildURI.bind(n),n}return function(e,t){if("function"!==typeof t&&null!==t)throw new TypeError("Super expression must either be null or a function, not "+typeof t);e.prototype=Object.create(t&&t.prototype,{constructor:{value:e,enumerable:!1,writable:!0,configurable:!0}}),t&&(Object.setPrototypeOf?Object.setPrototypeOf(e,t):e.__proto__=t)}(t,e),o(t,[{key:"buildURI",value:function(){return l.buildURI.apply(void 0,arguments)}},{key:"handleLegacy",value:function(e){var t=arguments.length>1&&void 0!==arguments[1]&&arguments[1];if(window.navigator.msSaveOrOpenBlob){e.preventDefault();var n=this.props,r=n.data,a=n.headers,o=n.separator,i=n.filename,s=n.enclosingCharacter,u=n.uFEFF,c=t&&"function"===typeof r?r():r,d=new Blob([u?"\ufeff":"",(0,l.toCSV)(c,a,o,s)]);return window.navigator.msSaveBlob(d,i),!1}}},{key:"handleAsyncClick",value:function(e){var t=this;this.props.onClick(e,(function(n){!1!==n?t.handleLegacy(e,!0):e.preventDefault()}))}},{key:"handleSyncClick",value:function(e){!1===this.props.onClick(e)?e.preventDefault():this.handleLegacy(e)}},{key:"handleClick",value:function(){var e=this;return function(t){if("function"===typeof e.props.onClick)return e.props.asyncOnClick?e.handleAsyncClick(t):e.handleSyncClick(t);e.handleLegacy(t)}}},{key:"render",value:function(){var e=this,t=this.props,n=t.data,r=t.headers,o=t.separator,i=t.filename,l=t.uFEFF,u=t.children,c=(t.onClick,t.asyncOnClick,t.enclosingCharacter),d=function(e,t){var n={};for(var r in e)t.indexOf(r)>=0||Object.prototype.hasOwnProperty.call(e,r)&&(n[r]=e[r]);return n}(t,["data","headers","separator","filename","uFEFF","children","onClick","asyncOnClick","enclosingCharacter"]),f="undefined"===typeof window?"":this.buildURI(n,l,r,o,c);return s.default.createElement("a",a({download:i},d,{ref:function(t){return e.link=t},target:"_self",href:f,onClick:this.handleClick()}),u)}}]),t}(s.default.Component);c.defaultProps=u.defaultProps,c.propTypes=u.propTypes,t.default=c},1509:function(e,t){"use strict";Object.defineProperty(t,"__esModule",{value:!0});var n="function"===typeof Symbol&&"symbol"===typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"===typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e};function r(e){if(Array.isArray(e)){for(var t=0,n=Array(e.length);t<e.length;t++)n[t]=e[t];return n}return Array.from(e)}var a=t.isSafari=function(){return/^((?!chrome|android).)*safari/i.test(navigator.userAgent)},o=t.isJsons=function(e){return Array.isArray(e)&&e.every((function(e){return"object"===("undefined"===typeof e?"undefined":n(e))&&!(e instanceof Array)}))},i=t.isArrays=function(e){return Array.isArray(e)&&e.every((function(e){return Array.isArray(e)}))},s=t.jsonsHeaders=function(e){return Array.from(e.map((function(e){return Object.keys(e)})).reduce((function(e,t){return new Set([].concat(r(e),r(t)))}),[]))},l=t.jsons2arrays=function(e,t){var n=t=t||s(e),a=t;o(t)&&(n=t.map((function(e){return e.label})),a=t.map((function(e){return e.key})));var i=e.map((function(e){return a.map((function(t){return u(t,e)}))}));return[n].concat(r(i))},u=t.getHeaderValue=function(e,t){var n=e.replace(/\[([^\]]+)]/g,".$1").split(".").reduce((function(e,t,n,r){var a=e[t];if(void 0!==a&&null!==a)return a;r.splice(1)}),t);return void 0===n?e in t?t[e]:"":n},c=t.elementOrEmpty=function(e){return"undefined"===typeof e||null===e?"":e},d=t.joiner=function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:",",n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:'"';return e.filter((function(e){return e})).map((function(e){return e.map((function(e){return c(e)})).map((function(e){return""+n+e+n})).join(t)})).join("\n")},f=t.arrays2csv=function(e,t,n,a){return d(t?[t].concat(r(e)):e,n,a)},p=t.jsons2csv=function(e,t,n,r){return d(l(e,t),n,r)},m=t.string2csv=function(e,t,n,r){return t?t.join(n)+"\n"+e:e.replace(/"/g,'""')},h=t.toCSV=function(e,t,n,r){if(o(e))return p(e,t,n,r);if(i(e))return f(e,t,n,r);if("string"===typeof e)return m(e,t,n);throw new TypeError('Data should be a "String", "Array of arrays" OR "Array of objects" ')};t.buildURI=function(e,t,n,r,o){var i=h(e,n,r,o),s=a()?"application/csv":"text/csv",l=new Blob([t?"\ufeff":"",i],{type:s}),u="data:"+s+";charset=utf-8,"+(t?"\ufeff":"")+i,c=window.URL||window.webkitURL;return"undefined"===typeof c.createObjectURL?u:c.createObjectURL(l)}},3561:function(e,t,n){"use strict";var r=o(n(8015)),a=o(n(9088));function o(e){return e&&e.__esModule?e:{default:e}}r.default,a.default},8333:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0}),t.PropsNotForwarded=t.defaultProps=t.propTypes=void 0;var r,a=n(2791),o=((r=a)&&r.__esModule,n(2007));t.propTypes={data:(0,o.oneOfType)([o.string,o.array,o.func]).isRequired,headers:o.array,target:o.string,separator:o.string,filename:o.string,uFEFF:o.bool,onClick:o.func,asyncOnClick:o.bool,enclosingCharacter:o.string},t.defaultProps={separator:",",filename:"generatedBy_react-csv.csv",uFEFF:!0,asyncOnClick:!1,enclosingCharacter:'"'},t.PropsNotForwarded=["data","headers"]},7786:function(e,t,n){"use strict";var r=this&&this.__read||function(e,t){var n="function"===typeof Symbol&&e[Symbol.iterator];if(!n)return e;var r,a,o=n.call(e),i=[];try{for(;(void 0===t||t-- >0)&&!(r=o.next()).done;)i.push(r.value)}catch(s){a={error:s}}finally{try{r&&!r.done&&(n=o.return)&&n.call(o)}finally{if(a)throw a.error}}return i},a=this&&this.__spread||function(){for(var e=[],t=0;t<arguments.length;t++)e=e.concat(r(arguments[t]));return e};Object.defineProperty(t,"__esModule",{value:!0});var o,i,s=n(4173),l=s;!function(e){e[e.DEFAULT=0]="DEFAULT",e[e.ADDED=1]="ADDED",e[e.REMOVED=2]="REMOVED"}(o=t.DiffType||(t.DiffType={})),function(e){e.CHARS="diffChars",e.WORDS="diffWords",e.WORDS_WITH_SPACE="diffWordsWithSpace",e.LINES="diffLines",e.TRIMMED_LINES="diffTrimmedLines",e.SENTENCES="diffSentences",e.CSS="diffCss"}(i=t.DiffMethod||(t.DiffMethod={}));var u=function(e){var t=e.split("\n");if(t.every((function(e){return!e})))return 2===t.length?[]:(t.pop(),t);var n=t[t.length-1],r=t[0];return n||t.pop(),r||t.shift(),t};t.computeLineInformation=function(e,t,n,r,c){void 0===n&&(n=!1),void 0===r&&(r=i.CHARS),void 0===c&&(c=0);var d=s.diffLines(e.trimRight(),t.trimRight(),{newlineIsToken:!0,ignoreWhitespace:!1,ignoreCase:!1}),f=c,p=c,m=[],h=0,v=[],b=[],y=function e(t,a,s,c,m){return u(t).map((function(t,y){var g={},_={};if(!(b.includes(a+"-"+y)||m&&0!==y)){if(s||c)if(v.includes(h)||v.push(h),c){p+=1,g.lineNumber=p,g.type=o.REMOVED,g.value=t||" ";var w=d[a+1];if(w&&w.added)if(u(w.value)[y]){var S=e(w.value,a,!0,!1,!0)[0].right,C=S.value,k=S.lineNumber,T=S.type;if(b.push(a+1+"-"+y),_.lineNumber=k,_.type=T,n)_.value=C;else{var x=function(e,t,n){void 0===n&&(n=i.CHARS);var r=l[n](e,t),a={left:[],right:[]};return r.forEach((function(e){var t=e.added,n=e.removed,r=e.value,i={};return t&&(i.type=o.ADDED,i.value=r,a.right.push(i)),n&&(i.type=o.REMOVED,i.value=r,a.left.push(i)),n||t||(i.type=o.DEFAULT,i.value=r,a.right.push(i),a.left.push(i)),i})),a}(t,C,r);_.value=x.right,g.value=x.left}}}else f+=1,_.lineNumber=f,_.type=o.ADDED,_.value=t;else p+=1,f+=1,g.lineNumber=p,g.type=o.DEFAULT,g.value=t,_.lineNumber=f,_.type=o.DEFAULT,_.value=t;return h+=1,{right:_,left:g}}})).filter(Boolean)};return d.forEach((function(e,t){var n=e.added,r=e.removed,o=e.value;m=a(m,y(o,t,n,r))})),{lineInformation:m,diffLines:v}}},1774:function(e,t,n){"use strict";var r=this&&this.__extends||function(){var e=function(t,n){return e=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var n in t)t.hasOwnProperty(n)&&(e[n]=t[n])},e(t,n)};return function(t,n){function r(){this.constructor=t}e(t,n),t.prototype=null===n?Object.create(n):(r.prototype=n.prototype,new r)}}();Object.defineProperty(t,"__esModule",{value:!0});var a=n(2791),o=n(2007),i=n(1694),s=n(7786);t.DiffMethod=s.DiffMethod;var l,u=n(2813),c=n(5781),d=c.default||c;!function(e){e.LEFT="L",e.RIGHT="R"}(l=t.LineNumberPrefix||(t.LineNumberPrefix={}));var f=function(e){function t(t){var n=e.call(this,t)||this;return n.resetCodeBlocks=function(){return n.state.expandedBlocks.length>0&&(n.setState({expandedBlocks:[]}),!0)},n.onBlockExpand=function(e){var t=n.state.expandedBlocks.slice();t.push(e),n.setState({expandedBlocks:t})},n.computeStyles=d(u.default),n.onLineNumberClickProxy=function(e){return n.props.onLineNumberClick?function(t){return n.props.onLineNumberClick(e,t)}:function(){}},n.renderWordDiff=function(e,t){return e.map((function(e,r){var o;return a.createElement("span",{key:r,className:i.default(n.styles.wordDiff,(o={},o[n.styles.wordAdded]=e.type===s.DiffType.ADDED,o[n.styles.wordRemoved]=e.type===s.DiffType.REMOVED,o))},t?t(e.value):e.value)}))},n.renderLine=function(e,t,r,o,l,u){var c,d,f,p,m,h=r+"-"+e,v=u+"-"+l,b=n.props.highlightLines.includes(h)||n.props.highlightLines.includes(v),y=t===s.DiffType.ADDED,g=t===s.DiffType.REMOVED;return m=Array.isArray(o)?n.renderWordDiff(o,n.props.renderContent):n.props.renderContent?n.props.renderContent(o):o,a.createElement(a.Fragment,null,!n.props.hideLineNumbers&&a.createElement("td",{onClick:e&&n.onLineNumberClickProxy(h),className:i.default(n.styles.gutter,(c={},c[n.styles.emptyGutter]=!e,c[n.styles.diffAdded]=y,c[n.styles.diffRemoved]=g,c[n.styles.highlightedGutter]=b,c))},a.createElement("pre",{className:n.styles.lineNumber},e)),!n.props.splitView&&!n.props.hideLineNumbers&&a.createElement("td",{onClick:l&&n.onLineNumberClickProxy(v),className:i.default(n.styles.gutter,(d={},d[n.styles.emptyGutter]=!l,d[n.styles.diffAdded]=y,d[n.styles.diffRemoved]=g,d[n.styles.highlightedGutter]=b,d))},a.createElement("pre",{className:n.styles.lineNumber},l)),a.createElement("td",{className:i.default(n.styles.marker,(f={},f[n.styles.emptyLine]=!m,f[n.styles.diffAdded]=y,f[n.styles.diffRemoved]=g,f[n.styles.highlightedLine]=b,f))},a.createElement("pre",null,y&&"+",g&&"-")),a.createElement("td",{className:i.default(n.styles.content,(p={},p[n.styles.emptyLine]=!m,p[n.styles.diffAdded]=y,p[n.styles.diffRemoved]=g,p[n.styles.highlightedLine]=b,p))},a.createElement("pre",{className:n.styles.contentText},m)))},n.renderSplitView=function(e,t){var r=e.left,o=e.right;return a.createElement("tr",{key:t,className:n.styles.line},n.renderLine(r.lineNumber,r.type,l.LEFT,r.value),n.renderLine(o.lineNumber,o.type,l.RIGHT,o.value))},n.renderInlineView=function(e,t){var r,o=e.left,i=e.right;return o.type===s.DiffType.REMOVED&&i.type===s.DiffType.ADDED?a.createElement(a.Fragment,{key:t},a.createElement("tr",{className:n.styles.line},n.renderLine(o.lineNumber,o.type,l.LEFT,o.value,null)),a.createElement("tr",{className:n.styles.line},n.renderLine(null,i.type,l.RIGHT,i.value,i.lineNumber))):(o.type===s.DiffType.REMOVED&&(r=n.renderLine(o.lineNumber,o.type,l.LEFT,o.value,null)),o.type===s.DiffType.DEFAULT&&(r=n.renderLine(o.lineNumber,o.type,l.LEFT,o.value,i.lineNumber,l.RIGHT)),i.type===s.DiffType.ADDED&&(r=n.renderLine(null,i.type,l.RIGHT,i.value,i.lineNumber)),a.createElement("tr",{key:t,className:n.styles.line},r))},n.onBlockClickProxy=function(e){return function(){return n.onBlockExpand(e)}},n.renderSkippedLineIndicator=function(e,t,r,o){var s,l=n.props,u=l.hideLineNumbers,c=l.splitView,d=n.props.codeFoldMessageRenderer?n.props.codeFoldMessageRenderer(e,r,o):a.createElement("pre",{className:n.styles.codeFoldContent},"Expand ",e," lines ..."),f=a.createElement("td",null,a.createElement("a",{onClick:n.onBlockClickProxy(t),tabIndex:0},d)),p=!c&&!u;return a.createElement("tr",{key:r+"-"+o,className:n.styles.codeFold},!u&&a.createElement("td",{className:n.styles.codeFoldGutter}),a.createElement("td",{className:i.default((s={},s[n.styles.codeFoldGutter]=p,s))}),p?a.createElement(a.Fragment,null,a.createElement("td",null),f):a.createElement(a.Fragment,null,f,a.createElement("td",null)),a.createElement("td",null),a.createElement("td",null))},n.renderDiff=function(){var e=n.props,t=e.oldValue,r=e.newValue,o=e.splitView,i=e.disableWordDiff,l=e.compareMethod,u=e.linesOffset,c=s.computeLineInformation(t,r,i,l,u),d=c.lineInformation,f=c.diffLines,p=n.props.extraLinesSurroundingDiff<0?0:n.props.extraLinesSurroundingDiff,m=[];return d.map((function(e,t){var r=f[0],i=r-t;if(n.props.showDiffOnly&&(i===-p&&(m=[],f.shift()),e.left.type===s.DiffType.DEFAULT&&(i>p||"undefined"===typeof r)&&!n.state.expandedBlocks.includes(r)))return m.push(t+1),t===d.length-1&&m.length>1?n.renderSkippedLineIndicator(m.length,r,e.left.lineNumber,e.right.lineNumber):null;var l=o?n.renderSplitView(e,t):n.renderInlineView(e,t);if(i===p&&m.length>0){var u=m.length;return m=[],a.createElement(a.Fragment,{key:t},n.renderSkippedLineIndicator(u,r,e.left.lineNumber,e.right.lineNumber),l)}return l}))},n.render=function(){var e,t=n.props,r=t.oldValue,o=t.newValue,s=t.useDarkTheme,l=t.leftTitle,u=t.rightTitle,c=t.splitView,d=t.hideLineNumbers;if("string"!==typeof r||"string"!==typeof o)throw Error('"oldValue" and "newValue" should be strings');n.styles=n.computeStyles(n.props.styles,s);var f=n.renderDiff(),p=d?2:3,m=d?2:4,h=(l||u)&&a.createElement("tr",null,a.createElement("td",{colSpan:c?p:m,className:n.styles.titleBlock},a.createElement("pre",{className:n.styles.contentText},l)),c&&a.createElement("td",{colSpan:p,className:n.styles.titleBlock},a.createElement("pre",{className:n.styles.contentText},u)));return a.createElement("table",{className:i.default(n.styles.diffContainer,(e={},e[n.styles.splitView]=c,e))},a.createElement("tbody",null,h,f))},n.state={expandedBlocks:[]},n}return r(t,e),t.defaultProps={oldValue:"",newValue:"",splitView:!0,highlightLines:[],disableWordDiff:!1,compareMethod:s.DiffMethod.CHARS,styles:{},hideLineNumbers:!1,extraLinesSurroundingDiff:3,showDiffOnly:!0,useDarkTheme:!1,linesOffset:0},t.propTypes={oldValue:o.string.isRequired,newValue:o.string.isRequired,splitView:o.bool,disableWordDiff:o.bool,compareMethod:o.oneOf(Object.values(s.DiffMethod)),renderContent:o.func,onLineNumberClick:o.func,extraLinesSurroundingDiff:o.number,styles:o.object,hideLineNumbers:o.bool,showDiffOnly:o.bool,highlightLines:o.arrayOf(o.string),leftTitle:o.oneOfType([o.string,o.element]),rightTitle:o.oneOfType([o.string,o.element]),linesOffset:o.number},t}(a.Component);t.default=f},2813:function(e,t,n){"use strict";var r=this&&this.__assign||function(){return r=Object.assign||function(e){for(var t,n=1,r=arguments.length;n<r;n++)for(var a in t=arguments[n])Object.prototype.hasOwnProperty.call(t,a)&&(e[a]=t[a]);return e},r.apply(this,arguments)},a=this&&this.__rest||function(e,t){var n={};for(var r in e)Object.prototype.hasOwnProperty.call(e,r)&&t.indexOf(r)<0&&(n[r]=e[r]);if(null!=e&&"function"===typeof Object.getOwnPropertySymbols){var a=0;for(r=Object.getOwnPropertySymbols(e);a<r.length;a++)t.indexOf(r[a])<0&&Object.prototype.propertyIsEnumerable.call(e,r[a])&&(n[r[a]]=e[r[a]])}return n};Object.defineProperty(t,"__esModule",{value:!0});var o=n(6025);t.default=function(e,t){var n,i,s,l,u,c,d;void 0===t&&(t=!1);var f=e.variables,p=void 0===f?{}:f,m=a(e,["variables"]),h={light:r({diffViewerBackground:"#fff",diffViewerColor:"212529",addedBackground:"#e6ffed",addedColor:"#24292e",removedBackground:"#ffeef0",removedColor:"#24292e",wordAddedBackground:"#acf2bd",wordRemovedBackground:"#fdb8c0",addedGutterBackground:"#cdffd8",removedGutterBackground:"#ffdce0",gutterBackground:"#f7f7f7",gutterBackgroundDark:"#f3f1f1",highlightBackground:"#fffbdd",highlightGutterBackground:"#fff5b1",codeFoldGutterBackground:"#dbedff",codeFoldBackground:"#f1f8ff",emptyLineBackground:"#fafbfc",gutterColor:"#212529",addedGutterColor:"#212529",removedGutterColor:"#212529",codeFoldContentColor:"#212529",diffViewerTitleBackground:"#fafbfc",diffViewerTitleColor:"#212529",diffViewerTitleBorderColor:"#eee"},p.light||{}),dark:r({diffViewerBackground:"#2e303c",diffViewerColor:"#FFF",addedBackground:"#044B53",addedColor:"white",removedBackground:"#632F34",removedColor:"white",wordAddedBackground:"#055d67",wordRemovedBackground:"#7d383f",addedGutterBackground:"#034148",removedGutterBackground:"#632b30",gutterBackground:"#2c2f3a",gutterBackgroundDark:"#262933",highlightBackground:"#2a3967",highlightGutterBackground:"#2d4077",codeFoldGutterBackground:"#21232b",codeFoldBackground:"#262831",emptyLineBackground:"#363946",gutterColor:"#464c67",addedGutterColor:"#8c8c8c",removedGutterColor:"#8c8c8c",codeFoldContentColor:"#555a7b",diffViewerTitleBackground:"#2f323e",diffViewerTitleColor:"#555a7b",diffViewerTitleBorderColor:"#353846"},p.dark||{})},v=t?h.dark:h.light,b=o.css({width:"100%",label:"content"}),y=o.css(((n={})["."+b]={width:"50%"},n.label="split-view",n)),g=o.css({width:"100%",background:v.diffViewerBackground,pre:{margin:0,whiteSpace:"pre-wrap",lineHeight:"25px"},label:"diff-container",borderCollapse:"collapse"}),_=o.css({color:v.codeFoldContentColor,label:"code-fold-content"}),w=o.css({color:v.diffViewerColor,label:"content-text"}),S=o.css(((i={background:v.diffViewerTitleBackground,padding:10,borderBottom:"1px solid "+v.diffViewerTitleBorderColor,label:"title-block",":last-child":{borderLeft:"1px solid "+v.diffViewerTitleBorderColor}})["."+w]={color:v.diffViewerTitleColor},i)),C=o.css({color:v.gutterColor,label:"line-number"}),k=o.css(((s={background:v.removedBackground,color:v.removedColor,pre:{color:v.removedColor}})["."+C]={color:v.removedGutterColor},s.label="diff-removed",s)),T=o.css(((l={background:v.addedBackground,color:v.addedColor,pre:{color:v.addedColor}})["."+C]={color:v.addedGutterColor},l.label="diff-added",l)),x=o.css({padding:2,display:"inline-flex",borderRadius:1,label:"word-diff"}),E=o.css({background:v.wordAddedBackground,label:"word-added"}),P=o.css({background:v.wordRemovedBackground,label:"word-removed"}),A=o.css({backgroundColor:v.codeFoldGutterBackground,label:"code-fold-gutter"}),R=o.css({backgroundColor:v.codeFoldBackground,height:40,fontSize:14,fontWeight:700,label:"code-fold",a:{textDecoration:"underline !important",cursor:"pointer",pre:{display:"inline"}}}),F=o.css({backgroundColor:v.emptyLineBackground,label:"empty-line"}),O=o.css(((u={width:25,paddingLeft:10,paddingRight:10,userSelect:"none",label:"marker"})["&."+T]={pre:{color:v.addedColor}},u["&."+k]={pre:{color:v.removedColor}},u)),N=o.css(((c={background:v.highlightBackground,label:"highlighted-line"})["."+E+", ."+P]={backgroundColor:"initial"},c)),M=o.css({label:"highlighted-gutter"}),I=o.css(((d={userSelect:"none",minWidth:50,padding:"0 10px",label:"gutter",textAlign:"right",background:v.gutterBackground,"&:hover":{cursor:"pointer",background:v.gutterBackgroundDark,pre:{opacity:1}},pre:{opacity:.5}})["&."+T]={background:v.addedGutterBackground},d["&."+k]={background:v.removedGutterBackground},d["&."+M]={background:v.highlightGutterBackground,"&:hover":{background:v.highlightGutterBackground}},d)),z=o.css({"&:hover":{background:v.gutterBackground,cursor:"initial"},label:"empty-gutter"}),L={diffContainer:g,diffRemoved:k,diffAdded:T,splitView:y,marker:O,highlightedGutter:M,highlightedLine:N,gutter:I,line:o.css({verticalAlign:"baseline",label:"line"}),wordDiff:x,wordAdded:E,wordRemoved:P,codeFoldGutter:A,codeFold:R,emptyGutter:z,emptyLine:F,lineNumber:C,contentText:w,content:b,codeFoldContent:_,titleBlock:S},D=Object.keys(m).reduce((function(e,t){var n;return r({},e,((n={})[t]=o.css(m[t]),n))}),{});return Object.keys(L).reduce((function(e,t){var n;return r({},e,((n={})[t]=D[t]?o.cx(L[t],D[t]):L[t],n))}),{})}},4463:function(e,t,n){"use strict";var r=n(2791),a=n(5296);function o(e){for(var t="https://reactjs.org/docs/error-decoder.html?invariant="+e,n=1;n<arguments.length;n++)t+="&args[]="+encodeURIComponent(arguments[n]);return"Minified React error #"+e+"; visit "+t+" for the full message or use the non-minified dev environment for full errors and additional helpful warnings."}var i=new Set,s={};function l(e,t){u(e,t),u(e+"Capture",t)}function u(e,t){for(s[e]=t,e=0;e<t.length;e++)i.add(t[e])}var c=!("undefined"===typeof window||"undefined"===typeof window.document||"undefined"===typeof window.document.createElement),d=Object.prototype.hasOwnProperty,f=/^[:A-Z_a-z\u00C0-\u00D6\u00D8-\u00F6\u00F8-\u02FF\u0370-\u037D\u037F-\u1FFF\u200C-\u200D\u2070-\u218F\u2C00-\u2FEF\u3001-\uD7FF\uF900-\uFDCF\uFDF0-\uFFFD][:A-Z_a-z\u00C0-\u00D6\u00D8-\u00F6\u00F8-\u02FF\u0370-\u037D\u037F-\u1FFF\u200C-\u200D\u2070-\u218F\u2C00-\u2FEF\u3001-\uD7FF\uF900-\uFDCF\uFDF0-\uFFFD\-.0-9\u00B7\u0300-\u036F\u203F-\u2040]*$/,p={},m={};function h(e,t,n,r,a,o,i){this.acceptsBooleans=2===t||3===t||4===t,this.attributeName=r,this.attributeNamespace=a,this.mustUseProperty=n,this.propertyName=e,this.type=t,this.sanitizeURL=o,this.removeEmptyString=i}var v={};"children dangerouslySetInnerHTML defaultValue defaultChecked innerHTML suppressContentEditableWarning suppressHydrationWarning style".split(" ").forEach((function(e){v[e]=new h(e,0,!1,e,null,!1,!1)})),[["acceptCharset","accept-charset"],["className","class"],["htmlFor","for"],["httpEquiv","http-equiv"]].forEach((function(e){var t=e[0];v[t]=new h(t,1,!1,e[1],null,!1,!1)})),["contentEditable","draggable","spellCheck","value"].forEach((function(e){v[e]=new h(e,2,!1,e.toLowerCase(),null,!1,!1)})),["autoReverse","externalResourcesRequired","focusable","preserveAlpha"].forEach((function(e){v[e]=new h(e,2,!1,e,null,!1,!1)})),"allowFullScreen async autoFocus autoPlay controls default defer disabled disablePictureInPicture disableRemotePlayback formNoValidate hidden loop noModule noValidate open playsInline readOnly required reversed scoped seamless itemScope".split(" ").forEach((function(e){v[e]=new h(e,3,!1,e.toLowerCase(),null,!1,!1)})),["checked","multiple","muted","selected"].forEach((function(e){v[e]=new h(e,3,!0,e,null,!1,!1)})),["capture","download"].forEach((function(e){v[e]=new h(e,4,!1,e,null,!1,!1)})),["cols","rows","size","span"].forEach((function(e){v[e]=new h(e,6,!1,e,null,!1,!1)})),["rowSpan","start"].forEach((function(e){v[e]=new h(e,5,!1,e.toLowerCase(),null,!1,!1)}));var b=/[\-:]([a-z])/g;function y(e){return e[1].toUpperCase()}function g(e,t,n,r){var a=v.hasOwnProperty(t)?v[t]:null;(null!==a?0!==a.type:r||!(2<t.length)||"o"!==t[0]&&"O"!==t[0]||"n"!==t[1]&&"N"!==t[1])&&(function(e,t,n,r){if(null===t||"undefined"===typeof t||function(e,t,n,r){if(null!==n&&0===n.type)return!1;switch(typeof t){case"function":case"symbol":return!0;case"boolean":return!r&&(null!==n?!n.acceptsBooleans:"data-"!==(e=e.toLowerCase().slice(0,5))&&"aria-"!==e);default:return!1}}(e,t,n,r))return!0;if(r)return!1;if(null!==n)switch(n.type){case 3:return!t;case 4:return!1===t;case 5:return isNaN(t);case 6:return isNaN(t)||1>t}return!1}(t,n,a,r)&&(n=null),r||null===a?function(e){return!!d.call(m,e)||!d.call(p,e)&&(f.test(e)?m[e]=!0:(p[e]=!0,!1))}(t)&&(null===n?e.removeAttribute(t):e.setAttribute(t,""+n)):a.mustUseProperty?e[a.propertyName]=null===n?3!==a.type&&"":n:(t=a.attributeName,r=a.attributeNamespace,null===n?e.removeAttribute(t):(n=3===(a=a.type)||4===a&&!0===n?"":""+n,r?e.setAttributeNS(r,t,n):e.setAttribute(t,n))))}"accent-height alignment-baseline arabic-form baseline-shift cap-height clip-path clip-rule color-interpolation color-interpolation-filters color-profile color-rendering dominant-baseline enable-background fill-opacity fill-rule flood-color flood-opacity font-family font-size font-size-adjust font-stretch font-style font-variant font-weight glyph-name glyph-orientation-horizontal glyph-orientation-vertical horiz-adv-x horiz-origin-x image-rendering letter-spacing lighting-color marker-end marker-mid marker-start overline-position overline-thickness paint-order panose-1 pointer-events rendering-intent shape-rendering stop-color stop-opacity strikethrough-position strikethrough-thickness stroke-dasharray stroke-dashoffset stroke-linecap stroke-linejoin stroke-miterlimit stroke-opacity stroke-width text-anchor text-decoration text-rendering underline-position underline-thickness unicode-bidi unicode-range units-per-em v-alphabetic v-hanging v-ideographic v-mathematical vector-effect vert-adv-y vert-origin-x vert-origin-y word-spacing writing-mode xmlns:xlink x-height".split(" ").forEach((function(e){var t=e.replace(b,y);v[t]=new h(t,1,!1,e,null,!1,!1)})),"xlink:actuate xlink:arcrole xlink:role xlink:show xlink:title xlink:type".split(" ").forEach((function(e){var t=e.replace(b,y);v[t]=new h(t,1,!1,e,"http://www.w3.org/1999/xlink",!1,!1)})),["xml:base","xml:lang","xml:space"].forEach((function(e){var t=e.replace(b,y);v[t]=new h(t,1,!1,e,"http://www.w3.org/XML/1998/namespace",!1,!1)})),["tabIndex","crossOrigin"].forEach((function(e){v[e]=new h(e,1,!1,e.toLowerCase(),null,!1,!1)})),v.xlinkHref=new h("xlinkHref",1,!1,"xlink:href","http://www.w3.org/1999/xlink",!0,!1),["src","href","action","formAction"].forEach((function(e){v[e]=new h(e,1,!1,e.toLowerCase(),null,!0,!0)}));var _=r.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED,w=Symbol.for("react.element"),S=Symbol.for("react.portal"),C=Symbol.for("react.fragment"),k=Symbol.for("react.strict_mode"),T=Symbol.for("react.profiler"),x=Symbol.for("react.provider"),E=Symbol.for("react.context"),P=Symbol.for("react.forward_ref"),A=Symbol.for("react.suspense"),R=Symbol.for("react.suspense_list"),F=Symbol.for("react.memo"),O=Symbol.for("react.lazy");Symbol.for("react.scope"),Symbol.for("react.debug_trace_mode");var N=Symbol.for("react.offscreen");Symbol.for("react.legacy_hidden"),Symbol.for("react.cache"),Symbol.for("react.tracing_marker");var M=Symbol.iterator;function I(e){return null===e||"object"!==typeof e?null:"function"===typeof(e=M&&e[M]||e["@@iterator"])?e:null}var z,L=Object.assign;function D(e){if(void 0===z)try{throw Error()}catch(n){var t=n.stack.trim().match(/\n( *(at )?)/);z=t&&t[1]||""}return"\n"+z+e}var j=!1;function Z(e,t){if(!e||j)return"";j=!0;var n=Error.prepareStackTrace;Error.prepareStackTrace=void 0;try{if(t)if(t=function(){throw Error()},Object.defineProperty(t.prototype,"props",{set:function(){throw Error()}}),"object"===typeof Reflect&&Reflect.construct){try{Reflect.construct(t,[])}catch(u){var r=u}Reflect.construct(e,[],t)}else{try{t.call()}catch(u){r=u}e.call(t.prototype)}else{try{throw Error()}catch(u){r=u}e()}}catch(u){if(u&&r&&"string"===typeof u.stack){for(var a=u.stack.split("\n"),o=r.stack.split("\n"),i=a.length-1,s=o.length-1;1<=i&&0<=s&&a[i]!==o[s];)s--;for(;1<=i&&0<=s;i--,s--)if(a[i]!==o[s]){if(1!==i||1!==s)do{if(i--,0>--s||a[i]!==o[s]){var l="\n"+a[i].replace(" at new "," at ");return e.displayName&&l.includes("<anonymous>")&&(l=l.replace("<anonymous>",e.displayName)),l}}while(1<=i&&0<=s);break}}}finally{j=!1,Error.prepareStackTrace=n}return(e=e?e.displayName||e.name:"")?D(e):""}function B(e){switch(e.tag){case 5:return D(e.type);case 16:return D("Lazy");case 13:return D("Suspense");case 19:return D("SuspenseList");case 0:case 2:case 15:return e=Z(e.type,!1);case 11:return e=Z(e.type.render,!1);case 1:return e=Z(e.type,!0);default:return""}}function W(e){if(null==e)return null;if("function"===typeof e)return e.displayName||e.name||null;if("string"===typeof e)return e;switch(e){case C:return"Fragment";case S:return"Portal";case T:return"Profiler";case k:return"StrictMode";case A:return"Suspense";case R:return"SuspenseList"}if("object"===typeof e)switch(e.$$typeof){case E:return(e.displayName||"Context")+".Consumer";case x:return(e._context.displayName||"Context")+".Provider";case P:var t=e.render;return(e=e.displayName)||(e=""!==(e=t.displayName||t.name||"")?"ForwardRef("+e+")":"ForwardRef"),e;case F:return null!==(t=e.displayName||null)?t:W(e.type)||"Memo";case O:t=e._payload,e=e._init;try{return W(e(t))}catch(n){}}return null}function U(e){var t=e.type;switch(e.tag){case 24:return"Cache";case 9:return(t.displayName||"Context")+".Consumer";case 10:return(t._context.displayName||"Context")+".Provider";case 18:return"DehydratedFragment";case 11:return e=(e=t.render).displayName||e.name||"",t.displayName||(""!==e?"ForwardRef("+e+")":"ForwardRef");case 7:return"Fragment";case 5:return t;case 4:return"Portal";case 3:return"Root";case 6:return"Text";case 16:return W(t);case 8:return t===k?"StrictMode":"Mode";case 22:return"Offscreen";case 12:return"Profiler";case 21:return"Scope";case 13:return"Suspense";case 19:return"SuspenseList";case 25:return"TracingMarker";case 1:case 0:case 17:case 2:case 14:case 15:if("function"===typeof t)return t.displayName||t.name||null;if("string"===typeof t)return t}return null}function V(e){switch(typeof e){case"boolean":case"number":case"string":case"undefined":case"object":return e;default:return""}}function G(e){var t=e.type;return(e=e.nodeName)&&"input"===e.toLowerCase()&&("checkbox"===t||"radio"===t)}function H(e){e._valueTracker||(e._valueTracker=function(e){var t=G(e)?"checked":"value",n=Object.getOwnPropertyDescriptor(e.constructor.prototype,t),r=""+e[t];if(!e.hasOwnProperty(t)&&"undefined"!==typeof n&&"function"===typeof n.get&&"function"===typeof n.set){var a=n.get,o=n.set;return Object.defineProperty(e,t,{configurable:!0,get:function(){return a.call(this)},set:function(e){r=""+e,o.call(this,e)}}),Object.defineProperty(e,t,{enumerable:n.enumerable}),{getValue:function(){return r},setValue:function(e){r=""+e},stopTracking:function(){e._valueTracker=null,delete e[t]}}}}(e))}function $(e){if(!e)return!1;var t=e._valueTracker;if(!t)return!0;var n=t.getValue(),r="";return e&&(r=G(e)?e.checked?"true":"false":e.value),(e=r)!==n&&(t.setValue(e),!0)}function J(e){if("undefined"===typeof(e=e||("undefined"!==typeof document?document:void 0)))return null;try{return e.activeElement||e.body}catch(t){return e.body}}function q(e,t){var n=t.checked;return L({},t,{defaultChecked:void 0,defaultValue:void 0,value:void 0,checked:null!=n?n:e._wrapperState.initialChecked})}function K(e,t){var n=null==t.defaultValue?"":t.defaultValue,r=null!=t.checked?t.checked:t.defaultChecked;n=V(null!=t.value?t.value:n),e._wrapperState={initialChecked:r,initialValue:n,controlled:"checkbox"===t.type||"radio"===t.type?null!=t.checked:null!=t.value}}function Q(e,t){null!=(t=t.checked)&&g(e,"checked",t,!1)}function Y(e,t){Q(e,t);var n=V(t.value),r=t.type;if(null!=n)"number"===r?(0===n&&""===e.value||e.value!=n)&&(e.value=""+n):e.value!==""+n&&(e.value=""+n);else if("submit"===r||"reset"===r)return void e.removeAttribute("value");t.hasOwnProperty("value")?ee(e,t.type,n):t.hasOwnProperty("defaultValue")&&ee(e,t.type,V(t.defaultValue)),null==t.checked&&null!=t.defaultChecked&&(e.defaultChecked=!!t.defaultChecked)}function X(e,t,n){if(t.hasOwnProperty("value")||t.hasOwnProperty("defaultValue")){var r=t.type;if(!("submit"!==r&&"reset"!==r||void 0!==t.value&&null!==t.value))return;t=""+e._wrapperState.initialValue,n||t===e.value||(e.value=t),e.defaultValue=t}""!==(n=e.name)&&(e.name=""),e.defaultChecked=!!e._wrapperState.initialChecked,""!==n&&(e.name=n)}function ee(e,t,n){"number"===t&&J(e.ownerDocument)===e||(null==n?e.defaultValue=""+e._wrapperState.initialValue:e.defaultValue!==""+n&&(e.defaultValue=""+n))}var te=Array.isArray;function ne(e,t,n,r){if(e=e.options,t){t={};for(var a=0;a<n.length;a++)t["$"+n[a]]=!0;for(n=0;n<e.length;n++)a=t.hasOwnProperty("$"+e[n].value),e[n].selected!==a&&(e[n].selected=a),a&&r&&(e[n].defaultSelected=!0)}else{for(n=""+V(n),t=null,a=0;a<e.length;a++){if(e[a].value===n)return e[a].selected=!0,void(r&&(e[a].defaultSelected=!0));null!==t||e[a].disabled||(t=e[a])}null!==t&&(t.selected=!0)}}function re(e,t){if(null!=t.dangerouslySetInnerHTML)throw Error(o(91));return L({},t,{value:void 0,defaultValue:void 0,children:""+e._wrapperState.initialValue})}function ae(e,t){var n=t.value;if(null==n){if(n=t.children,t=t.defaultValue,null!=n){if(null!=t)throw Error(o(92));if(te(n)){if(1<n.length)throw Error(o(93));n=n[0]}t=n}null==t&&(t=""),n=t}e._wrapperState={initialValue:V(n)}}function oe(e,t){var n=V(t.value),r=V(t.defaultValue);null!=n&&((n=""+n)!==e.value&&(e.value=n),null==t.defaultValue&&e.defaultValue!==n&&(e.defaultValue=n)),null!=r&&(e.defaultValue=""+r)}function ie(e){var t=e.textContent;t===e._wrapperState.initialValue&&""!==t&&null!==t&&(e.value=t)}function se(e){switch(e){case"svg":return"http://www.w3.org/2000/svg";case"math":return"http://www.w3.org/1998/Math/MathML";default:return"http://www.w3.org/1999/xhtml"}}function le(e,t){return null==e||"http://www.w3.org/1999/xhtml"===e?se(t):"http://www.w3.org/2000/svg"===e&&"foreignObject"===t?"http://www.w3.org/1999/xhtml":e}var ue,ce,de=(ce=function(e,t){if("http://www.w3.org/2000/svg"!==e.namespaceURI||"innerHTML"in e)e.innerHTML=t;else{for((ue=ue||document.createElement("div")).innerHTML="<svg>"+t.valueOf().toString()+"</svg>",t=ue.firstChild;e.firstChild;)e.removeChild(e.firstChild);for(;t.firstChild;)e.appendChild(t.firstChild)}},"undefined"!==typeof MSApp&&MSApp.execUnsafeLocalFunction?function(e,t,n,r){MSApp.execUnsafeLocalFunction((function(){return ce(e,t)}))}:ce);function fe(e,t){if(t){var n=e.firstChild;if(n&&n===e.lastChild&&3===n.nodeType)return void(n.nodeValue=t)}e.textContent=t}var pe={animationIterationCount:!0,aspectRatio:!0,borderImageOutset:!0,borderImageSlice:!0,borderImageWidth:!0,boxFlex:!0,boxFlexGroup:!0,boxOrdinalGroup:!0,columnCount:!0,columns:!0,flex:!0,flexGrow:!0,flexPositive:!0,flexShrink:!0,flexNegative:!0,flexOrder:!0,gridArea:!0,gridRow:!0,gridRowEnd:!0,gridRowSpan:!0,gridRowStart:!0,gridColumn:!0,gridColumnEnd:!0,gridColumnSpan:!0,gridColumnStart:!0,fontWeight:!0,lineClamp:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,tabSize:!0,widows:!0,zIndex:!0,zoom:!0,fillOpacity:!0,floodOpacity:!0,stopOpacity:!0,strokeDasharray:!0,strokeDashoffset:!0,strokeMiterlimit:!0,strokeOpacity:!0,strokeWidth:!0},me=["Webkit","ms","Moz","O"];function he(e,t,n){return null==t||"boolean"===typeof t||""===t?"":n||"number"!==typeof t||0===t||pe.hasOwnProperty(e)&&pe[e]?(""+t).trim():t+"px"}function ve(e,t){for(var n in e=e.style,t)if(t.hasOwnProperty(n)){var r=0===n.indexOf("--"),a=he(n,t[n],r);"float"===n&&(n="cssFloat"),r?e.setProperty(n,a):e[n]=a}}Object.keys(pe).forEach((function(e){me.forEach((function(t){t=t+e.charAt(0).toUpperCase()+e.substring(1),pe[t]=pe[e]}))}));var be=L({menuitem:!0},{area:!0,base:!0,br:!0,col:!0,embed:!0,hr:!0,img:!0,input:!0,keygen:!0,link:!0,meta:!0,param:!0,source:!0,track:!0,wbr:!0});function ye(e,t){if(t){if(be[e]&&(null!=t.children||null!=t.dangerouslySetInnerHTML))throw Error(o(137,e));if(null!=t.dangerouslySetInnerHTML){if(null!=t.children)throw Error(o(60));if("object"!==typeof t.dangerouslySetInnerHTML||!("__html"in t.dangerouslySetInnerHTML))throw Error(o(61))}if(null!=t.style&&"object"!==typeof t.style)throw Error(o(62))}}function ge(e,t){if(-1===e.indexOf("-"))return"string"===typeof t.is;switch(e){case"annotation-xml":case"color-profile":case"font-face":case"font-face-src":case"font-face-uri":case"font-face-format":case"font-face-name":case"missing-glyph":return!1;default:return!0}}var _e=null;function we(e){return(e=e.target||e.srcElement||window).correspondingUseElement&&(e=e.correspondingUseElement),3===e.nodeType?e.parentNode:e}var Se=null,Ce=null,ke=null;function Te(e){if(e=ga(e)){if("function"!==typeof Se)throw Error(o(280));var t=e.stateNode;t&&(t=wa(t),Se(e.stateNode,e.type,t))}}function xe(e){Ce?ke?ke.push(e):ke=[e]:Ce=e}function Ee(){if(Ce){var e=Ce,t=ke;if(ke=Ce=null,Te(e),t)for(e=0;e<t.length;e++)Te(t[e])}}function Pe(e,t){return e(t)}function Ae(){}var Re=!1;function Fe(e,t,n){if(Re)return e(t,n);Re=!0;try{return Pe(e,t,n)}finally{Re=!1,(null!==Ce||null!==ke)&&(Ae(),Ee())}}function Oe(e,t){var n=e.stateNode;if(null===n)return null;var r=wa(n);if(null===r)return null;n=r[t];e:switch(t){case"onClick":case"onClickCapture":case"onDoubleClick":case"onDoubleClickCapture":case"onMouseDown":case"onMouseDownCapture":case"onMouseMove":case"onMouseMoveCapture":case"onMouseUp":case"onMouseUpCapture":case"onMouseEnter":(r=!r.disabled)||(r=!("button"===(e=e.type)||"input"===e||"select"===e||"textarea"===e)),e=!r;break e;default:e=!1}if(e)return null;if(n&&"function"!==typeof n)throw Error(o(231,t,typeof n));return n}var Ne=!1;if(c)try{var Me={};Object.defineProperty(Me,"passive",{get:function(){Ne=!0}}),window.addEventListener("test",Me,Me),window.removeEventListener("test",Me,Me)}catch(ce){Ne=!1}function Ie(e,t,n,r,a,o,i,s,l){var u=Array.prototype.slice.call(arguments,3);try{t.apply(n,u)}catch(c){this.onError(c)}}var ze=!1,Le=null,De=!1,je=null,Ze={onError:function(e){ze=!0,Le=e}};function Be(e,t,n,r,a,o,i,s,l){ze=!1,Le=null,Ie.apply(Ze,arguments)}function We(e){var t=e,n=e;if(e.alternate)for(;t.return;)t=t.return;else{e=t;do{0!==(4098&(t=e).flags)&&(n=t.return),e=t.return}while(e)}return 3===t.tag?n:null}function Ue(e){if(13===e.tag){var t=e.memoizedState;if(null===t&&(null!==(e=e.alternate)&&(t=e.memoizedState)),null!==t)return t.dehydrated}return null}function Ve(e){if(We(e)!==e)throw Error(o(188))}function Ge(e){return null!==(e=function(e){var t=e.alternate;if(!t){if(null===(t=We(e)))throw Error(o(188));return t!==e?null:e}for(var n=e,r=t;;){var a=n.return;if(null===a)break;var i=a.alternate;if(null===i){if(null!==(r=a.return)){n=r;continue}break}if(a.child===i.child){for(i=a.child;i;){if(i===n)return Ve(a),e;if(i===r)return Ve(a),t;i=i.sibling}throw Error(o(188))}if(n.return!==r.return)n=a,r=i;else{for(var s=!1,l=a.child;l;){if(l===n){s=!0,n=a,r=i;break}if(l===r){s=!0,r=a,n=i;break}l=l.sibling}if(!s){for(l=i.child;l;){if(l===n){s=!0,n=i,r=a;break}if(l===r){s=!0,r=i,n=a;break}l=l.sibling}if(!s)throw Error(o(189))}}if(n.alternate!==r)throw Error(o(190))}if(3!==n.tag)throw Error(o(188));return n.stateNode.current===n?e:t}(e))?He(e):null}function He(e){if(5===e.tag||6===e.tag)return e;for(e=e.child;null!==e;){var t=He(e);if(null!==t)return t;e=e.sibling}return null}var $e=a.unstable_scheduleCallback,Je=a.unstable_cancelCallback,qe=a.unstable_shouldYield,Ke=a.unstable_requestPaint,Qe=a.unstable_now,Ye=a.unstable_getCurrentPriorityLevel,Xe=a.unstable_ImmediatePriority,et=a.unstable_UserBlockingPriority,tt=a.unstable_NormalPriority,nt=a.unstable_LowPriority,rt=a.unstable_IdlePriority,at=null,ot=null;var it=Math.clz32?Math.clz32:function(e){return 0===(e>>>=0)?32:31-(st(e)/lt|0)|0},st=Math.log,lt=Math.LN2;var ut=64,ct=4194304;function dt(e){switch(e&-e){case 1:return 1;case 2:return 2;case 4:return 4;case 8:return 8;case 16:return 16;case 32:return 32;case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return 4194240&e;case 4194304:case 8388608:case 16777216:case 33554432:case 67108864:return 130023424&e;case 134217728:return 134217728;case 268435456:return 268435456;case 536870912:return 536870912;case 1073741824:return 1073741824;default:return e}}function ft(e,t){var n=e.pendingLanes;if(0===n)return 0;var r=0,a=e.suspendedLanes,o=e.pingedLanes,i=268435455&n;if(0!==i){var s=i&~a;0!==s?r=dt(s):0!==(o&=i)&&(r=dt(o))}else 0!==(i=n&~a)?r=dt(i):0!==o&&(r=dt(o));if(0===r)return 0;if(0!==t&&t!==r&&0===(t&a)&&((a=r&-r)>=(o=t&-t)||16===a&&0!==(4194240&o)))return t;if(0!==(4&r)&&(r|=16&n),0!==(t=e.entangledLanes))for(e=e.entanglements,t&=r;0<t;)a=1<<(n=31-it(t)),r|=e[n],t&=~a;return r}function pt(e,t){switch(e){case 1:case 2:case 4:return t+250;case 8:case 16:case 32:case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return t+5e3;default:return-1}}function mt(e){return 0!==(e=-1073741825&e.pendingLanes)?e:1073741824&e?1073741824:0}function ht(){var e=ut;return 0===(4194240&(ut<<=1))&&(ut=64),e}function vt(e){for(var t=[],n=0;31>n;n++)t.push(e);return t}function bt(e,t,n){e.pendingLanes|=t,536870912!==t&&(e.suspendedLanes=0,e.pingedLanes=0),(e=e.eventTimes)[t=31-it(t)]=n}function yt(e,t){var n=e.entangledLanes|=t;for(e=e.entanglements;n;){var r=31-it(n),a=1<<r;a&t|e[r]&t&&(e[r]|=t),n&=~a}}var gt=0;function _t(e){return 1<(e&=-e)?4<e?0!==(268435455&e)?16:536870912:4:1}var wt,St,Ct,kt,Tt,xt=!1,Et=[],Pt=null,At=null,Rt=null,Ft=new Map,Ot=new Map,Nt=[],Mt="mousedown mouseup touchcancel touchend touchstart auxclick dblclick pointercancel pointerdown pointerup dragend dragstart drop compositionend compositionstart keydown keypress keyup input textInput copy cut paste click change contextmenu reset submit".split(" ");function It(e,t){switch(e){case"focusin":case"focusout":Pt=null;break;case"dragenter":case"dragleave":At=null;break;case"mouseover":case"mouseout":Rt=null;break;case"pointerover":case"pointerout":Ft.delete(t.pointerId);break;case"gotpointercapture":case"lostpointercapture":Ot.delete(t.pointerId)}}function zt(e,t,n,r,a,o){return null===e||e.nativeEvent!==o?(e={blockedOn:t,domEventName:n,eventSystemFlags:r,nativeEvent:o,targetContainers:[a]},null!==t&&(null!==(t=ga(t))&&St(t)),e):(e.eventSystemFlags|=r,t=e.targetContainers,null!==a&&-1===t.indexOf(a)&&t.push(a),e)}function Lt(e){var t=ya(e.target);if(null!==t){var n=We(t);if(null!==n)if(13===(t=n.tag)){if(null!==(t=Ue(n)))return e.blockedOn=t,void Tt(e.priority,(function(){Ct(n)}))}else if(3===t&&n.stateNode.current.memoizedState.isDehydrated)return void(e.blockedOn=3===n.tag?n.stateNode.containerInfo:null)}e.blockedOn=null}function Dt(e){if(null!==e.blockedOn)return!1;for(var t=e.targetContainers;0<t.length;){var n=qt(e.domEventName,e.eventSystemFlags,t[0],e.nativeEvent);if(null!==n)return null!==(t=ga(n))&&St(t),e.blockedOn=n,!1;var r=new(n=e.nativeEvent).constructor(n.type,n);_e=r,n.target.dispatchEvent(r),_e=null,t.shift()}return!0}function jt(e,t,n){Dt(e)&&n.delete(t)}function Zt(){xt=!1,null!==Pt&&Dt(Pt)&&(Pt=null),null!==At&&Dt(At)&&(At=null),null!==Rt&&Dt(Rt)&&(Rt=null),Ft.forEach(jt),Ot.forEach(jt)}function Bt(e,t){e.blockedOn===t&&(e.blockedOn=null,xt||(xt=!0,a.unstable_scheduleCallback(a.unstable_NormalPriority,Zt)))}function Wt(e){function t(t){return Bt(t,e)}if(0<Et.length){Bt(Et[0],e);for(var n=1;n<Et.length;n++){var r=Et[n];r.blockedOn===e&&(r.blockedOn=null)}}for(null!==Pt&&Bt(Pt,e),null!==At&&Bt(At,e),null!==Rt&&Bt(Rt,e),Ft.forEach(t),Ot.forEach(t),n=0;n<Nt.length;n++)(r=Nt[n]).blockedOn===e&&(r.blockedOn=null);for(;0<Nt.length&&null===(n=Nt[0]).blockedOn;)Lt(n),null===n.blockedOn&&Nt.shift()}var Ut=_.ReactCurrentBatchConfig,Vt=!0;function Gt(e,t,n,r){var a=gt,o=Ut.transition;Ut.transition=null;try{gt=1,$t(e,t,n,r)}finally{gt=a,Ut.transition=o}}function Ht(e,t,n,r){var a=gt,o=Ut.transition;Ut.transition=null;try{gt=4,$t(e,t,n,r)}finally{gt=a,Ut.transition=o}}function $t(e,t,n,r){if(Vt){var a=qt(e,t,n,r);if(null===a)Vr(e,t,r,Jt,n),It(e,r);else if(function(e,t,n,r,a){switch(t){case"focusin":return Pt=zt(Pt,e,t,n,r,a),!0;case"dragenter":return At=zt(At,e,t,n,r,a),!0;case"mouseover":return Rt=zt(Rt,e,t,n,r,a),!0;case"pointerover":var o=a.pointerId;return Ft.set(o,zt(Ft.get(o)||null,e,t,n,r,a)),!0;case"gotpointercapture":return o=a.pointerId,Ot.set(o,zt(Ot.get(o)||null,e,t,n,r,a)),!0}return!1}(a,e,t,n,r))r.stopPropagation();else if(It(e,r),4&t&&-1<Mt.indexOf(e)){for(;null!==a;){var o=ga(a);if(null!==o&&wt(o),null===(o=qt(e,t,n,r))&&Vr(e,t,r,Jt,n),o===a)break;a=o}null!==a&&r.stopPropagation()}else Vr(e,t,r,null,n)}}var Jt=null;function qt(e,t,n,r){if(Jt=null,null!==(e=ya(e=we(r))))if(null===(t=We(e)))e=null;else if(13===(n=t.tag)){if(null!==(e=Ue(t)))return e;e=null}else if(3===n){if(t.stateNode.current.memoizedState.isDehydrated)return 3===t.tag?t.stateNode.containerInfo:null;e=null}else t!==e&&(e=null);return Jt=e,null}function Kt(e){switch(e){case"cancel":case"click":case"close":case"contextmenu":case"copy":case"cut":case"auxclick":case"dblclick":case"dragend":case"dragstart":case"drop":case"focusin":case"focusout":case"input":case"invalid":case"keydown":case"keypress":case"keyup":case"mousedown":case"mouseup":case"paste":case"pause":case"play":case"pointercancel":case"pointerdown":case"pointerup":case"ratechange":case"reset":case"resize":case"seeked":case"submit":case"touchcancel":case"touchend":case"touchstart":case"volumechange":case"change":case"selectionchange":case"textInput":case"compositionstart":case"compositionend":case"compositionupdate":case"beforeblur":case"afterblur":case"beforeinput":case"blur":case"fullscreenchange":case"focus":case"hashchange":case"popstate":case"select":case"selectstart":return 1;case"drag":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"mousemove":case"mouseout":case"mouseover":case"pointermove":case"pointerout":case"pointerover":case"scroll":case"toggle":case"touchmove":case"wheel":case"mouseenter":case"mouseleave":case"pointerenter":case"pointerleave":return 4;case"message":switch(Ye()){case Xe:return 1;case et:return 4;case tt:case nt:return 16;case rt:return 536870912;default:return 16}default:return 16}}var Qt=null,Yt=null,Xt=null;function en(){if(Xt)return Xt;var e,t,n=Yt,r=n.length,a="value"in Qt?Qt.value:Qt.textContent,o=a.length;for(e=0;e<r&&n[e]===a[e];e++);var i=r-e;for(t=1;t<=i&&n[r-t]===a[o-t];t++);return Xt=a.slice(e,1<t?1-t:void 0)}function tn(e){var t=e.keyCode;return"charCode"in e?0===(e=e.charCode)&&13===t&&(e=13):e=t,10===e&&(e=13),32<=e||13===e?e:0}function nn(){return!0}function rn(){return!1}function an(e){function t(t,n,r,a,o){for(var i in this._reactName=t,this._targetInst=r,this.type=n,this.nativeEvent=a,this.target=o,this.currentTarget=null,e)e.hasOwnProperty(i)&&(t=e[i],this[i]=t?t(a):a[i]);return this.isDefaultPrevented=(null!=a.defaultPrevented?a.defaultPrevented:!1===a.returnValue)?nn:rn,this.isPropagationStopped=rn,this}return L(t.prototype,{preventDefault:function(){this.defaultPrevented=!0;var e=this.nativeEvent;e&&(e.preventDefault?e.preventDefault():"unknown"!==typeof e.returnValue&&(e.returnValue=!1),this.isDefaultPrevented=nn)},stopPropagation:function(){var e=this.nativeEvent;e&&(e.stopPropagation?e.stopPropagation():"unknown"!==typeof e.cancelBubble&&(e.cancelBubble=!0),this.isPropagationStopped=nn)},persist:function(){},isPersistent:nn}),t}var on,sn,ln,un={eventPhase:0,bubbles:0,cancelable:0,timeStamp:function(e){return e.timeStamp||Date.now()},defaultPrevented:0,isTrusted:0},cn=an(un),dn=L({},un,{view:0,detail:0}),fn=an(dn),pn=L({},dn,{screenX:0,screenY:0,clientX:0,clientY:0,pageX:0,pageY:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,getModifierState:Tn,button:0,buttons:0,relatedTarget:function(e){return void 0===e.relatedTarget?e.fromElement===e.srcElement?e.toElement:e.fromElement:e.relatedTarget},movementX:function(e){return"movementX"in e?e.movementX:(e!==ln&&(ln&&"mousemove"===e.type?(on=e.screenX-ln.screenX,sn=e.screenY-ln.screenY):sn=on=0,ln=e),on)},movementY:function(e){return"movementY"in e?e.movementY:sn}}),mn=an(pn),hn=an(L({},pn,{dataTransfer:0})),vn=an(L({},dn,{relatedTarget:0})),bn=an(L({},un,{animationName:0,elapsedTime:0,pseudoElement:0})),yn=L({},un,{clipboardData:function(e){return"clipboardData"in e?e.clipboardData:window.clipboardData}}),gn=an(yn),_n=an(L({},un,{data:0})),wn={Esc:"Escape",Spacebar:" ",Left:"ArrowLeft",Up:"ArrowUp",Right:"ArrowRight",Down:"ArrowDown",Del:"Delete",Win:"OS",Menu:"ContextMenu",Apps:"ContextMenu",Scroll:"ScrollLock",MozPrintableKey:"Unidentified"},Sn={8:"Backspace",9:"Tab",12:"Clear",13:"Enter",16:"Shift",17:"Control",18:"Alt",19:"Pause",20:"CapsLock",27:"Escape",32:" ",33:"PageUp",34:"PageDown",35:"End",36:"Home",37:"ArrowLeft",38:"ArrowUp",39:"ArrowRight",40:"ArrowDown",45:"Insert",46:"Delete",112:"F1",113:"F2",114:"F3",115:"F4",116:"F5",117:"F6",118:"F7",119:"F8",120:"F9",121:"F10",122:"F11",123:"F12",144:"NumLock",145:"ScrollLock",224:"Meta"},Cn={Alt:"altKey",Control:"ctrlKey",Meta:"metaKey",Shift:"shiftKey"};function kn(e){var t=this.nativeEvent;return t.getModifierState?t.getModifierState(e):!!(e=Cn[e])&&!!t[e]}function Tn(){return kn}var xn=L({},dn,{key:function(e){if(e.key){var t=wn[e.key]||e.key;if("Unidentified"!==t)return t}return"keypress"===e.type?13===(e=tn(e))?"Enter":String.fromCharCode(e):"keydown"===e.type||"keyup"===e.type?Sn[e.keyCode]||"Unidentified":""},code:0,location:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,repeat:0,locale:0,getModifierState:Tn,charCode:function(e){return"keypress"===e.type?tn(e):0},keyCode:function(e){return"keydown"===e.type||"keyup"===e.type?e.keyCode:0},which:function(e){return"keypress"===e.type?tn(e):"keydown"===e.type||"keyup"===e.type?e.keyCode:0}}),En=an(xn),Pn=an(L({},pn,{pointerId:0,width:0,height:0,pressure:0,tangentialPressure:0,tiltX:0,tiltY:0,twist:0,pointerType:0,isPrimary:0})),An=an(L({},dn,{touches:0,targetTouches:0,changedTouches:0,altKey:0,metaKey:0,ctrlKey:0,shiftKey:0,getModifierState:Tn})),Rn=an(L({},un,{propertyName:0,elapsedTime:0,pseudoElement:0})),Fn=L({},pn,{deltaX:function(e){return"deltaX"in e?e.deltaX:"wheelDeltaX"in e?-e.wheelDeltaX:0},deltaY:function(e){return"deltaY"in e?e.deltaY:"wheelDeltaY"in e?-e.wheelDeltaY:"wheelDelta"in e?-e.wheelDelta:0},deltaZ:0,deltaMode:0}),On=an(Fn),Nn=[9,13,27,32],Mn=c&&"CompositionEvent"in window,In=null;c&&"documentMode"in document&&(In=document.documentMode);var zn=c&&"TextEvent"in window&&!In,Ln=c&&(!Mn||In&&8<In&&11>=In),Dn=String.fromCharCode(32),jn=!1;function Zn(e,t){switch(e){case"keyup":return-1!==Nn.indexOf(t.keyCode);case"keydown":return 229!==t.keyCode;case"keypress":case"mousedown":case"focusout":return!0;default:return!1}}function Bn(e){return"object"===typeof(e=e.detail)&&"data"in e?e.data:null}var Wn=!1;var Un={color:!0,date:!0,datetime:!0,"datetime-local":!0,email:!0,month:!0,number:!0,password:!0,range:!0,search:!0,tel:!0,text:!0,time:!0,url:!0,week:!0};function Vn(e){var t=e&&e.nodeName&&e.nodeName.toLowerCase();return"input"===t?!!Un[e.type]:"textarea"===t}function Gn(e,t,n,r){xe(r),0<(t=Hr(t,"onChange")).length&&(n=new cn("onChange","change",null,n,r),e.push({event:n,listeners:t}))}var Hn=null,$n=null;function Jn(e){Dr(e,0)}function qn(e){if($(_a(e)))return e}function Kn(e,t){if("change"===e)return t}var Qn=!1;if(c){var Yn;if(c){var Xn="oninput"in document;if(!Xn){var er=document.createElement("div");er.setAttribute("oninput","return;"),Xn="function"===typeof er.oninput}Yn=Xn}else Yn=!1;Qn=Yn&&(!document.documentMode||9<document.documentMode)}function tr(){Hn&&(Hn.detachEvent("onpropertychange",nr),$n=Hn=null)}function nr(e){if("value"===e.propertyName&&qn($n)){var t=[];Gn(t,$n,e,we(e)),Fe(Jn,t)}}function rr(e,t,n){"focusin"===e?(tr(),$n=n,(Hn=t).attachEvent("onpropertychange",nr)):"focusout"===e&&tr()}function ar(e){if("selectionchange"===e||"keyup"===e||"keydown"===e)return qn($n)}function or(e,t){if("click"===e)return qn(t)}function ir(e,t){if("input"===e||"change"===e)return qn(t)}var sr="function"===typeof Object.is?Object.is:function(e,t){return e===t&&(0!==e||1/e===1/t)||e!==e&&t!==t};function lr(e,t){if(sr(e,t))return!0;if("object"!==typeof e||null===e||"object"!==typeof t||null===t)return!1;var n=Object.keys(e),r=Object.keys(t);if(n.length!==r.length)return!1;for(r=0;r<n.length;r++){var a=n[r];if(!d.call(t,a)||!sr(e[a],t[a]))return!1}return!0}function ur(e){for(;e&&e.firstChild;)e=e.firstChild;return e}function cr(e,t){var n,r=ur(e);for(e=0;r;){if(3===r.nodeType){if(n=e+r.textContent.length,e<=t&&n>=t)return{node:r,offset:t-e};e=n}e:{for(;r;){if(r.nextSibling){r=r.nextSibling;break e}r=r.parentNode}r=void 0}r=ur(r)}}function dr(e,t){return!(!e||!t)&&(e===t||(!e||3!==e.nodeType)&&(t&&3===t.nodeType?dr(e,t.parentNode):"contains"in e?e.contains(t):!!e.compareDocumentPosition&&!!(16&e.compareDocumentPosition(t))))}function fr(){for(var e=window,t=J();t instanceof e.HTMLIFrameElement;){try{var n="string"===typeof t.contentWindow.location.href}catch(r){n=!1}if(!n)break;t=J((e=t.contentWindow).document)}return t}function pr(e){var t=e&&e.nodeName&&e.nodeName.toLowerCase();return t&&("input"===t&&("text"===e.type||"search"===e.type||"tel"===e.type||"url"===e.type||"password"===e.type)||"textarea"===t||"true"===e.contentEditable)}function mr(e){var t=fr(),n=e.focusedElem,r=e.selectionRange;if(t!==n&&n&&n.ownerDocument&&dr(n.ownerDocument.documentElement,n)){if(null!==r&&pr(n))if(t=r.start,void 0===(e=r.end)&&(e=t),"selectionStart"in n)n.selectionStart=t,n.selectionEnd=Math.min(e,n.value.length);else if((e=(t=n.ownerDocument||document)&&t.defaultView||window).getSelection){e=e.getSelection();var a=n.textContent.length,o=Math.min(r.start,a);r=void 0===r.end?o:Math.min(r.end,a),!e.extend&&o>r&&(a=r,r=o,o=a),a=cr(n,o);var i=cr(n,r);a&&i&&(1!==e.rangeCount||e.anchorNode!==a.node||e.anchorOffset!==a.offset||e.focusNode!==i.node||e.focusOffset!==i.offset)&&((t=t.createRange()).setStart(a.node,a.offset),e.removeAllRanges(),o>r?(e.addRange(t),e.extend(i.node,i.offset)):(t.setEnd(i.node,i.offset),e.addRange(t)))}for(t=[],e=n;e=e.parentNode;)1===e.nodeType&&t.push({element:e,left:e.scrollLeft,top:e.scrollTop});for("function"===typeof n.focus&&n.focus(),n=0;n<t.length;n++)(e=t[n]).element.scrollLeft=e.left,e.element.scrollTop=e.top}}var hr=c&&"documentMode"in document&&11>=document.documentMode,vr=null,br=null,yr=null,gr=!1;function _r(e,t,n){var r=n.window===n?n.document:9===n.nodeType?n:n.ownerDocument;gr||null==vr||vr!==J(r)||("selectionStart"in(r=vr)&&pr(r)?r={start:r.selectionStart,end:r.selectionEnd}:r={anchorNode:(r=(r.ownerDocument&&r.ownerDocument.defaultView||window).getSelection()).anchorNode,anchorOffset:r.anchorOffset,focusNode:r.focusNode,focusOffset:r.focusOffset},yr&&lr(yr,r)||(yr=r,0<(r=Hr(br,"onSelect")).length&&(t=new cn("onSelect","select",null,t,n),e.push({event:t,listeners:r}),t.target=vr)))}function wr(e,t){var n={};return n[e.toLowerCase()]=t.toLowerCase(),n["Webkit"+e]="webkit"+t,n["Moz"+e]="moz"+t,n}var Sr={animationend:wr("Animation","AnimationEnd"),animationiteration:wr("Animation","AnimationIteration"),animationstart:wr("Animation","AnimationStart"),transitionend:wr("Transition","TransitionEnd")},Cr={},kr={};function Tr(e){if(Cr[e])return Cr[e];if(!Sr[e])return e;var t,n=Sr[e];for(t in n)if(n.hasOwnProperty(t)&&t in kr)return Cr[e]=n[t];return e}c&&(kr=document.createElement("div").style,"AnimationEvent"in window||(delete Sr.animationend.animation,delete Sr.animationiteration.animation,delete Sr.animationstart.animation),"TransitionEvent"in window||delete Sr.transitionend.transition);var xr=Tr("animationend"),Er=Tr("animationiteration"),Pr=Tr("animationstart"),Ar=Tr("transitionend"),Rr=new Map,Fr="abort auxClick cancel canPlay canPlayThrough click close contextMenu copy cut drag dragEnd dragEnter dragExit dragLeave dragOver dragStart drop durationChange emptied encrypted ended error gotPointerCapture input invalid keyDown keyPress keyUp load loadedData loadedMetadata loadStart lostPointerCapture mouseDown mouseMove mouseOut mouseOver mouseUp paste pause play playing pointerCancel pointerDown pointerMove pointerOut pointerOver pointerUp progress rateChange reset resize seeked seeking stalled submit suspend timeUpdate touchCancel touchEnd touchStart volumeChange scroll toggle touchMove waiting wheel".split(" ");function Or(e,t){Rr.set(e,t),l(t,[e])}for(var Nr=0;Nr<Fr.length;Nr++){var Mr=Fr[Nr];Or(Mr.toLowerCase(),"on"+(Mr[0].toUpperCase()+Mr.slice(1)))}Or(xr,"onAnimationEnd"),Or(Er,"onAnimationIteration"),Or(Pr,"onAnimationStart"),Or("dblclick","onDoubleClick"),Or("focusin","onFocus"),Or("focusout","onBlur"),Or(Ar,"onTransitionEnd"),u("onMouseEnter",["mouseout","mouseover"]),u("onMouseLeave",["mouseout","mouseover"]),u("onPointerEnter",["pointerout","pointerover"]),u("onPointerLeave",["pointerout","pointerover"]),l("onChange","change click focusin focusout input keydown keyup selectionchange".split(" ")),l("onSelect","focusout contextmenu dragend focusin keydown keyup mousedown mouseup selectionchange".split(" ")),l("onBeforeInput",["compositionend","keypress","textInput","paste"]),l("onCompositionEnd","compositionend focusout keydown keypress keyup mousedown".split(" ")),l("onCompositionStart","compositionstart focusout keydown keypress keyup mousedown".split(" ")),l("onCompositionUpdate","compositionupdate focusout keydown keypress keyup mousedown".split(" "));var Ir="abort canplay canplaythrough durationchange emptied encrypted ended error loadeddata loadedmetadata loadstart pause play playing progress ratechange resize seeked seeking stalled suspend timeupdate volumechange waiting".split(" "),zr=new Set("cancel close invalid load scroll toggle".split(" ").concat(Ir));function Lr(e,t,n){var r=e.type||"unknown-event";e.currentTarget=n,function(e,t,n,r,a,i,s,l,u){if(Be.apply(this,arguments),ze){if(!ze)throw Error(o(198));var c=Le;ze=!1,Le=null,De||(De=!0,je=c)}}(r,t,void 0,e),e.currentTarget=null}function Dr(e,t){t=0!==(4&t);for(var n=0;n<e.length;n++){var r=e[n],a=r.event;r=r.listeners;e:{var o=void 0;if(t)for(var i=r.length-1;0<=i;i--){var s=r[i],l=s.instance,u=s.currentTarget;if(s=s.listener,l!==o&&a.isPropagationStopped())break e;Lr(a,s,u),o=l}else for(i=0;i<r.length;i++){if(l=(s=r[i]).instance,u=s.currentTarget,s=s.listener,l!==o&&a.isPropagationStopped())break e;Lr(a,s,u),o=l}}}if(De)throw e=je,De=!1,je=null,e}function jr(e,t){var n=t[ha];void 0===n&&(n=t[ha]=new Set);var r=e+"__bubble";n.has(r)||(Ur(t,e,2,!1),n.add(r))}function Zr(e,t,n){var r=0;t&&(r|=4),Ur(n,e,r,t)}var Br="_reactListening"+Math.random().toString(36).slice(2);function Wr(e){if(!e[Br]){e[Br]=!0,i.forEach((function(t){"selectionchange"!==t&&(zr.has(t)||Zr(t,!1,e),Zr(t,!0,e))}));var t=9===e.nodeType?e:e.ownerDocument;null===t||t[Br]||(t[Br]=!0,Zr("selectionchange",!1,t))}}function Ur(e,t,n,r){switch(Kt(t)){case 1:var a=Gt;break;case 4:a=Ht;break;default:a=$t}n=a.bind(null,t,n,e),a=void 0,!Ne||"touchstart"!==t&&"touchmove"!==t&&"wheel"!==t||(a=!0),r?void 0!==a?e.addEventListener(t,n,{capture:!0,passive:a}):e.addEventListener(t,n,!0):void 0!==a?e.addEventListener(t,n,{passive:a}):e.addEventListener(t,n,!1)}function Vr(e,t,n,r,a){var o=r;if(0===(1&t)&&0===(2&t)&&null!==r)e:for(;;){if(null===r)return;var i=r.tag;if(3===i||4===i){var s=r.stateNode.containerInfo;if(s===a||8===s.nodeType&&s.parentNode===a)break;if(4===i)for(i=r.return;null!==i;){var l=i.tag;if((3===l||4===l)&&((l=i.stateNode.containerInfo)===a||8===l.nodeType&&l.parentNode===a))return;i=i.return}for(;null!==s;){if(null===(i=ya(s)))return;if(5===(l=i.tag)||6===l){r=o=i;continue e}s=s.parentNode}}r=r.return}Fe((function(){var r=o,a=we(n),i=[];e:{var s=Rr.get(e);if(void 0!==s){var l=cn,u=e;switch(e){case"keypress":if(0===tn(n))break e;case"keydown":case"keyup":l=En;break;case"focusin":u="focus",l=vn;break;case"focusout":u="blur",l=vn;break;case"beforeblur":case"afterblur":l=vn;break;case"click":if(2===n.button)break e;case"auxclick":case"dblclick":case"mousedown":case"mousemove":case"mouseup":case"mouseout":case"mouseover":case"contextmenu":l=mn;break;case"drag":case"dragend":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"dragstart":case"drop":l=hn;break;case"touchcancel":case"touchend":case"touchmove":case"touchstart":l=An;break;case xr:case Er:case Pr:l=bn;break;case Ar:l=Rn;break;case"scroll":l=fn;break;case"wheel":l=On;break;case"copy":case"cut":case"paste":l=gn;break;case"gotpointercapture":case"lostpointercapture":case"pointercancel":case"pointerdown":case"pointermove":case"pointerout":case"pointerover":case"pointerup":l=Pn}var c=0!==(4&t),d=!c&&"scroll"===e,f=c?null!==s?s+"Capture":null:s;c=[];for(var p,m=r;null!==m;){var h=(p=m).stateNode;if(5===p.tag&&null!==h&&(p=h,null!==f&&(null!=(h=Oe(m,f))&&c.push(Gr(m,h,p)))),d)break;m=m.return}0<c.length&&(s=new l(s,u,null,n,a),i.push({event:s,listeners:c}))}}if(0===(7&t)){if(l="mouseout"===e||"pointerout"===e,(!(s="mouseover"===e||"pointerover"===e)||n===_e||!(u=n.relatedTarget||n.fromElement)||!ya(u)&&!u[ma])&&(l||s)&&(s=a.window===a?a:(s=a.ownerDocument)?s.defaultView||s.parentWindow:window,l?(l=r,null!==(u=(u=n.relatedTarget||n.toElement)?ya(u):null)&&(u!==(d=We(u))||5!==u.tag&&6!==u.tag)&&(u=null)):(l=null,u=r),l!==u)){if(c=mn,h="onMouseLeave",f="onMouseEnter",m="mouse","pointerout"!==e&&"pointerover"!==e||(c=Pn,h="onPointerLeave",f="onPointerEnter",m="pointer"),d=null==l?s:_a(l),p=null==u?s:_a(u),(s=new c(h,m+"leave",l,n,a)).target=d,s.relatedTarget=p,h=null,ya(a)===r&&((c=new c(f,m+"enter",u,n,a)).target=p,c.relatedTarget=d,h=c),d=h,l&&u)e:{for(f=u,m=0,p=c=l;p;p=$r(p))m++;for(p=0,h=f;h;h=$r(h))p++;for(;0<m-p;)c=$r(c),m--;for(;0<p-m;)f=$r(f),p--;for(;m--;){if(c===f||null!==f&&c===f.alternate)break e;c=$r(c),f=$r(f)}c=null}else c=null;null!==l&&Jr(i,s,l,c,!1),null!==u&&null!==d&&Jr(i,d,u,c,!0)}if("select"===(l=(s=r?_a(r):window).nodeName&&s.nodeName.toLowerCase())||"input"===l&&"file"===s.type)var v=Kn;else if(Vn(s))if(Qn)v=ir;else{v=ar;var b=rr}else(l=s.nodeName)&&"input"===l.toLowerCase()&&("checkbox"===s.type||"radio"===s.type)&&(v=or);switch(v&&(v=v(e,r))?Gn(i,v,n,a):(b&&b(e,s,r),"focusout"===e&&(b=s._wrapperState)&&b.controlled&&"number"===s.type&&ee(s,"number",s.value)),b=r?_a(r):window,e){case"focusin":(Vn(b)||"true"===b.contentEditable)&&(vr=b,br=r,yr=null);break;case"focusout":yr=br=vr=null;break;case"mousedown":gr=!0;break;case"contextmenu":case"mouseup":case"dragend":gr=!1,_r(i,n,a);break;case"selectionchange":if(hr)break;case"keydown":case"keyup":_r(i,n,a)}var y;if(Mn)e:{switch(e){case"compositionstart":var g="onCompositionStart";break e;case"compositionend":g="onCompositionEnd";break e;case"compositionupdate":g="onCompositionUpdate";break e}g=void 0}else Wn?Zn(e,n)&&(g="onCompositionEnd"):"keydown"===e&&229===n.keyCode&&(g="onCompositionStart");g&&(Ln&&"ko"!==n.locale&&(Wn||"onCompositionStart"!==g?"onCompositionEnd"===g&&Wn&&(y=en()):(Yt="value"in(Qt=a)?Qt.value:Qt.textContent,Wn=!0)),0<(b=Hr(r,g)).length&&(g=new _n(g,e,null,n,a),i.push({event:g,listeners:b}),y?g.data=y:null!==(y=Bn(n))&&(g.data=y))),(y=zn?function(e,t){switch(e){case"compositionend":return Bn(t);case"keypress":return 32!==t.which?null:(jn=!0,Dn);case"textInput":return(e=t.data)===Dn&&jn?null:e;default:return null}}(e,n):function(e,t){if(Wn)return"compositionend"===e||!Mn&&Zn(e,t)?(e=en(),Xt=Yt=Qt=null,Wn=!1,e):null;switch(e){case"paste":default:return null;case"keypress":if(!(t.ctrlKey||t.altKey||t.metaKey)||t.ctrlKey&&t.altKey){if(t.char&&1<t.char.length)return t.char;if(t.which)return String.fromCharCode(t.which)}return null;case"compositionend":return Ln&&"ko"!==t.locale?null:t.data}}(e,n))&&(0<(r=Hr(r,"onBeforeInput")).length&&(a=new _n("onBeforeInput","beforeinput",null,n,a),i.push({event:a,listeners:r}),a.data=y))}Dr(i,t)}))}function Gr(e,t,n){return{instance:e,listener:t,currentTarget:n}}function Hr(e,t){for(var n=t+"Capture",r=[];null!==e;){var a=e,o=a.stateNode;5===a.tag&&null!==o&&(a=o,null!=(o=Oe(e,n))&&r.unshift(Gr(e,o,a)),null!=(o=Oe(e,t))&&r.push(Gr(e,o,a))),e=e.return}return r}function $r(e){if(null===e)return null;do{e=e.return}while(e&&5!==e.tag);return e||null}function Jr(e,t,n,r,a){for(var o=t._reactName,i=[];null!==n&&n!==r;){var s=n,l=s.alternate,u=s.stateNode;if(null!==l&&l===r)break;5===s.tag&&null!==u&&(s=u,a?null!=(l=Oe(n,o))&&i.unshift(Gr(n,l,s)):a||null!=(l=Oe(n,o))&&i.push(Gr(n,l,s))),n=n.return}0!==i.length&&e.push({event:t,listeners:i})}var qr=/\r\n?/g,Kr=/\u0000|\uFFFD/g;function Qr(e){return("string"===typeof e?e:""+e).replace(qr,"\n").replace(Kr,"")}function Yr(e,t,n){if(t=Qr(t),Qr(e)!==t&&n)throw Error(o(425))}function Xr(){}var ea=null,ta=null;function na(e,t){return"textarea"===e||"noscript"===e||"string"===typeof t.children||"number"===typeof t.children||"object"===typeof t.dangerouslySetInnerHTML&&null!==t.dangerouslySetInnerHTML&&null!=t.dangerouslySetInnerHTML.__html}var ra="function"===typeof setTimeout?setTimeout:void 0,aa="function"===typeof clearTimeout?clearTimeout:void 0,oa="function"===typeof Promise?Promise:void 0,ia="function"===typeof queueMicrotask?queueMicrotask:"undefined"!==typeof oa?function(e){return oa.resolve(null).then(e).catch(sa)}:ra;function sa(e){setTimeout((function(){throw e}))}function la(e,t){var n=t,r=0;do{var a=n.nextSibling;if(e.removeChild(n),a&&8===a.nodeType)if("/$"===(n=a.data)){if(0===r)return e.removeChild(a),void Wt(t);r--}else"$"!==n&&"$?"!==n&&"$!"!==n||r++;n=a}while(n);Wt(t)}function ua(e){for(;null!=e;e=e.nextSibling){var t=e.nodeType;if(1===t||3===t)break;if(8===t){if("$"===(t=e.data)||"$!"===t||"$?"===t)break;if("/$"===t)return null}}return e}function ca(e){e=e.previousSibling;for(var t=0;e;){if(8===e.nodeType){var n=e.data;if("$"===n||"$!"===n||"$?"===n){if(0===t)return e;t--}else"/$"===n&&t++}e=e.previousSibling}return null}var da=Math.random().toString(36).slice(2),fa="__reactFiber$"+da,pa="__reactProps$"+da,ma="__reactContainer$"+da,ha="__reactEvents$"+da,va="__reactListeners$"+da,ba="__reactHandles$"+da;function ya(e){var t=e[fa];if(t)return t;for(var n=e.parentNode;n;){if(t=n[ma]||n[fa]){if(n=t.alternate,null!==t.child||null!==n&&null!==n.child)for(e=ca(e);null!==e;){if(n=e[fa])return n;e=ca(e)}return t}n=(e=n).parentNode}return null}function ga(e){return!(e=e[fa]||e[ma])||5!==e.tag&&6!==e.tag&&13!==e.tag&&3!==e.tag?null:e}function _a(e){if(5===e.tag||6===e.tag)return e.stateNode;throw Error(o(33))}function wa(e){return e[pa]||null}var Sa=[],Ca=-1;function ka(e){return{current:e}}function Ta(e){0>Ca||(e.current=Sa[Ca],Sa[Ca]=null,Ca--)}function xa(e,t){Ca++,Sa[Ca]=e.current,e.current=t}var Ea={},Pa=ka(Ea),Aa=ka(!1),Ra=Ea;function Fa(e,t){var n=e.type.contextTypes;if(!n)return Ea;var r=e.stateNode;if(r&&r.__reactInternalMemoizedUnmaskedChildContext===t)return r.__reactInternalMemoizedMaskedChildContext;var a,o={};for(a in n)o[a]=t[a];return r&&((e=e.stateNode).__reactInternalMemoizedUnmaskedChildContext=t,e.__reactInternalMemoizedMaskedChildContext=o),o}function Oa(e){return null!==(e=e.childContextTypes)&&void 0!==e}function Na(){Ta(Aa),Ta(Pa)}function Ma(e,t,n){if(Pa.current!==Ea)throw Error(o(168));xa(Pa,t),xa(Aa,n)}function Ia(e,t,n){var r=e.stateNode;if(t=t.childContextTypes,"function"!==typeof r.getChildContext)return n;for(var a in r=r.getChildContext())if(!(a in t))throw Error(o(108,U(e)||"Unknown",a));return L({},n,r)}function za(e){return e=(e=e.stateNode)&&e.__reactInternalMemoizedMergedChildContext||Ea,Ra=Pa.current,xa(Pa,e),xa(Aa,Aa.current),!0}function La(e,t,n){var r=e.stateNode;if(!r)throw Error(o(169));n?(e=Ia(e,t,Ra),r.__reactInternalMemoizedMergedChildContext=e,Ta(Aa),Ta(Pa),xa(Pa,e)):Ta(Aa),xa(Aa,n)}var Da=null,ja=!1,Za=!1;function Ba(e){null===Da?Da=[e]:Da.push(e)}function Wa(){if(!Za&&null!==Da){Za=!0;var e=0,t=gt;try{var n=Da;for(gt=1;e<n.length;e++){var r=n[e];do{r=r(!0)}while(null!==r)}Da=null,ja=!1}catch(a){throw null!==Da&&(Da=Da.slice(e+1)),$e(Xe,Wa),a}finally{gt=t,Za=!1}}return null}var Ua=[],Va=0,Ga=null,Ha=0,$a=[],Ja=0,qa=null,Ka=1,Qa="";function Ya(e,t){Ua[Va++]=Ha,Ua[Va++]=Ga,Ga=e,Ha=t}function Xa(e,t,n){$a[Ja++]=Ka,$a[Ja++]=Qa,$a[Ja++]=qa,qa=e;var r=Ka;e=Qa;var a=32-it(r)-1;r&=~(1<<a),n+=1;var o=32-it(t)+a;if(30<o){var i=a-a%5;o=(r&(1<<i)-1).toString(32),r>>=i,a-=i,Ka=1<<32-it(t)+a|n<<a|r,Qa=o+e}else Ka=1<<o|n<<a|r,Qa=e}function eo(e){null!==e.return&&(Ya(e,1),Xa(e,1,0))}function to(e){for(;e===Ga;)Ga=Ua[--Va],Ua[Va]=null,Ha=Ua[--Va],Ua[Va]=null;for(;e===qa;)qa=$a[--Ja],$a[Ja]=null,Qa=$a[--Ja],$a[Ja]=null,Ka=$a[--Ja],$a[Ja]=null}var no=null,ro=null,ao=!1,oo=null;function io(e,t){var n=Fu(5,null,null,0);n.elementType="DELETED",n.stateNode=t,n.return=e,null===(t=e.deletions)?(e.deletions=[n],e.flags|=16):t.push(n)}function so(e,t){switch(e.tag){case 5:var n=e.type;return null!==(t=1!==t.nodeType||n.toLowerCase()!==t.nodeName.toLowerCase()?null:t)&&(e.stateNode=t,no=e,ro=ua(t.firstChild),!0);case 6:return null!==(t=""===e.pendingProps||3!==t.nodeType?null:t)&&(e.stateNode=t,no=e,ro=null,!0);case 13:return null!==(t=8!==t.nodeType?null:t)&&(n=null!==qa?{id:Ka,overflow:Qa}:null,e.memoizedState={dehydrated:t,treeContext:n,retryLane:1073741824},(n=Fu(18,null,null,0)).stateNode=t,n.return=e,e.child=n,no=e,ro=null,!0);default:return!1}}function lo(e){return 0!==(1&e.mode)&&0===(128&e.flags)}function uo(e){if(ao){var t=ro;if(t){var n=t;if(!so(e,t)){if(lo(e))throw Error(o(418));t=ua(n.nextSibling);var r=no;t&&so(e,t)?io(r,n):(e.flags=-4097&e.flags|2,ao=!1,no=e)}}else{if(lo(e))throw Error(o(418));e.flags=-4097&e.flags|2,ao=!1,no=e}}}function co(e){for(e=e.return;null!==e&&5!==e.tag&&3!==e.tag&&13!==e.tag;)e=e.return;no=e}function fo(e){if(e!==no)return!1;if(!ao)return co(e),ao=!0,!1;var t;if((t=3!==e.tag)&&!(t=5!==e.tag)&&(t="head"!==(t=e.type)&&"body"!==t&&!na(e.type,e.memoizedProps)),t&&(t=ro)){if(lo(e))throw po(),Error(o(418));for(;t;)io(e,t),t=ua(t.nextSibling)}if(co(e),13===e.tag){if(!(e=null!==(e=e.memoizedState)?e.dehydrated:null))throw Error(o(317));e:{for(e=e.nextSibling,t=0;e;){if(8===e.nodeType){var n=e.data;if("/$"===n){if(0===t){ro=ua(e.nextSibling);break e}t--}else"$"!==n&&"$!"!==n&&"$?"!==n||t++}e=e.nextSibling}ro=null}}else ro=no?ua(e.stateNode.nextSibling):null;return!0}function po(){for(var e=ro;e;)e=ua(e.nextSibling)}function mo(){ro=no=null,ao=!1}function ho(e){null===oo?oo=[e]:oo.push(e)}var vo=_.ReactCurrentBatchConfig;function bo(e,t){if(e&&e.defaultProps){for(var n in t=L({},t),e=e.defaultProps)void 0===t[n]&&(t[n]=e[n]);return t}return t}var yo=ka(null),go=null,_o=null,wo=null;function So(){wo=_o=go=null}function Co(e){var t=yo.current;Ta(yo),e._currentValue=t}function ko(e,t,n){for(;null!==e;){var r=e.alternate;if((e.childLanes&t)!==t?(e.childLanes|=t,null!==r&&(r.childLanes|=t)):null!==r&&(r.childLanes&t)!==t&&(r.childLanes|=t),e===n)break;e=e.return}}function To(e,t){go=e,wo=_o=null,null!==(e=e.dependencies)&&null!==e.firstContext&&(0!==(e.lanes&t)&&(_s=!0),e.firstContext=null)}function xo(e){var t=e._currentValue;if(wo!==e)if(e={context:e,memoizedValue:t,next:null},null===_o){if(null===go)throw Error(o(308));_o=e,go.dependencies={lanes:0,firstContext:e}}else _o=_o.next=e;return t}var Eo=null;function Po(e){null===Eo?Eo=[e]:Eo.push(e)}function Ao(e,t,n,r){var a=t.interleaved;return null===a?(n.next=n,Po(t)):(n.next=a.next,a.next=n),t.interleaved=n,Ro(e,r)}function Ro(e,t){e.lanes|=t;var n=e.alternate;for(null!==n&&(n.lanes|=t),n=e,e=e.return;null!==e;)e.childLanes|=t,null!==(n=e.alternate)&&(n.childLanes|=t),n=e,e=e.return;return 3===n.tag?n.stateNode:null}var Fo=!1;function Oo(e){e.updateQueue={baseState:e.memoizedState,firstBaseUpdate:null,lastBaseUpdate:null,shared:{pending:null,interleaved:null,lanes:0},effects:null}}function No(e,t){e=e.updateQueue,t.updateQueue===e&&(t.updateQueue={baseState:e.baseState,firstBaseUpdate:e.firstBaseUpdate,lastBaseUpdate:e.lastBaseUpdate,shared:e.shared,effects:e.effects})}function Mo(e,t){return{eventTime:e,lane:t,tag:0,payload:null,callback:null,next:null}}function Io(e,t,n){var r=e.updateQueue;if(null===r)return null;if(r=r.shared,0!==(2&Pl)){var a=r.pending;return null===a?t.next=t:(t.next=a.next,a.next=t),r.pending=t,Ro(e,n)}return null===(a=r.interleaved)?(t.next=t,Po(r)):(t.next=a.next,a.next=t),r.interleaved=t,Ro(e,n)}function zo(e,t,n){if(null!==(t=t.updateQueue)&&(t=t.shared,0!==(4194240&n))){var r=t.lanes;n|=r&=e.pendingLanes,t.lanes=n,yt(e,n)}}function Lo(e,t){var n=e.updateQueue,r=e.alternate;if(null!==r&&n===(r=r.updateQueue)){var a=null,o=null;if(null!==(n=n.firstBaseUpdate)){do{var i={eventTime:n.eventTime,lane:n.lane,tag:n.tag,payload:n.payload,callback:n.callback,next:null};null===o?a=o=i:o=o.next=i,n=n.next}while(null!==n);null===o?a=o=t:o=o.next=t}else a=o=t;return n={baseState:r.baseState,firstBaseUpdate:a,lastBaseUpdate:o,shared:r.shared,effects:r.effects},void(e.updateQueue=n)}null===(e=n.lastBaseUpdate)?n.firstBaseUpdate=t:e.next=t,n.lastBaseUpdate=t}function Do(e,t,n,r){var a=e.updateQueue;Fo=!1;var o=a.firstBaseUpdate,i=a.lastBaseUpdate,s=a.shared.pending;if(null!==s){a.shared.pending=null;var l=s,u=l.next;l.next=null,null===i?o=u:i.next=u,i=l;var c=e.alternate;null!==c&&((s=(c=c.updateQueue).lastBaseUpdate)!==i&&(null===s?c.firstBaseUpdate=u:s.next=u,c.lastBaseUpdate=l))}if(null!==o){var d=a.baseState;for(i=0,c=u=l=null,s=o;;){var f=s.lane,p=s.eventTime;if((r&f)===f){null!==c&&(c=c.next={eventTime:p,lane:0,tag:s.tag,payload:s.payload,callback:s.callback,next:null});e:{var m=e,h=s;switch(f=t,p=n,h.tag){case 1:if("function"===typeof(m=h.payload)){d=m.call(p,d,f);break e}d=m;break e;case 3:m.flags=-65537&m.flags|128;case 0:if(null===(f="function"===typeof(m=h.payload)?m.call(p,d,f):m)||void 0===f)break e;d=L({},d,f);break e;case 2:Fo=!0}}null!==s.callback&&0!==s.lane&&(e.flags|=64,null===(f=a.effects)?a.effects=[s]:f.push(s))}else p={eventTime:p,lane:f,tag:s.tag,payload:s.payload,callback:s.callback,next:null},null===c?(u=c=p,l=d):c=c.next=p,i|=f;if(null===(s=s.next)){if(null===(s=a.shared.pending))break;s=(f=s).next,f.next=null,a.lastBaseUpdate=f,a.shared.pending=null}}if(null===c&&(l=d),a.baseState=l,a.firstBaseUpdate=u,a.lastBaseUpdate=c,null!==(t=a.shared.interleaved)){a=t;do{i|=a.lane,a=a.next}while(a!==t)}else null===o&&(a.shared.lanes=0);zl|=i,e.lanes=i,e.memoizedState=d}}function jo(e,t,n){if(e=t.effects,t.effects=null,null!==e)for(t=0;t<e.length;t++){var r=e[t],a=r.callback;if(null!==a){if(r.callback=null,r=n,"function"!==typeof a)throw Error(o(191,a));a.call(r)}}}var Zo=(new r.Component).refs;function Bo(e,t,n,r){n=null===(n=n(r,t=e.memoizedState))||void 0===n?t:L({},t,n),e.memoizedState=n,0===e.lanes&&(e.updateQueue.baseState=n)}var Wo={isMounted:function(e){return!!(e=e._reactInternals)&&We(e)===e},enqueueSetState:function(e,t,n){e=e._reactInternals;var r=eu(),a=tu(e),o=Mo(r,a);o.payload=t,void 0!==n&&null!==n&&(o.callback=n),null!==(t=Io(e,o,a))&&(nu(t,e,a,r),zo(t,e,a))},enqueueReplaceState:function(e,t,n){e=e._reactInternals;var r=eu(),a=tu(e),o=Mo(r,a);o.tag=1,o.payload=t,void 0!==n&&null!==n&&(o.callback=n),null!==(t=Io(e,o,a))&&(nu(t,e,a,r),zo(t,e,a))},enqueueForceUpdate:function(e,t){e=e._reactInternals;var n=eu(),r=tu(e),a=Mo(n,r);a.tag=2,void 0!==t&&null!==t&&(a.callback=t),null!==(t=Io(e,a,r))&&(nu(t,e,r,n),zo(t,e,r))}};function Uo(e,t,n,r,a,o,i){return"function"===typeof(e=e.stateNode).shouldComponentUpdate?e.shouldComponentUpdate(r,o,i):!t.prototype||!t.prototype.isPureReactComponent||(!lr(n,r)||!lr(a,o))}function Vo(e,t,n){var r=!1,a=Ea,o=t.contextType;return"object"===typeof o&&null!==o?o=xo(o):(a=Oa(t)?Ra:Pa.current,o=(r=null!==(r=t.contextTypes)&&void 0!==r)?Fa(e,a):Ea),t=new t(n,o),e.memoizedState=null!==t.state&&void 0!==t.state?t.state:null,t.updater=Wo,e.stateNode=t,t._reactInternals=e,r&&((e=e.stateNode).__reactInternalMemoizedUnmaskedChildContext=a,e.__reactInternalMemoizedMaskedChildContext=o),t}function Go(e,t,n,r){e=t.state,"function"===typeof t.componentWillReceiveProps&&t.componentWillReceiveProps(n,r),"function"===typeof t.UNSAFE_componentWillReceiveProps&&t.UNSAFE_componentWillReceiveProps(n,r),t.state!==e&&Wo.enqueueReplaceState(t,t.state,null)}function Ho(e,t,n,r){var a=e.stateNode;a.props=n,a.state=e.memoizedState,a.refs=Zo,Oo(e);var o=t.contextType;"object"===typeof o&&null!==o?a.context=xo(o):(o=Oa(t)?Ra:Pa.current,a.context=Fa(e,o)),a.state=e.memoizedState,"function"===typeof(o=t.getDerivedStateFromProps)&&(Bo(e,t,o,n),a.state=e.memoizedState),"function"===typeof t.getDerivedStateFromProps||"function"===typeof a.getSnapshotBeforeUpdate||"function"!==typeof a.UNSAFE_componentWillMount&&"function"!==typeof a.componentWillMount||(t=a.state,"function"===typeof a.componentWillMount&&a.componentWillMount(),"function"===typeof a.UNSAFE_componentWillMount&&a.UNSAFE_componentWillMount(),t!==a.state&&Wo.enqueueReplaceState(a,a.state,null),Do(e,n,a,r),a.state=e.memoizedState),"function"===typeof a.componentDidMount&&(e.flags|=4194308)}function $o(e,t,n){if(null!==(e=n.ref)&&"function"!==typeof e&&"object"!==typeof e){if(n._owner){if(n=n._owner){if(1!==n.tag)throw Error(o(309));var r=n.stateNode}if(!r)throw Error(o(147,e));var a=r,i=""+e;return null!==t&&null!==t.ref&&"function"===typeof t.ref&&t.ref._stringRef===i?t.ref:(t=function(e){var t=a.refs;t===Zo&&(t=a.refs={}),null===e?delete t[i]:t[i]=e},t._stringRef=i,t)}if("string"!==typeof e)throw Error(o(284));if(!n._owner)throw Error(o(290,e))}return e}function Jo(e,t){throw e=Object.prototype.toString.call(t),Error(o(31,"[object Object]"===e?"object with keys {"+Object.keys(t).join(", ")+"}":e))}function qo(e){return(0,e._init)(e._payload)}function Ko(e){function t(t,n){if(e){var r=t.deletions;null===r?(t.deletions=[n],t.flags|=16):r.push(n)}}function n(n,r){if(!e)return null;for(;null!==r;)t(n,r),r=r.sibling;return null}function r(e,t){for(e=new Map;null!==t;)null!==t.key?e.set(t.key,t):e.set(t.index,t),t=t.sibling;return e}function a(e,t){return(e=Nu(e,t)).index=0,e.sibling=null,e}function i(t,n,r){return t.index=r,e?null!==(r=t.alternate)?(r=r.index)<n?(t.flags|=2,n):r:(t.flags|=2,n):(t.flags|=1048576,n)}function s(t){return e&&null===t.alternate&&(t.flags|=2),t}function l(e,t,n,r){return null===t||6!==t.tag?((t=Lu(n,e.mode,r)).return=e,t):((t=a(t,n)).return=e,t)}function u(e,t,n,r){var o=n.type;return o===C?d(e,t,n.props.children,r,n.key):null!==t&&(t.elementType===o||"object"===typeof o&&null!==o&&o.$$typeof===O&&qo(o)===t.type)?((r=a(t,n.props)).ref=$o(e,t,n),r.return=e,r):((r=Mu(n.type,n.key,n.props,null,e.mode,r)).ref=$o(e,t,n),r.return=e,r)}function c(e,t,n,r){return null===t||4!==t.tag||t.stateNode.containerInfo!==n.containerInfo||t.stateNode.implementation!==n.implementation?((t=Du(n,e.mode,r)).return=e,t):((t=a(t,n.children||[])).return=e,t)}function d(e,t,n,r,o){return null===t||7!==t.tag?((t=Iu(n,e.mode,r,o)).return=e,t):((t=a(t,n)).return=e,t)}function f(e,t,n){if("string"===typeof t&&""!==t||"number"===typeof t)return(t=Lu(""+t,e.mode,n)).return=e,t;if("object"===typeof t&&null!==t){switch(t.$$typeof){case w:return(n=Mu(t.type,t.key,t.props,null,e.mode,n)).ref=$o(e,null,t),n.return=e,n;case S:return(t=Du(t,e.mode,n)).return=e,t;case O:return f(e,(0,t._init)(t._payload),n)}if(te(t)||I(t))return(t=Iu(t,e.mode,n,null)).return=e,t;Jo(e,t)}return null}function p(e,t,n,r){var a=null!==t?t.key:null;if("string"===typeof n&&""!==n||"number"===typeof n)return null!==a?null:l(e,t,""+n,r);if("object"===typeof n&&null!==n){switch(n.$$typeof){case w:return n.key===a?u(e,t,n,r):null;case S:return n.key===a?c(e,t,n,r):null;case O:return p(e,t,(a=n._init)(n._payload),r)}if(te(n)||I(n))return null!==a?null:d(e,t,n,r,null);Jo(e,n)}return null}function m(e,t,n,r,a){if("string"===typeof r&&""!==r||"number"===typeof r)return l(t,e=e.get(n)||null,""+r,a);if("object"===typeof r&&null!==r){switch(r.$$typeof){case w:return u(t,e=e.get(null===r.key?n:r.key)||null,r,a);case S:return c(t,e=e.get(null===r.key?n:r.key)||null,r,a);case O:return m(e,t,n,(0,r._init)(r._payload),a)}if(te(r)||I(r))return d(t,e=e.get(n)||null,r,a,null);Jo(t,r)}return null}function h(a,o,s,l){for(var u=null,c=null,d=o,h=o=0,v=null;null!==d&&h<s.length;h++){d.index>h?(v=d,d=null):v=d.sibling;var b=p(a,d,s[h],l);if(null===b){null===d&&(d=v);break}e&&d&&null===b.alternate&&t(a,d),o=i(b,o,h),null===c?u=b:c.sibling=b,c=b,d=v}if(h===s.length)return n(a,d),ao&&Ya(a,h),u;if(null===d){for(;h<s.length;h++)null!==(d=f(a,s[h],l))&&(o=i(d,o,h),null===c?u=d:c.sibling=d,c=d);return ao&&Ya(a,h),u}for(d=r(a,d);h<s.length;h++)null!==(v=m(d,a,h,s[h],l))&&(e&&null!==v.alternate&&d.delete(null===v.key?h:v.key),o=i(v,o,h),null===c?u=v:c.sibling=v,c=v);return e&&d.forEach((function(e){return t(a,e)})),ao&&Ya(a,h),u}function v(a,s,l,u){var c=I(l);if("function"!==typeof c)throw Error(o(150));if(null==(l=c.call(l)))throw Error(o(151));for(var d=c=null,h=s,v=s=0,b=null,y=l.next();null!==h&&!y.done;v++,y=l.next()){h.index>v?(b=h,h=null):b=h.sibling;var g=p(a,h,y.value,u);if(null===g){null===h&&(h=b);break}e&&h&&null===g.alternate&&t(a,h),s=i(g,s,v),null===d?c=g:d.sibling=g,d=g,h=b}if(y.done)return n(a,h),ao&&Ya(a,v),c;if(null===h){for(;!y.done;v++,y=l.next())null!==(y=f(a,y.value,u))&&(s=i(y,s,v),null===d?c=y:d.sibling=y,d=y);return ao&&Ya(a,v),c}for(h=r(a,h);!y.done;v++,y=l.next())null!==(y=m(h,a,v,y.value,u))&&(e&&null!==y.alternate&&h.delete(null===y.key?v:y.key),s=i(y,s,v),null===d?c=y:d.sibling=y,d=y);return e&&h.forEach((function(e){return t(a,e)})),ao&&Ya(a,v),c}return function e(r,o,i,l){if("object"===typeof i&&null!==i&&i.type===C&&null===i.key&&(i=i.props.children),"object"===typeof i&&null!==i){switch(i.$$typeof){case w:e:{for(var u=i.key,c=o;null!==c;){if(c.key===u){if((u=i.type)===C){if(7===c.tag){n(r,c.sibling),(o=a(c,i.props.children)).return=r,r=o;break e}}else if(c.elementType===u||"object"===typeof u&&null!==u&&u.$$typeof===O&&qo(u)===c.type){n(r,c.sibling),(o=a(c,i.props)).ref=$o(r,c,i),o.return=r,r=o;break e}n(r,c);break}t(r,c),c=c.sibling}i.type===C?((o=Iu(i.props.children,r.mode,l,i.key)).return=r,r=o):((l=Mu(i.type,i.key,i.props,null,r.mode,l)).ref=$o(r,o,i),l.return=r,r=l)}return s(r);case S:e:{for(c=i.key;null!==o;){if(o.key===c){if(4===o.tag&&o.stateNode.containerInfo===i.containerInfo&&o.stateNode.implementation===i.implementation){n(r,o.sibling),(o=a(o,i.children||[])).return=r,r=o;break e}n(r,o);break}t(r,o),o=o.sibling}(o=Du(i,r.mode,l)).return=r,r=o}return s(r);case O:return e(r,o,(c=i._init)(i._payload),l)}if(te(i))return h(r,o,i,l);if(I(i))return v(r,o,i,l);Jo(r,i)}return"string"===typeof i&&""!==i||"number"===typeof i?(i=""+i,null!==o&&6===o.tag?(n(r,o.sibling),(o=a(o,i)).return=r,r=o):(n(r,o),(o=Lu(i,r.mode,l)).return=r,r=o),s(r)):n(r,o)}}var Qo=Ko(!0),Yo=Ko(!1),Xo={},ei=ka(Xo),ti=ka(Xo),ni=ka(Xo);function ri(e){if(e===Xo)throw Error(o(174));return e}function ai(e,t){switch(xa(ni,t),xa(ti,e),xa(ei,Xo),e=t.nodeType){case 9:case 11:t=(t=t.documentElement)?t.namespaceURI:le(null,"");break;default:t=le(t=(e=8===e?t.parentNode:t).namespaceURI||null,e=e.tagName)}Ta(ei),xa(ei,t)}function oi(){Ta(ei),Ta(ti),Ta(ni)}function ii(e){ri(ni.current);var t=ri(ei.current),n=le(t,e.type);t!==n&&(xa(ti,e),xa(ei,n))}function si(e){ti.current===e&&(Ta(ei),Ta(ti))}var li=ka(0);function ui(e){for(var t=e;null!==t;){if(13===t.tag){var n=t.memoizedState;if(null!==n&&(null===(n=n.dehydrated)||"$?"===n.data||"$!"===n.data))return t}else if(19===t.tag&&void 0!==t.memoizedProps.revealOrder){if(0!==(128&t.flags))return t}else if(null!==t.child){t.child.return=t,t=t.child;continue}if(t===e)break;for(;null===t.sibling;){if(null===t.return||t.return===e)return null;t=t.return}t.sibling.return=t.return,t=t.sibling}return null}var ci=[];function di(){for(var e=0;e<ci.length;e++)ci[e]._workInProgressVersionPrimary=null;ci.length=0}var fi=_.ReactCurrentDispatcher,pi=_.ReactCurrentBatchConfig,mi=0,hi=null,vi=null,bi=null,yi=!1,gi=!1,_i=0,wi=0;function Si(){throw Error(o(321))}function Ci(e,t){if(null===t)return!1;for(var n=0;n<t.length&&n<e.length;n++)if(!sr(e[n],t[n]))return!1;return!0}function ki(e,t,n,r,a,i){if(mi=i,hi=t,t.memoizedState=null,t.updateQueue=null,t.lanes=0,fi.current=null===e||null===e.memoizedState?ss:ls,e=n(r,a),gi){i=0;do{if(gi=!1,_i=0,25<=i)throw Error(o(301));i+=1,bi=vi=null,t.updateQueue=null,fi.current=us,e=n(r,a)}while(gi)}if(fi.current=is,t=null!==vi&&null!==vi.next,mi=0,bi=vi=hi=null,yi=!1,t)throw Error(o(300));return e}function Ti(){var e=0!==_i;return _i=0,e}function xi(){var e={memoizedState:null,baseState:null,baseQueue:null,queue:null,next:null};return null===bi?hi.memoizedState=bi=e:bi=bi.next=e,bi}function Ei(){if(null===vi){var e=hi.alternate;e=null!==e?e.memoizedState:null}else e=vi.next;var t=null===bi?hi.memoizedState:bi.next;if(null!==t)bi=t,vi=e;else{if(null===e)throw Error(o(310));e={memoizedState:(vi=e).memoizedState,baseState:vi.baseState,baseQueue:vi.baseQueue,queue:vi.queue,next:null},null===bi?hi.memoizedState=bi=e:bi=bi.next=e}return bi}function Pi(e,t){return"function"===typeof t?t(e):t}function Ai(e){var t=Ei(),n=t.queue;if(null===n)throw Error(o(311));n.lastRenderedReducer=e;var r=vi,a=r.baseQueue,i=n.pending;if(null!==i){if(null!==a){var s=a.next;a.next=i.next,i.next=s}r.baseQueue=a=i,n.pending=null}if(null!==a){i=a.next,r=r.baseState;var l=s=null,u=null,c=i;do{var d=c.lane;if((mi&d)===d)null!==u&&(u=u.next={lane:0,action:c.action,hasEagerState:c.hasEagerState,eagerState:c.eagerState,next:null}),r=c.hasEagerState?c.eagerState:e(r,c.action);else{var f={lane:d,action:c.action,hasEagerState:c.hasEagerState,eagerState:c.eagerState,next:null};null===u?(l=u=f,s=r):u=u.next=f,hi.lanes|=d,zl|=d}c=c.next}while(null!==c&&c!==i);null===u?s=r:u.next=l,sr(r,t.memoizedState)||(_s=!0),t.memoizedState=r,t.baseState=s,t.baseQueue=u,n.lastRenderedState=r}if(null!==(e=n.interleaved)){a=e;do{i=a.lane,hi.lanes|=i,zl|=i,a=a.next}while(a!==e)}else null===a&&(n.lanes=0);return[t.memoizedState,n.dispatch]}function Ri(e){var t=Ei(),n=t.queue;if(null===n)throw Error(o(311));n.lastRenderedReducer=e;var r=n.dispatch,a=n.pending,i=t.memoizedState;if(null!==a){n.pending=null;var s=a=a.next;do{i=e(i,s.action),s=s.next}while(s!==a);sr(i,t.memoizedState)||(_s=!0),t.memoizedState=i,null===t.baseQueue&&(t.baseState=i),n.lastRenderedState=i}return[i,r]}function Fi(){}function Oi(e,t){var n=hi,r=Ei(),a=t(),i=!sr(r.memoizedState,a);if(i&&(r.memoizedState=a,_s=!0),r=r.queue,Vi(Ii.bind(null,n,r,e),[e]),r.getSnapshot!==t||i||null!==bi&&1&bi.memoizedState.tag){if(n.flags|=2048,ji(9,Mi.bind(null,n,r,a,t),void 0,null),null===Al)throw Error(o(349));0!==(30&mi)||Ni(n,t,a)}return a}function Ni(e,t,n){e.flags|=16384,e={getSnapshot:t,value:n},null===(t=hi.updateQueue)?(t={lastEffect:null,stores:null},hi.updateQueue=t,t.stores=[e]):null===(n=t.stores)?t.stores=[e]:n.push(e)}function Mi(e,t,n,r){t.value=n,t.getSnapshot=r,zi(t)&&Li(e)}function Ii(e,t,n){return n((function(){zi(t)&&Li(e)}))}function zi(e){var t=e.getSnapshot;e=e.value;try{var n=t();return!sr(e,n)}catch(r){return!0}}function Li(e){var t=Ro(e,1);null!==t&&nu(t,e,1,-1)}function Di(e){var t=xi();return"function"===typeof e&&(e=e()),t.memoizedState=t.baseState=e,e={pending:null,interleaved:null,lanes:0,dispatch:null,lastRenderedReducer:Pi,lastRenderedState:e},t.queue=e,e=e.dispatch=ns.bind(null,hi,e),[t.memoizedState,e]}function ji(e,t,n,r){return e={tag:e,create:t,destroy:n,deps:r,next:null},null===(t=hi.updateQueue)?(t={lastEffect:null,stores:null},hi.updateQueue=t,t.lastEffect=e.next=e):null===(n=t.lastEffect)?t.lastEffect=e.next=e:(r=n.next,n.next=e,e.next=r,t.lastEffect=e),e}function Zi(){return Ei().memoizedState}function Bi(e,t,n,r){var a=xi();hi.flags|=e,a.memoizedState=ji(1|t,n,void 0,void 0===r?null:r)}function Wi(e,t,n,r){var a=Ei();r=void 0===r?null:r;var o=void 0;if(null!==vi){var i=vi.memoizedState;if(o=i.destroy,null!==r&&Ci(r,i.deps))return void(a.memoizedState=ji(t,n,o,r))}hi.flags|=e,a.memoizedState=ji(1|t,n,o,r)}function Ui(e,t){return Bi(8390656,8,e,t)}function Vi(e,t){return Wi(2048,8,e,t)}function Gi(e,t){return Wi(4,2,e,t)}function Hi(e,t){return Wi(4,4,e,t)}function $i(e,t){return"function"===typeof t?(e=e(),t(e),function(){t(null)}):null!==t&&void 0!==t?(e=e(),t.current=e,function(){t.current=null}):void 0}function Ji(e,t,n){return n=null!==n&&void 0!==n?n.concat([e]):null,Wi(4,4,$i.bind(null,t,e),n)}function qi(){}function Ki(e,t){var n=Ei();t=void 0===t?null:t;var r=n.memoizedState;return null!==r&&null!==t&&Ci(t,r[1])?r[0]:(n.memoizedState=[e,t],e)}function Qi(e,t){var n=Ei();t=void 0===t?null:t;var r=n.memoizedState;return null!==r&&null!==t&&Ci(t,r[1])?r[0]:(e=e(),n.memoizedState=[e,t],e)}function Yi(e,t,n){return 0===(21&mi)?(e.baseState&&(e.baseState=!1,_s=!0),e.memoizedState=n):(sr(n,t)||(n=ht(),hi.lanes|=n,zl|=n,e.baseState=!0),t)}function Xi(e,t){var n=gt;gt=0!==n&&4>n?n:4,e(!0);var r=pi.transition;pi.transition={};try{e(!1),t()}finally{gt=n,pi.transition=r}}function es(){return Ei().memoizedState}function ts(e,t,n){var r=tu(e);if(n={lane:r,action:n,hasEagerState:!1,eagerState:null,next:null},rs(e))as(t,n);else if(null!==(n=Ao(e,t,n,r))){nu(n,e,r,eu()),os(n,t,r)}}function ns(e,t,n){var r=tu(e),a={lane:r,action:n,hasEagerState:!1,eagerState:null,next:null};if(rs(e))as(t,a);else{var o=e.alternate;if(0===e.lanes&&(null===o||0===o.lanes)&&null!==(o=t.lastRenderedReducer))try{var i=t.lastRenderedState,s=o(i,n);if(a.hasEagerState=!0,a.eagerState=s,sr(s,i)){var l=t.interleaved;return null===l?(a.next=a,Po(t)):(a.next=l.next,l.next=a),void(t.interleaved=a)}}catch(u){}null!==(n=Ao(e,t,a,r))&&(nu(n,e,r,a=eu()),os(n,t,r))}}function rs(e){var t=e.alternate;return e===hi||null!==t&&t===hi}function as(e,t){gi=yi=!0;var n=e.pending;null===n?t.next=t:(t.next=n.next,n.next=t),e.pending=t}function os(e,t,n){if(0!==(4194240&n)){var r=t.lanes;n|=r&=e.pendingLanes,t.lanes=n,yt(e,n)}}var is={readContext:xo,useCallback:Si,useContext:Si,useEffect:Si,useImperativeHandle:Si,useInsertionEffect:Si,useLayoutEffect:Si,useMemo:Si,useReducer:Si,useRef:Si,useState:Si,useDebugValue:Si,useDeferredValue:Si,useTransition:Si,useMutableSource:Si,useSyncExternalStore:Si,useId:Si,unstable_isNewReconciler:!1},ss={readContext:xo,useCallback:function(e,t){return xi().memoizedState=[e,void 0===t?null:t],e},useContext:xo,useEffect:Ui,useImperativeHandle:function(e,t,n){return n=null!==n&&void 0!==n?n.concat([e]):null,Bi(4194308,4,$i.bind(null,t,e),n)},useLayoutEffect:function(e,t){return Bi(4194308,4,e,t)},useInsertionEffect:function(e,t){return Bi(4,2,e,t)},useMemo:function(e,t){var n=xi();return t=void 0===t?null:t,e=e(),n.memoizedState=[e,t],e},useReducer:function(e,t,n){var r=xi();return t=void 0!==n?n(t):t,r.memoizedState=r.baseState=t,e={pending:null,interleaved:null,lanes:0,dispatch:null,lastRenderedReducer:e,lastRenderedState:t},r.queue=e,e=e.dispatch=ts.bind(null,hi,e),[r.memoizedState,e]},useRef:function(e){return e={current:e},xi().memoizedState=e},useState:Di,useDebugValue:qi,useDeferredValue:function(e){return xi().memoizedState=e},useTransition:function(){var e=Di(!1),t=e[0];return e=Xi.bind(null,e[1]),xi().memoizedState=e,[t,e]},useMutableSource:function(){},useSyncExternalStore:function(e,t,n){var r=hi,a=xi();if(ao){if(void 0===n)throw Error(o(407));n=n()}else{if(n=t(),null===Al)throw Error(o(349));0!==(30&mi)||Ni(r,t,n)}a.memoizedState=n;var i={value:n,getSnapshot:t};return a.queue=i,Ui(Ii.bind(null,r,i,e),[e]),r.flags|=2048,ji(9,Mi.bind(null,r,i,n,t),void 0,null),n},useId:function(){var e=xi(),t=Al.identifierPrefix;if(ao){var n=Qa;t=":"+t+"R"+(n=(Ka&~(1<<32-it(Ka)-1)).toString(32)+n),0<(n=_i++)&&(t+="H"+n.toString(32)),t+=":"}else t=":"+t+"r"+(n=wi++).toString(32)+":";return e.memoizedState=t},unstable_isNewReconciler:!1},ls={readContext:xo,useCallback:Ki,useContext:xo,useEffect:Vi,useImperativeHandle:Ji,useInsertionEffect:Gi,useLayoutEffect:Hi,useMemo:Qi,useReducer:Ai,useRef:Zi,useState:function(){return Ai(Pi)},useDebugValue:qi,useDeferredValue:function(e){return Yi(Ei(),vi.memoizedState,e)},useTransition:function(){return[Ai(Pi)[0],Ei().memoizedState]},useMutableSource:Fi,useSyncExternalStore:Oi,useId:es,unstable_isNewReconciler:!1},us={readContext:xo,useCallback:Ki,useContext:xo,useEffect:Vi,useImperativeHandle:Ji,useInsertionEffect:Gi,useLayoutEffect:Hi,useMemo:Qi,useReducer:Ri,useRef:Zi,useState:function(){return Ri(Pi)},useDebugValue:qi,useDeferredValue:function(e){var t=Ei();return null===vi?t.memoizedState=e:Yi(t,vi.memoizedState,e)},useTransition:function(){return[Ri(Pi)[0],Ei().memoizedState]},useMutableSource:Fi,useSyncExternalStore:Oi,useId:es,unstable_isNewReconciler:!1};function cs(e,t){try{var n="",r=t;do{n+=B(r),r=r.return}while(r);var a=n}catch(o){a="\nError generating stack: "+o.message+"\n"+o.stack}return{value:e,source:t,stack:a,digest:null}}function ds(e,t,n){return{value:e,source:null,stack:null!=n?n:null,digest:null!=t?t:null}}function fs(e,t){try{console.error(t.value)}catch(n){setTimeout((function(){throw n}))}}var ps="function"===typeof WeakMap?WeakMap:Map;function ms(e,t,n){(n=Mo(-1,n)).tag=3,n.payload={element:null};var r=t.value;return n.callback=function(){Vl||(Vl=!0,Gl=r),fs(0,t)},n}function hs(e,t,n){(n=Mo(-1,n)).tag=3;var r=e.type.getDerivedStateFromError;if("function"===typeof r){var a=t.value;n.payload=function(){return r(a)},n.callback=function(){fs(0,t)}}var o=e.stateNode;return null!==o&&"function"===typeof o.componentDidCatch&&(n.callback=function(){fs(0,t),"function"!==typeof r&&(null===Hl?Hl=new Set([this]):Hl.add(this));var e=t.stack;this.componentDidCatch(t.value,{componentStack:null!==e?e:""})}),n}function vs(e,t,n){var r=e.pingCache;if(null===r){r=e.pingCache=new ps;var a=new Set;r.set(t,a)}else void 0===(a=r.get(t))&&(a=new Set,r.set(t,a));a.has(n)||(a.add(n),e=Tu.bind(null,e,t,n),t.then(e,e))}function bs(e){do{var t;if((t=13===e.tag)&&(t=null===(t=e.memoizedState)||null!==t.dehydrated),t)return e;e=e.return}while(null!==e);return null}function ys(e,t,n,r,a){return 0===(1&e.mode)?(e===t?e.flags|=65536:(e.flags|=128,n.flags|=131072,n.flags&=-52805,1===n.tag&&(null===n.alternate?n.tag=17:((t=Mo(-1,1)).tag=2,Io(n,t,1))),n.lanes|=1),e):(e.flags|=65536,e.lanes=a,e)}var gs=_.ReactCurrentOwner,_s=!1;function ws(e,t,n,r){t.child=null===e?Yo(t,null,n,r):Qo(t,e.child,n,r)}function Ss(e,t,n,r,a){n=n.render;var o=t.ref;return To(t,a),r=ki(e,t,n,r,o,a),n=Ti(),null===e||_s?(ao&&n&&eo(t),t.flags|=1,ws(e,t,r,a),t.child):(t.updateQueue=e.updateQueue,t.flags&=-2053,e.lanes&=~a,Vs(e,t,a))}function Cs(e,t,n,r,a){if(null===e){var o=n.type;return"function"!==typeof o||Ou(o)||void 0!==o.defaultProps||null!==n.compare||void 0!==n.defaultProps?((e=Mu(n.type,null,r,t,t.mode,a)).ref=t.ref,e.return=t,t.child=e):(t.tag=15,t.type=o,ks(e,t,o,r,a))}if(o=e.child,0===(e.lanes&a)){var i=o.memoizedProps;if((n=null!==(n=n.compare)?n:lr)(i,r)&&e.ref===t.ref)return Vs(e,t,a)}return t.flags|=1,(e=Nu(o,r)).ref=t.ref,e.return=t,t.child=e}function ks(e,t,n,r,a){if(null!==e){var o=e.memoizedProps;if(lr(o,r)&&e.ref===t.ref){if(_s=!1,t.pendingProps=r=o,0===(e.lanes&a))return t.lanes=e.lanes,Vs(e,t,a);0!==(131072&e.flags)&&(_s=!0)}}return Es(e,t,n,r,a)}function Ts(e,t,n){var r=t.pendingProps,a=r.children,o=null!==e?e.memoizedState:null;if("hidden"===r.mode)if(0===(1&t.mode))t.memoizedState={baseLanes:0,cachePool:null,transitions:null},xa(Nl,Ol),Ol|=n;else{if(0===(1073741824&n))return e=null!==o?o.baseLanes|n:n,t.lanes=t.childLanes=1073741824,t.memoizedState={baseLanes:e,cachePool:null,transitions:null},t.updateQueue=null,xa(Nl,Ol),Ol|=e,null;t.memoizedState={baseLanes:0,cachePool:null,transitions:null},r=null!==o?o.baseLanes:n,xa(Nl,Ol),Ol|=r}else null!==o?(r=o.baseLanes|n,t.memoizedState=null):r=n,xa(Nl,Ol),Ol|=r;return ws(e,t,a,n),t.child}function xs(e,t){var n=t.ref;(null===e&&null!==n||null!==e&&e.ref!==n)&&(t.flags|=512,t.flags|=2097152)}function Es(e,t,n,r,a){var o=Oa(n)?Ra:Pa.current;return o=Fa(t,o),To(t,a),n=ki(e,t,n,r,o,a),r=Ti(),null===e||_s?(ao&&r&&eo(t),t.flags|=1,ws(e,t,n,a),t.child):(t.updateQueue=e.updateQueue,t.flags&=-2053,e.lanes&=~a,Vs(e,t,a))}function Ps(e,t,n,r,a){if(Oa(n)){var o=!0;za(t)}else o=!1;if(To(t,a),null===t.stateNode)Us(e,t),Vo(t,n,r),Ho(t,n,r,a),r=!0;else if(null===e){var i=t.stateNode,s=t.memoizedProps;i.props=s;var l=i.context,u=n.contextType;"object"===typeof u&&null!==u?u=xo(u):u=Fa(t,u=Oa(n)?Ra:Pa.current);var c=n.getDerivedStateFromProps,d="function"===typeof c||"function"===typeof i.getSnapshotBeforeUpdate;d||"function"!==typeof i.UNSAFE_componentWillReceiveProps&&"function"!==typeof i.componentWillReceiveProps||(s!==r||l!==u)&&Go(t,i,r,u),Fo=!1;var f=t.memoizedState;i.state=f,Do(t,r,i,a),l=t.memoizedState,s!==r||f!==l||Aa.current||Fo?("function"===typeof c&&(Bo(t,n,c,r),l=t.memoizedState),(s=Fo||Uo(t,n,s,r,f,l,u))?(d||"function"!==typeof i.UNSAFE_componentWillMount&&"function"!==typeof i.componentWillMount||("function"===typeof i.componentWillMount&&i.componentWillMount(),"function"===typeof i.UNSAFE_componentWillMount&&i.UNSAFE_componentWillMount()),"function"===typeof i.componentDidMount&&(t.flags|=4194308)):("function"===typeof i.componentDidMount&&(t.flags|=4194308),t.memoizedProps=r,t.memoizedState=l),i.props=r,i.state=l,i.context=u,r=s):("function"===typeof i.componentDidMount&&(t.flags|=4194308),r=!1)}else{i=t.stateNode,No(e,t),s=t.memoizedProps,u=t.type===t.elementType?s:bo(t.type,s),i.props=u,d=t.pendingProps,f=i.context,"object"===typeof(l=n.contextType)&&null!==l?l=xo(l):l=Fa(t,l=Oa(n)?Ra:Pa.current);var p=n.getDerivedStateFromProps;(c="function"===typeof p||"function"===typeof i.getSnapshotBeforeUpdate)||"function"!==typeof i.UNSAFE_componentWillReceiveProps&&"function"!==typeof i.componentWillReceiveProps||(s!==d||f!==l)&&Go(t,i,r,l),Fo=!1,f=t.memoizedState,i.state=f,Do(t,r,i,a);var m=t.memoizedState;s!==d||f!==m||Aa.current||Fo?("function"===typeof p&&(Bo(t,n,p,r),m=t.memoizedState),(u=Fo||Uo(t,n,u,r,f,m,l)||!1)?(c||"function"!==typeof i.UNSAFE_componentWillUpdate&&"function"!==typeof i.componentWillUpdate||("function"===typeof i.componentWillUpdate&&i.componentWillUpdate(r,m,l),"function"===typeof i.UNSAFE_componentWillUpdate&&i.UNSAFE_componentWillUpdate(r,m,l)),"function"===typeof i.componentDidUpdate&&(t.flags|=4),"function"===typeof i.getSnapshotBeforeUpdate&&(t.flags|=1024)):("function"!==typeof i.componentDidUpdate||s===e.memoizedProps&&f===e.memoizedState||(t.flags|=4),"function"!==typeof i.getSnapshotBeforeUpdate||s===e.memoizedProps&&f===e.memoizedState||(t.flags|=1024),t.memoizedProps=r,t.memoizedState=m),i.props=r,i.state=m,i.context=l,r=u):("function"!==typeof i.componentDidUpdate||s===e.memoizedProps&&f===e.memoizedState||(t.flags|=4),"function"!==typeof i.getSnapshotBeforeUpdate||s===e.memoizedProps&&f===e.memoizedState||(t.flags|=1024),r=!1)}return As(e,t,n,r,o,a)}function As(e,t,n,r,a,o){xs(e,t);var i=0!==(128&t.flags);if(!r&&!i)return a&&La(t,n,!1),Vs(e,t,o);r=t.stateNode,gs.current=t;var s=i&&"function"!==typeof n.getDerivedStateFromError?null:r.render();return t.flags|=1,null!==e&&i?(t.child=Qo(t,e.child,null,o),t.child=Qo(t,null,s,o)):ws(e,t,s,o),t.memoizedState=r.state,a&&La(t,n,!0),t.child}function Rs(e){var t=e.stateNode;t.pendingContext?Ma(0,t.pendingContext,t.pendingContext!==t.context):t.context&&Ma(0,t.context,!1),ai(e,t.containerInfo)}function Fs(e,t,n,r,a){return mo(),ho(a),t.flags|=256,ws(e,t,n,r),t.child}var Os,Ns,Ms,Is={dehydrated:null,treeContext:null,retryLane:0};function zs(e){return{baseLanes:e,cachePool:null,transitions:null}}function Ls(e,t,n){var r,a=t.pendingProps,i=li.current,s=!1,l=0!==(128&t.flags);if((r=l)||(r=(null===e||null!==e.memoizedState)&&0!==(2&i)),r?(s=!0,t.flags&=-129):null!==e&&null===e.memoizedState||(i|=1),xa(li,1&i),null===e)return uo(t),null!==(e=t.memoizedState)&&null!==(e=e.dehydrated)?(0===(1&t.mode)?t.lanes=1:"$!"===e.data?t.lanes=8:t.lanes=1073741824,null):(l=a.children,e=a.fallback,s?(a=t.mode,s=t.child,l={mode:"hidden",children:l},0===(1&a)&&null!==s?(s.childLanes=0,s.pendingProps=l):s=zu(l,a,0,null),e=Iu(e,a,n,null),s.return=t,e.return=t,s.sibling=e,t.child=s,t.child.memoizedState=zs(n),t.memoizedState=Is,e):Ds(t,l));if(null!==(i=e.memoizedState)&&null!==(r=i.dehydrated))return function(e,t,n,r,a,i,s){if(n)return 256&t.flags?(t.flags&=-257,js(e,t,s,r=ds(Error(o(422))))):null!==t.memoizedState?(t.child=e.child,t.flags|=128,null):(i=r.fallback,a=t.mode,r=zu({mode:"visible",children:r.children},a,0,null),(i=Iu(i,a,s,null)).flags|=2,r.return=t,i.return=t,r.sibling=i,t.child=r,0!==(1&t.mode)&&Qo(t,e.child,null,s),t.child.memoizedState=zs(s),t.memoizedState=Is,i);if(0===(1&t.mode))return js(e,t,s,null);if("$!"===a.data){if(r=a.nextSibling&&a.nextSibling.dataset)var l=r.dgst;return r=l,js(e,t,s,r=ds(i=Error(o(419)),r,void 0))}if(l=0!==(s&e.childLanes),_s||l){if(null!==(r=Al)){switch(s&-s){case 4:a=2;break;case 16:a=8;break;case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:case 4194304:case 8388608:case 16777216:case 33554432:case 67108864:a=32;break;case 536870912:a=268435456;break;default:a=0}0!==(a=0!==(a&(r.suspendedLanes|s))?0:a)&&a!==i.retryLane&&(i.retryLane=a,Ro(e,a),nu(r,e,a,-1))}return hu(),js(e,t,s,r=ds(Error(o(421))))}return"$?"===a.data?(t.flags|=128,t.child=e.child,t=Eu.bind(null,e),a._reactRetry=t,null):(e=i.treeContext,ro=ua(a.nextSibling),no=t,ao=!0,oo=null,null!==e&&($a[Ja++]=Ka,$a[Ja++]=Qa,$a[Ja++]=qa,Ka=e.id,Qa=e.overflow,qa=t),(t=Ds(t,r.children)).flags|=4096,t)}(e,t,l,a,r,i,n);if(s){s=a.fallback,l=t.mode,r=(i=e.child).sibling;var u={mode:"hidden",children:a.children};return 0===(1&l)&&t.child!==i?((a=t.child).childLanes=0,a.pendingProps=u,t.deletions=null):(a=Nu(i,u)).subtreeFlags=14680064&i.subtreeFlags,null!==r?s=Nu(r,s):(s=Iu(s,l,n,null)).flags|=2,s.return=t,a.return=t,a.sibling=s,t.child=a,a=s,s=t.child,l=null===(l=e.child.memoizedState)?zs(n):{baseLanes:l.baseLanes|n,cachePool:null,transitions:l.transitions},s.memoizedState=l,s.childLanes=e.childLanes&~n,t.memoizedState=Is,a}return e=(s=e.child).sibling,a=Nu(s,{mode:"visible",children:a.children}),0===(1&t.mode)&&(a.lanes=n),a.return=t,a.sibling=null,null!==e&&(null===(n=t.deletions)?(t.deletions=[e],t.flags|=16):n.push(e)),t.child=a,t.memoizedState=null,a}function Ds(e,t){return(t=zu({mode:"visible",children:t},e.mode,0,null)).return=e,e.child=t}function js(e,t,n,r){return null!==r&&ho(r),Qo(t,e.child,null,n),(e=Ds(t,t.pendingProps.children)).flags|=2,t.memoizedState=null,e}function Zs(e,t,n){e.lanes|=t;var r=e.alternate;null!==r&&(r.lanes|=t),ko(e.return,t,n)}function Bs(e,t,n,r,a){var o=e.memoizedState;null===o?e.memoizedState={isBackwards:t,rendering:null,renderingStartTime:0,last:r,tail:n,tailMode:a}:(o.isBackwards=t,o.rendering=null,o.renderingStartTime=0,o.last=r,o.tail=n,o.tailMode=a)}function Ws(e,t,n){var r=t.pendingProps,a=r.revealOrder,o=r.tail;if(ws(e,t,r.children,n),0!==(2&(r=li.current)))r=1&r|2,t.flags|=128;else{if(null!==e&&0!==(128&e.flags))e:for(e=t.child;null!==e;){if(13===e.tag)null!==e.memoizedState&&Zs(e,n,t);else if(19===e.tag)Zs(e,n,t);else if(null!==e.child){e.child.return=e,e=e.child;continue}if(e===t)break e;for(;null===e.sibling;){if(null===e.return||e.return===t)break e;e=e.return}e.sibling.return=e.return,e=e.sibling}r&=1}if(xa(li,r),0===(1&t.mode))t.memoizedState=null;else switch(a){case"forwards":for(n=t.child,a=null;null!==n;)null!==(e=n.alternate)&&null===ui(e)&&(a=n),n=n.sibling;null===(n=a)?(a=t.child,t.child=null):(a=n.sibling,n.sibling=null),Bs(t,!1,a,n,o);break;case"backwards":for(n=null,a=t.child,t.child=null;null!==a;){if(null!==(e=a.alternate)&&null===ui(e)){t.child=a;break}e=a.sibling,a.sibling=n,n=a,a=e}Bs(t,!0,n,null,o);break;case"together":Bs(t,!1,null,null,void 0);break;default:t.memoizedState=null}return t.child}function Us(e,t){0===(1&t.mode)&&null!==e&&(e.alternate=null,t.alternate=null,t.flags|=2)}function Vs(e,t,n){if(null!==e&&(t.dependencies=e.dependencies),zl|=t.lanes,0===(n&t.childLanes))return null;if(null!==e&&t.child!==e.child)throw Error(o(153));if(null!==t.child){for(n=Nu(e=t.child,e.pendingProps),t.child=n,n.return=t;null!==e.sibling;)e=e.sibling,(n=n.sibling=Nu(e,e.pendingProps)).return=t;n.sibling=null}return t.child}function Gs(e,t){if(!ao)switch(e.tailMode){case"hidden":t=e.tail;for(var n=null;null!==t;)null!==t.alternate&&(n=t),t=t.sibling;null===n?e.tail=null:n.sibling=null;break;case"collapsed":n=e.tail;for(var r=null;null!==n;)null!==n.alternate&&(r=n),n=n.sibling;null===r?t||null===e.tail?e.tail=null:e.tail.sibling=null:r.sibling=null}}function Hs(e){var t=null!==e.alternate&&e.alternate.child===e.child,n=0,r=0;if(t)for(var a=e.child;null!==a;)n|=a.lanes|a.childLanes,r|=14680064&a.subtreeFlags,r|=14680064&a.flags,a.return=e,a=a.sibling;else for(a=e.child;null!==a;)n|=a.lanes|a.childLanes,r|=a.subtreeFlags,r|=a.flags,a.return=e,a=a.sibling;return e.subtreeFlags|=r,e.childLanes=n,t}function $s(e,t,n){var r=t.pendingProps;switch(to(t),t.tag){case 2:case 16:case 15:case 0:case 11:case 7:case 8:case 12:case 9:case 14:return Hs(t),null;case 1:case 17:return Oa(t.type)&&Na(),Hs(t),null;case 3:return r=t.stateNode,oi(),Ta(Aa),Ta(Pa),di(),r.pendingContext&&(r.context=r.pendingContext,r.pendingContext=null),null!==e&&null!==e.child||(fo(t)?t.flags|=4:null===e||e.memoizedState.isDehydrated&&0===(256&t.flags)||(t.flags|=1024,null!==oo&&(iu(oo),oo=null))),Hs(t),null;case 5:si(t);var a=ri(ni.current);if(n=t.type,null!==e&&null!=t.stateNode)Ns(e,t,n,r),e.ref!==t.ref&&(t.flags|=512,t.flags|=2097152);else{if(!r){if(null===t.stateNode)throw Error(o(166));return Hs(t),null}if(e=ri(ei.current),fo(t)){r=t.stateNode,n=t.type;var i=t.memoizedProps;switch(r[fa]=t,r[pa]=i,e=0!==(1&t.mode),n){case"dialog":jr("cancel",r),jr("close",r);break;case"iframe":case"object":case"embed":jr("load",r);break;case"video":case"audio":for(a=0;a<Ir.length;a++)jr(Ir[a],r);break;case"source":jr("error",r);break;case"img":case"image":case"link":jr("error",r),jr("load",r);break;case"details":jr("toggle",r);break;case"input":K(r,i),jr("invalid",r);break;case"select":r._wrapperState={wasMultiple:!!i.multiple},jr("invalid",r);break;case"textarea":ae(r,i),jr("invalid",r)}for(var l in ye(n,i),a=null,i)if(i.hasOwnProperty(l)){var u=i[l];"children"===l?"string"===typeof u?r.textContent!==u&&(!0!==i.suppressHydrationWarning&&Yr(r.textContent,u,e),a=["children",u]):"number"===typeof u&&r.textContent!==""+u&&(!0!==i.suppressHydrationWarning&&Yr(r.textContent,u,e),a=["children",""+u]):s.hasOwnProperty(l)&&null!=u&&"onScroll"===l&&jr("scroll",r)}switch(n){case"input":H(r),X(r,i,!0);break;case"textarea":H(r),ie(r);break;case"select":case"option":break;default:"function"===typeof i.onClick&&(r.onclick=Xr)}r=a,t.updateQueue=r,null!==r&&(t.flags|=4)}else{l=9===a.nodeType?a:a.ownerDocument,"http://www.w3.org/1999/xhtml"===e&&(e=se(n)),"http://www.w3.org/1999/xhtml"===e?"script"===n?((e=l.createElement("div")).innerHTML="<script><\/script>",e=e.removeChild(e.firstChild)):"string"===typeof r.is?e=l.createElement(n,{is:r.is}):(e=l.createElement(n),"select"===n&&(l=e,r.multiple?l.multiple=!0:r.size&&(l.size=r.size))):e=l.createElementNS(e,n),e[fa]=t,e[pa]=r,Os(e,t),t.stateNode=e;e:{switch(l=ge(n,r),n){case"dialog":jr("cancel",e),jr("close",e),a=r;break;case"iframe":case"object":case"embed":jr("load",e),a=r;break;case"video":case"audio":for(a=0;a<Ir.length;a++)jr(Ir[a],e);a=r;break;case"source":jr("error",e),a=r;break;case"img":case"image":case"link":jr("error",e),jr("load",e),a=r;break;case"details":jr("toggle",e),a=r;break;case"input":K(e,r),a=q(e,r),jr("invalid",e);break;case"option":default:a=r;break;case"select":e._wrapperState={wasMultiple:!!r.multiple},a=L({},r,{value:void 0}),jr("invalid",e);break;case"textarea":ae(e,r),a=re(e,r),jr("invalid",e)}for(i in ye(n,a),u=a)if(u.hasOwnProperty(i)){var c=u[i];"style"===i?ve(e,c):"dangerouslySetInnerHTML"===i?null!=(c=c?c.__html:void 0)&&de(e,c):"children"===i?"string"===typeof c?("textarea"!==n||""!==c)&&fe(e,c):"number"===typeof c&&fe(e,""+c):"suppressContentEditableWarning"!==i&&"suppressHydrationWarning"!==i&&"autoFocus"!==i&&(s.hasOwnProperty(i)?null!=c&&"onScroll"===i&&jr("scroll",e):null!=c&&g(e,i,c,l))}switch(n){case"input":H(e),X(e,r,!1);break;case"textarea":H(e),ie(e);break;case"option":null!=r.value&&e.setAttribute("value",""+V(r.value));break;case"select":e.multiple=!!r.multiple,null!=(i=r.value)?ne(e,!!r.multiple,i,!1):null!=r.defaultValue&&ne(e,!!r.multiple,r.defaultValue,!0);break;default:"function"===typeof a.onClick&&(e.onclick=Xr)}switch(n){case"button":case"input":case"select":case"textarea":r=!!r.autoFocus;break e;case"img":r=!0;break e;default:r=!1}}r&&(t.flags|=4)}null!==t.ref&&(t.flags|=512,t.flags|=2097152)}return Hs(t),null;case 6:if(e&&null!=t.stateNode)Ms(0,t,e.memoizedProps,r);else{if("string"!==typeof r&&null===t.stateNode)throw Error(o(166));if(n=ri(ni.current),ri(ei.current),fo(t)){if(r=t.stateNode,n=t.memoizedProps,r[fa]=t,(i=r.nodeValue!==n)&&null!==(e=no))switch(e.tag){case 3:Yr(r.nodeValue,n,0!==(1&e.mode));break;case 5:!0!==e.memoizedProps.suppressHydrationWarning&&Yr(r.nodeValue,n,0!==(1&e.mode))}i&&(t.flags|=4)}else(r=(9===n.nodeType?n:n.ownerDocument).createTextNode(r))[fa]=t,t.stateNode=r}return Hs(t),null;case 13:if(Ta(li),r=t.memoizedState,null===e||null!==e.memoizedState&&null!==e.memoizedState.dehydrated){if(ao&&null!==ro&&0!==(1&t.mode)&&0===(128&t.flags))po(),mo(),t.flags|=98560,i=!1;else if(i=fo(t),null!==r&&null!==r.dehydrated){if(null===e){if(!i)throw Error(o(318));if(!(i=null!==(i=t.memoizedState)?i.dehydrated:null))throw Error(o(317));i[fa]=t}else mo(),0===(128&t.flags)&&(t.memoizedState=null),t.flags|=4;Hs(t),i=!1}else null!==oo&&(iu(oo),oo=null),i=!0;if(!i)return 65536&t.flags?t:null}return 0!==(128&t.flags)?(t.lanes=n,t):((r=null!==r)!==(null!==e&&null!==e.memoizedState)&&r&&(t.child.flags|=8192,0!==(1&t.mode)&&(null===e||0!==(1&li.current)?0===Ml&&(Ml=3):hu())),null!==t.updateQueue&&(t.flags|=4),Hs(t),null);case 4:return oi(),null===e&&Wr(t.stateNode.containerInfo),Hs(t),null;case 10:return Co(t.type._context),Hs(t),null;case 19:if(Ta(li),null===(i=t.memoizedState))return Hs(t),null;if(r=0!==(128&t.flags),null===(l=i.rendering))if(r)Gs(i,!1);else{if(0!==Ml||null!==e&&0!==(128&e.flags))for(e=t.child;null!==e;){if(null!==(l=ui(e))){for(t.flags|=128,Gs(i,!1),null!==(r=l.updateQueue)&&(t.updateQueue=r,t.flags|=4),t.subtreeFlags=0,r=n,n=t.child;null!==n;)e=r,(i=n).flags&=14680066,null===(l=i.alternate)?(i.childLanes=0,i.lanes=e,i.child=null,i.subtreeFlags=0,i.memoizedProps=null,i.memoizedState=null,i.updateQueue=null,i.dependencies=null,i.stateNode=null):(i.childLanes=l.childLanes,i.lanes=l.lanes,i.child=l.child,i.subtreeFlags=0,i.deletions=null,i.memoizedProps=l.memoizedProps,i.memoizedState=l.memoizedState,i.updateQueue=l.updateQueue,i.type=l.type,e=l.dependencies,i.dependencies=null===e?null:{lanes:e.lanes,firstContext:e.firstContext}),n=n.sibling;return xa(li,1&li.current|2),t.child}e=e.sibling}null!==i.tail&&Qe()>Wl&&(t.flags|=128,r=!0,Gs(i,!1),t.lanes=4194304)}else{if(!r)if(null!==(e=ui(l))){if(t.flags|=128,r=!0,null!==(n=e.updateQueue)&&(t.updateQueue=n,t.flags|=4),Gs(i,!0),null===i.tail&&"hidden"===i.tailMode&&!l.alternate&&!ao)return Hs(t),null}else 2*Qe()-i.renderingStartTime>Wl&&1073741824!==n&&(t.flags|=128,r=!0,Gs(i,!1),t.lanes=4194304);i.isBackwards?(l.sibling=t.child,t.child=l):(null!==(n=i.last)?n.sibling=l:t.child=l,i.last=l)}return null!==i.tail?(t=i.tail,i.rendering=t,i.tail=t.sibling,i.renderingStartTime=Qe(),t.sibling=null,n=li.current,xa(li,r?1&n|2:1&n),t):(Hs(t),null);case 22:case 23:return du(),r=null!==t.memoizedState,null!==e&&null!==e.memoizedState!==r&&(t.flags|=8192),r&&0!==(1&t.mode)?0!==(1073741824&Ol)&&(Hs(t),6&t.subtreeFlags&&(t.flags|=8192)):Hs(t),null;case 24:case 25:return null}throw Error(o(156,t.tag))}function Js(e,t){switch(to(t),t.tag){case 1:return Oa(t.type)&&Na(),65536&(e=t.flags)?(t.flags=-65537&e|128,t):null;case 3:return oi(),Ta(Aa),Ta(Pa),di(),0!==(65536&(e=t.flags))&&0===(128&e)?(t.flags=-65537&e|128,t):null;case 5:return si(t),null;case 13:if(Ta(li),null!==(e=t.memoizedState)&&null!==e.dehydrated){if(null===t.alternate)throw Error(o(340));mo()}return 65536&(e=t.flags)?(t.flags=-65537&e|128,t):null;case 19:return Ta(li),null;case 4:return oi(),null;case 10:return Co(t.type._context),null;case 22:case 23:return du(),null;default:return null}}Os=function(e,t){for(var n=t.child;null!==n;){if(5===n.tag||6===n.tag)e.appendChild(n.stateNode);else if(4!==n.tag&&null!==n.child){n.child.return=n,n=n.child;continue}if(n===t)break;for(;null===n.sibling;){if(null===n.return||n.return===t)return;n=n.return}n.sibling.return=n.return,n=n.sibling}},Ns=function(e,t,n,r){var a=e.memoizedProps;if(a!==r){e=t.stateNode,ri(ei.current);var o,i=null;switch(n){case"input":a=q(e,a),r=q(e,r),i=[];break;case"select":a=L({},a,{value:void 0}),r=L({},r,{value:void 0}),i=[];break;case"textarea":a=re(e,a),r=re(e,r),i=[];break;default:"function"!==typeof a.onClick&&"function"===typeof r.onClick&&(e.onclick=Xr)}for(c in ye(n,r),n=null,a)if(!r.hasOwnProperty(c)&&a.hasOwnProperty(c)&&null!=a[c])if("style"===c){var l=a[c];for(o in l)l.hasOwnProperty(o)&&(n||(n={}),n[o]="")}else"dangerouslySetInnerHTML"!==c&&"children"!==c&&"suppressContentEditableWarning"!==c&&"suppressHydrationWarning"!==c&&"autoFocus"!==c&&(s.hasOwnProperty(c)?i||(i=[]):(i=i||[]).push(c,null));for(c in r){var u=r[c];if(l=null!=a?a[c]:void 0,r.hasOwnProperty(c)&&u!==l&&(null!=u||null!=l))if("style"===c)if(l){for(o in l)!l.hasOwnProperty(o)||u&&u.hasOwnProperty(o)||(n||(n={}),n[o]="");for(o in u)u.hasOwnProperty(o)&&l[o]!==u[o]&&(n||(n={}),n[o]=u[o])}else n||(i||(i=[]),i.push(c,n)),n=u;else"dangerouslySetInnerHTML"===c?(u=u?u.__html:void 0,l=l?l.__html:void 0,null!=u&&l!==u&&(i=i||[]).push(c,u)):"children"===c?"string"!==typeof u&&"number"!==typeof u||(i=i||[]).push(c,""+u):"suppressContentEditableWarning"!==c&&"suppressHydrationWarning"!==c&&(s.hasOwnProperty(c)?(null!=u&&"onScroll"===c&&jr("scroll",e),i||l===u||(i=[])):(i=i||[]).push(c,u))}n&&(i=i||[]).push("style",n);var c=i;(t.updateQueue=c)&&(t.flags|=4)}},Ms=function(e,t,n,r){n!==r&&(t.flags|=4)};var qs=!1,Ks=!1,Qs="function"===typeof WeakSet?WeakSet:Set,Ys=null;function Xs(e,t){var n=e.ref;if(null!==n)if("function"===typeof n)try{n(null)}catch(r){ku(e,t,r)}else n.current=null}function el(e,t,n){try{n()}catch(r){ku(e,t,r)}}var tl=!1;function nl(e,t,n){var r=t.updateQueue;if(null!==(r=null!==r?r.lastEffect:null)){var a=r=r.next;do{if((a.tag&e)===e){var o=a.destroy;a.destroy=void 0,void 0!==o&&el(t,n,o)}a=a.next}while(a!==r)}}function rl(e,t){if(null!==(t=null!==(t=t.updateQueue)?t.lastEffect:null)){var n=t=t.next;do{if((n.tag&e)===e){var r=n.create;n.destroy=r()}n=n.next}while(n!==t)}}function al(e){var t=e.ref;if(null!==t){var n=e.stateNode;e.tag,e=n,"function"===typeof t?t(e):t.current=e}}function ol(e){var t=e.alternate;null!==t&&(e.alternate=null,ol(t)),e.child=null,e.deletions=null,e.sibling=null,5===e.tag&&(null!==(t=e.stateNode)&&(delete t[fa],delete t[pa],delete t[ha],delete t[va],delete t[ba])),e.stateNode=null,e.return=null,e.dependencies=null,e.memoizedProps=null,e.memoizedState=null,e.pendingProps=null,e.stateNode=null,e.updateQueue=null}function il(e){return 5===e.tag||3===e.tag||4===e.tag}function sl(e){e:for(;;){for(;null===e.sibling;){if(null===e.return||il(e.return))return null;e=e.return}for(e.sibling.return=e.return,e=e.sibling;5!==e.tag&&6!==e.tag&&18!==e.tag;){if(2&e.flags)continue e;if(null===e.child||4===e.tag)continue e;e.child.return=e,e=e.child}if(!(2&e.flags))return e.stateNode}}function ll(e,t,n){var r=e.tag;if(5===r||6===r)e=e.stateNode,t?8===n.nodeType?n.parentNode.insertBefore(e,t):n.insertBefore(e,t):(8===n.nodeType?(t=n.parentNode).insertBefore(e,n):(t=n).appendChild(e),null!==(n=n._reactRootContainer)&&void 0!==n||null!==t.onclick||(t.onclick=Xr));else if(4!==r&&null!==(e=e.child))for(ll(e,t,n),e=e.sibling;null!==e;)ll(e,t,n),e=e.sibling}function ul(e,t,n){var r=e.tag;if(5===r||6===r)e=e.stateNode,t?n.insertBefore(e,t):n.appendChild(e);else if(4!==r&&null!==(e=e.child))for(ul(e,t,n),e=e.sibling;null!==e;)ul(e,t,n),e=e.sibling}var cl=null,dl=!1;function fl(e,t,n){for(n=n.child;null!==n;)pl(e,t,n),n=n.sibling}function pl(e,t,n){if(ot&&"function"===typeof ot.onCommitFiberUnmount)try{ot.onCommitFiberUnmount(at,n)}catch(s){}switch(n.tag){case 5:Ks||Xs(n,t);case 6:var r=cl,a=dl;cl=null,fl(e,t,n),dl=a,null!==(cl=r)&&(dl?(e=cl,n=n.stateNode,8===e.nodeType?e.parentNode.removeChild(n):e.removeChild(n)):cl.removeChild(n.stateNode));break;case 18:null!==cl&&(dl?(e=cl,n=n.stateNode,8===e.nodeType?la(e.parentNode,n):1===e.nodeType&&la(e,n),Wt(e)):la(cl,n.stateNode));break;case 4:r=cl,a=dl,cl=n.stateNode.containerInfo,dl=!0,fl(e,t,n),cl=r,dl=a;break;case 0:case 11:case 14:case 15:if(!Ks&&(null!==(r=n.updateQueue)&&null!==(r=r.lastEffect))){a=r=r.next;do{var o=a,i=o.destroy;o=o.tag,void 0!==i&&(0!==(2&o)||0!==(4&o))&&el(n,t,i),a=a.next}while(a!==r)}fl(e,t,n);break;case 1:if(!Ks&&(Xs(n,t),"function"===typeof(r=n.stateNode).componentWillUnmount))try{r.props=n.memoizedProps,r.state=n.memoizedState,r.componentWillUnmount()}catch(s){ku(n,t,s)}fl(e,t,n);break;case 21:fl(e,t,n);break;case 22:1&n.mode?(Ks=(r=Ks)||null!==n.memoizedState,fl(e,t,n),Ks=r):fl(e,t,n);break;default:fl(e,t,n)}}function ml(e){var t=e.updateQueue;if(null!==t){e.updateQueue=null;var n=e.stateNode;null===n&&(n=e.stateNode=new Qs),t.forEach((function(t){var r=Pu.bind(null,e,t);n.has(t)||(n.add(t),t.then(r,r))}))}}function hl(e,t){var n=t.deletions;if(null!==n)for(var r=0;r<n.length;r++){var a=n[r];try{var i=e,s=t,l=s;e:for(;null!==l;){switch(l.tag){case 5:cl=l.stateNode,dl=!1;break e;case 3:case 4:cl=l.stateNode.containerInfo,dl=!0;break e}l=l.return}if(null===cl)throw Error(o(160));pl(i,s,a),cl=null,dl=!1;var u=a.alternate;null!==u&&(u.return=null),a.return=null}catch(c){ku(a,t,c)}}if(12854&t.subtreeFlags)for(t=t.child;null!==t;)vl(t,e),t=t.sibling}function vl(e,t){var n=e.alternate,r=e.flags;switch(e.tag){case 0:case 11:case 14:case 15:if(hl(t,e),bl(e),4&r){try{nl(3,e,e.return),rl(3,e)}catch(v){ku(e,e.return,v)}try{nl(5,e,e.return)}catch(v){ku(e,e.return,v)}}break;case 1:hl(t,e),bl(e),512&r&&null!==n&&Xs(n,n.return);break;case 5:if(hl(t,e),bl(e),512&r&&null!==n&&Xs(n,n.return),32&e.flags){var a=e.stateNode;try{fe(a,"")}catch(v){ku(e,e.return,v)}}if(4&r&&null!=(a=e.stateNode)){var i=e.memoizedProps,s=null!==n?n.memoizedProps:i,l=e.type,u=e.updateQueue;if(e.updateQueue=null,null!==u)try{"input"===l&&"radio"===i.type&&null!=i.name&&Q(a,i),ge(l,s);var c=ge(l,i);for(s=0;s<u.length;s+=2){var d=u[s],f=u[s+1];"style"===d?ve(a,f):"dangerouslySetInnerHTML"===d?de(a,f):"children"===d?fe(a,f):g(a,d,f,c)}switch(l){case"input":Y(a,i);break;case"textarea":oe(a,i);break;case"select":var p=a._wrapperState.wasMultiple;a._wrapperState.wasMultiple=!!i.multiple;var m=i.value;null!=m?ne(a,!!i.multiple,m,!1):p!==!!i.multiple&&(null!=i.defaultValue?ne(a,!!i.multiple,i.defaultValue,!0):ne(a,!!i.multiple,i.multiple?[]:"",!1))}a[pa]=i}catch(v){ku(e,e.return,v)}}break;case 6:if(hl(t,e),bl(e),4&r){if(null===e.stateNode)throw Error(o(162));a=e.stateNode,i=e.memoizedProps;try{a.nodeValue=i}catch(v){ku(e,e.return,v)}}break;case 3:if(hl(t,e),bl(e),4&r&&null!==n&&n.memoizedState.isDehydrated)try{Wt(t.containerInfo)}catch(v){ku(e,e.return,v)}break;case 4:default:hl(t,e),bl(e);break;case 13:hl(t,e),bl(e),8192&(a=e.child).flags&&(i=null!==a.memoizedState,a.stateNode.isHidden=i,!i||null!==a.alternate&&null!==a.alternate.memoizedState||(Bl=Qe())),4&r&&ml(e);break;case 22:if(d=null!==n&&null!==n.memoizedState,1&e.mode?(Ks=(c=Ks)||d,hl(t,e),Ks=c):hl(t,e),bl(e),8192&r){if(c=null!==e.memoizedState,(e.stateNode.isHidden=c)&&!d&&0!==(1&e.mode))for(Ys=e,d=e.child;null!==d;){for(f=Ys=d;null!==Ys;){switch(m=(p=Ys).child,p.tag){case 0:case 11:case 14:case 15:nl(4,p,p.return);break;case 1:Xs(p,p.return);var h=p.stateNode;if("function"===typeof h.componentWillUnmount){r=p,n=p.return;try{t=r,h.props=t.memoizedProps,h.state=t.memoizedState,h.componentWillUnmount()}catch(v){ku(r,n,v)}}break;case 5:Xs(p,p.return);break;case 22:if(null!==p.memoizedState){wl(f);continue}}null!==m?(m.return=p,Ys=m):wl(f)}d=d.sibling}e:for(d=null,f=e;;){if(5===f.tag){if(null===d){d=f;try{a=f.stateNode,c?"function"===typeof(i=a.style).setProperty?i.setProperty("display","none","important"):i.display="none":(l=f.stateNode,s=void 0!==(u=f.memoizedProps.style)&&null!==u&&u.hasOwnProperty("display")?u.display:null,l.style.display=he("display",s))}catch(v){ku(e,e.return,v)}}}else if(6===f.tag){if(null===d)try{f.stateNode.nodeValue=c?"":f.memoizedProps}catch(v){ku(e,e.return,v)}}else if((22!==f.tag&&23!==f.tag||null===f.memoizedState||f===e)&&null!==f.child){f.child.return=f,f=f.child;continue}if(f===e)break e;for(;null===f.sibling;){if(null===f.return||f.return===e)break e;d===f&&(d=null),f=f.return}d===f&&(d=null),f.sibling.return=f.return,f=f.sibling}}break;case 19:hl(t,e),bl(e),4&r&&ml(e);case 21:}}function bl(e){var t=e.flags;if(2&t){try{e:{for(var n=e.return;null!==n;){if(il(n)){var r=n;break e}n=n.return}throw Error(o(160))}switch(r.tag){case 5:var a=r.stateNode;32&r.flags&&(fe(a,""),r.flags&=-33),ul(e,sl(e),a);break;case 3:case 4:var i=r.stateNode.containerInfo;ll(e,sl(e),i);break;default:throw Error(o(161))}}catch(s){ku(e,e.return,s)}e.flags&=-3}4096&t&&(e.flags&=-4097)}function yl(e,t,n){Ys=e,gl(e,t,n)}function gl(e,t,n){for(var r=0!==(1&e.mode);null!==Ys;){var a=Ys,o=a.child;if(22===a.tag&&r){var i=null!==a.memoizedState||qs;if(!i){var s=a.alternate,l=null!==s&&null!==s.memoizedState||Ks;s=qs;var u=Ks;if(qs=i,(Ks=l)&&!u)for(Ys=a;null!==Ys;)l=(i=Ys).child,22===i.tag&&null!==i.memoizedState?Sl(a):null!==l?(l.return=i,Ys=l):Sl(a);for(;null!==o;)Ys=o,gl(o,t,n),o=o.sibling;Ys=a,qs=s,Ks=u}_l(e)}else 0!==(8772&a.subtreeFlags)&&null!==o?(o.return=a,Ys=o):_l(e)}}function _l(e){for(;null!==Ys;){var t=Ys;if(0!==(8772&t.flags)){var n=t.alternate;try{if(0!==(8772&t.flags))switch(t.tag){case 0:case 11:case 15:Ks||rl(5,t);break;case 1:var r=t.stateNode;if(4&t.flags&&!Ks)if(null===n)r.componentDidMount();else{var a=t.elementType===t.type?n.memoizedProps:bo(t.type,n.memoizedProps);r.componentDidUpdate(a,n.memoizedState,r.__reactInternalSnapshotBeforeUpdate)}var i=t.updateQueue;null!==i&&jo(t,i,r);break;case 3:var s=t.updateQueue;if(null!==s){if(n=null,null!==t.child)switch(t.child.tag){case 5:case 1:n=t.child.stateNode}jo(t,s,n)}break;case 5:var l=t.stateNode;if(null===n&&4&t.flags){n=l;var u=t.memoizedProps;switch(t.type){case"button":case"input":case"select":case"textarea":u.autoFocus&&n.focus();break;case"img":u.src&&(n.src=u.src)}}break;case 6:case 4:case 12:case 19:case 17:case 21:case 22:case 23:case 25:break;case 13:if(null===t.memoizedState){var c=t.alternate;if(null!==c){var d=c.memoizedState;if(null!==d){var f=d.dehydrated;null!==f&&Wt(f)}}}break;default:throw Error(o(163))}Ks||512&t.flags&&al(t)}catch(p){ku(t,t.return,p)}}if(t===e){Ys=null;break}if(null!==(n=t.sibling)){n.return=t.return,Ys=n;break}Ys=t.return}}function wl(e){for(;null!==Ys;){var t=Ys;if(t===e){Ys=null;break}var n=t.sibling;if(null!==n){n.return=t.return,Ys=n;break}Ys=t.return}}function Sl(e){for(;null!==Ys;){var t=Ys;try{switch(t.tag){case 0:case 11:case 15:var n=t.return;try{rl(4,t)}catch(l){ku(t,n,l)}break;case 1:var r=t.stateNode;if("function"===typeof r.componentDidMount){var a=t.return;try{r.componentDidMount()}catch(l){ku(t,a,l)}}var o=t.return;try{al(t)}catch(l){ku(t,o,l)}break;case 5:var i=t.return;try{al(t)}catch(l){ku(t,i,l)}}}catch(l){ku(t,t.return,l)}if(t===e){Ys=null;break}var s=t.sibling;if(null!==s){s.return=t.return,Ys=s;break}Ys=t.return}}var Cl,kl=Math.ceil,Tl=_.ReactCurrentDispatcher,xl=_.ReactCurrentOwner,El=_.ReactCurrentBatchConfig,Pl=0,Al=null,Rl=null,Fl=0,Ol=0,Nl=ka(0),Ml=0,Il=null,zl=0,Ll=0,Dl=0,jl=null,Zl=null,Bl=0,Wl=1/0,Ul=null,Vl=!1,Gl=null,Hl=null,$l=!1,Jl=null,ql=0,Kl=0,Ql=null,Yl=-1,Xl=0;function eu(){return 0!==(6&Pl)?Qe():-1!==Yl?Yl:Yl=Qe()}function tu(e){return 0===(1&e.mode)?1:0!==(2&Pl)&&0!==Fl?Fl&-Fl:null!==vo.transition?(0===Xl&&(Xl=ht()),Xl):0!==(e=gt)?e:e=void 0===(e=window.event)?16:Kt(e.type)}function nu(e,t,n,r){if(50<Kl)throw Kl=0,Ql=null,Error(o(185));bt(e,n,r),0!==(2&Pl)&&e===Al||(e===Al&&(0===(2&Pl)&&(Ll|=n),4===Ml&&su(e,Fl)),ru(e,r),1===n&&0===Pl&&0===(1&t.mode)&&(Wl=Qe()+500,ja&&Wa()))}function ru(e,t){var n=e.callbackNode;!function(e,t){for(var n=e.suspendedLanes,r=e.pingedLanes,a=e.expirationTimes,o=e.pendingLanes;0<o;){var i=31-it(o),s=1<<i,l=a[i];-1===l?0!==(s&n)&&0===(s&r)||(a[i]=pt(s,t)):l<=t&&(e.expiredLanes|=s),o&=~s}}(e,t);var r=ft(e,e===Al?Fl:0);if(0===r)null!==n&&Je(n),e.callbackNode=null,e.callbackPriority=0;else if(t=r&-r,e.callbackPriority!==t){if(null!=n&&Je(n),1===t)0===e.tag?function(e){ja=!0,Ba(e)}(lu.bind(null,e)):Ba(lu.bind(null,e)),ia((function(){0===(6&Pl)&&Wa()})),n=null;else{switch(_t(r)){case 1:n=Xe;break;case 4:n=et;break;case 16:default:n=tt;break;case 536870912:n=rt}n=Au(n,au.bind(null,e))}e.callbackPriority=t,e.callbackNode=n}}function au(e,t){if(Yl=-1,Xl=0,0!==(6&Pl))throw Error(o(327));var n=e.callbackNode;if(Su()&&e.callbackNode!==n)return null;var r=ft(e,e===Al?Fl:0);if(0===r)return null;if(0!==(30&r)||0!==(r&e.expiredLanes)||t)t=vu(e,r);else{t=r;var a=Pl;Pl|=2;var i=mu();for(Al===e&&Fl===t||(Ul=null,Wl=Qe()+500,fu(e,t));;)try{yu();break}catch(l){pu(e,l)}So(),Tl.current=i,Pl=a,null!==Rl?t=0:(Al=null,Fl=0,t=Ml)}if(0!==t){if(2===t&&(0!==(a=mt(e))&&(r=a,t=ou(e,a))),1===t)throw n=Il,fu(e,0),su(e,r),ru(e,Qe()),n;if(6===t)su(e,r);else{if(a=e.current.alternate,0===(30&r)&&!function(e){for(var t=e;;){if(16384&t.flags){var n=t.updateQueue;if(null!==n&&null!==(n=n.stores))for(var r=0;r<n.length;r++){var a=n[r],o=a.getSnapshot;a=a.value;try{if(!sr(o(),a))return!1}catch(s){return!1}}}if(n=t.child,16384&t.subtreeFlags&&null!==n)n.return=t,t=n;else{if(t===e)break;for(;null===t.sibling;){if(null===t.return||t.return===e)return!0;t=t.return}t.sibling.return=t.return,t=t.sibling}}return!0}(a)&&(2===(t=vu(e,r))&&(0!==(i=mt(e))&&(r=i,t=ou(e,i))),1===t))throw n=Il,fu(e,0),su(e,r),ru(e,Qe()),n;switch(e.finishedWork=a,e.finishedLanes=r,t){case 0:case 1:throw Error(o(345));case 2:case 5:wu(e,Zl,Ul);break;case 3:if(su(e,r),(130023424&r)===r&&10<(t=Bl+500-Qe())){if(0!==ft(e,0))break;if(((a=e.suspendedLanes)&r)!==r){eu(),e.pingedLanes|=e.suspendedLanes&a;break}e.timeoutHandle=ra(wu.bind(null,e,Zl,Ul),t);break}wu(e,Zl,Ul);break;case 4:if(su(e,r),(4194240&r)===r)break;for(t=e.eventTimes,a=-1;0<r;){var s=31-it(r);i=1<<s,(s=t[s])>a&&(a=s),r&=~i}if(r=a,10<(r=(120>(r=Qe()-r)?120:480>r?480:1080>r?1080:1920>r?1920:3e3>r?3e3:4320>r?4320:1960*kl(r/1960))-r)){e.timeoutHandle=ra(wu.bind(null,e,Zl,Ul),r);break}wu(e,Zl,Ul);break;default:throw Error(o(329))}}}return ru(e,Qe()),e.callbackNode===n?au.bind(null,e):null}function ou(e,t){var n=jl;return e.current.memoizedState.isDehydrated&&(fu(e,t).flags|=256),2!==(e=vu(e,t))&&(t=Zl,Zl=n,null!==t&&iu(t)),e}function iu(e){null===Zl?Zl=e:Zl.push.apply(Zl,e)}function su(e,t){for(t&=~Dl,t&=~Ll,e.suspendedLanes|=t,e.pingedLanes&=~t,e=e.expirationTimes;0<t;){var n=31-it(t),r=1<<n;e[n]=-1,t&=~r}}function lu(e){if(0!==(6&Pl))throw Error(o(327));Su();var t=ft(e,0);if(0===(1&t))return ru(e,Qe()),null;var n=vu(e,t);if(0!==e.tag&&2===n){var r=mt(e);0!==r&&(t=r,n=ou(e,r))}if(1===n)throw n=Il,fu(e,0),su(e,t),ru(e,Qe()),n;if(6===n)throw Error(o(345));return e.finishedWork=e.current.alternate,e.finishedLanes=t,wu(e,Zl,Ul),ru(e,Qe()),null}function uu(e,t){var n=Pl;Pl|=1;try{return e(t)}finally{0===(Pl=n)&&(Wl=Qe()+500,ja&&Wa())}}function cu(e){null!==Jl&&0===Jl.tag&&0===(6&Pl)&&Su();var t=Pl;Pl|=1;var n=El.transition,r=gt;try{if(El.transition=null,gt=1,e)return e()}finally{gt=r,El.transition=n,0===(6&(Pl=t))&&Wa()}}function du(){Ol=Nl.current,Ta(Nl)}function fu(e,t){e.finishedWork=null,e.finishedLanes=0;var n=e.timeoutHandle;if(-1!==n&&(e.timeoutHandle=-1,aa(n)),null!==Rl)for(n=Rl.return;null!==n;){var r=n;switch(to(r),r.tag){case 1:null!==(r=r.type.childContextTypes)&&void 0!==r&&Na();break;case 3:oi(),Ta(Aa),Ta(Pa),di();break;case 5:si(r);break;case 4:oi();break;case 13:case 19:Ta(li);break;case 10:Co(r.type._context);break;case 22:case 23:du()}n=n.return}if(Al=e,Rl=e=Nu(e.current,null),Fl=Ol=t,Ml=0,Il=null,Dl=Ll=zl=0,Zl=jl=null,null!==Eo){for(t=0;t<Eo.length;t++)if(null!==(r=(n=Eo[t]).interleaved)){n.interleaved=null;var a=r.next,o=n.pending;if(null!==o){var i=o.next;o.next=a,r.next=i}n.pending=r}Eo=null}return e}function pu(e,t){for(;;){var n=Rl;try{if(So(),fi.current=is,yi){for(var r=hi.memoizedState;null!==r;){var a=r.queue;null!==a&&(a.pending=null),r=r.next}yi=!1}if(mi=0,bi=vi=hi=null,gi=!1,_i=0,xl.current=null,null===n||null===n.return){Ml=1,Il=t,Rl=null;break}e:{var i=e,s=n.return,l=n,u=t;if(t=Fl,l.flags|=32768,null!==u&&"object"===typeof u&&"function"===typeof u.then){var c=u,d=l,f=d.tag;if(0===(1&d.mode)&&(0===f||11===f||15===f)){var p=d.alternate;p?(d.updateQueue=p.updateQueue,d.memoizedState=p.memoizedState,d.lanes=p.lanes):(d.updateQueue=null,d.memoizedState=null)}var m=bs(s);if(null!==m){m.flags&=-257,ys(m,s,l,0,t),1&m.mode&&vs(i,c,t),u=c;var h=(t=m).updateQueue;if(null===h){var v=new Set;v.add(u),t.updateQueue=v}else h.add(u);break e}if(0===(1&t)){vs(i,c,t),hu();break e}u=Error(o(426))}else if(ao&&1&l.mode){var b=bs(s);if(null!==b){0===(65536&b.flags)&&(b.flags|=256),ys(b,s,l,0,t),ho(cs(u,l));break e}}i=u=cs(u,l),4!==Ml&&(Ml=2),null===jl?jl=[i]:jl.push(i),i=s;do{switch(i.tag){case 3:i.flags|=65536,t&=-t,i.lanes|=t,Lo(i,ms(0,u,t));break e;case 1:l=u;var y=i.type,g=i.stateNode;if(0===(128&i.flags)&&("function"===typeof y.getDerivedStateFromError||null!==g&&"function"===typeof g.componentDidCatch&&(null===Hl||!Hl.has(g)))){i.flags|=65536,t&=-t,i.lanes|=t,Lo(i,hs(i,l,t));break e}}i=i.return}while(null!==i)}_u(n)}catch(_){t=_,Rl===n&&null!==n&&(Rl=n=n.return);continue}break}}function mu(){var e=Tl.current;return Tl.current=is,null===e?is:e}function hu(){0!==Ml&&3!==Ml&&2!==Ml||(Ml=4),null===Al||0===(268435455&zl)&&0===(268435455&Ll)||su(Al,Fl)}function vu(e,t){var n=Pl;Pl|=2;var r=mu();for(Al===e&&Fl===t||(Ul=null,fu(e,t));;)try{bu();break}catch(a){pu(e,a)}if(So(),Pl=n,Tl.current=r,null!==Rl)throw Error(o(261));return Al=null,Fl=0,Ml}function bu(){for(;null!==Rl;)gu(Rl)}function yu(){for(;null!==Rl&&!qe();)gu(Rl)}function gu(e){var t=Cl(e.alternate,e,Ol);e.memoizedProps=e.pendingProps,null===t?_u(e):Rl=t,xl.current=null}function _u(e){var t=e;do{var n=t.alternate;if(e=t.return,0===(32768&t.flags)){if(null!==(n=$s(n,t,Ol)))return void(Rl=n)}else{if(null!==(n=Js(n,t)))return n.flags&=32767,void(Rl=n);if(null===e)return Ml=6,void(Rl=null);e.flags|=32768,e.subtreeFlags=0,e.deletions=null}if(null!==(t=t.sibling))return void(Rl=t);Rl=t=e}while(null!==t);0===Ml&&(Ml=5)}function wu(e,t,n){var r=gt,a=El.transition;try{El.transition=null,gt=1,function(e,t,n,r){do{Su()}while(null!==Jl);if(0!==(6&Pl))throw Error(o(327));n=e.finishedWork;var a=e.finishedLanes;if(null===n)return null;if(e.finishedWork=null,e.finishedLanes=0,n===e.current)throw Error(o(177));e.callbackNode=null,e.callbackPriority=0;var i=n.lanes|n.childLanes;if(function(e,t){var n=e.pendingLanes&~t;e.pendingLanes=t,e.suspendedLanes=0,e.pingedLanes=0,e.expiredLanes&=t,e.mutableReadLanes&=t,e.entangledLanes&=t,t=e.entanglements;var r=e.eventTimes;for(e=e.expirationTimes;0<n;){var a=31-it(n),o=1<<a;t[a]=0,r[a]=-1,e[a]=-1,n&=~o}}(e,i),e===Al&&(Rl=Al=null,Fl=0),0===(2064&n.subtreeFlags)&&0===(2064&n.flags)||$l||($l=!0,Au(tt,(function(){return Su(),null}))),i=0!==(15990&n.flags),0!==(15990&n.subtreeFlags)||i){i=El.transition,El.transition=null;var s=gt;gt=1;var l=Pl;Pl|=4,xl.current=null,function(e,t){if(ea=Vt,pr(e=fr())){if("selectionStart"in e)var n={start:e.selectionStart,end:e.selectionEnd};else e:{var r=(n=(n=e.ownerDocument)&&n.defaultView||window).getSelection&&n.getSelection();if(r&&0!==r.rangeCount){n=r.anchorNode;var a=r.anchorOffset,i=r.focusNode;r=r.focusOffset;try{n.nodeType,i.nodeType}catch(w){n=null;break e}var s=0,l=-1,u=-1,c=0,d=0,f=e,p=null;t:for(;;){for(var m;f!==n||0!==a&&3!==f.nodeType||(l=s+a),f!==i||0!==r&&3!==f.nodeType||(u=s+r),3===f.nodeType&&(s+=f.nodeValue.length),null!==(m=f.firstChild);)p=f,f=m;for(;;){if(f===e)break t;if(p===n&&++c===a&&(l=s),p===i&&++d===r&&(u=s),null!==(m=f.nextSibling))break;p=(f=p).parentNode}f=m}n=-1===l||-1===u?null:{start:l,end:u}}else n=null}n=n||{start:0,end:0}}else n=null;for(ta={focusedElem:e,selectionRange:n},Vt=!1,Ys=t;null!==Ys;)if(e=(t=Ys).child,0!==(1028&t.subtreeFlags)&&null!==e)e.return=t,Ys=e;else for(;null!==Ys;){t=Ys;try{var h=t.alternate;if(0!==(1024&t.flags))switch(t.tag){case 0:case 11:case 15:case 5:case 6:case 4:case 17:break;case 1:if(null!==h){var v=h.memoizedProps,b=h.memoizedState,y=t.stateNode,g=y.getSnapshotBeforeUpdate(t.elementType===t.type?v:bo(t.type,v),b);y.__reactInternalSnapshotBeforeUpdate=g}break;case 3:var _=t.stateNode.containerInfo;1===_.nodeType?_.textContent="":9===_.nodeType&&_.documentElement&&_.removeChild(_.documentElement);break;default:throw Error(o(163))}}catch(w){ku(t,t.return,w)}if(null!==(e=t.sibling)){e.return=t.return,Ys=e;break}Ys=t.return}h=tl,tl=!1}(e,n),vl(n,e),mr(ta),Vt=!!ea,ta=ea=null,e.current=n,yl(n,e,a),Ke(),Pl=l,gt=s,El.transition=i}else e.current=n;if($l&&($l=!1,Jl=e,ql=a),0===(i=e.pendingLanes)&&(Hl=null),function(e){if(ot&&"function"===typeof ot.onCommitFiberRoot)try{ot.onCommitFiberRoot(at,e,void 0,128===(128&e.current.flags))}catch(t){}}(n.stateNode),ru(e,Qe()),null!==t)for(r=e.onRecoverableError,n=0;n<t.length;n++)r((a=t[n]).value,{componentStack:a.stack,digest:a.digest});if(Vl)throw Vl=!1,e=Gl,Gl=null,e;0!==(1&ql)&&0!==e.tag&&Su(),0!==(1&(i=e.pendingLanes))?e===Ql?Kl++:(Kl=0,Ql=e):Kl=0,Wa()}(e,t,n,r)}finally{El.transition=a,gt=r}return null}function Su(){if(null!==Jl){var e=_t(ql),t=El.transition,n=gt;try{if(El.transition=null,gt=16>e?16:e,null===Jl)var r=!1;else{if(e=Jl,Jl=null,ql=0,0!==(6&Pl))throw Error(o(331));var a=Pl;for(Pl|=4,Ys=e.current;null!==Ys;){var i=Ys,s=i.child;if(0!==(16&Ys.flags)){var l=i.deletions;if(null!==l){for(var u=0;u<l.length;u++){var c=l[u];for(Ys=c;null!==Ys;){var d=Ys;switch(d.tag){case 0:case 11:case 15:nl(8,d,i)}var f=d.child;if(null!==f)f.return=d,Ys=f;else for(;null!==Ys;){var p=(d=Ys).sibling,m=d.return;if(ol(d),d===c){Ys=null;break}if(null!==p){p.return=m,Ys=p;break}Ys=m}}}var h=i.alternate;if(null!==h){var v=h.child;if(null!==v){h.child=null;do{var b=v.sibling;v.sibling=null,v=b}while(null!==v)}}Ys=i}}if(0!==(2064&i.subtreeFlags)&&null!==s)s.return=i,Ys=s;else e:for(;null!==Ys;){if(0!==(2048&(i=Ys).flags))switch(i.tag){case 0:case 11:case 15:nl(9,i,i.return)}var y=i.sibling;if(null!==y){y.return=i.return,Ys=y;break e}Ys=i.return}}var g=e.current;for(Ys=g;null!==Ys;){var _=(s=Ys).child;if(0!==(2064&s.subtreeFlags)&&null!==_)_.return=s,Ys=_;else e:for(s=g;null!==Ys;){if(0!==(2048&(l=Ys).flags))try{switch(l.tag){case 0:case 11:case 15:rl(9,l)}}catch(S){ku(l,l.return,S)}if(l===s){Ys=null;break e}var w=l.sibling;if(null!==w){w.return=l.return,Ys=w;break e}Ys=l.return}}if(Pl=a,Wa(),ot&&"function"===typeof ot.onPostCommitFiberRoot)try{ot.onPostCommitFiberRoot(at,e)}catch(S){}r=!0}return r}finally{gt=n,El.transition=t}}return!1}function Cu(e,t,n){e=Io(e,t=ms(0,t=cs(n,t),1),1),t=eu(),null!==e&&(bt(e,1,t),ru(e,t))}function ku(e,t,n){if(3===e.tag)Cu(e,e,n);else for(;null!==t;){if(3===t.tag){Cu(t,e,n);break}if(1===t.tag){var r=t.stateNode;if("function"===typeof t.type.getDerivedStateFromError||"function"===typeof r.componentDidCatch&&(null===Hl||!Hl.has(r))){t=Io(t,e=hs(t,e=cs(n,e),1),1),e=eu(),null!==t&&(bt(t,1,e),ru(t,e));break}}t=t.return}}function Tu(e,t,n){var r=e.pingCache;null!==r&&r.delete(t),t=eu(),e.pingedLanes|=e.suspendedLanes&n,Al===e&&(Fl&n)===n&&(4===Ml||3===Ml&&(130023424&Fl)===Fl&&500>Qe()-Bl?fu(e,0):Dl|=n),ru(e,t)}function xu(e,t){0===t&&(0===(1&e.mode)?t=1:(t=ct,0===(130023424&(ct<<=1))&&(ct=4194304)));var n=eu();null!==(e=Ro(e,t))&&(bt(e,t,n),ru(e,n))}function Eu(e){var t=e.memoizedState,n=0;null!==t&&(n=t.retryLane),xu(e,n)}function Pu(e,t){var n=0;switch(e.tag){case 13:var r=e.stateNode,a=e.memoizedState;null!==a&&(n=a.retryLane);break;case 19:r=e.stateNode;break;default:throw Error(o(314))}null!==r&&r.delete(t),xu(e,n)}function Au(e,t){return $e(e,t)}function Ru(e,t,n,r){this.tag=e,this.key=n,this.sibling=this.child=this.return=this.stateNode=this.type=this.elementType=null,this.index=0,this.ref=null,this.pendingProps=t,this.dependencies=this.memoizedState=this.updateQueue=this.memoizedProps=null,this.mode=r,this.subtreeFlags=this.flags=0,this.deletions=null,this.childLanes=this.lanes=0,this.alternate=null}function Fu(e,t,n,r){return new Ru(e,t,n,r)}function Ou(e){return!(!(e=e.prototype)||!e.isReactComponent)}function Nu(e,t){var n=e.alternate;return null===n?((n=Fu(e.tag,t,e.key,e.mode)).elementType=e.elementType,n.type=e.type,n.stateNode=e.stateNode,n.alternate=e,e.alternate=n):(n.pendingProps=t,n.type=e.type,n.flags=0,n.subtreeFlags=0,n.deletions=null),n.flags=14680064&e.flags,n.childLanes=e.childLanes,n.lanes=e.lanes,n.child=e.child,n.memoizedProps=e.memoizedProps,n.memoizedState=e.memoizedState,n.updateQueue=e.updateQueue,t=e.dependencies,n.dependencies=null===t?null:{lanes:t.lanes,firstContext:t.firstContext},n.sibling=e.sibling,n.index=e.index,n.ref=e.ref,n}function Mu(e,t,n,r,a,i){var s=2;if(r=e,"function"===typeof e)Ou(e)&&(s=1);else if("string"===typeof e)s=5;else e:switch(e){case C:return Iu(n.children,a,i,t);case k:s=8,a|=8;break;case T:return(e=Fu(12,n,t,2|a)).elementType=T,e.lanes=i,e;case A:return(e=Fu(13,n,t,a)).elementType=A,e.lanes=i,e;case R:return(e=Fu(19,n,t,a)).elementType=R,e.lanes=i,e;case N:return zu(n,a,i,t);default:if("object"===typeof e&&null!==e)switch(e.$$typeof){case x:s=10;break e;case E:s=9;break e;case P:s=11;break e;case F:s=14;break e;case O:s=16,r=null;break e}throw Error(o(130,null==e?e:typeof e,""))}return(t=Fu(s,n,t,a)).elementType=e,t.type=r,t.lanes=i,t}function Iu(e,t,n,r){return(e=Fu(7,e,r,t)).lanes=n,e}function zu(e,t,n,r){return(e=Fu(22,e,r,t)).elementType=N,e.lanes=n,e.stateNode={isHidden:!1},e}function Lu(e,t,n){return(e=Fu(6,e,null,t)).lanes=n,e}function Du(e,t,n){return(t=Fu(4,null!==e.children?e.children:[],e.key,t)).lanes=n,t.stateNode={containerInfo:e.containerInfo,pendingChildren:null,implementation:e.implementation},t}function ju(e,t,n,r,a){this.tag=t,this.containerInfo=e,this.finishedWork=this.pingCache=this.current=this.pendingChildren=null,this.timeoutHandle=-1,this.callbackNode=this.pendingContext=this.context=null,this.callbackPriority=0,this.eventTimes=vt(0),this.expirationTimes=vt(-1),this.entangledLanes=this.finishedLanes=this.mutableReadLanes=this.expiredLanes=this.pingedLanes=this.suspendedLanes=this.pendingLanes=0,this.entanglements=vt(0),this.identifierPrefix=r,this.onRecoverableError=a,this.mutableSourceEagerHydrationData=null}function Zu(e,t,n,r,a,o,i,s,l){return e=new ju(e,t,n,s,l),1===t?(t=1,!0===o&&(t|=8)):t=0,o=Fu(3,null,null,t),e.current=o,o.stateNode=e,o.memoizedState={element:r,isDehydrated:n,cache:null,transitions:null,pendingSuspenseBoundaries:null},Oo(o),e}function Bu(e,t,n){var r=3<arguments.length&&void 0!==arguments[3]?arguments[3]:null;return{$$typeof:S,key:null==r?null:""+r,children:e,containerInfo:t,implementation:n}}function Wu(e){if(!e)return Ea;e:{if(We(e=e._reactInternals)!==e||1!==e.tag)throw Error(o(170));var t=e;do{switch(t.tag){case 3:t=t.stateNode.context;break e;case 1:if(Oa(t.type)){t=t.stateNode.__reactInternalMemoizedMergedChildContext;break e}}t=t.return}while(null!==t);throw Error(o(171))}if(1===e.tag){var n=e.type;if(Oa(n))return Ia(e,n,t)}return t}function Uu(e,t,n,r,a,o,i,s,l){return(e=Zu(n,r,!0,e,0,o,0,s,l)).context=Wu(null),n=e.current,(o=Mo(r=eu(),a=tu(n))).callback=void 0!==t&&null!==t?t:null,Io(n,o,a),e.current.lanes=a,bt(e,a,r),ru(e,r),e}function Vu(e,t,n,r){var a=t.current,o=eu(),i=tu(a);return n=Wu(n),null===t.context?t.context=n:t.pendingContext=n,(t=Mo(o,i)).payload={element:e},null!==(r=void 0===r?null:r)&&(t.callback=r),null!==(e=Io(a,t,i))&&(nu(e,a,i,o),zo(e,a,i)),i}function Gu(e){return(e=e.current).child?(e.child.tag,e.child.stateNode):null}function Hu(e,t){if(null!==(e=e.memoizedState)&&null!==e.dehydrated){var n=e.retryLane;e.retryLane=0!==n&&n<t?n:t}}function $u(e,t){Hu(e,t),(e=e.alternate)&&Hu(e,t)}Cl=function(e,t,n){if(null!==e)if(e.memoizedProps!==t.pendingProps||Aa.current)_s=!0;else{if(0===(e.lanes&n)&&0===(128&t.flags))return _s=!1,function(e,t,n){switch(t.tag){case 3:Rs(t),mo();break;case 5:ii(t);break;case 1:Oa(t.type)&&za(t);break;case 4:ai(t,t.stateNode.containerInfo);break;case 10:var r=t.type._context,a=t.memoizedProps.value;xa(yo,r._currentValue),r._currentValue=a;break;case 13:if(null!==(r=t.memoizedState))return null!==r.dehydrated?(xa(li,1&li.current),t.flags|=128,null):0!==(n&t.child.childLanes)?Ls(e,t,n):(xa(li,1&li.current),null!==(e=Vs(e,t,n))?e.sibling:null);xa(li,1&li.current);break;case 19:if(r=0!==(n&t.childLanes),0!==(128&e.flags)){if(r)return Ws(e,t,n);t.flags|=128}if(null!==(a=t.memoizedState)&&(a.rendering=null,a.tail=null,a.lastEffect=null),xa(li,li.current),r)break;return null;case 22:case 23:return t.lanes=0,Ts(e,t,n)}return Vs(e,t,n)}(e,t,n);_s=0!==(131072&e.flags)}else _s=!1,ao&&0!==(1048576&t.flags)&&Xa(t,Ha,t.index);switch(t.lanes=0,t.tag){case 2:var r=t.type;Us(e,t),e=t.pendingProps;var a=Fa(t,Pa.current);To(t,n),a=ki(null,t,r,e,a,n);var i=Ti();return t.flags|=1,"object"===typeof a&&null!==a&&"function"===typeof a.render&&void 0===a.$$typeof?(t.tag=1,t.memoizedState=null,t.updateQueue=null,Oa(r)?(i=!0,za(t)):i=!1,t.memoizedState=null!==a.state&&void 0!==a.state?a.state:null,Oo(t),a.updater=Wo,t.stateNode=a,a._reactInternals=t,Ho(t,r,e,n),t=As(null,t,r,!0,i,n)):(t.tag=0,ao&&i&&eo(t),ws(null,t,a,n),t=t.child),t;case 16:r=t.elementType;e:{switch(Us(e,t),e=t.pendingProps,r=(a=r._init)(r._payload),t.type=r,a=t.tag=function(e){if("function"===typeof e)return Ou(e)?1:0;if(void 0!==e&&null!==e){if((e=e.$$typeof)===P)return 11;if(e===F)return 14}return 2}(r),e=bo(r,e),a){case 0:t=Es(null,t,r,e,n);break e;case 1:t=Ps(null,t,r,e,n);break e;case 11:t=Ss(null,t,r,e,n);break e;case 14:t=Cs(null,t,r,bo(r.type,e),n);break e}throw Error(o(306,r,""))}return t;case 0:return r=t.type,a=t.pendingProps,Es(e,t,r,a=t.elementType===r?a:bo(r,a),n);case 1:return r=t.type,a=t.pendingProps,Ps(e,t,r,a=t.elementType===r?a:bo(r,a),n);case 3:e:{if(Rs(t),null===e)throw Error(o(387));r=t.pendingProps,a=(i=t.memoizedState).element,No(e,t),Do(t,r,null,n);var s=t.memoizedState;if(r=s.element,i.isDehydrated){if(i={element:r,isDehydrated:!1,cache:s.cache,pendingSuspenseBoundaries:s.pendingSuspenseBoundaries,transitions:s.transitions},t.updateQueue.baseState=i,t.memoizedState=i,256&t.flags){t=Fs(e,t,r,n,a=cs(Error(o(423)),t));break e}if(r!==a){t=Fs(e,t,r,n,a=cs(Error(o(424)),t));break e}for(ro=ua(t.stateNode.containerInfo.firstChild),no=t,ao=!0,oo=null,n=Yo(t,null,r,n),t.child=n;n;)n.flags=-3&n.flags|4096,n=n.sibling}else{if(mo(),r===a){t=Vs(e,t,n);break e}ws(e,t,r,n)}t=t.child}return t;case 5:return ii(t),null===e&&uo(t),r=t.type,a=t.pendingProps,i=null!==e?e.memoizedProps:null,s=a.children,na(r,a)?s=null:null!==i&&na(r,i)&&(t.flags|=32),xs(e,t),ws(e,t,s,n),t.child;case 6:return null===e&&uo(t),null;case 13:return Ls(e,t,n);case 4:return ai(t,t.stateNode.containerInfo),r=t.pendingProps,null===e?t.child=Qo(t,null,r,n):ws(e,t,r,n),t.child;case 11:return r=t.type,a=t.pendingProps,Ss(e,t,r,a=t.elementType===r?a:bo(r,a),n);case 7:return ws(e,t,t.pendingProps,n),t.child;case 8:case 12:return ws(e,t,t.pendingProps.children,n),t.child;case 10:e:{if(r=t.type._context,a=t.pendingProps,i=t.memoizedProps,s=a.value,xa(yo,r._currentValue),r._currentValue=s,null!==i)if(sr(i.value,s)){if(i.children===a.children&&!Aa.current){t=Vs(e,t,n);break e}}else for(null!==(i=t.child)&&(i.return=t);null!==i;){var l=i.dependencies;if(null!==l){s=i.child;for(var u=l.firstContext;null!==u;){if(u.context===r){if(1===i.tag){(u=Mo(-1,n&-n)).tag=2;var c=i.updateQueue;if(null!==c){var d=(c=c.shared).pending;null===d?u.next=u:(u.next=d.next,d.next=u),c.pending=u}}i.lanes|=n,null!==(u=i.alternate)&&(u.lanes|=n),ko(i.return,n,t),l.lanes|=n;break}u=u.next}}else if(10===i.tag)s=i.type===t.type?null:i.child;else if(18===i.tag){if(null===(s=i.return))throw Error(o(341));s.lanes|=n,null!==(l=s.alternate)&&(l.lanes|=n),ko(s,n,t),s=i.sibling}else s=i.child;if(null!==s)s.return=i;else for(s=i;null!==s;){if(s===t){s=null;break}if(null!==(i=s.sibling)){i.return=s.return,s=i;break}s=s.return}i=s}ws(e,t,a.children,n),t=t.child}return t;case 9:return a=t.type,r=t.pendingProps.children,To(t,n),r=r(a=xo(a)),t.flags|=1,ws(e,t,r,n),t.child;case 14:return a=bo(r=t.type,t.pendingProps),Cs(e,t,r,a=bo(r.type,a),n);case 15:return ks(e,t,t.type,t.pendingProps,n);case 17:return r=t.type,a=t.pendingProps,a=t.elementType===r?a:bo(r,a),Us(e,t),t.tag=1,Oa(r)?(e=!0,za(t)):e=!1,To(t,n),Vo(t,r,a),Ho(t,r,a,n),As(null,t,r,!0,e,n);case 19:return Ws(e,t,n);case 22:return Ts(e,t,n)}throw Error(o(156,t.tag))};var Ju="function"===typeof reportError?reportError:function(e){console.error(e)};function qu(e){this._internalRoot=e}function Ku(e){this._internalRoot=e}function Qu(e){return!(!e||1!==e.nodeType&&9!==e.nodeType&&11!==e.nodeType)}function Yu(e){return!(!e||1!==e.nodeType&&9!==e.nodeType&&11!==e.nodeType&&(8!==e.nodeType||" react-mount-point-unstable "!==e.nodeValue))}function Xu(){}function ec(e,t,n,r,a){var o=n._reactRootContainer;if(o){var i=o;if("function"===typeof a){var s=a;a=function(){var e=Gu(i);s.call(e)}}Vu(t,i,e,a)}else i=function(e,t,n,r,a){if(a){if("function"===typeof r){var o=r;r=function(){var e=Gu(i);o.call(e)}}var i=Uu(t,r,e,0,null,!1,0,"",Xu);return e._reactRootContainer=i,e[ma]=i.current,Wr(8===e.nodeType?e.parentNode:e),cu(),i}for(;a=e.lastChild;)e.removeChild(a);if("function"===typeof r){var s=r;r=function(){var e=Gu(l);s.call(e)}}var l=Zu(e,0,!1,null,0,!1,0,"",Xu);return e._reactRootContainer=l,e[ma]=l.current,Wr(8===e.nodeType?e.parentNode:e),cu((function(){Vu(t,l,n,r)})),l}(n,t,e,a,r);return Gu(i)}Ku.prototype.render=qu.prototype.render=function(e){var t=this._internalRoot;if(null===t)throw Error(o(409));Vu(e,t,null,null)},Ku.prototype.unmount=qu.prototype.unmount=function(){var e=this._internalRoot;if(null!==e){this._internalRoot=null;var t=e.containerInfo;cu((function(){Vu(null,e,null,null)})),t[ma]=null}},Ku.prototype.unstable_scheduleHydration=function(e){if(e){var t=kt();e={blockedOn:null,target:e,priority:t};for(var n=0;n<Nt.length&&0!==t&&t<Nt[n].priority;n++);Nt.splice(n,0,e),0===n&&Lt(e)}},wt=function(e){switch(e.tag){case 3:var t=e.stateNode;if(t.current.memoizedState.isDehydrated){var n=dt(t.pendingLanes);0!==n&&(yt(t,1|n),ru(t,Qe()),0===(6&Pl)&&(Wl=Qe()+500,Wa()))}break;case 13:cu((function(){var t=Ro(e,1);if(null!==t){var n=eu();nu(t,e,1,n)}})),$u(e,1)}},St=function(e){if(13===e.tag){var t=Ro(e,134217728);if(null!==t)nu(t,e,134217728,eu());$u(e,134217728)}},Ct=function(e){if(13===e.tag){var t=tu(e),n=Ro(e,t);if(null!==n)nu(n,e,t,eu());$u(e,t)}},kt=function(){return gt},Tt=function(e,t){var n=gt;try{return gt=e,t()}finally{gt=n}},Se=function(e,t,n){switch(t){case"input":if(Y(e,n),t=n.name,"radio"===n.type&&null!=t){for(n=e;n.parentNode;)n=n.parentNode;for(n=n.querySelectorAll("input[name="+JSON.stringify(""+t)+'][type="radio"]'),t=0;t<n.length;t++){var r=n[t];if(r!==e&&r.form===e.form){var a=wa(r);if(!a)throw Error(o(90));$(r),Y(r,a)}}}break;case"textarea":oe(e,n);break;case"select":null!=(t=n.value)&&ne(e,!!n.multiple,t,!1)}},Pe=uu,Ae=cu;var tc={usingClientEntryPoint:!1,Events:[ga,_a,wa,xe,Ee,uu]},nc={findFiberByHostInstance:ya,bundleType:0,version:"18.2.0",rendererPackageName:"react-dom"},rc={bundleType:nc.bundleType,version:nc.version,rendererPackageName:nc.rendererPackageName,rendererConfig:nc.rendererConfig,overrideHookState:null,overrideHookStateDeletePath:null,overrideHookStateRenamePath:null,overrideProps:null,overridePropsDeletePath:null,overridePropsRenamePath:null,setErrorHandler:null,setSuspenseHandler:null,scheduleUpdate:null,currentDispatcherRef:_.ReactCurrentDispatcher,findHostInstanceByFiber:function(e){return null===(e=Ge(e))?null:e.stateNode},findFiberByHostInstance:nc.findFiberByHostInstance||function(){return null},findHostInstancesForRefresh:null,scheduleRefresh:null,scheduleRoot:null,setRefreshHandler:null,getCurrentFiber:null,reconcilerVersion:"18.2.0-next-9e3b772b8-20220608"};if("undefined"!==typeof __REACT_DEVTOOLS_GLOBAL_HOOK__){var ac=__REACT_DEVTOOLS_GLOBAL_HOOK__;if(!ac.isDisabled&&ac.supportsFiber)try{at=ac.inject(rc),ot=ac}catch(ce){}}t.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED=tc,t.createPortal=function(e,t){var n=2<arguments.length&&void 0!==arguments[2]?arguments[2]:null;if(!Qu(t))throw Error(o(200));return Bu(e,t,null,n)},t.createRoot=function(e,t){if(!Qu(e))throw Error(o(299));var n=!1,r="",a=Ju;return null!==t&&void 0!==t&&(!0===t.unstable_strictMode&&(n=!0),void 0!==t.identifierPrefix&&(r=t.identifierPrefix),void 0!==t.onRecoverableError&&(a=t.onRecoverableError)),t=Zu(e,1,!1,null,0,n,0,r,a),e[ma]=t.current,Wr(8===e.nodeType?e.parentNode:e),new qu(t)},t.findDOMNode=function(e){if(null==e)return null;if(1===e.nodeType)return e;var t=e._reactInternals;if(void 0===t){if("function"===typeof e.render)throw Error(o(188));throw e=Object.keys(e).join(","),Error(o(268,e))}return e=null===(e=Ge(t))?null:e.stateNode},t.flushSync=function(e){return cu(e)},t.hydrate=function(e,t,n){if(!Yu(t))throw Error(o(200));return ec(null,e,t,!0,n)},t.hydrateRoot=function(e,t,n){if(!Qu(e))throw Error(o(405));var r=null!=n&&n.hydratedSources||null,a=!1,i="",s=Ju;if(null!==n&&void 0!==n&&(!0===n.unstable_strictMode&&(a=!0),void 0!==n.identifierPrefix&&(i=n.identifierPrefix),void 0!==n.onRecoverableError&&(s=n.onRecoverableError)),t=Uu(t,null,e,1,null!=n?n:null,a,0,i,s),e[ma]=t.current,Wr(e),r)for(e=0;e<r.length;e++)a=(a=(n=r[e])._getVersion)(n._source),null==t.mutableSourceEagerHydrationData?t.mutableSourceEagerHydrationData=[n,a]:t.mutableSourceEagerHydrationData.push(n,a);return new Ku(t)},t.render=function(e,t,n){if(!Yu(t))throw Error(o(200));return ec(null,e,t,!1,n)},t.unmountComponentAtNode=function(e){if(!Yu(e))throw Error(o(40));return!!e._reactRootContainer&&(cu((function(){ec(null,null,e,!1,(function(){e._reactRootContainer=null,e[ma]=null}))})),!0)},t.unstable_batchedUpdates=uu,t.unstable_renderSubtreeIntoContainer=function(e,t,n,r){if(!Yu(n))throw Error(o(200));if(null==e||void 0===e._reactInternals)throw Error(o(38));return ec(e,t,n,!1,r)},t.version="18.2.0-next-9e3b772b8-20220608"},1250:function(e,t,n){"use strict";var r=n(4164);t.createRoot=r.createRoot,t.hydrateRoot=r.hydrateRoot},4164:function(e,t,n){"use strict";!function e(){if("undefined"!==typeof __REACT_DEVTOOLS_GLOBAL_HOOK__&&"function"===typeof __REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE)try{__REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE(e)}catch(t){console.error(t)}}(),e.exports=n(4463)},6374:function(e,t,n){"use strict";var r=n(2791),a=Symbol.for("react.element"),o=Symbol.for("react.fragment"),i=Object.prototype.hasOwnProperty,s=r.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED.ReactCurrentOwner,l={key:!0,ref:!0,__self:!0,__source:!0};function u(e,t,n){var r,o={},u=null,c=null;for(r in void 0!==n&&(u=""+n),void 0!==t.key&&(u=""+t.key),void 0!==t.ref&&(c=t.ref),t)i.call(t,r)&&!l.hasOwnProperty(r)&&(o[r]=t[r]);if(e&&e.defaultProps)for(r in t=e.defaultProps)void 0===o[r]&&(o[r]=t[r]);return{$$typeof:a,type:e,key:u,ref:c,props:o,_owner:s.current}}t.Fragment=o,t.jsx=u,t.jsxs=u},9117:function(e,t){"use strict";var n=Symbol.for("react.element"),r=Symbol.for("react.portal"),a=Symbol.for("react.fragment"),o=Symbol.for("react.strict_mode"),i=Symbol.for("react.profiler"),s=Symbol.for("react.provider"),l=Symbol.for("react.context"),u=Symbol.for("react.forward_ref"),c=Symbol.for("react.suspense"),d=Symbol.for("react.memo"),f=Symbol.for("react.lazy"),p=Symbol.iterator;var m={isMounted:function(){return!1},enqueueForceUpdate:function(){},enqueueReplaceState:function(){},enqueueSetState:function(){}},h=Object.assign,v={};function b(e,t,n){this.props=e,this.context=t,this.refs=v,this.updater=n||m}function y(){}function g(e,t,n){this.props=e,this.context=t,this.refs=v,this.updater=n||m}b.prototype.isReactComponent={},b.prototype.setState=function(e,t){if("object"!==typeof e&&"function"!==typeof e&&null!=e)throw Error("setState(...): takes an object of state variables to update or a function which returns an object of state variables.");this.updater.enqueueSetState(this,e,t,"setState")},b.prototype.forceUpdate=function(e){this.updater.enqueueForceUpdate(this,e,"forceUpdate")},y.prototype=b.prototype;var _=g.prototype=new y;_.constructor=g,h(_,b.prototype),_.isPureReactComponent=!0;var w=Array.isArray,S=Object.prototype.hasOwnProperty,C={current:null},k={key:!0,ref:!0,__self:!0,__source:!0};function T(e,t,r){var a,o={},i=null,s=null;if(null!=t)for(a in void 0!==t.ref&&(s=t.ref),void 0!==t.key&&(i=""+t.key),t)S.call(t,a)&&!k.hasOwnProperty(a)&&(o[a]=t[a]);var l=arguments.length-2;if(1===l)o.children=r;else if(1<l){for(var u=Array(l),c=0;c<l;c++)u[c]=arguments[c+2];o.children=u}if(e&&e.defaultProps)for(a in l=e.defaultProps)void 0===o[a]&&(o[a]=l[a]);return{$$typeof:n,type:e,key:i,ref:s,props:o,_owner:C.current}}function x(e){return"object"===typeof e&&null!==e&&e.$$typeof===n}var E=/\/+/g;function P(e,t){return"object"===typeof e&&null!==e&&null!=e.key?function(e){var t={"=":"=0",":":"=2"};return"$"+e.replace(/[=:]/g,(function(e){return t[e]}))}(""+e.key):t.toString(36)}function A(e,t,a,o,i){var s=typeof e;"undefined"!==s&&"boolean"!==s||(e=null);var l=!1;if(null===e)l=!0;else switch(s){case"string":case"number":l=!0;break;case"object":switch(e.$$typeof){case n:case r:l=!0}}if(l)return i=i(l=e),e=""===o?"."+P(l,0):o,w(i)?(a="",null!=e&&(a=e.replace(E,"$&/")+"/"),A(i,t,a,"",(function(e){return e}))):null!=i&&(x(i)&&(i=function(e,t){return{$$typeof:n,type:e.type,key:t,ref:e.ref,props:e.props,_owner:e._owner}}(i,a+(!i.key||l&&l.key===i.key?"":(""+i.key).replace(E,"$&/")+"/")+e)),t.push(i)),1;if(l=0,o=""===o?".":o+":",w(e))for(var u=0;u<e.length;u++){var c=o+P(s=e[u],u);l+=A(s,t,a,c,i)}else if(c=function(e){return null===e||"object"!==typeof e?null:"function"===typeof(e=p&&e[p]||e["@@iterator"])?e:null}(e),"function"===typeof c)for(e=c.call(e),u=0;!(s=e.next()).done;)l+=A(s=s.value,t,a,c=o+P(s,u++),i);else if("object"===s)throw t=String(e),Error("Objects are not valid as a React child (found: "+("[object Object]"===t?"object with keys {"+Object.keys(e).join(", ")+"}":t)+"). If you meant to render a collection of children, use an array instead.");return l}function R(e,t,n){if(null==e)return e;var r=[],a=0;return A(e,r,"","",(function(e){return t.call(n,e,a++)})),r}function F(e){if(-1===e._status){var t=e._result;(t=t()).then((function(t){0!==e._status&&-1!==e._status||(e._status=1,e._result=t)}),(function(t){0!==e._status&&-1!==e._status||(e._status=2,e._result=t)})),-1===e._status&&(e._status=0,e._result=t)}if(1===e._status)return e._result.default;throw e._result}var O={current:null},N={transition:null},M={ReactCurrentDispatcher:O,ReactCurrentBatchConfig:N,ReactCurrentOwner:C};t.Children={map:R,forEach:function(e,t,n){R(e,(function(){t.apply(this,arguments)}),n)},count:function(e){var t=0;return R(e,(function(){t++})),t},toArray:function(e){return R(e,(function(e){return e}))||[]},only:function(e){if(!x(e))throw Error("React.Children.only expected to receive a single React element child.");return e}},t.Component=b,t.Fragment=a,t.Profiler=i,t.PureComponent=g,t.StrictMode=o,t.Suspense=c,t.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED=M,t.cloneElement=function(e,t,r){if(null===e||void 0===e)throw Error("React.cloneElement(...): The argument must be a React element, but you passed "+e+".");var a=h({},e.props),o=e.key,i=e.ref,s=e._owner;if(null!=t){if(void 0!==t.ref&&(i=t.ref,s=C.current),void 0!==t.key&&(o=""+t.key),e.type&&e.type.defaultProps)var l=e.type.defaultProps;for(u in t)S.call(t,u)&&!k.hasOwnProperty(u)&&(a[u]=void 0===t[u]&&void 0!==l?l[u]:t[u])}var u=arguments.length-2;if(1===u)a.children=r;else if(1<u){l=Array(u);for(var c=0;c<u;c++)l[c]=arguments[c+2];a.children=l}return{$$typeof:n,type:e.type,key:o,ref:i,props:a,_owner:s}},t.createContext=function(e){return(e={$$typeof:l,_currentValue:e,_currentValue2:e,_threadCount:0,Provider:null,Consumer:null,_defaultValue:null,_globalName:null}).Provider={$$typeof:s,_context:e},e.Consumer=e},t.createElement=T,t.createFactory=function(e){var t=T.bind(null,e);return t.type=e,t},t.createRef=function(){return{current:null}},t.forwardRef=function(e){return{$$typeof:u,render:e}},t.isValidElement=x,t.lazy=function(e){return{$$typeof:f,_payload:{_status:-1,_result:e},_init:F}},t.memo=function(e,t){return{$$typeof:d,type:e,compare:void 0===t?null:t}},t.startTransition=function(e){var t=N.transition;N.transition={};try{e()}finally{N.transition=t}},t.unstable_act=function(){throw Error("act(...) is not supported in production builds of React.")},t.useCallback=function(e,t){return O.current.useCallback(e,t)},t.useContext=function(e){return O.current.useContext(e)},t.useDebugValue=function(){},t.useDeferredValue=function(e){return O.current.useDeferredValue(e)},t.useEffect=function(e,t){return O.current.useEffect(e,t)},t.useId=function(){return O.current.useId()},t.useImperativeHandle=function(e,t,n){return O.current.useImperativeHandle(e,t,n)},t.useInsertionEffect=function(e,t){return O.current.useInsertionEffect(e,t)},t.useLayoutEffect=function(e,t){return O.current.useLayoutEffect(e,t)},t.useMemo=function(e,t){return O.current.useMemo(e,t)},t.useReducer=function(e,t,n){return O.current.useReducer(e,t,n)},t.useRef=function(e){return O.current.useRef(e)},t.useState=function(e){return O.current.useState(e)},t.useSyncExternalStore=function(e,t,n){return O.current.useSyncExternalStore(e,t,n)},t.useTransition=function(){return O.current.useTransition()},t.version="18.2.0"},2791:function(e,t,n){"use strict";e.exports=n(9117)},184:function(e,t,n){"use strict";e.exports=n(6374)},6813:function(e,t){"use strict";function n(e,t){var n=e.length;e.push(t);e:for(;0<n;){var r=n-1>>>1,a=e[r];if(!(0<o(a,t)))break e;e[r]=t,e[n]=a,n=r}}function r(e){return 0===e.length?null:e[0]}function a(e){if(0===e.length)return null;var t=e[0],n=e.pop();if(n!==t){e[0]=n;e:for(var r=0,a=e.length,i=a>>>1;r<i;){var s=2*(r+1)-1,l=e[s],u=s+1,c=e[u];if(0>o(l,n))u<a&&0>o(c,l)?(e[r]=c,e[u]=n,r=u):(e[r]=l,e[s]=n,r=s);else{if(!(u<a&&0>o(c,n)))break e;e[r]=c,e[u]=n,r=u}}}return t}function o(e,t){var n=e.sortIndex-t.sortIndex;return 0!==n?n:e.id-t.id}if("object"===typeof performance&&"function"===typeof performance.now){var i=performance;t.unstable_now=function(){return i.now()}}else{var s=Date,l=s.now();t.unstable_now=function(){return s.now()-l}}var u=[],c=[],d=1,f=null,p=3,m=!1,h=!1,v=!1,b="function"===typeof setTimeout?setTimeout:null,y="function"===typeof clearTimeout?clearTimeout:null,g="undefined"!==typeof setImmediate?setImmediate:null;function _(e){for(var t=r(c);null!==t;){if(null===t.callback)a(c);else{if(!(t.startTime<=e))break;a(c),t.sortIndex=t.expirationTime,n(u,t)}t=r(c)}}function w(e){if(v=!1,_(e),!h)if(null!==r(u))h=!0,N(S);else{var t=r(c);null!==t&&M(w,t.startTime-e)}}function S(e,n){h=!1,v&&(v=!1,y(x),x=-1),m=!0;var o=p;try{for(_(n),f=r(u);null!==f&&(!(f.expirationTime>n)||e&&!A());){var i=f.callback;if("function"===typeof i){f.callback=null,p=f.priorityLevel;var s=i(f.expirationTime<=n);n=t.unstable_now(),"function"===typeof s?f.callback=s:f===r(u)&&a(u),_(n)}else a(u);f=r(u)}if(null!==f)var l=!0;else{var d=r(c);null!==d&&M(w,d.startTime-n),l=!1}return l}finally{f=null,p=o,m=!1}}"undefined"!==typeof navigator&&void 0!==navigator.scheduling&&void 0!==navigator.scheduling.isInputPending&&navigator.scheduling.isInputPending.bind(navigator.scheduling);var C,k=!1,T=null,x=-1,E=5,P=-1;function A(){return!(t.unstable_now()-P<E)}function R(){if(null!==T){var e=t.unstable_now();P=e;var n=!0;try{n=T(!0,e)}finally{n?C():(k=!1,T=null)}}else k=!1}if("function"===typeof g)C=function(){g(R)};else if("undefined"!==typeof MessageChannel){var F=new MessageChannel,O=F.port2;F.port1.onmessage=R,C=function(){O.postMessage(null)}}else C=function(){b(R,0)};function N(e){T=e,k||(k=!0,C())}function M(e,n){x=b((function(){e(t.unstable_now())}),n)}t.unstable_IdlePriority=5,t.unstable_ImmediatePriority=1,t.unstable_LowPriority=4,t.unstable_NormalPriority=3,t.unstable_Profiling=null,t.unstable_UserBlockingPriority=2,t.unstable_cancelCallback=function(e){e.callback=null},t.unstable_continueExecution=function(){h||m||(h=!0,N(S))},t.unstable_forceFrameRate=function(e){0>e||125<e?console.error("forceFrameRate takes a positive int between 0 and 125, forcing frame rates higher than 125 fps is not supported"):E=0<e?Math.floor(1e3/e):5},t.unstable_getCurrentPriorityLevel=function(){return p},t.unstable_getFirstCallbackNode=function(){return r(u)},t.unstable_next=function(e){switch(p){case 1:case 2:case 3:var t=3;break;default:t=p}var n=p;p=t;try{return e()}finally{p=n}},t.unstable_pauseExecution=function(){},t.unstable_requestPaint=function(){},t.unstable_runWithPriority=function(e,t){switch(e){case 1:case 2:case 3:case 4:case 5:break;default:e=3}var n=p;p=e;try{return t()}finally{p=n}},t.unstable_scheduleCallback=function(e,a,o){var i=t.unstable_now();switch("object"===typeof o&&null!==o?o="number"===typeof(o=o.delay)&&0<o?i+o:i:o=i,e){case 1:var s=-1;break;case 2:s=250;break;case 5:s=1073741823;break;case 4:s=1e4;break;default:s=5e3}return e={id:d++,callback:a,priorityLevel:e,startTime:o,expirationTime:s=o+s,sortIndex:-1},o>i?(e.sortIndex=o,n(c,e),null===r(u)&&e===r(c)&&(v?(y(x),x=-1):v=!0,M(w,o-i))):(e.sortIndex=s,n(u,e),h||m||(h=!0,N(S))),e},t.unstable_shouldYield=A,t.unstable_wrapCallback=function(e){var t=p;return function(){var n=p;p=t;try{return e.apply(this,arguments)}finally{p=n}}}},5296:function(e,t,n){"use strict";e.exports=n(6813)},4836:function(e){e.exports=function(e){return e&&e.__esModule?e:{default:e}},e.exports.__esModule=!0,e.exports.default=e.exports},907:function(e,t,n){"use strict";function r(e,t){(null==t||t>e.length)&&(t=e.length);for(var n=0,r=new Array(t);n<t;n++)r[n]=e[n];return r}n.d(t,{Z:function(){return r}})},4942:function(e,t,n){"use strict";function r(e,t,n){return t in e?Object.defineProperty(e,t,{value:n,enumerable:!0,configurable:!0,writable:!0}):e[t]=n,e}n.d(t,{Z:function(){return r}})},7462:function(e,t,n){"use strict";function r(){return r=Object.assign?Object.assign.bind():function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e},r.apply(this,arguments)}n.d(t,{Z:function(){return r}})},3366:function(e,t,n){"use strict";function r(e,t){if(null==e)return{};var n,r,a={},o=Object.keys(e);for(r=0;r<o.length;r++)n=o[r],t.indexOf(n)>=0||(a[n]=e[n]);return a}n.d(t,{Z:function(){return r}})},885:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(181);function a(e,t){return function(e){if(Array.isArray(e))return e}(e)||function(e,t){var n=null==e?null:"undefined"!==typeof Symbol&&e[Symbol.iterator]||e["@@iterator"];if(null!=n){var r,a,o=[],i=!0,s=!1;try{for(n=n.call(e);!(i=(r=n.next()).done)&&(o.push(r.value),!t||o.length!==t);i=!0);}catch(l){s=!0,a=l}finally{try{i||null==n.return||n.return()}finally{if(s)throw a}}return o}}(e,t)||(0,r.Z)(e,t)||function(){throw new TypeError("Invalid attempt to destructure non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}},2982:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(907);var a=n(181);function o(e){return function(e){if(Array.isArray(e))return(0,r.Z)(e)}(e)||function(e){if("undefined"!==typeof Symbol&&null!=e[Symbol.iterator]||null!=e["@@iterator"])return Array.from(e)}(e)||(0,a.Z)(e)||function(){throw new TypeError("Invalid attempt to spread non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}},181:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(907);function a(e,t){if(e){if("string"===typeof e)return(0,r.Z)(e,t);var n=Object.prototype.toString.call(e).slice(8,-1);return"Object"===n&&e.constructor&&(n=e.constructor.name),"Map"===n||"Set"===n?Array.from(e):"Arguments"===n||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(n)?(0,r.Z)(e,t):void 0}}}},t={};function n(r){var a=t[r];if(void 0!==a)return a.exports;var o=t[r]={exports:{}};return e[r].call(o.exports,o,o.exports,n),o.exports}n.n=function(e){var t=e&&e.__esModule?function(){return e.default}:function(){return e};return n.d(t,{a:t}),t},function(){var e,t=Object.getPrototypeOf?function(e){return Object.getPrototypeOf(e)}:function(e){return e.__proto__};n.t=function(r,a){if(1&a&&(r=this(r)),8&a)return r;if("object"===typeof r&&r){if(4&a&&r.__esModule)return r;if(16&a&&"function"===typeof r.then)return r}var o=Object.create(null);n.r(o);var i={};e=e||[null,t({}),t([]),t(t)];for(var s=2&a&&r;"object"==typeof s&&!~e.indexOf(s);s=t(s))Object.getOwnPropertyNames(s).forEach((function(e){i[e]=function(){return r[e]}}));return i.default=function(){return r},n.d(o,i),o}}(),n.d=function(e,t){for(var r in t)n.o(t,r)&&!n.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},n.o=function(e,t){return Object.prototype.hasOwnProperty.call(e,t)},n.r=function(e){"undefined"!==typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},function(){"use strict";var e=n(2791),t=n(1250),r=n(7462),a=n(5513),o=(n(76),n(9886)),i=(n(2110),n(5438)),s=n(9140),l=n(2561),u=(0,o.w)((function(t,n){var r=t.styles,a=(0,s.O)([r],void 0,(0,e.useContext)(o.T)),u=(0,e.useRef)();return(0,l.j)((function(){var e=n.key+"-global",t=new n.sheet.constructor({key:e,nonce:n.sheet.nonce,container:n.sheet.container,speedy:n.sheet.isSpeedy}),r=!1,o=document.querySelector('style[data-emotion="'+e+" "+a.name+'"]');return n.sheet.tags.length&&(t.before=n.sheet.tags[0]),null!==o&&(r=!0,o.setAttribute("data-emotion",e),t.hydrate([o])),u.current=[t,r],function(){t.flush()}}),[n]),(0,l.j)((function(){var e=u.current,t=e[0];if(e[1])e[1]=!1;else{if(void 0!==a.next&&(0,i.My)(n,a.next,!0),t.tags.length){var r=t.tags[t.tags.length-1].nextElementSibling;t.before=r,t.flush()}n.insert("",a,t,!1)}}),[n,a.name]),null}));function c(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];return(0,s.O)(t)}var d=function(){var e=c.apply(void 0,arguments),t="animation-"+e.name;return{name:t,styles:"@keyframes "+t+"{"+e.styles+"}",anim:1,toString:function(){return"_EMO_"+this.name+"_"+this.styles+"_EMO_"}}};var f=n(184);function p(e){var t=e.styles,n=e.defaultTheme,r=void 0===n?{}:n,a="function"===typeof t?function(e){return t(void 0===(n=e)||null===n||0===Object.keys(n).length?r:e);var n}:t;return(0,f.jsx)(u,{styles:a})}var m=n(4205);var h=function(e){return(0,f.jsx)(p,(0,r.Z)({},e,{defaultTheme:m.Z}))},v=function(e,t){return(0,r.Z)({WebkitFontSmoothing:"antialiased",MozOsxFontSmoothing:"grayscale",boxSizing:"border-box",WebkitTextSizeAdjust:"100%"},t&&{colorScheme:e.palette.mode})},b=function(e){return(0,r.Z)({color:(e.vars||e).palette.text.primary},e.typography.body1,{backgroundColor:(e.vars||e).palette.background.default,"@media print":{backgroundColor:(e.vars||e).palette.common.white}})};var y=function(t){var n=(0,a.Z)({props:t,name:"MuiCssBaseline"}),o=n.children,i=n.enableColorScheme,s=void 0!==i&&i;return(0,f.jsxs)(e.Fragment,{children:[(0,f.jsx)(h,{styles:function(e){return function(e){var t,n,a={html:v(e,arguments.length>1&&void 0!==arguments[1]&&arguments[1]),"*, *::before, *::after":{boxSizing:"inherit"},"strong, b":{fontWeight:e.typography.fontWeightBold},body:(0,r.Z)({margin:0},b(e),{"&::backdrop":{backgroundColor:(e.vars||e).palette.background.default}})},o=null==(t=e.components)||null==(n=t.MuiCssBaseline)?void 0:n.styleOverrides;return o&&(a=[a,o]),a}(e,s)}}),o]})},g=n(885),_=n(4942),w=n(3366),S=n(8182),C=n(7312),k=n(1217),T=n(4419),x=n(8691),E=(0,n(4046).ZP)(),P=n(5080),A=["className","component","disableGutters","fixed","maxWidth","classes"],R=(0,P.Z)(),F=E("div",{name:"MuiContainer",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t["maxWidth".concat((0,C.Z)(String(n.maxWidth)))],n.fixed&&t.fixed,n.disableGutters&&t.disableGutters]}}),O=function(e){return(0,x.Z)({props:e,name:"MuiContainer",defaultTheme:R})},N=function(e,t){var n=e.classes,r=e.fixed,a=e.disableGutters,o=e.maxWidth,i={root:["root",o&&"maxWidth".concat((0,C.Z)(String(o))),r&&"fixed",a&&"disableGutters"]};return(0,T.Z)(i,(function(e){return(0,k.Z)(t,e)}),n)};var M=n(9853),I=n(277),z=function(){var t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},n=t.createStyledComponent,a=void 0===n?F:n,o=t.useThemeProps,i=void 0===o?O:o,s=t.componentName,l=void 0===s?"MuiContainer":s,u=a((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({width:"100%",marginLeft:"auto",boxSizing:"border-box",marginRight:"auto",display:"block"},!n.disableGutters&&(0,_.Z)({paddingLeft:t.spacing(2),paddingRight:t.spacing(2)},t.breakpoints.up("sm"),{paddingLeft:t.spacing(3),paddingRight:t.spacing(3)}))}),(function(e){var t=e.theme;return e.ownerState.fixed&&Object.keys(t.breakpoints.values).reduce((function(e,n){var r=n,a=t.breakpoints.values[r];return 0!==a&&(e[t.breakpoints.up(r)]={maxWidth:"".concat(a).concat(t.breakpoints.unit)}),e}),{})}),(function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({},"xs"===n.maxWidth&&(0,_.Z)({},t.breakpoints.up("xs"),{maxWidth:Math.max(t.breakpoints.values.xs,444)}),n.maxWidth&&"xs"!==n.maxWidth&&(0,_.Z)({},t.breakpoints.up(n.maxWidth),{maxWidth:"".concat(t.breakpoints.values[n.maxWidth]).concat(t.breakpoints.unit)}))})),c=e.forwardRef((function(e,t){var n=i(e),a=n.className,o=n.component,s=void 0===o?"div":o,c=n.disableGutters,d=void 0!==c&&c,p=n.fixed,m=void 0!==p&&p,h=n.maxWidth,v=void 0===h?"lg":h,b=(0,w.Z)(n,A),y=(0,r.Z)({},n,{component:s,disableGutters:d,fixed:m,maxWidth:v}),g=N(y,l);return(0,f.jsx)(u,(0,r.Z)({as:s,ownerState:y,className:(0,S.Z)(g.root,a),ref:t},b))}));return c}({createStyledComponent:(0,I.ZP)("div",{name:"MuiContainer",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t["maxWidth".concat((0,M.Z)(String(n.maxWidth)))],n.fixed&&t.fixed,n.disableGutters&&t.disableGutters]}}),useThemeProps:function(e){return(0,a.Z)({props:e,name:"MuiContainer"})}}),L=z,D=n(2421),j=n(104),Z=n(2982),B=n(2466),W=n(114),U=["sx"];function V(e){var t,n=e.sx,a=function(e){var t={systemProps:{},otherProps:{}};return Object.keys(e).forEach((function(n){W.Gc[n]?t.systemProps[n]=e[n]:t.otherProps[n]=e[n]})),t}((0,w.Z)(e,U)),o=a.systemProps,i=a.otherProps;return t=Array.isArray(n)?[o].concat((0,Z.Z)(n)):"function"===typeof n?function(){var e=n.apply(void 0,arguments);return(0,B.P)(e)?(0,r.Z)({},o,e):o}:(0,r.Z)({},o,n),(0,r.Z)({},i,{sx:t})}var G=n(886),H=["className","component"];var $=n(5902),J=n(4360),q=function(){var t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},n=t.defaultTheme,a=t.defaultClassName,o=void 0===a?"MuiBox-root":a,i=t.generateClassName,s=t.styleFunctionSx,l=void 0===s?j.Z:s,u=(0,D.ZP)("div",{shouldForwardProp:function(e){return"theme"!==e&&"sx"!==e&&"as"!==e}})(l),c=e.forwardRef((function(e,t){var a=(0,G.Z)(n),s=V(e),l=s.className,c=s.component,d=void 0===c?"div":c,p=(0,w.Z)(s,H);return(0,f.jsx)(u,(0,r.Z)({as:d,ref:t,className:(0,S.Z)(l,i?i(o):o),theme:a},p))}));return c}({defaultTheme:(0,J.Z)(),defaultClassName:"MuiBox-root",generateClassName:$.Z.generate}),K=q,Q=JSON.parse('{"e":6,"C":[{"nctid":"NCT03033511","version_a":31,"version_b":32,"version_a_date":"2019-02-27","version_b_date":"2019-03-20","pom_a":[{"label":"1.","content":"Progression-free survival (PFS) determined by a Central Radiographic Assessment Committee (CRAC)[ Time Frame: Approximately 24 months since the first subject enrolled ]PFS is defined as the number of months from randomization to disease progression, as assessed by the CRAC per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death of any cause, whichever occurs first."},{"label":"2.","content":"Overall survival (OS)[ Time Frame: Approximately 31 months since first subject enrolled ]OS is defined as the number of months from randomization to death of any cause."}],"pom_b":[{"label":"1.","content":"Progression-free survival (PFS) determined by a Central Radiographic Assessment Committee (CRAC) in participants with ED SCLC tumors with a high level of DLL3 expression[ Time Frame: Approximately 24 months since the first subject enrolled ]PFS is defined as the number of months from randomization to disease progression, as assessed by the CRAC per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death of any cause, whichever occurs first."},{"label":"2.","content":"Overall survival (OS) in participants with ED SCLC tumors with a high level of DLL3 expression[ Time Frame: Approximately 31 months since first subject enrolled ]OS is defined as the number of months from randomization to death of any cause."}],"start_date":"February 7, 2017","primary_completion_date":"November 20, 2019","completion_date":"November 20, 2019","first_posted":"January 26, 2017","results_first_posted":"December 21, 2020","last_update_posted":"July 29, 2021"},{"nctid":"NCT03033511","version_a":40,"version_b":41,"version_a_date":"2019-12-04","version_b_date":"2020-11-11","pom_a":[{"label":"1.","content":"Progression-free survival (PFS) determined by a Central Radiographic Assessment Committee (CRAC) in participants with ED SCLC tumors with a high level of DLL3 expression[ Time Frame: Approximately 24 months since the first subject enrolled ]PFS is defined as the number of months from randomization to disease progression, as assessed by the CRAC per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death of any cause, whichever occurs first."},{"label":"2.","content":"Overall survival (OS) in participants with ED SCLC tumors with a high level of DLL3 expression[ Time Frame: Approximately 31 months since first subject enrolled ]OS is defined as the number of months from randomization to death of any cause."}],"pom_b":[{"label":"1.","content":"Overall Survival (OS) in Participants With Extensive-Stage Small Cell Lung Cancer With Delta-Like Protein 3 High Expression in Tumor (DLL3high)[ Time Frame: Survival follow-up continued until the endpoint of death, participant was lost to follow-up or withdrew consent, or termination of the study by AbbVie, whichever occurred first. Median time on study overall was 11.9 months. ]OS is defined as the number of months from randomization to death of any cause. Calculated using the Kaplan-Meier methodology."}],"start_date":"February 7, 2017","primary_completion_date":"November 20, 2019","completion_date":"November 20, 2019","first_posted":"January 26, 2017","results_first_posted":"December 21, 2020","last_update_posted":"July 29, 2021"},{"nctid":"NCT02380027","version_a":1,"version_b":2,"version_a_date":"2015-02-27","version_b_date":"2015-03-24","pom_a":[{"label":"1.","content":"Proportion of men with clinically significant detected[ Time Frame: When histology results available, at an expected average of 30 days post-biopsy ]"},{"label":"2.","content":"Proportion of men with clinically insignificant detected[ Time Frame: When histology results available, at an expected average of 30 days post-biopsy ]"}],"pom_b":[{"label":"1.","content":"Proportion of men with clinically significant detected[ Time Frame: When histology results available, at an expected average of 30 days post-biopsy ]"}],"start_date":"January 2016","primary_completion_date":"December 31, 2017","completion_date":"December 31, 2017","first_posted":"March 5, 2015","last_update_posted":"May 1, 2018"},{"nctid":"NCT00510692","version_a":3,"version_b":4,"version_a_date":"2008-10-16","version_b_date":"2014-08-06","pom_a":[{"label":"1.","content":"Absolute change in the number of polyps measured in a defined focal area of the rectum.[ Time Frame: 6 months ]"}],"pom_b":[{"label":"1.","content":"Absolute Change in the Number of Polyps Measured in a Focal Area of the Rectum.[ Time Frame: 6 months compared to baseline. ]Absolute change in the number of polyps measured in a defined focal area of the rectum."}],"start_date":"November 2006","primary_completion_date":"April 2008","completion_date":"April 2008","first_posted":"August 2, 2007","results_first_posted":"August 22, 2014","last_update_posted":"August 22, 2014"},{"nctid":"NCT00003830","version_a":16,"version_b":17,"version_a_date":"2009-09-22","version_b_date":"2010-01-05","pom_a":[],"pom_b":[{"label":"1.","content":"Morbidity as measured by arm edema, sensory neuropathy, and arm function - mobility[ Time Frame: Before and after surgery ]"},{"label":"2.","content":"Overall Survival as measured by death from any cause.[ Time Frame: Time from surgery to death from any cause ]"},{"label":"3.","content":"Disease-free Survival as measured by breast cancer recurrence, any second primary cancer, and death from any cause in patients without a prior event.[ Time Frame: Time from surgery to recurrence, second primary, or death ]"}],"start_date":"May 1999","primary_completion_date":"September 2010","completion_date":"February 2014","first_posted":"January 28, 2003","results_first_posted":"December 13, 2017","last_update_posted":"December 13, 2017"},{"nctid":"NCT00003830","version_a":21,"version_b":22,"version_a_date":"2014-03-06","version_b_date":"2017-11-14","pom_a":[{"label":"1.","content":"Morbidity as measured by arm edema, sensory neuropathy, and arm function - mobility[ Time Frame: Before and after surgery ]"},{"label":"2.","content":"Overall Survival as measured by death from any cause.[ Time Frame: Time from surgery to death from any cause ]"},{"label":"3.","content":"Disease-free Survival as measured by breast cancer recurrence, any second primary cancer, and death from any cause in patients without a prior event.[ Time Frame: Time from surgery to recurrence, second primary, or death ]"}],"pom_b":[{"label":"1.","content":"Morbidity - Number of Participants With Residual Shoulder Abduction Deficit[ Time Frame: Before and after surgery (within 30 days of randomization) ]Morbidity as measured by residual shoulder abduction deficit. Shoulder Abduction Deficit definition: Shoulder range of motion decreased by greater than or equal to 10% as compared with that measured prior to surgery."},{"label":"2.","content":"Morbidity - Number of Participants With Residual Arm Volume Difference[ Time Frame: before and after surgery (within 30 days of randomization) ]Morbidity as measured by residual arm volume difference. Residual Arm Volume Difference definition: Arm volume differences greater than or equal to 10% as compared with that measured prior to surgery"},{"label":"3.","content":"Morbidity - Number of Participants With Residual Arm Numbness[ Time Frame: before and after surgery (within 30 days of randomization) ]Morbidity as measured by residual arm numbness"},{"label":"4.","content":"Morbidity - Number of Participants With Residual Arm Tingling[ Time Frame: before and after surgery (within 30 days of randomization) ]Morbidity as measured by residual arm tingling"},{"label":"5.","content":"Overall Survival[ Time Frame: 8 years ]Measured at the time from randomization to any death to determine the percentage of patients alive at 8 years"},{"label":"6.","content":"Disease-free Survival as Measured by Breast Cancer Recurrence, Any Second Primary Cancer, and Death From Any Cause in Patients Without a Prior Event.[ Time Frame: 8 years ]Measured at time from randomization to recurrence, second primary, or death to determine the percentage of patients disease free at 8 years."}],"start_date":"May 1999","primary_completion_date":"September 2010","completion_date":"February 2014","first_posted":"January 28, 2003","results_first_posted":"December 13, 2017","last_update_posted":"December 13, 2017"},{"nctid":"NCT00880191","version_a":104,"version_b":105,"version_a_date":"2011-02-05","version_b_date":"2015-05-20","pom_a":[{"label":"1.","content":"Comparison of percentage of complete responders, with complete response being defined as no emetic episodes and no use of rescue therapy for days 2 through 6"},{"label":"2.","content":"Complete response, defined as no emetic episodes, no more than a mean of 2.5 on the nausea numeric analogue scale, and no rescue agents"},{"label":"3.","content":"Comparison of percentages of complete responders on day 1, vs days 1 through 6 vs days 2 through 6"},{"label":"4.","content":"Comparison of the proportion of patients experiencing emetic episodes and the proportion needing rescue agents"},{"label":"5.","content":"Toxicity"},{"label":"6.","content":"Comparison fo sum of the daily distress questions as well as the individual daily responses"},{"label":"7.","content":"Level of satisfaction for the control of nausea with the mean severity of nausea over the six days in the diary as well as the nausea subscale on the Functional Living Index - Emesis questionnaire"}],"pom_b":[{"label":"1.","content":"Comparison of Percentage of Complete Responders[ Time Frame: Days 2 through 6 ]Complete response being defined as no emetic episodes and no use of rescue therapy for days 2 through 6. If a patient does not complete the study or does not provide complete data, they will be assumed to be a non-responder."}],"start_date":"April 2009","primary_completion_date":"March 2011","completion_date":"May 2015","first_posted":"April 13, 2009","results_first_posted":"May 21, 2015","last_update_posted":"July 6, 2016"},{"nctid":"NCT02466971","version_a":114,"version_b":115,"version_a_date":"2017-03-23","version_b_date":"2017-04-11","pom_a":[{"label":"1.","content":"Progression-free survival (PFS)[ Time Frame: Time (in months) since registration to date first documented recurrence, death or last follow-up visit (contact), assessed up to 5 years ]Product-limit estimates according to the method of Kaplan and Meier and the one sided log-rank test (alpha = 0.1) will be used to compare survival endpoint (PFS) between treatment arms. In addition, adjusted hazard ratios and respective 95% confidence intervals will be calculated using the Cox proportional hazards regression model."}],"pom_b":[{"label":"1.","content":"Progression-free survival (PFS)[ Time Frame: Time (in months) since registration to date first documented recurrence/progression, death or last follow-up visit (contact), assessed up to 5 years ]Product-limit estimates according to the method of Kaplan and Meier and the one sided log-rank test (alpha = 0.1) will be used to compare survival endpoint (PFS) between treatment arms. In addition, adjusted hazard ratios and respective 95% confidence intervals will be calculated using the Cox proportional hazards regression model."}],"start_date":"January 15, 2016","primary_completion_date":"July 23, 2023","completion_date":"July 23, 2023","first_posted":"June 9, 2015","last_update_posted":"September 19, 2022"},{"nctid":"NCT02466971","version_a":263,"version_b":264,"version_a_date":"2018-10-04","version_b_date":"2019-04-08","pom_a":[{"label":"1.","content":"Progression-free survival (PFS)[ Time Frame: Time (in months) since registration to date first documented recurrence/progression, death or last follow-up visit (contact), assessed up to 5 years ]Product-limit estimates according to the method of Kaplan and Meier and the one sided log-rank test (alpha = 0.1) will be used to compare survival endpoint (PFS) between treatment arms. In addition, adjusted hazard ratios and respective 95% confidence intervals will be calculated using the Cox proportional hazards regression model."}],"pom_b":[{"label":"1.","content":"Progression-free survival (PFS)[ Time Frame: Time (in months) since registration (and randomization) onto the study to the date of first documented recurrence/progression, death or last follow-up visit (contact), assessed up to 5 years ]Product-limit estimates according to the method of Kaplan and Meier and the one sided log-rank test (alpha = 0.1) will be used to compare survival endpoint (PFS) between treatment arms. In addition, adjusted hazard ratios and respective 95% confidence intervals will be calculated using the Cox proportional hazards regression model."}],"start_date":"January 15, 2016","primary_completion_date":"July 23, 2023","completion_date":"July 23, 2023","first_posted":"June 9, 2015","last_update_posted":"September 19, 2022"},{"nctid":"NCT02466971","version_a":349,"version_b":350,"version_a_date":"2020-01-03","version_b_date":"2020-01-10","pom_a":[{"label":"1.","content":"Progression-free survival (PFS)[ Time Frame: Time (in months) since registration (and randomization) onto the study to the date of first documented recurrence/progression, death or last follow-up visit (contact), assessed up to 5 years ]Product-limit estimates according to the method of Kaplan and Meier and the one sided log-rank test (alpha = 0.1) will be used to compare survival endpoint (PFS) between treatment arms. In addition, adjusted hazard ratios and respective 95% confidence intervals will be calculated using the Cox proportional hazards regression model."}],"pom_b":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: Time (in months) since registration (and randomization) onto the study to the date death or last contact, assessed up to 5 years ]Product-limit estimates according to the method of Kaplan and Meier and the one sided log-rank test (alpha = 0.1) will be used to compare survival endpoint (OS) between treatment arms. In addition, adjusted hazard ratios and respective 95% confidence intervals will be calculated using the Cox proportional hazards regression model."}],"start_date":"January 15, 2016","primary_completion_date":"July 23, 2023","completion_date":"July 23, 2023","first_posted":"June 9, 2015","last_update_posted":"September 19, 2022"},{"nctid":"NCT03476239","version_a":9,"version_b":10,"version_a_date":"2018-10-15","version_b_date":"2018-11-27","pom_a":[{"label":"1.","content":"Change in rate of hematological response [CR/CRh] induced by blinatumomab[ Time Frame: Within 2 cycles of treatment (6 weeks/cycle) ]BM smears (slides) at screening and at the end of each treatment cycle (6 weeks/cycle) will be collected for cytomorphology testing.The degree of BM infiltration defined by the percentage of leukemic blasts in BM will be evaluated by local laboratories as per cytological assessment. In addition, the BM slides will be provided to the designated central laboratories for hematological assessment.The results of the local laboratory are applicable for inclusion into the study and for the decision if pre-treatment should be administered if the results of the central laboratory are not yet available at the time these decisions are made. For evaluation of baseline and response, the result of the central laboratory will prevail."}],"pom_b":[{"label":"1.","content":"Change in rate of hematological response [CR/CRh] induced by blinatumomab[ Time Frame: Within 2 cycles of treatment (6 weeks/cycle) ]BM smears (slides) at screening and at the end of each treatment cycle (6 weeks/cycle) will be collected for cytomorphology testing.The degree of BM infiltration defined by the percentage of leukemic blasts in BM will be evaluated by local laboratories as per cytological assessment. In addition, the BM slides will be provided to the designated central laboratories for hematological assessment.The results of the local laboratory are applicable for inclusion into the study and for the decision if pre-treatment and/or blinatumomab treatment should be administered if the results of the central laboratory are not yet available at the time these decisions are made. For evaluation of baseline and response, the result of the central laboratory will prevail."}],"start_date":"October 18, 2017","primary_completion_date":"August 21, 2019","completion_date":"April 8, 2021","first_posted":"March 26, 2018","results_first_posted":"September 14, 2020","last_update_posted":"May 2, 2022"},{"nctid":"NCT03476239","version_a":12,"version_b":13,"version_a_date":"2019-10-28","version_b_date":"2020-08-25","pom_a":[{"label":"1.","content":"Change in rate of hematological response [CR/CRh] induced by blinatumomab[ Time Frame: Within 2 cycles of treatment (6 weeks/cycle) ]BM smears (slides) at screening and at the end of each treatment cycle (6 weeks/cycle) will be collected for cytomorphology testing.The degree of BM infiltration defined by the percentage of leukemic blasts in BM will be evaluated by local laboratories as per cytological assessment. In addition, the BM slides will be provided to the designated central laboratories for hematological assessment.The results of the local laboratory are applicable for inclusion into the study and for the decision if pre-treatment and/or blinatumomab treatment should be administered if the results of the central laboratory are not yet available at the time these decisions are made. For evaluation of baseline and response, the result of the central laboratory will prevail."}],"pom_b":[{"label":"1.","content":"Percentage of Participants With a Hematological Response of Complete Remission (CR) or Complete Remission With Partial Hematological Recovery (CRh*) Within 2 Treatment Cycles With Blinatumomab[ Time Frame: Within 2 cycles of treatment (12 weeks) ]A CR is defined as having \u2264 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts (platelets > 100,000/\u03bcL, and absolute neutrophil count [ANC] > 1,000/\u03bcL).CRh* is defined as \u2264 5% blasts in the bone marrow, no evidence of disease and partial recovery of peripheral blood counts: platelets > 50,000/\u03bcl, and ANC > 500/\u03bcl.CR/CRh* rate is defined as the percentage of participants who achieve CR/CRh* within 2 cycles of treatment with blinatumomab. Participants without response assessment were accounted for in the denominator when calculating the response rate, ie, these participants were counted as non-responders.The interim analysis was to become the primary analysis by meeting pre-specified efficacy and safety criteria based on an O\'Brien-Fleming alpha spending function with the critical boundary 42.2%."}],"start_date":"October 18, 2017","primary_completion_date":"August 21, 2019","completion_date":"April 8, 2021","first_posted":"March 26, 2018","results_first_posted":"September 14, 2020","last_update_posted":"May 2, 2022"},{"nctid":"NCT03476239","version_a":16,"version_b":17,"version_a_date":"2021-12-06","version_b_date":"2022-04-01","pom_a":[{"label":"1.","content":"Percentage of Participants With a Hematological Response of Complete Remission (CR) or Complete Remission With Partial Hematological Recovery (CRh*) Within 2 Treatment Cycles With Blinatumomab[ Time Frame: Within 2 cycles of treatment (12 weeks) ]A CR is defined as having \u2264 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts (platelets > 100,000/\u03bcL, and absolute neutrophil count [ANC] > 1,000/\u03bcL).CRh* is defined as \u2264 5% blasts in the bone marrow, no evidence of disease and partial recovery of peripheral blood counts: platelets > 50,000/\u03bcl, and ANC > 500/\u03bcl.CR/CRh* rate is defined as the percentage of participants who achieve CR/CRh* within 2 cycles of treatment with blinatumomab. Participants without response assessment were accounted for in the denominator when calculating the response rate, ie, these participants were counted as non-responders.The interim analysis was to become the primary analysis by meeting pre-specified efficacy and safety criteria based on an O\'Brien-Fleming alpha spending function with the critical boundary 42.2%."}],"pom_b":[{"label":"1.","content":"Percentage of Participants With a Hematological Response of Complete Remission (CR) or Complete Remission With Partial Hematological Recovery (CRh*) During the First 2 Treatment Cycles With Blinatumomab[ Time Frame: Within 2 cycles of treatment (12 weeks) ]A CR is defined as having \u2264 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts (platelets > 100,000/\u03bcL, and absolute neutrophil count [ANC] > 1,000/\u03bcL).CRh* is defined as \u2264 5% blasts in the bone marrow, no evidence of disease and partial recovery of peripheral blood counts: platelets > 50,000/\u03bcl, and ANC > 500/\u03bcl.CR/CRh* rate is defined as the percentage of participants who achieve CR/CRh* within 2 cycles of treatment with blinatumomab. Participants without response assessment were accounted for in the denominator when calculating the response rate, ie, these participants were counted as non-responders.The interim analysis was to become the primary analysis by meeting pre-specified efficacy and safety criteria based on an O\'Brien-Fleming alpha spending function with the critical boundary 42.2%. Results for both the interim and final analysis are reported."}],"start_date":"October 18, 2017","primary_completion_date":"August 21, 2019","completion_date":"April 8, 2021","first_posted":"March 26, 2018","results_first_posted":"September 14, 2020","last_update_posted":"May 2, 2022"},{"nctid":"NCT00849030","version_a":5,"version_b":6,"version_a_date":"2010-12-09","version_b_date":"2012-06-05","pom_a":[{"label":"1.","content":"Time to recurrence of breast cancer[ Time Frame: Earliest of local or distant recurrence, new primary breast cancer, or death ]"},{"label":"2.","content":"Safety and side effects"}],"pom_b":[{"label":"1.","content":"Time to recurrence of breast cancer[ Time Frame: Earliest of local or distant recurrence, new primary breast cancer, or death ]"},{"label":"2.","content":"Safety and side effects[ Time Frame: Earliest of local or distant recurrence, new primary breast cancer, or death ]"}],"start_date":"July 1996","primary_completion_date":"June 2001","completion_date":"April 2010","first_posted":"February 23, 2009","last_update_posted":"June 6, 2012"},{"nctid":"NCT05232916","version_a":1,"version_b":2,"version_a_date":"2022-01-31","version_b_date":"2022-02-13","pom_a":[{"label":"1.","content":"Invasive Breast Cancer-free Survival (IBCFS)[ Time Frame: Over 4 years of follow-up ]IBCFS is defined as the time from the first dose of study medication until the date of ipsilateral invasive breast cancer recurrence, ipsilateral local-regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, or any cause mortality."}],"pom_b":[{"label":"1.","content":"Invasive Breast Cancer-free Survival (IBCFS)[ Time Frame: Median 4 years of follow-up (interim analysis planned) ]IBCFS is defined as the time from the first dose of study medication until the date of ipsilateral invasive breast cancer recurrence, ipsilateral local-regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, or any cause mortality."}],"start_date":"September 2022","primary_completion_date":"December 2026","completion_date":"December 2026","first_posted":"February 10, 2022","last_update_posted":"September 16, 2022"},{"nctid":"NCT03224182","version_a":5,"version_b":6,"version_a_date":"2019-11-15","version_b_date":"2021-08-30","pom_a":[{"label":"1.","content":"Time to Recurrence[ Time Frame: Up-to 5 years ]To evaluate the Time to Recurrence in patients with low- to intermediate-risk non-muscle invasive bladder cancer (NMIBC) who receive either 8 mg Qapzola or placebo post transurethral resection of bladder tumor (TURBT)."}],"pom_b":[{"label":"1.","content":"Time to Recurrence[ Time Frame: From randomization to date of histologically confirmed recurrence of bladder cancer (up to 2.1 years) ]Time from randomization to the date of histologically confirmed recurrence of bladder cancer. A recurrence was defined as any pathologically confirmed disease of \u2265Ta tumor histology or carcinoma in situ (CIS) post-treatment."}],"start_date":"August 4, 2017","primary_completion_date":"September 26, 2019","completion_date":"September 26, 2019","first_posted":"July 21, 2017","results_first_posted":"September 28, 2021","last_update_posted":"September 28, 2021"},{"nctid":"NCT03116698","version_a":6,"version_b":7,"version_a_date":"2018-08-15","version_b_date":"2019-04-02","pom_a":[{"label":"1.","content":"The proportion of subjects with complete clearance (absence of clinically visible or palpable AK lesions in the treatment area) of AK lesions at the End of Study Visit at 16 weeks[ Time Frame: 16 Weeks ]"}],"pom_b":[{"label":"1.","content":"Proportion of Subjects With Complete Clearance of AK Lesions at the End of Study Visit at 16 Weeks[ Time Frame: 16 Weeks ]The proportion of subjects with complete clearance (absence of clinically visible or palpable AK lesions in the treatment area) of AK lesions at the End of Study Visit at 16 weeks (12 weeks treatment and 4 weeks treatment-free follow-up)"}],"start_date":"February 14, 2017","primary_completion_date":"November 13, 2017","completion_date":"July 5, 2018","first_posted":"April 17, 2017","results_first_posted":"April 24, 2019","last_update_posted":"April 24, 2019"},{"nctid":"NCT00375648","version_a":9,"version_b":10,"version_a_date":"2009-11-27","version_b_date":"2010-02-17","pom_a":[],"pom_b":[{"label":"1.","content":"to measure the intensity of the pain relief of the patients at the end of treatment with a five classes score (TOTPAR = TOTal PAin Relief)[ Time Frame: at 12 weeks or at 16 weeks (end of treatment) ]"}],"start_date":"June 2005","primary_completion_date":"July 2007","first_posted":"September 13, 2006","last_update_posted":"June 2, 2017"},{"nctid":"NCT01419717","version_a":44,"version_b":45,"version_a_date":"2018-08-29","version_b_date":"2019-08-01","pom_a":[{"label":"1.","content":"Subject incidence of treatment-emergent adverse events[ Time Frame: Study duration (expected to be approximately 1 year per subject) ]"}],"pom_b":[{"label":"1.","content":"Number of Participants With Adverse Events[ Time Frame: From first dose of denosumab in Study 20110113 to end of study; median (minimum, maximum) time on study was 13.93 (0.0, 74.7) months. ]An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant. The event does not necessarily have a causal relationship with study treatment.Each AE was graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, where Grade 1 = Mild AE Grade 2 = Moderate AE Grade 3 = Severe AE Grade 4 = Life-threatening or disabling AE Grade 5 = Death related to AE. Treatment-related adverse events (TRAEs) includes events for which the investigator indicated there was a reasonable possibility they may have been caused by investigational product."}],"start_date":"November 22, 2011","primary_completion_date":"August 10, 2018","completion_date":"August 10, 2018","first_posted":"August 18, 2011","results_first_posted":"September 9, 2019","last_update_posted":"September 24, 2019"},{"nctid":"NCT03248440","version_a":3,"version_b":4,"version_a_date":"2020-09-17","version_b_date":"2021-07-07","pom_a":[{"label":"1.","content":"Complete response (CR) of the study chalazion by Day 15 \xb1 1[ Time Frame: Baseline to Day 15 \xb1 1 ]"}],"pom_b":[{"label":"1.","content":"Complete Response (CR) of the Study Chalazion by Day 15 \xb1 1[ Time Frame: Baseline to Day 15 \xb1 1 ]Complete response was defined as the absence of any significant clinical signs of a chalazion, based on clinical judgment by an investigator."}],"start_date":"July 31, 2017","primary_completion_date":"August 17, 2018","completion_date":"August 17, 2018","first_posted":"August 14, 2017","results_first_posted":"August 5, 2021","last_update_posted":"August 5, 2021"},{"nctid":"NCT03248440","version_a":4,"version_b":5,"version_a_date":"2021-07-07","version_b_date":"2021-08-03","pom_a":[{"label":"1.","content":"Complete Response (CR) of the Study Chalazion by Day 15 \xb1 1[ Time Frame: Baseline to Day 15 \xb1 1 ]Complete response was defined as the absence of any significant clinical signs of a chalazion, based on clinical judgment by an investigator."}],"pom_b":[{"label":"1.","content":"The Proportions of Participants Who Experienced Complete Response of the Study Chalazion by Day 15 \xb1 1[ Time Frame: Baseline to Day 15 \xb1 1 ]Complete response was defined as the absence of any significant clinical signs of a chalazion, based on clinical judgment by an investigator."}],"start_date":"July 31, 2017","primary_completion_date":"August 17, 2018","completion_date":"August 17, 2018","first_posted":"August 14, 2017","results_first_posted":"August 5, 2021","last_update_posted":"August 5, 2021"},{"nctid":"NCT00574275","version_a":5,"version_b":6,"version_a_date":"2008-06-02","version_b_date":"2008-08-21","pom_a":[{"label":"1.","content":"Overall survival (OS)"}],"pom_b":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: Study period ]"}],"start_date":"December 2007","primary_completion_date":"October 2009","completion_date":"November 2010","first_posted":"December 17, 2007","results_first_posted":"September 25, 2012","last_update_posted":"June 7, 2016"},{"nctid":"NCT00574275","version_a":14,"version_b":15,"version_a_date":"2011-07-21","version_b_date":"2012-09-24","pom_a":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: Study period ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: From the first randomization until the end of study data cutoff date (approximately 2 years) ]OS is the time interval from the date of randomization to the date of death due to any cause. If death was not observed during the study, data on OS were censored at the earlier of the last date participant was known to be alive, or the study data cutoff date (11 September 2009).OS time was estimated from Kaplan-Meier Plots."}],"start_date":"December 2007","primary_completion_date":"October 2009","completion_date":"November 2010","first_posted":"December 17, 2007","results_first_posted":"September 25, 2012","last_update_posted":"June 7, 2016"},{"nctid":"NCT03084471","version_a":3,"version_b":4,"version_a_date":"2017-04-21","version_b_date":"2017-05-10","pom_a":[{"label":"1.","content":"Safety: Number of participants with adverse events of special interest (AESI).[ Time Frame: From Screening (Day -28) up to Safety follow up visit (90 days after last dose). ]Information on AESIs reported in participants who are treated with durvalumab and tremelimumab combination therapy or durvalumab monotherapy, using fixed dosing will be collected.This will be a common primary objective for all tumor sub-studies."},{"label":"2.","content":"Safety: Percentage of participants with AESI[ Time Frame: From Screening (Day -28) up to Safety follow up visit (90 days after last dose). ]Information on AESIs reported in participants who are treated with durvalumab and tremelimumab combination therapy or durvalumab monotherapy, using fixed dosing will be collected.This will be a common primary objective for all tumor sub-studies."}],"pom_b":[{"label":"1.","content":"Safety: Number of patients with adverse events of special interest (AESI).[ Time Frame: From screening to safety follow up visit (90 days after last dose). ]To assess the AESI as a criteria of safety and tolerability variables."}],"start_date":"June 5, 2017","primary_completion_date":"March 31, 2020","completion_date":"August 31, 2022","first_posted":"March 21, 2017","results_first_posted":"June 15, 2021","last_update_posted":"August 19, 2022"},{"nctid":"NCT03084471","version_a":12,"version_b":13,"version_a_date":"2018-01-31","version_b_date":"2018-04-09","pom_a":[{"label":"1.","content":"Safety: Number of patients with adverse events of special interest (AESI).[ Time Frame: From screening to safety follow up visit (90 days after last dose). ]To assess the AESI as a criteria of safety and tolerability variables."}],"pom_b":[{"label":"1.","content":"Safety: Number of patients with adverse events of special interest (AESIs).[ Time Frame: From screening to safety follow up visit (90 days after last dose). ]To assess the AESIs as a criteria of safety and tolerability variables."}],"start_date":"June 5, 2017","primary_completion_date":"March 31, 2020","completion_date":"August 31, 2022","first_posted":"March 21, 2017","results_first_posted":"June 15, 2021","last_update_posted":"August 19, 2022"},{"nctid":"NCT03084471","version_a":37,"version_b":38,"version_a_date":"2021-02-22","version_b_date":"2021-03-22","pom_a":[{"label":"1.","content":"Safety: Number of patients with adverse events of special interest (AESIs).[ Time Frame: From screening to safety follow up visit (90 days after last dose). ]To assess the AESIs as a criteria of safety and tolerability variables."}],"pom_b":[{"label":"1.","content":"Number of Participants With Adverse Events of Special Interest (AESIs)[ Time Frame: From screening to safety follow up visit (90 days after last dose), maximum up to 4 years. ]Incidence, severity, nature, seriousness, intervention/treatment, outcome, and causality of AESIs were assessed. AESIs included events with a potential inflammatory or immune-mediated mechanism that required interventions such as steroids, immunosuppressants, and/or hormone replacement therapy."},{"label":"Quality Control Review Comment provided by the National Library of Medicine:","content":"The Time Frame appears inconsistent with information provided here or in other parts of the record."}],"start_date":"June 5, 2017","primary_completion_date":"March 31, 2020","completion_date":"August 31, 2022","first_posted":"March 21, 2017","results_first_posted":"June 15, 2021","last_update_posted":"August 19, 2022"},{"nctid":"NCT03084471","version_a":38,"version_b":39,"version_a_date":"2021-03-22","version_b_date":"2021-05-20","pom_a":[{"label":"1.","content":"Number of Participants With Adverse Events of Special Interest (AESIs)[ Time Frame: From screening to safety follow up visit (90 days after last dose), maximum up to 4 years. ]Incidence, severity, nature, seriousness, intervention/treatment, outcome, and causality of AESIs were assessed. AESIs included events with a potential inflammatory or immune-mediated mechanism that required interventions such as steroids, immunosuppressants, and/or hormone replacement therapy."},{"label":"Quality Control Review Comment provided by the National Library of Medicine:","content":"The Time Frame appears inconsistent with information provided here or in other parts of the record."}],"pom_b":[{"label":"1.","content":"Number of Participants With Adverse Events of Special Interest (AESIs)[ Time Frame: From screening to safety follow up visit (90 days after last dose), up to approximately 3 years. ]Incidence, severity, nature, seriousness, intervention/treatment, outcome, and causality of AESIs were assessed. AESIs included events with a potential inflammatory or immune-mediated mechanism that required interventions such as steroids, immunosuppressants, and/or hormone replacement therapy."}],"start_date":"June 5, 2017","primary_completion_date":"March 31, 2020","completion_date":"August 31, 2022","first_posted":"March 21, 2017","results_first_posted":"June 15, 2021","last_update_posted":"August 19, 2022"},{"nctid":"NCT03200704","version_a":4,"version_b":5,"version_a_date":"2018-09-10","version_b_date":"2019-01-18","pom_a":[{"label":"1.","content":"The proportion of lymph nodes identified by IC2000 and SPY-PHI will be compared to the proportion of lymph nodes identified by Isosulfan Blue.[ Time Frame: During treatment period ]"}],"pom_b":[{"label":"1.","content":"To assess the effectiveness of IC2000 and SPY-PHI (SPY Portable Handheld Imager; also called \\"IC2000 and SPY\\") Fluorescence Imaging System in the identification of lymph nodes (histology confirmed lymph nodes), during lymphatic mapping[ Time Frame: During treatment period ]Proportion of lymph nodes identified by IC2000/SPY-PHI, and the proportion of lymph nodes identified by Tc99m/Gamma Probe"}],"start_date":"January 4, 2019","primary_completion_date":"August 27, 2020","completion_date":"September 28, 2020","first_posted":"June 27, 2017","last_update_posted":"August 23, 2021"},{"nctid":"NCT03200704","version_a":6,"version_b":7,"version_a_date":"2019-02-05","version_b_date":"2019-03-24","pom_a":[{"label":"1.","content":"To assess the effectiveness of IC2000 and SPY-PHI (SPY Portable Handheld Imager; also called \\"IC2000 and SPY\\") Fluorescence Imaging System in the identification of lymph nodes (histology confirmed lymph nodes), during lymphatic mapping[ Time Frame: During treatment period ]Proportion of lymph nodes identified by IC2000/SPY-PHI, and the proportion of lymph nodes identified by Tc99m/Gamma Probe"}],"pom_b":[{"label":"1.","content":"To assess the effectiveness of IC2000 and SPY-PHI (SPY Portable Handheld Imager) Fluorescence Imaging System in the identification of lymph nodes (histology confirmed lymph nodes), during lymphatic mapping[ Time Frame: During treatment period ]Proportion of lymph nodes identified by IC2000/SPY-PHI compared to the proportion of lymph nodes identified by Tc99m/Gamma Probe"}],"start_date":"January 4, 2019","primary_completion_date":"August 27, 2020","completion_date":"September 28, 2020","first_posted":"June 27, 2017","last_update_posted":"August 23, 2021"},{"nctid":"NCT00191100","version_a":4,"version_b":5,"version_a_date":"2007-11-26","version_b_date":"2008-10-01","pom_a":[{"label":"1.","content":"Overall survival - the expected median overall survival for the experimental arm is 78.6 months."}],"pom_b":[{"label":"1.","content":"Progression free survival[ Time Frame: 3 years ]"}],"start_date":"May 2002","primary_completion_date":"April 2008","completion_date":"April 2008","first_posted":"September 19, 2005","results_first_posted":"May 25, 2009","last_update_posted":"August 11, 2009"},{"nctid":"NCT00191100","version_a":6,"version_b":7,"version_a_date":"2008-10-30","version_b_date":"2009-03-30","pom_a":[{"label":"1.","content":"Progression free survival[ Time Frame: 3 years ]"}],"pom_b":[{"label":"1.","content":"Number of Participants With Progressive Disease or Death Due to Any Cause at 3 Years[ Time Frame: Tumor assessments at baseline, weekly during chemoradiation & brachytherapy, on Day 1 of adjuvant Cycles 1&2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively ]Original outcome was Progression-Free Survival (PFS) probability at 3 years. PFS=time from baseline to progressive disease (PD) or death from any cause. Probability is not an accepted \\"Measure Type\\", so number of progression-free patients still at risk and cumulative number of patients that had an event (PD or death of any cause) are presented."}],"start_date":"May 2002","primary_completion_date":"April 2008","completion_date":"April 2008","first_posted":"September 19, 2005","results_first_posted":"May 25, 2009","last_update_posted":"August 11, 2009"},{"nctid":"NCT00952588","version_a":28,"version_b":29,"version_a_date":"2012-10-09","version_b_date":"2014-02-13","pom_a":[{"label":"1.","content":"Overall Complete Response Rate: Defined as the proportion of patients achieving a Complete Remission or Complete Remission with incomplete recovery of neutrophils and platelets[ Time Frame: Day 1 Predose and day 28 of each cycle, treatment stop and follow-up visits. ]"}],"pom_b":[{"label":"1.","content":"Percentage of Patients With Overall Complete Response for Stage I[ Time Frame: IWG Cheson criteria every 28 days from randomization for study duration (24 months, between 2009 - 2011) ]Percentage of patients achieving either a complete response (CR) or a confirmed complete remission with incomplete recovery of neutrophils or platelets (confirmed CRi). Per Cheson Criteria: Confirmed complete remission (CRi) is defined as a disappearance of blasts in the peripheral blood; a decrease in bone marrow blasts to <5% total bone marrow nucleated cells demonstrated in bone marrow aspirate; absence of Auer rods; no persistent extramedullary leukaemia. Complete response (CR) is defined as all requirements to meet CRi and in addition: recovery of neutrophils to \u22651.0 x 109/L and platelets to \u2265100 x 109/L; transfusion-independence."}],"start_date":"July 2009","primary_completion_date":"June 2011","completion_date":"June 2011","first_posted":"August 6, 2009","results_first_posted":"March 31, 2014","last_update_posted":"February 24, 2020"},{"nctid":"NCT00005975","version_a":12,"version_b":13,"version_a_date":"2009-05-09","version_b_date":"2013-01-30","pom_a":[],"pom_b":[{"label":"1.","content":"Effectiveness and duration of the benefit of placebo and 2 dose levels of megestrol acetate in reduction of severe and/or frequent hot flashes in patients with history of adequate local and regional treatment of invasive breast cancer[ Time Frame: 3, 6, and 9 months ]"}],"start_date":"April 1998","primary_completion_date":"September 2001","completion_date":"March 2002","first_posted":"June 28, 2004","last_update_posted":"November 18, 2015"},{"nctid":"NCT00036543","version_a":1,"version_b":2,"version_a_date":"2005-06-23","version_b_date":"2006-02-13","pom_a":[],"pom_b":[{"label":"1.","content":"The primary objective of this study is to evaluate safety and efficacy as measured by time-to-disease progression"}],"start_date":"May 2001","first_posted":"May 13, 2002","last_update_posted":"August 15, 2006"},{"nctid":"NCT01905943","version_a":77,"version_b":78,"version_a_date":"2016-05-04","version_b_date":"2016-07-19","pom_a":[{"label":"1.","content":"Safety: Incidence, type and severity of adverse events, based on the NCI-CTCAE v.4.0[ Time Frame: approximately 30 months ]"}],"pom_b":[{"label":"1.","content":"Number of participants with adverse events (AEs) and serious adverse events (SAEs) based on the national cancer institute common terminology criteria for AEs, Version 4.0 (NCI-CTCAE, v4.0)[ Time Frame: Baseline up to end of study (Approximately 5 years) ]"}],"start_date":"November 4, 2013","primary_completion_date":"December 29, 2016","completion_date":"October 8, 2018","first_posted":"July 23, 2013","results_first_posted":"October 29, 2018","last_update_posted":"October 28, 2019"},{"nctid":"NCT01905943","version_a":81,"version_b":82,"version_a_date":"2017-10-12","version_b_date":"2018-10-26","pom_a":[{"label":"1.","content":"Number of participants with adverse events (AEs) and serious adverse events (SAEs) based on the national cancer institute common terminology criteria for AEs, Version 4.0 (NCI-CTCAE, v4.0)[ Time Frame: Baseline up to end of study (Approximately 5 years) ]"}],"pom_b":[{"label":"1.","content":"Number of Participants With Adverse Events (AEs)[ Time Frame: Baseline up to data base lock date at time of primary study completion (up to approximately 3 years) ]An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs, including AEs of Special Interest and AEs of Particular Interest, were reported based on the national cancer institute common terminology criteria for AEs, Version 4.0 (NCI-CTCAE, v4.0). Reported are the number of subjects with AEs, Grade 3-5 AEs, and Serious Adverse Events (SAEs)."},{"label":"2.","content":"Number of Participants With Adverse Events of Special Interest (AESIs)[ Time Frame: Baseline up to data base lock date at time of primary study completion (up to approximately 3 years) ]The following AEs were defined as AESIs: AEs with the preferred term Tumour Lysis Syndrome (TLS), Infusion-Related Reactions (IRRs) defined as AEs that occurred during or within 24 hours of the completion of obinutuzumab infusion and were assessed as related to obinutuzumab by the Investigator, Infections defined as AEs from System Organ Class (SOC) \\"Infections and infestations\\" and AEs with the preferred term Neutropenia. Reported are number of participants with total AESIs, IRRs, Infections, Neutropenia and TLS."},{"label":"3.","content":"Number of Participants With Adverse Events of Particular Interest (AEPIs)[ Time Frame: Baseline up to data base lock date at time of primary study completion (up to approximately 3 years) ]The following AEs were defined as AEPIs: AEs with the preferred term Progressive multifocal leukoencephalopathy (PML), hepatitis B reactivation defined as AEs with preferred term containing \\"Hepatitis B\\" or \\"hepatitis acute\\", thrombocytopenia defined via Roche MedDRA basket subgroup \\"haematopoietic thrombocytopenia\\", second malignancies defined as AEs from the SOC \\"Neoplasms benign, malignant and unspecified\\" starting 6 months after the first study drug intake, second malignancies based on standardised MedDRA queries (SMQ) starting 6 months after the first study drug intake based on the MedDRA SMQ \\"Malignant or unspecified tumours\\", in which benign neoplasms are not included, Cardiac events including AEs from the SOC \\"Cardiac disorders\\", and hemorrhagic events defined via Roche MedDRA basket subgroup \\"Haemorrhagic events\\". Reported are number of participants with total AEPIs and each of the AEPI categories."}],"start_date":"November 4, 2013","primary_completion_date":"December 29, 2016","completion_date":"October 8, 2018","first_posted":"July 23, 2013","results_first_posted":"October 29, 2018","last_update_posted":"October 28, 2019"},{"nctid":"NCT01905943","version_a":83,"version_b":84,"version_a_date":"2018-11-19","version_b_date":"2019-10-24","pom_a":[{"label":"1.","content":"Number of Participants With Adverse Events (AEs)[ Time Frame: Baseline up to data base lock date at time of primary study completion (up to approximately 3 years) ]An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs, including AEs of Special Interest and AEs of Particular Interest, were reported based on the national cancer institute common terminology criteria for AEs, Version 4.0 (NCI-CTCAE, v4.0). Reported are the number of subjects with AEs, Grade 3-5 AEs, and Serious Adverse Events (SAEs)."},{"label":"2.","content":"Number of Participants With Adverse Events of Special Interest (AESIs)[ Time Frame: Baseline up to data base lock date at time of primary study completion (up to approximately 3 years) ]The following AEs were defined as AESIs: AEs with the preferred term Tumour Lysis Syndrome (TLS), Infusion-Related Reactions (IRRs) defined as AEs that occurred during or within 24 hours of the completion of obinutuzumab infusion and were assessed as related to obinutuzumab by the Investigator, Infections defined as AEs from System Organ Class (SOC) \\"Infections and infestations\\" and AEs with the preferred term Neutropenia. Reported are number of participants with total AESIs, IRRs, Infections, Neutropenia and TLS."},{"label":"3.","content":"Number of Participants With Adverse Events of Particular Interest (AEPIs)[ Time Frame: Baseline up to data base lock date at time of primary study completion (up to approximately 3 years) ]The following AEs were defined as AEPIs: AEs with the preferred term Progressive multifocal leukoencephalopathy (PML), hepatitis B reactivation defined as AEs with preferred term containing \\"Hepatitis B\\" or \\"hepatitis acute\\", thrombocytopenia defined via Roche MedDRA basket subgroup \\"haematopoietic thrombocytopenia\\", second malignancies defined as AEs from the SOC \\"Neoplasms benign, malignant and unspecified\\" starting 6 months after the first study drug intake, second malignancies based on standardised MedDRA queries (SMQ) starting 6 months after the first study drug intake based on the MedDRA SMQ \\"Malignant or unspecified tumours\\", in which benign neoplasms are not included, Cardiac events including AEs from the SOC \\"Cardiac disorders\\", and hemorrhagic events defined via Roche MedDRA basket subgroup \\"Haemorrhagic events\\". Reported are number of participants with total AEPIs and each of the AEPI categories."}],"pom_b":[{"label":"1.","content":"Number of Participants With Adverse Events (AEs)[ Time Frame: Baseline up to time of primary completion (3 years) ]An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs, including AEs of Special Interest and AEs of Particular Interest, were reported based on the national cancer institute common terminology criteria for AEs, Version 4.0 (NCI-CTCAE, v4.0). Reported are the number of subjects with AEs, Grade 3-5 AEs, and Serious Adverse Events (SAEs)."},{"label":"2.","content":"Number of Participants With Adverse Events of Special Interest (AESIs)[ Time Frame: Baseline up to time of primary completion (3 years) ]The following AEs were defined as AESIs: AEs with the preferred term Tumour Lysis Syndrome (TLS), Infusion-Related Reactions (IRRs) defined as AEs that occurred during or within 24 hours of the completion of obinutuzumab infusion and were assessed as related to obinutuzumab by the Investigator, Infections defined as AEs from System Organ Class (SOC) \\"Infections and infestations\\" and AEs with the preferred term Neutropenia. Reported are number of participants with total AESIs, IRRs, Infections, Neutropenia and TLS."},{"label":"3.","content":"Number of Participants With Adverse Events of Particular Interest (AEPIs)[ Time Frame: Baseline up to time of primary completion (3 years) ]The following AEs were defined as AEPIs: AEs with the preferred term Progressive multifocal leukoencephalopathy (PML), hepatitis B reactivation defined as AEs with preferred term containing \\"Hepatitis B\\" or \\"hepatitis acute\\", thrombocytopenia defined via Roche MedDRA basket subgroup \\"haematopoietic thrombocytopenia\\", second malignancies defined as AEs from the SOC \\"Neoplasms benign, malignant and unspecified\\" starting 6 months after the first study drug intake, second malignancies based on standardised MedDRA queries (SMQ) starting 6 months after the first study drug intake based on the MedDRA SMQ \\"Malignant or unspecified tumours\\", in which benign neoplasms are not included, Cardiac events including AEs from the SOC \\"Cardiac disorders\\", and hemorrhagic events defined via Roche MedDRA basket subgroup \\"Haemorrhagic events\\". Reported are number of participants with total AEPIs and each of the AEPI categories."}],"start_date":"November 4, 2013","primary_completion_date":"December 29, 2016","completion_date":"October 8, 2018","first_posted":"July 23, 2013","results_first_posted":"October 29, 2018","last_update_posted":"October 28, 2019"},{"nctid":"NCT01307397","version_a":1,"version_b":2,"version_a_date":"2011-02-28","version_b_date":"2011-03-15","pom_a":[],"pom_b":[{"label":"1.","content":"Safety: Incidence of adverse events[ Time Frame: 22 months ]"}],"start_date":"March 1, 2011","primary_completion_date":"February 24, 2016","completion_date":"February 24, 2016","first_posted":"March 2, 2011","results_first_posted":"December 18, 2017","last_update_posted":"December 18, 2017"},{"nctid":"NCT01307397","version_a":11,"version_b":12,"version_a_date":"2011-12-05","version_b_date":"2012-01-17","pom_a":[{"label":"1.","content":"Safety: Incidence of adverse events[ Time Frame: 22 months ]"}],"pom_b":[{"label":"1.","content":"Safety: Incidence of adverse events[ Time Frame: approximately 4 years ]"}],"start_date":"March 1, 2011","primary_completion_date":"February 24, 2016","completion_date":"February 24, 2016","first_posted":"March 2, 2011","results_first_posted":"December 18, 2017","last_update_posted":"December 18, 2017"},{"nctid":"NCT01307397","version_a":112,"version_b":113,"version_a_date":"2016-04-02","version_b_date":"2017-07-21","pom_a":[{"label":"1.","content":"Safety: Incidence of adverse events[ Time Frame: approximately 4 years ]"}],"pom_b":[{"label":"1.","content":"Percentage of Participants Experiencing Any Grade 3 or 4 Adverse Events (AEs) as Determined by National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version 4.0[ Time Frame: Baseline up to 28 days post end of treatment (maximum up to 46 months) ]The intensity of AEs were graded on a 5-point scale (Grade 1 to 5) according to the NCI-CTCAE version 4.0, where Grade 1 indicates \\"Mild\\" severity and Grade 5 indicates \\"Death\\". The CTCAE defines Grades 3 and 4 as follows: Grade 3 means \\"Severe\\"; Inability to work or perform normal daily activity; treatment or medical intervention is indicated in order to improve the overall well-being or symptoms; delaying the onset of treatment is not putting the survival of the participant at direct risk. Grade 4 means \\"Life-threatening, Disabling\\"; based on extreme limitation in activity; significant medical intervention/therapy required; and hospitalization probable."},{"label":"2.","content":"Percentage of Participants With at Least 1 AE Leading to Study Drug Interruption or Drug Discontinuation[ Time Frame: Baseline up to 28 days post end of treatment (maximum up to 46 months) ]An AE was considered as any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Pre existing conditions that worsened during the study and laboratory or clinical tests that resulted in a change in treatment or discontinuation from study drug were reported as adverse events. Percentage of participants with dose interruption or discontinuation due to AE was presented."},{"label":"3.","content":"Percentage of Participants With AEs of Special Interest[ Time Frame: Baseline up to 28 days post end of treatment (maximum up to 46 months) ]AEs of special interest included cutaneous squamous cell carcinoma (SCC), rash, photosensitivity, liver injury, arthralgia, fatigue, gastrointestinal (GI) polyps, pancreatitis, potentiation of radiation toxicity, prolongation of cardiac repolarization or arrhythmia, non-cutaneous SCC and other primary malignancies (other than cutaneous SCC or new primary melanoma)."},{"label":"4.","content":"Mean Cumulative Dose of Vemurafenib[ Time Frame: Baseline up to end of treatment or death (maximum up to 46 months) ]"},{"label":"5.","content":"Duration of Vemurafenib Treatment[ Time Frame: Baseline up to end of treatment or death (maximum upto 46 months) ]Exposure excluding treatment interruptions: Duration during which participants actually took vemurafenib. Any time without dose-taken due to adverse events, non-compliance or any other reasons was not counted.Exposure including treatment interruptions: date of last dose - date of first dose + 1; duration during which participants actually took vemurafenib as well as duration on which medication was not taken were included in this calculation."},{"label":"6.","content":"Mean Total Vemurafenib Dose Per Day[ Time Frame: Baseline up to end of treatment or death (maximum up to 46 months) ]Exposure excluding treatment interruptions: Duration during which participants actually took vemurafenib. Any time without dose-taken due to adverse events, non-compliance or any other reasons was not counted.Exposure including treatment interruptions: date of last dose - date of first dose + 1; duration during which participants actually took vemurafenib as well as duration on which medication was not taken were included in this calculation. Average total dose per day: total actual dose taken divided by total actual days on treatment."},{"label":"7.","content":"Dose Intensity of Vemurafenib[ Time Frame: Baseline up to end of treatment or death (maximum upto 46 months) ]Dose intensity was defined as (total actual doses taken/total planned doses) *100, where total planned doses = prescribed doses * planned days on treatment, where planned days on treatment were defined as the interval between date of first dose and date of last dose."}],"start_date":"March 1, 2011","primary_completion_date":"February 24, 2016","completion_date":"February 24, 2016","first_posted":"March 2, 2011","results_first_posted":"December 18, 2017","last_update_posted":"December 18, 2017"},{"nctid":"NCT03873402","version_a":1,"version_b":2,"version_a_date":"2019-03-12","version_b_date":"2019-06-04","pom_a":[{"label":"1.","content":"Progression free survival (PFS)[ Time Frame: Up to 19 months ]Blinded independent central review (BICR) assessed per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1"}],"pom_b":[{"label":"1.","content":"Progression free survival (PFS)[ Time Frame: Up to 34 months ]Blinded independent central review (BICR) assessed per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1"},{"label":"2.","content":"Objective Response Rate (ORR)[ Time Frame: Up to 23 months ]Including Complete Response (CR), by BICR per RECIST 1.1"}],"start_date":"June 21, 2019","primary_completion_date":"September 14, 2022","completion_date":"March 11, 2025","first_posted":"March 13, 2019","last_update_posted":"February 10, 2022"},{"nctid":"NCT03873402","version_a":26,"version_b":27,"version_a_date":"2020-03-16","version_b_date":"2020-10-15","pom_a":[{"label":"1.","content":"Progression free survival (PFS)[ Time Frame: Up to 34 months ]Blinded independent central review (BICR) assessed per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1"},{"label":"2.","content":"Objective Response Rate (ORR)[ Time Frame: Up to 23 months ]Including Complete Response (CR), by BICR per RECIST 1.1"}],"pom_b":[{"label":"1.","content":"Progression free survival (PFS) by blinded independent central review (BICR)[ Time Frame: Up to 34 months ]"},{"label":"2.","content":"Objective response rate (ORR) by BICR[ Time Frame: Up to 23 months ]"}],"start_date":"June 21, 2019","primary_completion_date":"September 14, 2022","completion_date":"March 11, 2025","first_posted":"March 13, 2019","last_update_posted":"February 10, 2022"},{"nctid":"NCT04250922","version_a":4,"version_b":5,"version_a_date":"2021-07-13","version_b_date":"2022-08-09","pom_a":[{"label":"1.","content":"To evaluate the efficacy of 2-OHOA in combination with the standard of care (SoC) treatment of radiotherapy (RT) and TMZ.[ Time Frame: Assessed after observing at least 124 PFS events ]To evaluate the efficacy of 2-OHOA in combination with the standard of care (SoC) treatment of radiotherapy (RT) and TMZ, as assessed by- Progression Free Survival (PFS) using the Response Assessment in Neuro-Oncology (RANO) criteria for conditional marketing authorization (CMA) application."},{"label":"2.","content":"To evaluate the efficacy of 2-OHOA in combination with the standard of care (SoC) treatment of radiotherapy (RT) and TMZ.[ Time Frame: Assessed after observing at least 124 OS events ]To evaluate the efficacy of 2-OHOA in combination with the standard of care (SoC) treatment of radiotherapy (RT) and TMZ, as assessed by- Overall Survival (OS), for full marketing authorization (FMA) application."}],"pom_b":[{"label":"1.","content":"To evaluate the efficacy of 2-OHOA in combination with the standard of care (SoC) treatment of radiotherapy (RT) and TMZ.[ Time Frame: Assessed after observing at least 66 PFS events ]To evaluate the efficacy of 2-OHOA in combination with the standard of care (SoC) treatment of radiotherapy (RT) and TMZ, as assessed by- Progression Free Survival (PFS) using the Response Assessment in Neuro-Oncology (RANO) criteria for conditional marketing authorization (CMA) application."},{"label":"2.","content":"To evaluate the efficacy of 2-OHOA in combination with the standard of care (SoC) treatment of radiotherapy (RT) and TMZ.[ Time Frame: Assessed after observing at least 90 OS events ]To evaluate the efficacy of 2-OHOA in combination with the standard of care (SoC) treatment of radiotherapy (RT) and TMZ, as assessed by- Overall Survival (OS), for full marketing authorization (FMA) application."}],"start_date":"December 1, 2019","primary_completion_date":"February 28, 2024","completion_date":"May 30, 2025","first_posted":"January 31, 2020","last_update_posted":"August 12, 2022"},{"nctid":"NCT02242942","version_a":40,"version_b":41,"version_a_date":"2016-09-01","version_b_date":"2017-02-14","pom_a":[{"label":"1.","content":"Progression-free survival (PFS), defined as the time from randomization to the first occurrence of progression, relapse or death from any cause as assessed by the investigator using IWCLL criteria[ Time Frame: Up to 5 years ]"}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS) Based on Investigator Assessment (Using IWCLL Criteria), Defined as the Time From Randomization to the First Occurrence of Progression, Relapse or Death From Any Cause[ Time Frame: Baseline until disease progression or death (up to approximately 7 years) ]"}],"start_date":"December 31, 2014","primary_completion_date":"August 17, 2018","completion_date":"August 31, 2025","first_posted":"September 17, 2014","results_first_posted":"October 1, 2019","last_update_posted":"June 30, 2022"},{"nctid":"NCT02242942","version_a":51,"version_b":52,"version_a_date":"2019-02-20","version_b_date":"2019-09-10","pom_a":[{"label":"1.","content":"Progression-Free Survival (PFS) Based on Investigator Assessment (Using IWCLL Criteria), Defined as the Time From Randomization to the First Occurrence of Progression, Relapse or Death From Any Cause[ Time Frame: Baseline until disease progression or death (up to approximately 7 years) ]"}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS) Based on Investigator Assessment According to IWCLL Criteria[ Time Frame: Baseline until disease progression or death up to approximately 3.75 years ]PFS was determined according to IWCLL 2008 criteria and defined as the time from randomization to the first occurrence of PD or death from any cause. Disease progression was characterized by at least one of the following: 1) >/= 50% increase in the absolute number of circulating lymphocytes to at least 5*10^9/L, 2) Appearance of new palpable lymph nodes (> 15 mm in longest diameter) or any new extra-nodal lesion; 3) >/= 50% increase in the longest diameter of any previous site of lymphadenopathy; 4) >/= 50% increase in the enlargement of the liver and/or spleen; 5) Transformation to a more aggressive histology."}],"start_date":"December 31, 2014","primary_completion_date":"August 17, 2018","completion_date":"August 31, 2025","first_posted":"September 17, 2014","results_first_posted":"October 1, 2019","last_update_posted":"June 30, 2022"},{"nctid":"NCT03302234","version_a":72,"version_b":73,"version_a_date":"2019-07-31","version_b_date":"2020-07-22","pom_a":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Up to approximately 2 years ]OS is the time from randomization to death due to any cause."},{"label":"2.","content":"Progression-free Survival (PFS)[ Time Frame: Up to approximately 2 years ]PFS is the time from randomization to first documented disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR)."}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Up to approximately 27 months ]OS is the time from randomization to death due to any cause."},{"label":"2.","content":"Progression-free Survival (PFS)[ Time Frame: Up to approximately 19 months ]PFS is the time from randomization to first documented disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR)."}],"start_date":"December 14, 2017","primary_completion_date":"September 1, 2020","completion_date":"September 7, 2022","first_posted":"October 5, 2017","results_first_posted":"September 10, 2021","last_update_posted":"June 21, 2022"},{"nctid":"NCT03302234","version_a":74,"version_b":75,"version_a_date":"2020-12-28","version_b_date":"2021-08-12","pom_a":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Up to approximately 27 months ]OS is the time from randomization to death due to any cause."},{"label":"2.","content":"Progression-free Survival (PFS)[ Time Frame: Up to approximately 19 months ]PFS is the time from randomization to first documented disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR)."}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Up to approximately 32 months (through data cut-off date: 01 Sep 2020) ]OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of analysis were censored at the date of last known contact. The median survival (in months) and the associated 95% confidence intervals (CIs) were reported using Kaplan-Meier method was used. Cox regression model with Efron\'s method of tie handling with treatment as a covariate stratified by ECOG performance status (0 versus 1), geographic region of the enrolling site (East Asia versus non-East Asia), and predominant tumor history (squamous versus non-squamous) was used to estimate hazard ratio (HR) and 95% CIs for first course study treatment per protocol."},{"label":"2.","content":"Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR)[ Time Frame: Up to approximately 32 months (through data cut-off date 01 Sep 2020) ]PFS was defined as the time from randomization to the first documented disease progression (PD) per RECIST 1.1 based on BICR or death due to any cause, whichever occurs first. PD is defined as \u226520% increase in sum of diameters of target lesions. In addition to relative increase of 20%, sum must also demonstrate an absolute increase of \u22655 mm. The appearance of one or more new lesions is also considered PD. RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The median survival (in months) and associated 95% CIs were reported using Kaplan-Meier method. Cox regression model with Efron\'s method of tie handling with treatment as covariate stratified by ECOG performance status (0 vs. 1), geographic region of the enrolling site (East Asia vs. non-East Asia), and predominant tumor history (squamous vs. non-squamous) was used to estimate HR and 95% CIs for first course study treatment per protocol."}],"start_date":"December 14, 2017","primary_completion_date":"September 1, 2020","completion_date":"September 7, 2022","first_posted":"October 5, 2017","results_first_posted":"September 10, 2021","last_update_posted":"June 21, 2022"},{"nctid":"NCT00071799","version_a":21,"version_b":22,"version_a_date":"2006-10-25","version_b_date":"2007-11-14","pom_a":[{"label":"1.","content":"Survival"}],"pom_b":[{"label":"1.","content":"Survival[ Time Frame: 4 years ]"}],"start_date":"November 1, 2003","primary_completion_date":"July 1, 2007","completion_date":"July 1, 2007","first_posted":"November 5, 2003","results_first_posted":"July 5, 2010","last_update_posted":"October 29, 2019"},{"nctid":"NCT00071799","version_a":27,"version_b":28,"version_a_date":"2009-10-08","version_b_date":"2010-06-01","pom_a":[{"label":"1.","content":"Survival[ Time Frame: 4 years ]"}],"pom_b":[{"label":"1.","content":"Kaplan-Meier Estimates for Median Time to Death From Any Cause[ Time Frame: Day 1 (randomization) to 42 months ]Kaplan-Meier estimates for the median months until death from any cause within the intent-to-treat population. Patients surviving at the end of the follow-up period were censored at the date of last contact. If a patient withdrew consent to follow-up or was lost to follow-up, the patient was censored as of the last date of contact."},{"label":"2.","content":"Summary of Subgroup Analyses for Kaplan-Meier Estimates for Time to Death From Any Cause[ Time Frame: Day 1 (randomization) to 42 months ]Kaplan-Meier estimates for the median months until death from any cause within the intent-to-treat population. Patients surviving at the end of the follow-up period were censored at the date of last contact. If a patient withdrew consent to follow-up or was lost to follow-up, the patient was censored as of the last date of contact.Subgroups that were analyzed are age, gender, French-American-British (FAB) classification, World Health Organization (WHO) classification and International Prognostic Scoring System (IPSS) classification."},{"label":"3.","content":"Number of Participants Who Died[ Time Frame: 42 months ]Count of participants who died during the study"}],"start_date":"November 1, 2003","primary_completion_date":"July 1, 2007","completion_date":"July 1, 2007","first_posted":"November 5, 2003","results_first_posted":"July 5, 2010","last_update_posted":"October 29, 2019"},{"nctid":"NCT03165734","version_a":26,"version_b":27,"version_a_date":"2019-10-10","version_b_date":"2020-01-24","pom_a":[{"label":"1.","content":"Spleen volume[ Time Frame: 24 weeks ]The primary efficacy variable for dosage selection is the percent reduction in spleen volume from baseline as measured by MRI or CT. For evaluation as part of the dose-response relationship will include the percentage of patients who achieve at least 35% reduction in spleen volume"}],"pom_b":[{"label":"1.","content":"Spleen volume[ Time Frame: From baseline to 24 weeks ]To compare the efficacy of pacritinib with that of physician\'s choice (P/C) therapy, as assessed by the proportion of patients achieving a \u226535% spleen volume reduction (SVR) as measured by magnetic resonance imaging (MRI, preferred) or computed tomography (CT) scans"}],"start_date":"June 26, 2017","primary_completion_date":"June 30, 2025","completion_date":"December 31, 2025","first_posted":"May 24, 2017","last_update_posted":"September 10, 2022"},{"nctid":"NCT03165734","version_a":50,"version_b":51,"version_a_date":"2022-04-05","version_b_date":"2022-08-09","pom_a":[{"label":"1.","content":"Spleen volume[ Time Frame: From baseline to 24 weeks ]To compare the efficacy of pacritinib with that of physician\'s choice (P/C) therapy, as assessed by the proportion of patients achieving a \u226535% spleen volume reduction (SVR) as measured by magnetic resonance imaging (MRI, preferred) or computed tomography (CT) scans"}],"pom_b":[{"label":"1.","content":"Spleen volume[ Time Frame: From baseline at 24 weeks ]To compare the efficacy of pacritinib with that of physician\'s choice (P/C) therapy, as assessed by the proportion of patients achieving a \u226535% spleen volume reduction (SVR) as measured by magnetic resonance imaging (MRI, preferred) or computed tomography (CT) scans"},{"label":"2.","content":"Total Symptom Score (TSS)[ Time Frame: From baseline at Week 24 ]To compare the efficacy of pacritinib with P/C therapy, as assessed by the proportion of patients achieving a \u226550% reduction in Total Symptom Score (TSS)"}],"start_date":"June 26, 2017","primary_completion_date":"June 30, 2025","completion_date":"December 31, 2025","first_posted":"May 24, 2017","last_update_posted":"September 10, 2022"},{"nctid":"NCT03165734","version_a":51,"version_b":52,"version_a_date":"2022-08-09","version_b_date":"2022-08-22","pom_a":[{"label":"1.","content":"Spleen volume[ Time Frame: From baseline at 24 weeks ]To compare the efficacy of pacritinib with that of physician\'s choice (P/C) therapy, as assessed by the proportion of patients achieving a \u226535% spleen volume reduction (SVR) as measured by magnetic resonance imaging (MRI, preferred) or computed tomography (CT) scans"},{"label":"2.","content":"Total Symptom Score (TSS)[ Time Frame: From baseline at Week 24 ]To compare the efficacy of pacritinib with P/C therapy, as assessed by the proportion of patients achieving a \u226550% reduction in Total Symptom Score (TSS)"}],"pom_b":[{"label":"1.","content":"Spleen volume[ Time Frame: From baseline at 24 weeks ]To compare the efficacy of pacritinib with that of physician\'s choice (P/C) therapy, as assessed by the proportion of patients achieving a \u226535% spleen volume reduction (SVR) as measured by magnetic resonance imaging (MRI, preferred) or computed tomography (CT) scans"},{"label":"2.","content":"Total Symptom Score (TSS)[ Time Frame: From baseline at Week 24 ]To compare the efficacy of pacritinib with P/C therapy, as assessed by the proportion of patients achieving a \u226550% reduction in Total Symptom Score (TSS). The TSS is the sum of the individual symptom scores for tiredness, early satiety, abdominal discomfort, night sweats, pruritus, bone pain, and pain under ribs on the left side. Symptoms are ranked 0 (absent) to 10 (worst imaginable)"}],"start_date":"June 26, 2017","primary_completion_date":"June 30, 2025","completion_date":"December 31, 2025","first_posted":"May 24, 2017","last_update_posted":"September 10, 2022"},{"nctid":"NCT00316914","version_a":20,"version_b":21,"version_a_date":"2006-10-18","version_b_date":"2006-11-09","pom_a":[],"pom_b":[{"label":"1.","content":"Percentage of patients with oxaliplatin-induced neurotoxicity as assessed by CTCAE v3.0"}],"start_date":"January 2006","primary_completion_date":"January 2008","completion_date":"November 2012","first_posted":"April 21, 2006","results_first_posted":"March 25, 2013","last_update_posted":"August 11, 2016"},{"nctid":"NCT00316914","version_a":66,"version_b":67,"version_a_date":"2011-01-13","version_b_date":"2013-02-19","pom_a":[{"label":"1.","content":"Percentage of patients with oxaliplatin-induced neurotoxicity as assessed by CTCAE v3.0"}],"pom_b":[{"label":"1.","content":"Percentage of Patients With Oxaliplatin-induced Grade 2+ Chronic Neuropathic Adverse Event[ Time Frame: 127 days ]Neuropathic adverse events were assessed by Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Neurotoxicity evaluation grade: loss of deep tendon reflexes or paresthesia, including tingling, but not interfering with function (Grade 1); objective sensory alteration or paresthesia, including tingling, interfering with function, but not with activities of daily living (Grade 2); sensory alteration or paresthesia interfering with activities of daily living (Grade 3); permanent sensory losses that are disabling (Grade 4)"}],"start_date":"January 2006","primary_completion_date":"January 2008","completion_date":"November 2012","first_posted":"April 21, 2006","results_first_posted":"March 25, 2013","last_update_posted":"August 11, 2016"},{"nctid":"NCT02102204","version_a":21,"version_b":22,"version_a_date":"2017-07-11","version_b_date":"2017-10-18","pom_a":[{"label":"1.","content":"Measure the subject incidence of adverse events reported[ Time Frame: 2.5 Years ]"}],"pom_b":[{"label":"1.","content":"Number of Participants With Adverse Events[ Time Frame: From the date of first dose of etelcalcetide (in the current study) and up to 30 days after the last dose; median duration of treatment was 563 days. ]A serious adverse event is an AE that met at least 1 of the following criteria:fatallife threateningrequired in-patient hospitalization or prolongation of existing hospitalizationresulted in persistent or significant disability/incapacitycongenital anomaly/birth defectother medically important serious event.The relationship of each AE to study treatment was assessed by the investigator.The following AE grading scale was used:Mild: Transient or mild discomfort; no limitation in activity; no medical intervention/therapy required Moderate: Mild to moderate limitation in activity-some assistance may be needed; no or minimal medical intervention/therapy required Severe: Marked limitation in activity, some assistance usually required; medical intervention/therapy required, hospitalization possible Life-threatening: Extreme limitation in activity, significant assistance required, significant medical intervention/therapy required, hospitalization probable."}],"start_date":"March 25, 2014","primary_completion_date":"November 4, 2016","completion_date":"June 26, 2017","first_posted":"April 2, 2014","results_first_posted":"November 17, 2017","last_update_posted":"November 17, 2017"},{"nctid":"NCT00004859","version_a":53,"version_b":54,"version_a_date":"2006-10-25","version_b_date":"2006-11-08","pom_a":[],"pom_b":[{"label":"1.","content":"Survival at median"}],"start_date":"January 2000","primary_completion_date":"December 2009","completion_date":"March 2010","first_posted":"January 27, 2003","results_first_posted":"March 22, 2012","last_update_posted":"June 2, 2014"},{"nctid":"NCT00004859","version_a":66,"version_b":67,"version_a_date":"2011-06-21","version_b_date":"2012-02-16","pom_a":[{"label":"1.","content":"Survival at median"}],"pom_b":[{"label":"1.","content":"Survival Time[ Time Frame: every other month until 24 months from study entry, then every 3 months for year 3, every 4 months for year 4 and every 6 months for year 5 ]"}],"start_date":"January 2000","primary_completion_date":"December 2009","completion_date":"March 2010","first_posted":"January 27, 2003","results_first_posted":"March 22, 2012","last_update_posted":"June 2, 2014"},{"nctid":"NCT00004859","version_a":67,"version_b":68,"version_a_date":"2012-02-16","version_b_date":"2012-03-23","pom_a":[{"label":"1.","content":"Survival Time[ Time Frame: every other month until 24 months from study entry, then every 3 months for year 3, every 4 months for year 4 and every 6 months for year 5 ]"}],"pom_b":[{"label":"1.","content":"Overall Survival Time[ Time Frame: every other month until 24 months from study entry, then every 3 months for year 3, every 4 months for year 4 and every 6 months for year 5 ]Survival time is defined as time from study entry to death from any cause"}],"start_date":"January 2000","primary_completion_date":"December 2009","completion_date":"March 2010","first_posted":"January 27, 2003","results_first_posted":"March 22, 2012","last_update_posted":"June 2, 2014"},{"nctid":"NCT00382070","version_a":4,"version_b":5,"version_a_date":"2006-10-25","version_b_date":"2006-12-04","pom_a":[],"pom_b":[{"label":"1.","content":"Disease-free survival"}],"start_date":"August 2006","primary_completion_date":"January 2016","completion_date":"December 2022","first_posted":"September 28, 2006","results_first_posted":"May 20, 2021","last_update_posted":"October 6, 2021"},{"nctid":"NCT00382070","version_a":484,"version_b":485,"version_a_date":"2010-01-08","version_b_date":"2010-04-13","pom_a":[{"label":"1.","content":"Disease-free survival"}],"pom_b":[{"label":"1.","content":"Disease-free survival[ Time Frame: Time from randomization to local recurrence following mastectomy or lumpectomy (IBTR), regional recurrence, distant recurrence, second primary cancer or death from any cause prior to recurrence or second primary cancer. ]"}],"start_date":"August 2006","primary_completion_date":"January 2016","completion_date":"December 2022","first_posted":"September 28, 2006","results_first_posted":"May 20, 2021","last_update_posted":"October 6, 2021"},{"nctid":"NCT00382070","version_a":492,"version_b":493,"version_a_date":"2019-01-08","version_b_date":"2021-04-28","pom_a":[{"label":"1.","content":"Disease-free survival[ Time Frame: Time from randomization to local recurrence following mastectomy or lumpectomy (IBTR), regional recurrence, distant recurrence, second primary cancer or death from any cause prior to recurrence or second primary cancer. ]"}],"pom_b":[{"label":"1.","content":"Disease-free Survival[ Time Frame: 7 years. ]Percentage of patients free from DFS events. DFS events include local, regional, or distant recurrence, second primary cancer or death from any cause prior to recurrence or second primary cancer."}],"start_date":"August 2006","primary_completion_date":"January 2016","completion_date":"December 2022","first_posted":"September 28, 2006","results_first_posted":"May 20, 2021","last_update_posted":"October 6, 2021"},{"nctid":"NCT02147197","version_a":13,"version_b":14,"version_a_date":"2017-03-16","version_b_date":"2019-03-15","pom_a":[{"label":"1.","content":"Absence of bleeding[ Time Frame: 12 weeks ]"},{"label":"2.","content":"Time to absence of bleeding[ Time Frame: 12 weeks ]"}],"pom_b":[{"label":"1.","content":"Percentage of Participants With Absence of Bleeding During the Last 35 Consecutive Days on Treatment[ Time Frame: Last 35 consecutive days on treatment in the 12-week Treatment Period ]Participants recorded bleeding in a daily diary. Absence of bleeding was defined as no bleeding days (i.e. no entries for bleeding or heavy bleeding; however, spotting was allowed), during the last 35 consecutive days on treatment in the 12-week Treatment Period."},{"label":"2.","content":"Time to Absence of Bleeding on Treatment[ Time Frame: From first dose up to the end of the 12-week Treatment Period ]Time to absence of bleeding was defined as the duration in days from first dose to the first day in the time interval in which absence of bleeding occurs and persists through the last dose on treatment. The persistence of absence of bleeding occurred for a minimum of 35 consecutive days counting backward from the last dose on treatment in the 12-week Treatment Period."}],"start_date":"March 31, 2014","primary_completion_date":"March 29, 2016","completion_date":"March 29, 2016","first_posted":"May 26, 2014","results_first_posted":"April 5, 2019","last_update_posted":"April 30, 2019"},{"nctid":"NCT05378763","version_a":1,"version_b":2,"version_a_date":"2022-05-12","version_b_date":"2022-06-10","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: Up to approximately 3 years ]PFS is defined as the time (in months) from the start of the study treatment to the date of first documented disease progression by central radiographic evaluation per the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v.1.1) or death due to any cause, whichever occurs first."}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: Up to approximately 5 years ]PFS is defined as the time (in months) from the start of the study treatment to the date of first documented disease progression by central radiographic evaluation per the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v.1.1) or death due to any cause, whichever occurs first."}],"start_date":"May 12, 2022","primary_completion_date":"December 25, 2027","completion_date":"December 25, 2028","first_posted":"May 18, 2022","last_update_posted":"June 14, 2022"},{"nctid":"NCT00789581","version_a":54,"version_b":55,"version_a_date":"2014-01-22","version_b_date":"2015-01-27","pom_a":[{"label":"1.","content":"To compare the disease-free survival (DFS) of women with triple-negative early-stage breast cancer following adjuvant treatment with AC followed by every-3-week ixabepilone vs. AC followed by weekly paclitaxel.[ Time Frame: 5 years ]"}],"pom_b":[{"label":"1.","content":"Disease Free Survival[ Time Frame: 5.25 years ]Disease-free survival (DFS) defined as the time between randomization and the date of first documented disease recurrence, or death from any cause."}],"start_date":"December 2008","primary_completion_date":"December 2015","completion_date":"November 2016","first_posted":"November 13, 2008","results_first_posted":"April 12, 2017","last_update_posted":"July 2, 2017"},{"nctid":"NCT00789581","version_a":57,"version_b":58,"version_a_date":"2016-06-01","version_b_date":"2017-03-01","pom_a":[{"label":"1.","content":"Disease Free Survival[ Time Frame: 5.25 years ]Disease-free survival (DFS) defined as the time between randomization and the date of first documented disease recurrence, or death from any cause."}],"pom_b":[{"label":"1.","content":"Disease-free Survival[ Time Frame: up to 5.25 years (63 months) ]The percentage of participants with disease-free survival at 3 and 5 years. Disease-free survival (DFS) is measured from the time between randomization and the date of first documented disease recurrence, or death from any cause."}],"start_date":"December 2008","primary_completion_date":"December 2015","completion_date":"November 2016","first_posted":"November 13, 2008","results_first_posted":"April 12, 2017","last_update_posted":"July 2, 2017"},{"nctid":"NCT03615326","version_a":118,"version_b":119,"version_a_date":"2021-06-24","version_b_date":"2021-07-06","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS) per RECIST 1.1 assessed by BICR[ Time Frame: Up to 4 years ]PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 as assessed by BICR or death due to any cause, whichever occurs first. Per RECIST 1.1, progressive disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. PFS will be determined for each treatment arm."},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Up to 5 years ]OS is defined as the time from randomization to death due to any cause. OS will be determined for each treatment arm."}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS) per RECIST 1.1 assessed by BICR[ Time Frame: Up to approximately 4 years ]PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 as assessed by BICR or death due to any cause, whichever occurs first. Per RECIST 1.1, progressive disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. PFS will be determined for each treatment arm."},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Up to approximately 5 years ]OS is defined as the time from randomization to death due to any cause. OS will be determined for each treatment arm."}],"start_date":"October 5, 2018","primary_completion_date":"December 15, 2023","completion_date":"December 30, 2024","first_posted":"August 3, 2018","last_update_posted":"July 22, 2022"},{"nctid":"NCT00662597","version_a":10,"version_b":11,"version_a_date":"2009-03-17","version_b_date":"2009-03-20","pom_a":[{"label":"1.","content":"Overall survival rate"}],"pom_b":[{"label":"1.","content":"Overall survival rate[ Time Frame: when patients die ]"}],"start_date":"April 2008","primary_completion_date":"May 2010","completion_date":"May 2010","first_posted":"April 21, 2008","last_update_posted":"December 24, 2020"},{"nctid":"NCT00662597","version_a":14,"version_b":15,"version_a_date":"2009-04-29","version_b_date":"2009-05-27","pom_a":[{"label":"1.","content":"Overall survival rate[ Time Frame: when patients die ]"}],"pom_b":[{"label":"1.","content":"Overall survival rate[ Time Frame: Patients will be followed every six weeks for survival following treatment completion, discontinuation, or documented disease progression until either death or the data cut off date. ]"}],"start_date":"April 2008","primary_completion_date":"May 2010","completion_date":"May 2010","first_posted":"April 21, 2008","last_update_posted":"December 24, 2020"},{"nctid":"NCT03180307","version_a":9,"version_b":10,"version_a_date":"2021-09-15","version_b_date":"2021-10-14","pom_a":[{"label":"1.","content":"Efficacy patient level[ Time Frame: 30 days ]\u2022 Proportion of patients with at least one evaluable FR+ ovarian cancer lesion confirmed by central pathology (Standard of truth) that was detected using the combination of OTL38 and fluorescent light but not under normal light or palpation"}],"pom_b":[{"label":"1.","content":"Efficacy Patient Level[ Time Frame: 30 days ]Proportion of patients with at least one evaluable FR+ ovarian cancer lesion confirmed by central pathology (Standard of truth) that was detected using the combination of OTL38 and fluorescent light but not under normal light or palpation (Full Analysis Set)"}],"start_date":"January 26, 2018","primary_completion_date":"April 16, 2020","completion_date":"October 16, 2020","first_posted":"June 8, 2017","results_first_posted":"February 4, 2022","last_update_posted":"February 4, 2022"},{"nctid":"NCT03180307","version_a":10,"version_b":11,"version_a_date":"2021-10-14","version_b_date":"2021-12-03","pom_a":[{"label":"1.","content":"Efficacy Patient Level[ Time Frame: 30 days ]Proportion of patients with at least one evaluable FR+ ovarian cancer lesion confirmed by central pathology (Standard of truth) that was detected using the combination of OTL38 and fluorescent light but not under normal light or palpation (Full Analysis Set)"}],"pom_b":[{"label":"1.","content":"Efficacy Patient Level[ Time Frame: 30 days ]Percentage of patients with at least one evaluable FR+ ovarian cancer lesion confirmed by central pathology (Standard of truth) that was detected using the combination of OTL38 and fluorescent light but not under normal light or palpation (Full Analysis Set)"}],"start_date":"January 26, 2018","primary_completion_date":"April 16, 2020","completion_date":"October 16, 2020","first_posted":"June 8, 2017","results_first_posted":"February 4, 2022","last_update_posted":"February 4, 2022"},{"nctid":"NCT04305470","version_a":1,"version_b":2,"version_a_date":"2020-03-09","version_b_date":"2020-06-29","pom_a":[{"label":"1.","content":"Proportion of participants for which Gleolan-induced PpIX fluorescence allows the surgeon to visually obtain correct information as to the presence or absence of tumor in tissue where there is uncertainty based on WL visualization alone.[ Time Frame: Surgery (Day 1) ]Per Protocol Population"}],"pom_b":[{"label":"1.","content":"The proportion of participants who have at least one indeterminate tissue or unexpected fluorescent End of Surgery (EOS) tissue where Gleolan-induced PpIX fluorescence status is consistent with histology.[ Time Frame: Surgery (Day 1) ]Per Protocol Population"}],"start_date":"October 28, 2020","primary_completion_date":"June 1, 2022","completion_date":"June 1, 2022","first_posted":"March 12, 2020","last_update_posted":"April 20, 2022"},{"nctid":"NCT00326898","version_a":21,"version_b":22,"version_a_date":"2006-10-25","version_b_date":"2006-11-09","pom_a":[],"pom_b":[{"label":"1.","content":"Disease-free survival"}],"start_date":"April 24, 2006","primary_completion_date":"August 27, 2015","completion_date":"September 1, 2021","first_posted":"May 17, 2006","results_first_posted":"December 12, 2016","last_update_posted":"February 8, 2022"},{"nctid":"NCT00326898","version_a":637,"version_b":638,"version_a_date":"2010-09-02","version_b_date":"2012-08-24","pom_a":[{"label":"1.","content":"Disease-free survival"}],"pom_b":[{"label":"1.","content":"Disease-free survival (DFS)[ Time Frame: Time from randomization to recurrence, development of second primary cancer, or death from any cause, assessed up to 6.5 years ]A weighted mixture of the log hazard rates was used to estimate the effective (increased) hazard rate on the experimental arm. Using this adjusted alternative hazard rate, the target is instead a reduction in the hazard rate of 20% for DFS events when comparing each experimental arm to placebo."}],"start_date":"April 24, 2006","primary_completion_date":"August 27, 2015","completion_date":"September 1, 2021","first_posted":"May 17, 2006","results_first_posted":"December 12, 2016","last_update_posted":"February 8, 2022"},{"nctid":"NCT00326898","version_a":647,"version_b":648,"version_a_date":"2014-05-07","version_b_date":"2014-06-23","pom_a":[{"label":"1.","content":"Disease-free survival (DFS)[ Time Frame: Time from randomization to recurrence, development of second primary cancer, or death from any cause, assessed up to 6.5 years ]A weighted mixture of the log hazard rates was used to estimate the effective (increased) hazard rate on the experimental arm. Using this adjusted alternative hazard rate, the target is instead a reduction in the hazard rate of 20% for DFS events when comparing each experimental arm to placebo."}],"pom_b":[{"label":"1.","content":"Disease-free survival (DFS)[ Time Frame: Time from randomization to recurrence, development of second primary cancer, or death from any cause, assessed up to 10 years ]A weighted mixture of the log hazard rates was used to estimate the effective (increased) hazard rate on the experimental arm. Using this adjusted alternative hazard rate, the target is instead a reduction in the hazard rate of 20% for DFS events when comparing each experimental arm to placebo."}],"start_date":"April 24, 2006","primary_completion_date":"August 27, 2015","completion_date":"September 1, 2021","first_posted":"May 17, 2006","results_first_posted":"December 12, 2016","last_update_posted":"February 8, 2022"},{"nctid":"NCT00326898","version_a":1044,"version_b":1045,"version_a_date":"2016-07-18","version_b_date":"2016-10-18","pom_a":[{"label":"1.","content":"Disease-free survival (DFS)[ Time Frame: Time from randomization to recurrence, development of second primary cancer, or death from any cause, assessed up to 10 years ]A weighted mixture of the log hazard rates was used to estimate the effective (increased) hazard rate on the experimental arm. Using this adjusted alternative hazard rate, the target is instead a reduction in the hazard rate of 20% for DFS events when comparing each experimental arm to placebo."}],"pom_b":[{"label":"1.","content":"Disease-free Survival (DFS)[ Time Frame: Assessed every 3 months if patient is < 2 years from study entry; every 6 months if patient is 2 - 5 years from study entry; then annually if patient is 5 - 10 years from study entry ]Disease-free survival (DFS) is defined as time from randomization to recurrence, development of second primary cancer (except localized breast or prostate cancer or nonmelanoma skin cancer), or death from any cause. Patients who were alive without recurrence or qualifying second primary cancer were censored at the date of last disease evaluation."}],"start_date":"April 24, 2006","primary_completion_date":"August 27, 2015","completion_date":"September 1, 2021","first_posted":"May 17, 2006","results_first_posted":"December 12, 2016","last_update_posted":"February 8, 2022"},{"nctid":"NCT02993731","version_a":18,"version_b":19,"version_a_date":"2020-07-17","version_b_date":"2021-05-17","pom_a":[{"label":"1.","content":"Overall Survival[ Time Frame: 36 months ]To assess the effect of napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine on the Overall Survival of patients with metastatic pancreatic ductal adenocarcinoma."}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: From 4 weeks after the patient has been off study therapy, every 4 weeks thereafter for 6 months, then every 3 months thereafter until death, the study closes or 3 years since treatment discontinuation. ]To assess the effect of napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine on the Overall Survival of patients with metastatic pancreatic ductal adenocarcinoma."}],"start_date":"December 2016","primary_completion_date":"March 2020","completion_date":"March 2020","first_posted":"December 15, 2016","results_first_posted":"June 10, 2021","last_update_posted":"April 6, 2022"},{"nctid":"NCT02993523","version_a":11,"version_b":12,"version_a_date":"2017-11-30","version_b_date":"2017-12-18","pom_a":[{"label":"1.","content":"Proportion of participants with complete remission (CR) or complete remission with incomplete marrow recovery (CRi)[ Time Frame: Up to 6 months after the first 225 subjects are randomized ]This will be calculated based on current International Working Group (IWG) criteria. CR is defined as absolute neutrophil count > 10^3/ microliter (mcL), platelets >= 10^5/mcL, red cell transfusion independence, and bone marrow with < 5% blasts. CRi is defined as bone marrow with less than 5% blasts, and absolute neutrophils of < 10^3/mcL or platelets < 10^5/mcL."},{"label":"2.","content":"Overall survival (OS)[ Time Frame: Measured up to 2 years after the last participant is randomized ]OS is defined as the number of days from the date of randomization to the date of death."}],"pom_b":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: Measured up to 2 years after the last participant is randomized ]OS is defined as the number of days from the date of randomization to the date of death."},{"label":"2.","content":"Proportion of participants with complete remission (CR) or complete remission with incomplete marrow recovery (CRi)[ Time Frame: Up to 6 months after the first 225 subjects are randomized ]This will be calculated based on current International Working Group (IWG) criteria. CR is defined as absolute neutrophil count > 10^3/ microliter (mcL), platelets >= 10^5/mcL, red cell transfusion independence, and bone marrow with < 5% blasts. CRi is defined as bone marrow with less than 5% blasts, and absolute neutrophils of < 10^3/mcL or platelets < 10^5/mcL."}],"start_date":"February 2, 2017","primary_completion_date":"December 1, 2021","completion_date":"September 25, 2023","first_posted":"December 15, 2016","last_update_posted":"July 1, 2022"},{"nctid":"NCT02993523","version_a":20,"version_b":21,"version_a_date":"2018-07-31","version_b_date":"2018-08-30","pom_a":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: Measured up to 2 years after the last participant is randomized ]OS is defined as the number of days from the date of randomization to the date of death."},{"label":"2.","content":"Proportion of participants with complete remission (CR) or complete remission with incomplete marrow recovery (CRi)[ Time Frame: Up to 6 months after the first 225 subjects are randomized ]This will be calculated based on current International Working Group (IWG) criteria. CR is defined as absolute neutrophil count > 10^3/ microliter (mcL), platelets >= 10^5/mcL, red cell transfusion independence, and bone marrow with < 5% blasts. CRi is defined as bone marrow with less than 5% blasts, and absolute neutrophils of < 10^3/mcL or platelets < 10^5/mcL."}],"pom_b":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: Measured up to 2 years after the last participant is randomized ]OS is defined as the number of days from the date of randomization to the date of death."},{"label":"2.","content":"Proportion of participants with complete remission (CR) and complete remission with incomplete marrow recovery (CRi)[ Time Frame: Measured up to 2 years after the last participant is randomized ]This will be calculated based on current International Working Group (IWG) criteria. CR is defined as absolute neutrophil count >= 10^3/ microliter (mcL), platelets >= 10^5/mcL, red cell transfusion independence, and bone marrow with < 5% blasts. CRi is defined as bone marrow with less than 5% blasts, and absolute neutrophils of < 10^3/mcL or platelets < 10^5/mcL."}],"start_date":"February 2, 2017","primary_completion_date":"December 1, 2021","completion_date":"September 25, 2023","first_posted":"December 15, 2016","last_update_posted":"July 1, 2022"},{"nctid":"NCT02993523","version_a":33,"version_b":34,"version_a_date":"2019-05-08","version_b_date":"2019-05-23","pom_a":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: Measured up to 2 years after the last participant is randomized ]OS is defined as the number of days from the date of randomization to the date of death."},{"label":"2.","content":"Proportion of participants with complete remission (CR) and complete remission with incomplete marrow recovery (CRi)[ Time Frame: Measured up to 2 years after the last participant is randomized ]This will be calculated based on current International Working Group (IWG) criteria. CR is defined as absolute neutrophil count >= 10^3/ microliter (mcL), platelets >= 10^5/mcL, red cell transfusion independence, and bone marrow with < 5% blasts. CRi is defined as bone marrow with less than 5% blasts, and absolute neutrophils of < 10^3/mcL or platelets < 10^5/mcL."}],"pom_b":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: Measured up to 2 years after the last participant is randomized ]OS is defined as the number of days from the date of randomization to the date of death."},{"label":"2.","content":"Percentage of participants with complete remission (CR) and complete remission with incomplete marrow recovery (CRi)[ Time Frame: Measured up to 2 years after the last participant is randomized ]This will be calculated based on current International Working Group (IWG) criteria. CR is defined as absolute neutrophil count >= 10^3/ microliter (mcL), platelets >= 10^5/mcL, red cell transfusion independence, and bone marrow with < 5% blasts. CRi is defined as bone marrow with less than 5% blasts, and absolute neutrophils of < 10^3/mcL or platelets < 10^5/mcL."}],"start_date":"February 2, 2017","primary_completion_date":"December 1, 2021","completion_date":"September 25, 2023","first_posted":"December 15, 2016","last_update_posted":"July 1, 2022"},{"nctid":"NCT02993523","version_a":35,"version_b":36,"version_a_date":"2019-06-12","version_b_date":"2019-08-26","pom_a":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: Measured up to 2 years after the last participant is randomized ]OS is defined as the number of days from the date of randomization to the date of death."},{"label":"2.","content":"Percentage of participants with complete remission (CR) and complete remission with incomplete marrow recovery (CRi)[ Time Frame: Measured up to 2 years after the last participant is randomized ]This will be calculated based on current International Working Group (IWG) criteria. CR is defined as absolute neutrophil count >= 10^3/ microliter (mcL), platelets >= 10^5/mcL, red cell transfusion independence, and bone marrow with < 5% blasts. CRi is defined as bone marrow with less than 5% blasts, and absolute neutrophils of < 10^3/mcL or platelets < 10^5/mcL."}],"pom_b":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: Measured up to 2 years after the last participant is randomized ]OS is defined as the number of days from the date of randomization to the date of death."},{"label":"2.","content":"Percentage of participants with complete remission (CR) and complete remission with incomplete marrow recovery (CRi)[ Time Frame: Measured up to 2 years after the last participant is randomized ]This will be calculated based on current International Working Group (IWG) criteria. CR is defined as absolute neutrophil count > 10^3/ microliter (mcL), platelets > 10^5/mcL, red cell transfusion independence, and bone marrow with < 5% blasts. CRi is defined as bone marrow with less than 5% blasts, and absolute neutrophils of <= 10^3/mcL or platelets <= 10^5/mcL."}],"start_date":"February 2, 2017","primary_completion_date":"December 1, 2021","completion_date":"September 25, 2023","first_posted":"December 15, 2016","last_update_posted":"July 1, 2022"},{"nctid":"NCT02413580","version_a":9,"version_b":10,"version_a_date":"2018-10-03","version_b_date":"2020-04-09","pom_a":[{"label":"1.","content":"Change in quantitative myasthenia gravis (QMG) scale score[ Time Frame: From Baseline (Day 0) to Day 14 ]"}],"pom_b":[{"label":"1.","content":"Change in Quantitative Myasthenia Gravis (QMG) Scale Score[ Time Frame: From Baseline (Day 0) to Day 14 ]Mean Change in Quantitative Myasthenia Gravis (QMG) Scale Score from Baseline (Day 0) to Day 14. The minimum and maximum scores of the QMG Scale are 0 and 39, respectively, and a higher score means a worse outcome."}],"start_date":"March 2015","primary_completion_date":"April 2018","completion_date":"April 2018","first_posted":"April 10, 2015","results_first_posted":"April 24, 2020","last_update_posted":"April 24, 2020"},{"nctid":"NCT00179647","version_a":55,"version_b":56,"version_a_date":"2007-03-12","version_b_date":"2008-01-29","pom_a":[{"label":"1.","content":"To provide lenalidomide to subjects with a high likelihood of benefit."}],"pom_b":[{"label":"1.","content":"To provide lenalidomide to subjects with a high likelihood of benefit.[ Time Frame: Until Lenalidomide is commercially available in Canada ]"}],"start_date":"September 2005","primary_completion_date":"December 2008","completion_date":"April 2009","first_posted":"September 16, 2005","results_first_posted":"March 3, 2010","last_update_posted":"March 16, 2010"},{"nctid":"NCT00179647","version_a":60,"version_b":61,"version_a_date":"2009-09-10","version_b_date":"2009-10-02","pom_a":[{"label":"1.","content":"To provide lenalidomide to subjects with a high likelihood of benefit.[ Time Frame: Until Lenalidomide is commercially available in Canada ]"}],"pom_b":[{"label":"1.","content":"Incidence of adverse events summarized by system organ class, preferred term, severity, seriousness, and relationship to treatment.[ Time Frame: Until lenalidomide is commercially available for the indication of multiple myeloma ]"}],"start_date":"September 2005","primary_completion_date":"December 2008","completion_date":"April 2009","first_posted":"September 16, 2005","results_first_posted":"March 3, 2010","last_update_posted":"March 16, 2010"},{"nctid":"NCT00179647","version_a":61,"version_b":62,"version_a_date":"2009-10-02","version_b_date":"2010-02-02","pom_a":[{"label":"1.","content":"Incidence of adverse events summarized by system organ class, preferred term, severity, seriousness, and relationship to treatment.[ Time Frame: Until lenalidomide is commercially available for the indication of multiple myeloma ]"}],"pom_b":[{"label":"1.","content":"Incidence of Adverse Events Summarized by System Organ Class, Preferred Term, Severity, Seriousness, and Relationship to Treatment.[ Time Frame: Median time-on-study=18.3 weeks ]Incidence is defined as the number of subjects who experience an adverse event within their period of participation in this study."},{"label":"2.","content":"Overall Incidence of Adverse Events[ Time Frame: Median time-on-study=18.3 weeks ]Data from all subjects who receive any study drug will be included in the analysis. Adverse events will be classified using the MedDRA classification system. A subject having the same event more than once will be counted only once. Adverse events will be summarized by worst NCI CTCAE VERSION 3.0 grade. Incidence is defined as the number of subjects who experience an adverse event within their period of participation in this study."}],"start_date":"September 2005","primary_completion_date":"December 2008","completion_date":"April 2009","first_posted":"September 16, 2005","results_first_posted":"March 3, 2010","last_update_posted":"March 16, 2010"},{"nctid":"NCT00179647","version_a":62,"version_b":63,"version_a_date":"2010-02-02","version_b_date":"2010-03-10","pom_a":[{"label":"1.","content":"Incidence of Adverse Events Summarized by System Organ Class, Preferred Term, Severity, Seriousness, and Relationship to Treatment.[ Time Frame: Median time-on-study=18.3 weeks ]Incidence is defined as the number of subjects who experience an adverse event within their period of participation in this study."},{"label":"2.","content":"Overall Incidence of Adverse Events[ Time Frame: Median time-on-study=18.3 weeks ]Data from all subjects who receive any study drug will be included in the analysis. Adverse events will be classified using the MedDRA classification system. A subject having the same event more than once will be counted only once. Adverse events will be summarized by worst NCI CTCAE VERSION 3.0 grade. Incidence is defined as the number of subjects who experience an adverse event within their period of participation in this study."}],"pom_b":[{"label":"1.","content":"Incidence of Adverse Events Summarized by System Organ Class, Preferred Term, Severity, Seriousness, and Relationship to Treatment.[ Time Frame: Median time-on-study=18.3 weeks ]Data from all subjects who received any study drug were included in the analysis. Adverse events were classified using the Medical Dictionary for Regulatory Activities (MedDRA) classification system. A subject having the same event more than once was counted only once. Adverse events were summarized by worst NCI (National Cancer Institute) CTCAE (Common Terminology Criteria for Adverse Events) VERSION 3.0 grade. Incidence was defined as the number of subjects who experienced an adverse event within their period of participation in this study."},{"label":"2.","content":"Overall Incidence of Adverse Events[ Time Frame: Median time-on-study=18.3 weeks ]Data from all subjects who received any study drug were included in the analysis. Adverse events were classified using the Medical Dictionary for Regulatory Activities (MedDRA) classification system. A subject having the same event more than once was counted only once. Adverse events were summarized by worst NCI (National Cancer Institute) CTCAE (Common Terminology Criteria for Adverse Events) VERSION 3.0 grade. Incidence was defined as the number of subjects who experienced an adverse event within their period of participation in this study."}],"start_date":"September 2005","primary_completion_date":"December 2008","completion_date":"April 2009","first_posted":"September 16, 2005","results_first_posted":"March 3, 2010","last_update_posted":"March 16, 2010"},{"nctid":"NCT00075855","version_a":24,"version_b":25,"version_a_date":"2012-02-19","version_b_date":"2015-07-07","pom_a":[],"pom_b":[{"label":"1.","content":"Overall mood[ Time Frame: Up to 6 months ]"}],"start_date":"April 2004","primary_completion_date":"May 2007","completion_date":"October 2007","first_posted":"January 13, 2004","last_update_posted":"July 13, 2016"},{"nctid":"NCT00003120","version_a":12,"version_b":13,"version_a_date":"2011-07-19","version_b_date":"2012-06-13","pom_a":[],"pom_b":[{"label":"1.","content":"progression-free survival[ Time Frame: duration between date of enrollment and date first recurrence or death due to any cause. ]"}],"start_date":"November 1997","primary_completion_date":"June 2003","completion_date":"November 2012","first_posted":"February 20, 2004","last_update_posted":"October 9, 2014"},{"nctid":"NCT03375320","version_a":1,"version_b":2,"version_a_date":"2017-12-15","version_b_date":"2018-02-15","pom_a":[{"label":"1.","content":"Progression-free survival (PFS) assessed per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 determined by independent central review[ Time Frame: From randomization to the first radiographic documentation of disease progression, or death from any cause, assessed for up to 8 years ]Will be compared between treatment arms using the stratified log rank test at one-sided level 0.025. The stratification factors will be used for the analysis. The hazard ratio (HR) for PFS will be estimated using a stratified Cox proportional hazards model, and the 95% confidence interval (CI) for the HR will be provided. Results from an unstratified analysis will also be provided. Kaplan-Meier methodology will be used to estimate the median PFS for each treatment arm, and Kaplan-Meier curves will be produced. Brookmeyer Crowley methodology will be used to construct the 95% CI for the median P"}],"pom_b":[{"label":"1.","content":"Progression-free survival (PFS) assessed per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 determined by independent central review[ Time Frame: From randomization to the first radiographic documentation of disease progression, or death from any cause, assessed for up to 8 years ]Will be compared between treatment arms using the stratified log rank test at one-sided level 0.025. The stratification factors will be used for the analysis. The hazard ratio (HR) for PFS will be estimated using a stratified Cox proportional hazards model, and the 95% confidence interval (CI) for the HR will be provided. Results from an unstratified analysis will also be provided. Kaplan-Meier methodology will be used to estimate the median PFS for each treatment arm, and Kaplan-Meier curves will be produced. Brookmeyer Crowley methodology will be used to construct the 95% CI for the median PFS for each treatment arm."}],"start_date":"July 18, 2018","primary_completion_date":"October 1, 2025","completion_date":"October 1, 2025","first_posted":"December 18, 2017","last_update_posted":"September 19, 2022"},{"nctid":"NCT03375320","version_a":6,"version_b":7,"version_a_date":"2018-07-04","version_b_date":"2018-07-23","pom_a":[{"label":"1.","content":"Progression-free survival (PFS) assessed per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 determined by independent central review[ Time Frame: From randomization to the first radiographic documentation of disease progression, or death from any cause, assessed for up to 8 years ]Will be compared between treatment arms using the stratified log rank test at one-sided level 0.025. The stratification factors will be used for the analysis. The hazard ratio (HR) for PFS will be estimated using a stratified Cox proportional hazards model, and the 95% confidence interval (CI) for the HR will be provided. Results from an unstratified analysis will also be provided. Kaplan-Meier methodology will be used to estimate the median PFS for each treatment arm, and Kaplan-Meier curves will be produced. Brookmeyer Crowley methodology will be used to construct the 95% CI for the median PFS for each treatment arm."}],"pom_b":[{"label":"1.","content":"Progression-free survival (PFS) assessed per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 determined by retrospective independent central review[ Time Frame: From randomization to the first radiographic documentation of disease progression, or death from any cause, assessed for up to 8 years ]Will be compared between treatment arms using the stratified log rank test at one-sided level 0.025. The stratification factors will be used for the analysis. The hazard ratio (HR) for PFS will be estimated using a stratified Cox proportional hazards model, and the 95% confidence interval (CI) for the HR will be provided. Results from an unstratified analysis will also be provided. Kaplan-Meier methodology will be used to estimate the median PFS for each treatment arm, and Kaplan-Meier curves will be produced. Brookmeyer Crowley methodology will be used to construct the 95% CI for the median PFS for each treatment arm."}],"start_date":"July 18, 2018","primary_completion_date":"October 1, 2025","completion_date":"October 1, 2025","first_posted":"December 18, 2017","last_update_posted":"September 19, 2022"},{"nctid":"NCT03375320","version_a":98,"version_b":99,"version_a_date":"2019-04-22","version_b_date":"2019-05-15","pom_a":[{"label":"1.","content":"Progression-free survival (PFS) assessed per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 determined by retrospective independent central review[ Time Frame: From randomization to the first radiographic documentation of disease progression, or death from any cause, assessed for up to 8 years ]Will be compared between treatment arms using the stratified log rank test at one-sided level 0.025. The stratification factors will be used for the analysis. The hazard ratio (HR) for PFS will be estimated using a stratified Cox proportional hazards model, and the 95% confidence interval (CI) for the HR will be provided. Results from an unstratified analysis will also be provided. Kaplan-Meier methodology will be used to estimate the median PFS for each treatment arm, and Kaplan-Meier curves will be produced. Brookmeyer Crowley methodology will be used to construct the 95% CI for the median PFS for each treatment arm."}],"pom_b":[{"label":"1.","content":"Progression-free survival (PFS)[ Time Frame: From randomization to the first radiographic documentation of disease progression, or death from any cause, assessed for up to 8 years ]Will be assessed per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 determined by retrospective independent central review. Will be compared between treatment arms using the stratified log rank test at one-sided level 0.025. The stratification factors will be used for the analysis. The hazard ratio (HR) for PFS will be estimated using a stratified Cox proportional hazards model, and the 95% confidence interval (CI) for the HR will be provided. Results from an unstratified analysis will also be provided. Kaplan-Meier methodology will be used to estimate the median PFS for each treatment arm, and Kaplan-Meier curves will be produced. Brookmeyer Crowley methodology will be used to construct the 95% CI for the median PFS for each treatment arm."}],"start_date":"July 18, 2018","primary_completion_date":"October 1, 2025","completion_date":"October 1, 2025","first_posted":"December 18, 2017","last_update_posted":"September 19, 2022"},{"nctid":"NCT00329940","version_a":1,"version_b":2,"version_a_date":"2006-05-23","version_b_date":"2006-06-01","pom_a":[],"pom_b":[{"label":"1.","content":"To evaluate the rheumatological tolerability of letrozole 2.5 mg/day in patients treated with anastrozole 1 mg/day"}],"start_date":"November 2005","primary_completion_date":"January 2008","first_posted":"May 25, 2006","last_update_posted":"February 24, 2017"},{"nctid":"NCT00329940","version_a":10,"version_b":11,"version_a_date":"2008-10-02","version_b_date":"2008-10-23","pom_a":[{"label":"1.","content":"To evaluate the rheumatological tolerability of letrozole 2.5 mg/day in patients treated with anastrozole 1 mg/day"}],"pom_b":[{"label":"1.","content":"To evaluate the rheumatological tolerability of letrozole 2.5 mg/day in patients treated with anastrozole 1 mg/day[ Time Frame: every month for 7 months ]"}],"start_date":"November 2005","primary_completion_date":"January 2008","first_posted":"May 25, 2006","last_update_posted":"February 24, 2017"},{"nctid":"NCT00329940","version_a":13,"version_b":14,"version_a_date":"2009-11-17","version_b_date":"2010-04-08","pom_a":[{"label":"1.","content":"To evaluate the rheumatological tolerability of letrozole 2.5 mg/day in patients treated with anastrozole 1 mg/day[ Time Frame: every month for 7 months ]"}],"pom_b":[{"label":"1.","content":"To evaluate the rheumatological tolerability of letrozole 2.5 mg/day in patients treated with anastrozole 1 mg/day[ Time Frame: at 1, 3 and 6 months of letrozole treatment ]"}],"start_date":"November 2005","primary_completion_date":"January 2008","first_posted":"May 25, 2006","last_update_posted":"February 24, 2017"},{"nctid":"NCT00002527","version_a":20,"version_b":21,"version_a_date":"2013-09-27","version_b_date":"2016-07-01","pom_a":[],"pom_b":[{"label":"1.","content":"Reduction in size of tumors[ Time Frame: Up to 4 years ]"},{"label":"2.","content":"Reduction in number of tumors[ Time Frame: Up to 4 years ]"},{"label":"3.","content":"Disease free survival[ Time Frame: Up to 4 years ]"}],"start_date":"May 1993","primary_completion_date":"March 2003","completion_date":"January 2006","first_posted":"August 31, 2004","last_update_posted":"July 4, 2016"},{"nctid":"NCT02032277","version_a":20,"version_b":21,"version_a_date":"2018-01-12","version_b_date":"2018-05-08","pom_a":[{"label":"1.","content":"Pathological Complete Response (pCR).[ Time Frame: At the time of definitive surgery (approximately 24-36 weeks from first dose of study drug). ]Pathological complete response (pCR) in the breast tissue and the lymph node tissue will be assessed upon completion of pre-operative systemic therapy and definitive surgery. Subjects who do not complete definitive surgery for reasons other than withdrawal of consent will be considered not to have achieved pCR."}],"pom_b":[{"label":"1.","content":"Pathological Complete Response (pCR).[ Time Frame: At the time of definitive surgery (approximately 24-36 weeks from first dose of study drug). ]Pathological complete response (pCR) in the breast tissue and the lymph node tissue will be assessed upon completion of pre-operative systemic therapy and definitive surgery."}],"start_date":"April 2, 2014","primary_completion_date":"March 18, 2016","completion_date":"November 12, 2020","first_posted":"January 10, 2014","last_update_posted":"January 20, 2021"},{"nctid":"NCT00075764","version_a":56,"version_b":57,"version_a_date":"2006-10-25","version_b_date":"2006-11-08","pom_a":[],"pom_b":[{"label":"1.","content":"Time to tumor progression"}],"start_date":"April 2004","primary_completion_date":"December 2012","completion_date":"October 1, 2018","first_posted":"January 13, 2004","results_first_posted":"April 4, 2017","last_update_posted":"January 13, 2021"},{"nctid":"NCT00075764","version_a":370,"version_b":371,"version_a_date":"2011-07-21","version_b_date":"2012-10-05","pom_a":[{"label":"1.","content":"Time to tumor progression"}],"pom_b":[{"label":"1.","content":"Time to tumor progression[ Time Frame: 13 months ]"}],"start_date":"April 2004","primary_completion_date":"December 2012","completion_date":"October 1, 2018","first_posted":"January 13, 2004","results_first_posted":"April 4, 2017","last_update_posted":"January 13, 2021"},{"nctid":"NCT00075764","version_a":373,"version_b":374,"version_a_date":"2014-05-08","version_b_date":"2017-02-15","pom_a":[{"label":"1.","content":"Time to tumor progression[ Time Frame: 13 months ]"}],"pom_b":[{"label":"1.","content":"Time to Tumor Progression[ Time Frame: Every 4 weeks while on treatment. Then every 3 months until progression, then six months for two years then annually until four years or until death, which ever occurs first. ]Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target measurable lesions over the smallest sum observed (over baseline if no decrease during therapy) using the same techniques as baseline. Unequivocal progression of non-measurable disease in the opinion of the treating physician. Appearance of any new lesion/site. Death due to disease without prior documentation of progression and without symptomatic deterioration. From date of randomization to time of first documentation of progression, symptomatic deterioration or death due to any cause. Patients last known to be alive and progression free are considered at last date of contact."}],"start_date":"April 2004","primary_completion_date":"December 2012","completion_date":"October 1, 2018","first_posted":"January 13, 2004","results_first_posted":"April 4, 2017","last_update_posted":"January 13, 2021"},{"nctid":"NCT02941926","version_a":5,"version_b":6,"version_a_date":"2016-12-31","version_b_date":"2017-02-07","pom_a":[{"label":"1.","content":"The number of participants with adverse events as a measure of safety and tolerability[ Time Frame: Up to approximately 24 months ]Incidence of AEs, Grade 3/4 AEs & SAEs during treatment with ribociclib + letrozole"}],"pom_b":[{"label":"1.","content":"The number of participants with adverse events as a measure of safety and tolerability[ Time Frame: Up to approximately 36 months ]AEs, Grade 3/4 AEs & SAEs during treatment with ribociclib + letrozole"}],"start_date":"November 30, 2016","primary_completion_date":"November 8, 2019","completion_date":"September 5, 2022","first_posted":"October 21, 2016","results_first_posted":"May 9, 2022","last_update_posted":"July 11, 2022"},{"nctid":"NCT02941926","version_a":54,"version_b":55,"version_a_date":"2021-06-22","version_b_date":"2021-08-24","pom_a":[{"label":"1.","content":"The number of participants with adverse events as a measure of safety and tolerability[ Time Frame: Up to approximately 36 months ]AEs, Grade 3/4 AEs & SAEs during treatment with ribociclib + letrozole"}],"pom_b":[{"label":"1.","content":"Number of participants with adverse events (AEs) and Serious AEs (SAEs) as a measure of safety and tolerability (Core phase)[ Time Frame: Up to approximately 36 months ]Number of participants with AEs, Grade 3/4 AEs and SAEs during treatment with ribociclib + letrozole in the core phase"}],"start_date":"November 30, 2016","primary_completion_date":"November 8, 2019","completion_date":"September 5, 2022","first_posted":"October 21, 2016","results_first_posted":"May 9, 2022","last_update_posted":"July 11, 2022"},{"nctid":"NCT02941926","version_a":58,"version_b":59,"version_a_date":"2021-12-03","version_b_date":"2022-04-11","pom_a":[{"label":"1.","content":"Number of participants with adverse events (AEs) and Serious AEs (SAEs) as a measure of safety and tolerability (Core phase)[ Time Frame: Up to approximately 36 months ]Number of participants with AEs, Grade 3/4 AEs and SAEs during treatment with ribociclib + letrozole in the core phase"}],"pom_b":[{"label":"1.","content":"Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) During Treatment With Ribociclib + Letrozole in the Core Phase[ Time Frame: From start of treatment up to 30 days after last treatment (for participants who did not enter to the Extension Phase) or up to last treatment in the Core Phase (for participants who entered the Extension Phase), assessed up to approximately 33 months. ]AEs were defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s).SAEs were defined as meeting at least 1 of the following criteria: is fatal or life-threatening, Results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, is medically significant, requires inpatient hospitalization or prolongation of existing hospitalization. A SAE which caused death of the participant was considered as fatal SAE.AEs were assessed and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Grade 1 to 5 were used to characterize the severity of the Adverse Event. Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening and Grade 5: death related to AE.A participant with multiple severity grades for an AE is only counted under the maximum grade."}],"start_date":"November 30, 2016","primary_completion_date":"November 8, 2019","completion_date":"September 5, 2022","first_posted":"October 21, 2016","results_first_posted":"May 9, 2022","last_update_posted":"July 11, 2022"},{"nctid":"NCT00582426","version_a":5,"version_b":6,"version_a_date":"2009-10-02","version_b_date":"2009-11-16","pom_a":[{"label":"1.","content":"Incidence of diarrhea grades 1 to 4"}],"pom_b":[{"label":"1.","content":"Incidence of diarrhea grades 1 to 4[ Time Frame: after 6 months of treatment ]"}],"start_date":"April 2008","primary_completion_date":"September 2010","completion_date":"September 2010","first_posted":"December 28, 2007","results_first_posted":"March 27, 2012","last_update_posted":"May 4, 2015"},{"nctid":"NCT00582426","version_a":10,"version_b":11,"version_a_date":"2011-06-27","version_b_date":"2012-02-22","pom_a":[{"label":"1.","content":"Incidence of diarrhea grades 1 to 4[ Time Frame: after 6 months of treatment ]"}],"pom_b":[{"label":"1.","content":"Percentage of Participants Developing Diarrhea (Grade 1 to 4)[ Time Frame: 6 month overall ]The percentage of patients developing diarrhea (incidence of grade 1 to 4) during treatment, considering only the worst grade of diarrhea for each patient. Diarrhea was graded according to Common Toxicity Criteria where Grade 0=None, 1 = Increase of <4 stools/day over pretreatment, Grade 2 = Increase of 4-6 stools/day, or nocturnal stools, Grade 3 = Increase of \u22657 stools/day or incontinence; or need for parenteral support for dehydration and Grade 4= Physiologic consequences requiring intensive care; or hemodynamic collapse."}],"start_date":"April 2008","primary_completion_date":"September 2010","completion_date":"September 2010","first_posted":"December 28, 2007","results_first_posted":"March 27, 2012","last_update_posted":"May 4, 2015"},{"nctid":"NCT01494506","version_a":33,"version_b":34,"version_a_date":"2015-10-15","version_b_date":"2016-02-11","pom_a":[{"label":"1.","content":"Overall Survival[ Time Frame: 24 months ]"}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: From randomization to death; until the data cut off 14 Feb 2014. The maximum time in follow up was 25 months. ]Overall survival was the primary efficacy endpoint of the study and was defined as the time from the date of patient randomization to the date of death or the date the patient was last known to be alive. OS was summarized by Kaplan-Meier methodology for each treatment group. Pairwise treatment group comparisons were carried out using unstratified log rank analyses on the ITT population. Hazard ratio estimates are from Cox regression analysis.The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol."}],"start_date":"November 2011","primary_completion_date":"February 2014","completion_date":"October 2015","first_posted":"December 19, 2011","results_first_posted":"February 12, 2016","last_update_posted":"June 17, 2016"},{"nctid":"NCT03773302","version_a":6,"version_b":7,"version_a_date":"2019-04-26","version_b_date":"2020-01-17","pom_a":[{"label":"1.","content":"Number of participants with progression-free survival (Central Imaging Assessment)[ Time Frame: Month 12 ]Defined as the time from randomization until date of disease progression by central independent imaging assessment (Response Evaluation Criteria in Solid Tumors [RECIST] v. 1.1) or death, whichever occurs first."}],"pom_b":[{"label":"1.","content":"Progression-free survival (central imaging assessment)[ Time Frame: Approximately 11 months on average ]Defined as the time from randomization until date of disease progression by blinded independent central imaging assessment (Response Evaluation Criteria in Solid Tumors [RECIST] v. 1.1) or death, whichever occurs first."}],"start_date":"December 27, 2019","primary_completion_date":"January 30, 2026","completion_date":"December 30, 2026","first_posted":"December 12, 2018","last_update_posted":"August 29, 2022"},{"nctid":"NCT00003855","version_a":23,"version_b":24,"version_a_date":"2013-01-29","version_b_date":"2015-07-06","pom_a":[],"pom_b":[{"label":"1.","content":"Overall survival[ Time Frame: Up to 10 years ]"},{"label":"2.","content":"Morbidity[ Time Frame: Up to 10 years ]"},{"label":"3.","content":"Disease-free survival[ Time Frame: Up to 10 years ]"}],"start_date":"April 1999","primary_completion_date":"August 2007","completion_date":"February 2011","first_posted":"January 27, 2003","last_update_posted":"April 29, 2020"},{"nctid":"NCT00037635","version_a":6,"version_b":7,"version_a_date":"2007-08-30","version_b_date":"2007-09-06","pom_a":[],"pom_b":[{"label":"1.","content":"To evaluate the efficacy of AMG 073 compared with placebo by determining the proportion of subjects with a mean intact parathyroid hormone (iPTH) value <= 250 pg/mL (26.5 pmol/L) during the efficacy assessment phase."}],"start_date":"December 2001","primary_completion_date":"March 2003","completion_date":"March 2003","first_posted":"May 20, 2002","last_update_posted":"May 8, 2013"},{"nctid":"NCT00037635","version_a":9,"version_b":10,"version_a_date":"2007-12-20","version_b_date":"2008-02-20","pom_a":[{"label":"1.","content":"To evaluate the efficacy of AMG 073 compared with placebo by determining the proportion of subjects with a mean intact parathyroid hormone (iPTH) value <= 250 pg/mL (26.5 pmol/L) during the efficacy assessment phase."}],"pom_b":[{"label":"1.","content":"To evaluate the efficacy of AMG 073 compared with placebo by determining the proportion of subjects with a mean intact parathyroid hormone (iPTH) value <= 250 pg/mL (26.5 pmol/L) during the efficacy assessment phase.[ Time Frame: efficacy assessment phase (last 14 weeks of treatment) ]"}],"start_date":"December 2001","primary_completion_date":"March 2003","completion_date":"March 2003","first_posted":"May 20, 2002","last_update_posted":"May 8, 2013"},{"nctid":"NCT02054338","version_a":1,"version_b":2,"version_a_date":"2014-02-03","version_b_date":"2019-08-09","pom_a":[{"label":"1.","content":"Progression Free Survival[ Time Frame: Every 6 weeks until disease progression ]"}],"pom_b":[{"label":"1.","content":"Progression Free Survival[ Time Frame: PFS was calculated from the registration date until the date of progression or death due to any cause if no progression was recorded first (median duration of follow-up: 14.1 months) ]The primary efficacy parameter was Progression-free survival (PFS) analysed in the Intent-to-treat (ITT) population. PFS was defined as the time elapsed from randomisation date until the date of progression or death due to any cause (whichever came first).Tumor response was evaluated using the RECIST version 1.0 every 6 weeks until progression was recorded."}],"start_date":"June 2006","primary_completion_date":"June 2011","completion_date":"February 2015","first_posted":"February 4, 2014","results_first_posted":"August 28, 2019","last_update_posted":"August 28, 2019"},{"nctid":"NCT03093870","version_a":5,"version_b":6,"version_a_date":"2018-05-24","version_b_date":"2018-06-02","pom_a":[{"label":"1.","content":"Incidence of Adverse events (AE) - safety lead-in[ Time Frame: Through 28-days post last study medication administration ]Safety-lead-in: Incidence of AEs, categorized in accordance to CTCAE 4.03 and changes from baseline in safety parameters (including vital signs, ECG parameters, clinical laboratory tests)"},{"label":"2.","content":"Objective response rate (ORR) - part 1[ Time Frame: 3 months after last subject in or when 70% of the subjects (84 subjects) have experienced a PFS event in Part 1 ]Part 1: ORR defined as the proportion of subjects with a best objective response (BOR) of complete response (CR) or partial response (PR), as assessed by an Independent Central Review defined by the RECIST v1.1 criteria"},{"label":"3.","content":"Progression-free survival (PFS) - part 1[ Time Frame: 3 months after last subject in or when 70% of the subjects (84 subjects) have experienced a PFS event in Part 1 ]Part 1: Progression-free survival (PFS), defined as the time from randomization until the date of objective disease progression or death (by any cause in the absence of progression). Progression is defined in accordance with the RECIST v1.1 criteria and will be derived programmatically based on data from the ICR of radiological data."},{"label":"4.","content":"Overall survival (OS) - part 2[ Time Frame: When 247 OS events have occurred. With median OS times of 8.6 months and 6 months for respective arms, 247 OS is estimated to occur after approximately 31 months. ]Part 2; Overall survival (OS) Defined as the time from randomization until death by any cause"}],"pom_b":[{"label":"1.","content":"Incidence of Adverse events (AE) - safety lead-in[ Time Frame: Through 28-days post last study medication administration ]Safety-lead-in: Incidence of AEs, categorized in accordance to CTCAE 4.03 and changes from baseline in safety parameters (including vital signs, ECG parameters, clinical laboratory tests)"},{"label":"2.","content":"Objective response rate (ORR) - part 1[ Time Frame: the later of 3 months after last subject in or when 70% of the subjects (84 subjects) have experienced a PFS event in Part 1 ]Part 1: ORR defined as the proportion of subjects with a best objective response (BOR) of complete response (CR) or partial response (PR), as assessed by an Independent Central Review(ICR) defined by the RECIST v1.1 criteria"},{"label":"3.","content":"Progression-free survival (PFS) - part 1[ Time Frame: The later of 3 months after last subject in or when 70% of the subjects (84 subjects) have experienced a PFS event in Part 1 ]Part 1: Progression-free survival (PFS), defined as the time from randomization until the date of objective disease progression or death (by any cause in the absence of progression). Progression is defined in accordance with the RECIST v1.1 criteria and will be derived programmatically based on data from the ICR of radiological data."},{"label":"4.","content":"Overall survival (OS) - part 2[ Time Frame: When 247 OS events have occurred. With median OS times of 8.6 months and 6 months for respective arms, 247 OS is estimated to occur after approximately 31 months. ]Part 2; Overall survival (OS) Defined as the time from randomization until death by any cause"}],"start_date":"July 4, 2017","primary_completion_date":"November 12, 2019","completion_date":"April 17, 2020","first_posted":"March 28, 2017","results_first_posted":"August 3, 2021","last_update_posted":"August 3, 2021"},{"nctid":"NCT03093870","version_a":12,"version_b":13,"version_a_date":"2018-12-29","version_b_date":"2021-05-17","pom_a":[{"label":"1.","content":"Incidence of Adverse events (AE) - safety lead-in[ Time Frame: Through 28-days post last study medication administration ]Safety-lead-in: Incidence of AEs, categorized in accordance to CTCAE 4.03 and changes from baseline in safety parameters (including vital signs, ECG parameters, clinical laboratory tests)"},{"label":"2.","content":"Objective response rate (ORR) - part 1[ Time Frame: the later of 3 months after last subject in or when 70% of the subjects (84 subjects) have experienced a PFS event in Part 1 ]Part 1: ORR defined as the proportion of subjects with a best objective response (BOR) of complete response (CR) or partial response (PR), as assessed by an Independent Central Review(ICR) defined by the RECIST v1.1 criteria"},{"label":"3.","content":"Progression-free survival (PFS) - part 1[ Time Frame: The later of 3 months after last subject in or when 70% of the subjects (84 subjects) have experienced a PFS event in Part 1 ]Part 1: Progression-free survival (PFS), defined as the time from randomization until the date of objective disease progression or death (by any cause in the absence of progression). Progression is defined in accordance with the RECIST v1.1 criteria and will be derived programmatically based on data from the ICR of radiological data."},{"label":"4.","content":"Overall survival (OS) - part 2[ Time Frame: When 247 OS events have occurred. With median OS times of 8.6 months and 6 months for respective arms, 247 OS is estimated to occur after approximately 31 months. ]Part 2; Overall survival (OS) Defined as the time from randomization until death by any cause"}],"pom_b":[{"label":"1.","content":"Objective Response Rate (ORR) - Part 1[ Time Frame: Data obtained up until progression, or until last evaluable assessment in the absence of progression, was included in the assessment of ORR, regardless of whether subjects discontinued treatment or received a subsequent therapy prior to progression ]Part 1: The ORR was defined as the number (%) of subjects with \u2265 1 visit response of complete response (CR) or partial response (PR). Data obtained up until progression, or until last evaluable assessment in the absence of progression, was included in the assessment of ORR, regardless of whether subjects discontinued treatment or received a subsequent therapy prior to progression. Best overall RECIST Response (BOR) was calculated based on the overall visit responses from each RECIST assessment, i.e. the best response a subject had following randomization and prior to RECIST progression or the last evaluable assessment in the absence of RECIST progression. Categorization of BOR was based on the RECIST criteria using the following response categories: CR, PR, stable disease (SD), progressive disease (PD) and not evaluable (NE)."},{"label":"Quality Control Review Comment provided by the National Library of Medicine:","content":"There does not appear to be sufficient information to understand the Time Frame. One or more of these comments also apply to other measures in the record."},{"label":"2.","content":"Progression-free Survival (PFS) - Part 1[ Time Frame: Time from randomization until the date of objective disease progression or death (by any cause in the absence of disease progression) regardless of whether the subject withdrew from randomized therapy or received another antitumor therapy prior to PD. ]Part 1: Progression-free survival (PFS) was defined as the time from randomization (or starting treatment for the Safety Lead-in) until the date of objective disease progression or death (by any cause in the absence of disease progression) regardless of whether the subject withdrew from randomized therapy or received another antitumor therapy prior to disease progression. Subjects who did not experience disease progression or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment. However, if the patient progressed or died after \u2265 2 missed visits (12 weeks \xb1 5 days maximum), the subject was censored at the time of the latest evaluable RECIST assessment. The PFS time was based on the scan/assessment dates rather than visit dates."},{"label":"Quality Control Review Comment provided by the National Library of Medicine:","content":"There does not appear to be sufficient information to understand the Time Frame."}],"start_date":"July 4, 2017","primary_completion_date":"November 12, 2019","completion_date":"April 17, 2020","first_posted":"March 28, 2017","results_first_posted":"August 3, 2021","last_update_posted":"August 3, 2021"},{"nctid":"NCT03093870","version_a":13,"version_b":14,"version_a_date":"2021-05-17","version_b_date":"2021-07-12","pom_a":[{"label":"1.","content":"Objective Response Rate (ORR) - Part 1[ Time Frame: Data obtained up until progression, or until last evaluable assessment in the absence of progression, was included in the assessment of ORR, regardless of whether subjects discontinued treatment or received a subsequent therapy prior to progression ]Part 1: The ORR was defined as the number (%) of subjects with \u2265 1 visit response of complete response (CR) or partial response (PR). Data obtained up until progression, or until last evaluable assessment in the absence of progression, was included in the assessment of ORR, regardless of whether subjects discontinued treatment or received a subsequent therapy prior to progression. Best overall RECIST Response (BOR) was calculated based on the overall visit responses from each RECIST assessment, i.e. the best response a subject had following randomization and prior to RECIST progression or the last evaluable assessment in the absence of RECIST progression. Categorization of BOR was based on the RECIST criteria using the following response categories: CR, PR, stable disease (SD), progressive disease (PD) and not evaluable (NE)."},{"label":"Quality Control Review Comment provided by the National Library of Medicine:","content":"There does not appear to be sufficient information to understand the Time Frame. One or more of these comments also apply to other measures in the record."},{"label":"2.","content":"Progression-free Survival (PFS) - Part 1[ Time Frame: Time from randomization until the date of objective disease progression or death (by any cause in the absence of disease progression) regardless of whether the subject withdrew from randomized therapy or received another antitumor therapy prior to PD. ]Part 1: Progression-free survival (PFS) was defined as the time from randomization (or starting treatment for the Safety Lead-in) until the date of objective disease progression or death (by any cause in the absence of disease progression) regardless of whether the subject withdrew from randomized therapy or received another antitumor therapy prior to disease progression. Subjects who did not experience disease progression or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment. However, if the patient progressed or died after \u2265 2 missed visits (12 weeks \xb1 5 days maximum), the subject was censored at the time of the latest evaluable RECIST assessment. The PFS time was based on the scan/assessment dates rather than visit dates."},{"label":"Quality Control Review Comment provided by the National Library of Medicine:","content":"There does not appear to be sufficient information to understand the Time Frame."}],"pom_b":[{"label":"1.","content":"Objective Response Rate (ORR) - Part 1[ Time Frame: Data obtained up until progression, or until last evaluable assessment in the absence of progression, regardless of whether subjects discontinued treatment or received a subsequent therapy prior to progression, up to 2 years. ]Part 1: The ORR was defined as the number (%) of subjects with \u2265 1 visit response of complete response (CR) or partial response (PR). Data obtained up until progression, or until last evaluable assessment in the absence of progression, was included in the assessment of ORR, regardless of whether subjects discontinued treatment or received a subsequent therapy prior to progression. Best overall RECIST Response (BOR) was calculated based on the overall visit responses from each RECIST assessment, i.e. the best response a subject had following randomization and prior to RECIST progression or the last evaluable assessment in the absence of RECIST progression. Categorization of BOR was based on the RECIST criteria using the following response categories: CR, PR, stable disease (SD), progressive disease (PD) and not evaluable (NE)."},{"label":"2.","content":"Progression-free Survival (PFS) - Part 1[ Time Frame: Time from randomization until date of objective disease progression or death (by any cause in absence of disease progression) regardless of whether subject withdrew from randomized therapy or received another antitumor therapy prior to PD, up to 2 years. ]Part 1: Progression-free survival (PFS) was defined as the time from randomization (or starting treatment for the Safety Lead-in) until the date of objective disease progression or death (by any cause in the absence of disease progression) regardless of whether the subject withdrew from randomized therapy or received another antitumor therapy prior to disease progression. Subjects who did not experience disease progression or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment. However, if the patient progressed or died after \u2265 2 missed visits (12 weeks \xb1 5 days maximum), the subject was censored at the time of the latest evaluable RECIST assessment. The PFS time was based on the scan/assessment dates rather than visit dates."}],"start_date":"July 4, 2017","primary_completion_date":"November 12, 2019","completion_date":"April 17, 2020","first_posted":"March 28, 2017","results_first_posted":"August 3, 2021","last_update_posted":"August 3, 2021"},{"nctid":"NCT02925494","version_a":13,"version_b":14,"version_a_date":"2019-04-09","version_b_date":"2020-06-12","pom_a":[{"label":"1.","content":"Percentage of Responders based on menstrual blood loss volume reduction[ Time Frame: From Month 0 (Baseline in Pivotal Study) to Final Month of Treatment Period (up through 12 months) ]Assessed using alkaline hematin methodology."}],"pom_b":[{"label":"1.","content":"Percentage of Participants Meeting the Criteria for Responder[ Time Frame: From Month 0 (Baseline in Pivotal Study) to Final Month of Treatment Period (up through Month 6 in Extension Study) ]Percentage of responders, defined as participants who met the following conditions:Menstrual blood loss (MBL) volume < 80 mL during the Final Month (the last 28 days prior to and including the last dose date), and\u2265 50% reduction in MBL volume from Baseline to the Final Month.Participants who prematurely discontinued study drug due to \\"lack of efficacy,\\" \\"requires surgery or invasive intervention for treatment of uterine fibroids,\\" or \\"adverse events\\" were considered non-responders regardless of whether she meets the two aforementioned responder criteria or not."}],"start_date":"September 14, 2016","primary_completion_date":"May 7, 2018","completion_date":"March 22, 2019","first_posted":"October 6, 2016","results_first_posted":"June 30, 2020","last_update_posted":"July 13, 2021"},{"nctid":"NCT00601900","version_a":231,"version_b":232,"version_a_date":"2010-05-13","version_b_date":"2010-05-21","pom_a":[{"label":"1.","content":"Progression-free survival defined as the interval from randomization until disease progression or death, whichever occurs first in patients treated with letrozole"},{"label":"2.","content":"Estimation of adverse events rate, especially for stroke, proteinuria, thrombosis, hypertension in patients treated with tamoxifen citrate"},{"label":"3.","content":"Toxicity"}],"pom_b":[{"label":"1.","content":"Progression-free survival"},{"label":"2.","content":"Adverse events rate, especially for stroke, proteinuria, thrombosis, and hypertension in patients treated with tamoxifen citrate"},{"label":"3.","content":"Toxicity"}],"start_date":"May 15, 2008","primary_completion_date":"June 30, 2014","first_posted":"January 28, 2008","results_first_posted":"August 23, 2016","last_update_posted":"September 19, 2022"},{"nctid":"NCT00601900","version_a":368,"version_b":369,"version_a_date":"2011-04-06","version_b_date":"2012-09-06","pom_a":[{"label":"1.","content":"Progression-free survival"},{"label":"2.","content":"Adverse events rate, especially for stroke, proteinuria, thrombosis, and hypertension in patients treated with tamoxifen citrate"},{"label":"3.","content":"Toxicity"}],"pom_b":[{"label":"1.","content":"Progression-free survival"},{"label":"2.","content":"Adverse events rate, especially for stroke, proteinuria, thrombosis, and hypertension in patients treated with tamoxifen citrate (As of 5/15/2011, patients only receive letrozole)"},{"label":"3.","content":"Toxicity"}],"start_date":"May 15, 2008","primary_completion_date":"June 30, 2014","first_posted":"January 28, 2008","results_first_posted":"August 23, 2016","last_update_posted":"September 19, 2022"},{"nctid":"NCT00601900","version_a":369,"version_b":370,"version_a_date":"2012-09-06","version_b_date":"2012-11-08","pom_a":[{"label":"1.","content":"Progression-free survival"},{"label":"2.","content":"Adverse events rate, especially for stroke, proteinuria, thrombosis, and hypertension in patients treated with tamoxifen citrate (As of 5/15/2011, patients only receive letrozole)"},{"label":"3.","content":"Toxicity"}],"pom_b":[{"label":"1.","content":"Progression-free survival[ Time Frame: From randomization until disease progression or death, assessed up to 3 years ]"},{"label":"2.","content":"Adverse events rate, especially for stroke, proteinuria, thrombosis, and hypertension in patients treated with tamoxifen citrate (As of 5/15/2011, patients only receive letrozole)[ Time Frame: Within 30 days of the last dose of investigational agent ]Graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Interpreted using P-values from the chi-square test (with one-sided alpha of 0.05)."},{"label":"3.","content":"Occurrence of grade 3, 4, or 5 toxicity[ Time Frame: Assessed up to 3 years ]Graded using the NCI CTCAE version 4.0."}],"start_date":"May 15, 2008","primary_completion_date":"June 30, 2014","first_posted":"January 28, 2008","results_first_posted":"August 23, 2016","last_update_posted":"September 19, 2022"},{"nctid":"NCT00601900","version_a":373,"version_b":374,"version_a_date":"2013-06-17","version_b_date":"2013-09-09","pom_a":[{"label":"1.","content":"Progression-free survival[ Time Frame: From randomization until disease progression or death, assessed up to 3 years ]"},{"label":"2.","content":"Adverse events rate, especially for stroke, proteinuria, thrombosis, and hypertension in patients treated with tamoxifen citrate (As of 5/15/2011, patients only receive letrozole)[ Time Frame: Within 30 days of the last dose of investigational agent ]Graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Interpreted using P-values from the chi-square test (with one-sided alpha of 0.05)."},{"label":"3.","content":"Occurrence of grade 3, 4, or 5 toxicity[ Time Frame: Assessed up to 3 years ]Graded using the NCI CTCAE version 4.0."}],"pom_b":[{"label":"1.","content":"Progression-free survival[ Time Frame: From randomization until disease progression or death, assessed up to 5 years ]"},{"label":"2.","content":"Adverse events rate, especially for stroke, proteinuria, thrombosis, and hypertension in patients treated with tamoxifen citrate (As of 5/15/2011, patients only receive letrozole)[ Time Frame: Within 30 days of the last dose of investigational agent ]Graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Interpreted using P-values from the chi-square test (with one-sided alpha of 0.05)."},{"label":"3.","content":"Occurrence of grade 3, 4, or 5 toxicity[ Time Frame: Assessed up to 5 years ]Graded using the NCI CTCAE version 4.0."}],"start_date":"May 15, 2008","primary_completion_date":"June 30, 2014","first_posted":"January 28, 2008","results_first_posted":"August 23, 2016","last_update_posted":"September 19, 2022"},{"nctid":"NCT00601900","version_a":390,"version_b":391,"version_a_date":"2015-03-06","version_b_date":"2015-04-23","pom_a":[{"label":"1.","content":"Progression-free survival[ Time Frame: From randomization until disease progression or death, assessed up to 5 years ]"},{"label":"2.","content":"Adverse events rate, especially for stroke, proteinuria, thrombosis, and hypertension in patients treated with tamoxifen citrate (As of 5/15/2011, patients only receive letrozole)[ Time Frame: Within 30 days of the last dose of investigational agent ]Graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Interpreted using P-values from the chi-square test (with one-sided alpha of 0.05)."},{"label":"3.","content":"Occurrence of grade 3, 4, or 5 toxicity[ Time Frame: Assessed up to 5 years ]Graded using the NCI CTCAE version 4.0."}],"pom_b":[{"label":"1.","content":"Progression-free survival[ Time Frame: From randomization until disease progression or death, assessed up to 5 years ]Progression-free survival (PFS) was defined as the time from randomization until disease progression or death, whichever occurs first. The median PFS was estimated using the Kaplan-Meier method. Progression was assessed per RECIST criteria, and defined as at least a 20% increase in the sum of the longest diameters of target lesions or the appearance of new lesions"}],"start_date":"May 15, 2008","primary_completion_date":"June 30, 2014","first_posted":"January 28, 2008","results_first_posted":"August 23, 2016","last_update_posted":"September 19, 2022"},{"nctid":"NCT00601900","version_a":391,"version_b":392,"version_a_date":"2015-04-23","version_b_date":"2016-07-13","pom_a":[{"label":"1.","content":"Progression-free survival[ Time Frame: From randomization until disease progression or death, assessed up to 5 years ]Progression-free survival (PFS) was defined as the time from randomization until disease progression or death, whichever occurs first. The median PFS was estimated using the Kaplan-Meier method. Progression was assessed per RECIST criteria, and defined as at least a 20% increase in the sum of the longest diameters of target lesions or the appearance of new lesions"}],"pom_b":[{"label":"1.","content":"Progression-free Survival[ Time Frame: From randomization until disease progression or death whichever occurs first, assessed up to 5 years ]The Primary Endpoint for this study was to compare the progression-free survival of letrozole therapy alone with the combination of letrozole therapy plus bevacizumab as first-line treatment in women with estrogen- and/or progesterone-receptor-positive advanced breast cancer. Progression-free survival (PFS) was defined as the time from randomization until disease progression or death, whichever occurs first. The median PFS was estimated using the Kaplan-Meier method. Progression was assessed per RECIST criteria, and defined as at least a 20% increase in the sum of the longest diameters of target lesions from baseline or the appearance of new lesions."}],"start_date":"May 15, 2008","primary_completion_date":"June 30, 2014","first_posted":"January 28, 2008","results_first_posted":"August 23, 2016","last_update_posted":"September 19, 2022"},{"nctid":"NCT01578499","version_a":12,"version_b":13,"version_a_date":"2013-07-23","version_b_date":"2013-08-18","pom_a":[{"label":"1.","content":"Proportion of patients achieving an objective response that lasts at least 4 months[ Time Frame: Change in response at the end of 21 day cycles: 3,6,9,12, and 15; at EOT; then every 12 weeks for a minimum of 24 months, and thereafter every 6 months until disease progression or study closure for up to 3 years post treatment ]To determine ORR, lasting at least 4 months, with brentuximab vedotin in patients with CD30+ MF or pcALCL compared to that achieved with therapy in the control arm"}],"pom_b":[{"label":"1.","content":"Proportion of patients achieving an objective response that lasts at least 4 months[ Time Frame: Until disease progression, death or study closure (up to 3 years after the enrollment of the last patient) ]To determine ORR, lasting at least 4 months, with brentuximab vedotin in patients with CD30+ MF or pcALCL compared to that achieved with therapy in the control arm"}],"start_date":"June 11, 2012","primary_completion_date":"May 31, 2016","completion_date":"July 6, 2018","first_posted":"April 17, 2012","results_first_posted":"March 16, 2018","last_update_posted":"January 5, 2021"},{"nctid":"NCT01578499","version_a":19,"version_b":20,"version_a_date":"2017-02-07","version_b_date":"2018-02-19","pom_a":[{"label":"1.","content":"Proportion of patients achieving an objective response that lasts at least 4 months[ Time Frame: Until disease progression, death or study closure (up to 3 years after the enrollment of the last patient) ]To determine ORR, lasting at least 4 months, with brentuximab vedotin in patients with CD30+ MF or pcALCL compared to that achieved with therapy in the control arm"}],"pom_b":[{"label":"1.","content":"Percentage of Participants Achieving an Objective Response That Lasts at Least 4 Months (ORR4)[ Time Frame: Each Cycle until disease progression, death or data cutoff (Median overall follow-up 22.9 months) ]ORR4 was determined by an Independent Review Facility (IRF) based on Global Response Score (GRS) which consisted of a skin assessment by the investigator using the modified severity-weighted assessment tool (mSWAT), nodal and visceral radiographic assessment by an IRF and for the participants with mycosis fungoides (MF) only, detection of circulation Sezary cells. Participants whose first response occurred after the start of subsequent anticancer therapy were excluded. Response Criteria was based on International Society for Cutaneous Lymphomas (ISCL), United States Cutaneous Lymphoma Consortium (USCLC) and Cutaneous Lymphoma Task Force (CLTF) of the European Organisation for Research and Treatment of Cancer (EORTC) Consensus guidelines (Olsen, 2011)."}],"start_date":"June 11, 2012","primary_completion_date":"May 31, 2016","completion_date":"July 6, 2018","first_posted":"April 17, 2012","results_first_posted":"March 16, 2018","last_update_posted":"January 5, 2021"},{"nctid":"NCT01578499","version_a":21,"version_b":22,"version_a_date":"2018-07-24","version_b_date":"2019-08-29","pom_a":[{"label":"1.","content":"Percentage of Participants Achieving an Objective Response That Lasts at Least 4 Months (ORR4)[ Time Frame: Each Cycle until disease progression, death or data cutoff (Median overall follow-up 22.9 months) ]ORR4 was determined by an Independent Review Facility (IRF) based on Global Response Score (GRS) which consisted of a skin assessment by the investigator using the modified severity-weighted assessment tool (mSWAT), nodal and visceral radiographic assessment by an IRF and for the participants with mycosis fungoides (MF) only, detection of circulation Sezary cells. Participants whose first response occurred after the start of subsequent anticancer therapy were excluded. Response Criteria was based on International Society for Cutaneous Lymphomas (ISCL), United States Cutaneous Lymphoma Consortium (USCLC) and Cutaneous Lymphoma Task Force (CLTF) of the European Organisation for Research and Treatment of Cancer (EORTC) Consensus guidelines (Olsen, 2011)."}],"pom_b":[{"label":"1.","content":"Percentage of Participants Achieving an Objective Response That Lasts at Least 4 Months (ORR4)[ Time Frame: Each Cycle until disease progression, death End of treatment (Median overall follow-up 38.8 months) ]ORR4 was determined by an Independent Review Facility (IRF) based on Global Response Score (GRS) which consisted of a skin assessment by the investigator using the modified severity-weighted assessment tool (mSWAT), nodal and visceral radiographic assessment by an IRF and for the participants with mycosis fungoides (MF) only, detection of circulation Sezary cells. Participants whose first response occurred after the start of subsequent anticancer therapy were excluded. Response Criteria was based on International Society for Cutaneous Lymphomas (ISCL), United States Cutaneous Lymphoma Consortium (USCLC) and Cutaneous Lymphoma Task Force (CLTF) of the European Organisation for Research and Treatment of Cancer (EORTC) Consensus guidelines (Olsen, 2011)."}],"start_date":"June 11, 2012","primary_completion_date":"May 31, 2016","completion_date":"July 6, 2018","first_posted":"April 17, 2012","results_first_posted":"March 16, 2018","last_update_posted":"January 5, 2021"}]}'),Y=n(1184);var X=e.createContext(),ee=n(5878);function te(e){return(0,k.Z)("MuiGrid",e)}var ne=["auto",!0,1,2,3,4,5,6,7,8,9,10,11,12],re=(0,ee.Z)("MuiGrid",["root","container","item","zeroMinWidth"].concat((0,Z.Z)([0,1,2,3,4,5,6,7,8,9,10].map((function(e){return"spacing-xs-".concat(e)}))),(0,Z.Z)(["column-reverse","column","row-reverse","row"].map((function(e){return"direction-xs-".concat(e)}))),(0,Z.Z)(["nowrap","wrap-reverse","wrap"].map((function(e){return"wrap-xs-".concat(e)}))),(0,Z.Z)(ne.map((function(e){return"grid-xs-".concat(e)}))),(0,Z.Z)(ne.map((function(e){return"grid-sm-".concat(e)}))),(0,Z.Z)(ne.map((function(e){return"grid-md-".concat(e)}))),(0,Z.Z)(ne.map((function(e){return"grid-lg-".concat(e)}))),(0,Z.Z)(ne.map((function(e){return"grid-xl-".concat(e)}))))),ae=re,oe=["className","columns","columnSpacing","component","container","direction","item","rowSpacing","spacing","wrap","zeroMinWidth"];function ie(e){var t=parseFloat(e);return"".concat(t).concat(String(e).replace(String(t),"")||"px")}function se(e){var t=e.breakpoints,n=e.values,r="";Object.keys(n).forEach((function(e){""===r&&0!==n[e]&&(r=e)}));var a=Object.keys(t).sort((function(e,n){return t[e]-t[n]}));return a.slice(0,a.indexOf(r))}var le=(0,I.ZP)("div",{name:"MuiGrid",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState,r=n.container,a=n.direction,o=n.item,i=n.spacing,s=n.wrap,l=n.zeroMinWidth,u=n.breakpoints,c=[];r&&(c=function(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};if(!e||e<=0)return[];if("string"===typeof e&&!Number.isNaN(Number(e))||"number"===typeof e)return[n["spacing-xs-".concat(String(e))]];var r=[];return t.forEach((function(t){var a=e[t];Number(a)>0&&r.push(n["spacing-".concat(t,"-").concat(String(a))])})),r}(i,u,t));var d=[];return u.forEach((function(e){var r=n[e];r&&d.push(t["grid-".concat(e,"-").concat(String(r))])})),[t.root,r&&t.container,o&&t.item,l&&t.zeroMinWidth].concat((0,Z.Z)(c),["row"!==a&&t["direction-xs-".concat(String(a))],"wrap"!==s&&t["wrap-xs-".concat(String(s))]],d)}})((function(e){var t=e.ownerState;return(0,r.Z)({boxSizing:"border-box"},t.container&&{display:"flex",flexWrap:"wrap",width:"100%"},t.item&&{margin:0},t.zeroMinWidth&&{minWidth:0},"wrap"!==t.wrap&&{flexWrap:t.wrap})}),(function(e){var t=e.theme,n=e.ownerState,r=(0,Y.P$)({values:n.direction,breakpoints:t.breakpoints.values});return(0,Y.k9)({theme:t},r,(function(e){var t={flexDirection:e};return 0===e.indexOf("column")&&(t["& > .".concat(ae.item)]={maxWidth:"none"}),t}))}),(function(e){var t=e.theme,n=e.ownerState,r=n.container,a=n.rowSpacing,o={};if(r&&0!==a){var i,s=(0,Y.P$)({values:a,breakpoints:t.breakpoints.values});"object"===typeof s&&(i=se({breakpoints:t.breakpoints.values,values:s})),o=(0,Y.k9)({theme:t},s,(function(e,n){var r,a=t.spacing(e);return"0px"!==a?(0,_.Z)({marginTop:"-".concat(ie(a))},"& > .".concat(ae.item),{paddingTop:ie(a)}):null!=(r=i)&&r.includes(n)?{}:(0,_.Z)({marginTop:0},"& > .".concat(ae.item),{paddingTop:0})}))}return o}),(function(e){var t=e.theme,n=e.ownerState,r=n.container,a=n.columnSpacing,o={};if(r&&0!==a){var i,s=(0,Y.P$)({values:a,breakpoints:t.breakpoints.values});"object"===typeof s&&(i=se({breakpoints:t.breakpoints.values,values:s})),o=(0,Y.k9)({theme:t},s,(function(e,n){var r,a=t.spacing(e);return"0px"!==a?(0,_.Z)({width:"calc(100% + ".concat(ie(a),")"),marginLeft:"-".concat(ie(a))},"& > .".concat(ae.item),{paddingLeft:ie(a)}):null!=(r=i)&&r.includes(n)?{}:(0,_.Z)({width:"100%",marginLeft:0},"& > .".concat(ae.item),{paddingLeft:0})}))}return o}),(function(e){var t,n=e.theme,a=e.ownerState;return n.breakpoints.keys.reduce((function(e,o){var i={};if(a[o]&&(t=a[o]),!t)return e;if(!0===t)i={flexBasis:0,flexGrow:1,maxWidth:"100%"};else if("auto"===t)i={flexBasis:"auto",flexGrow:0,flexShrink:0,maxWidth:"none",width:"auto"};else{var s=(0,Y.P$)({values:a.columns,breakpoints:n.breakpoints.values}),l="object"===typeof s?s[o]:s;if(void 0===l||null===l)return e;var u="".concat(Math.round(t/l*1e8)/1e6,"%"),c={};if(a.container&&a.item&&0!==a.columnSpacing){var d=n.spacing(a.columnSpacing);if("0px"!==d){var f="calc(".concat(u," + ").concat(ie(d),")");c={flexBasis:f,maxWidth:f}}}i=(0,r.Z)({flexBasis:u,flexGrow:0,maxWidth:u},c)}return 0===n.breakpoints.values[o]?Object.assign(e,i):e[n.breakpoints.up(o)]=i,e}),{})}));var ue=function(e){var t=e.classes,n=e.container,r=e.direction,a=e.item,o=e.spacing,i=e.wrap,s=e.zeroMinWidth,l=e.breakpoints,u=[];n&&(u=function(e,t){if(!e||e<=0)return[];if("string"===typeof e&&!Number.isNaN(Number(e))||"number"===typeof e)return["spacing-xs-".concat(String(e))];var n=[];return t.forEach((function(t){var r=e[t];if(Number(r)>0){var a="spacing-".concat(t,"-").concat(String(r));n.push(a)}})),n}(o,l));var c=[];l.forEach((function(t){var n=e[t];n&&c.push("grid-".concat(t,"-").concat(String(n)))}));var d={root:["root",n&&"container",a&&"item",s&&"zeroMinWidth"].concat((0,Z.Z)(u),["row"!==r&&"direction-xs-".concat(String(r)),"wrap"!==i&&"wrap-xs-".concat(String(i))],c)};return(0,T.Z)(d,te,t)},ce=e.forwardRef((function(t,n){var o=(0,a.Z)({props:t,name:"MuiGrid"}),i=(0,G.Z)(m.Z).breakpoints,s=V(o),l=s.className,u=s.columns,c=s.columnSpacing,d=s.component,p=void 0===d?"div":d,h=s.container,v=void 0!==h&&h,b=s.direction,y=void 0===b?"row":b,g=s.item,_=void 0!==g&&g,C=s.rowSpacing,k=s.spacing,T=void 0===k?0:k,x=s.wrap,E=void 0===x?"wrap":x,P=s.zeroMinWidth,A=void 0!==P&&P,R=(0,w.Z)(s,oe),F=C||T,O=c||T,N=e.useContext(X),M=v?u||12:N,I={},z=(0,r.Z)({},R);i.keys.forEach((function(e){null!=R[e]&&(I[e]=R[e],delete z[e])}));var L=(0,r.Z)({},s,{columns:M,container:v,direction:y,item:_,rowSpacing:F,columnSpacing:O,wrap:E,zeroMinWidth:A,spacing:T},I,{breakpoints:i.keys}),D=ue(L);return(0,f.jsx)(X.Provider,{value:M,children:(0,f.jsx)(le,(0,r.Z)({ownerState:L,className:(0,S.Z)(D.root,l),as:p,ref:n},z))})})),de=ce,fe=n(2065);function pe(e){return(0,k.Z)("MuiPaper",e)}(0,ee.Z)("MuiPaper",["root","rounded","outlined","elevation","elevation0","elevation1","elevation2","elevation3","elevation4","elevation5","elevation6","elevation7","elevation8","elevation9","elevation10","elevation11","elevation12","elevation13","elevation14","elevation15","elevation16","elevation17","elevation18","elevation19","elevation20","elevation21","elevation22","elevation23","elevation24"]);var me=["className","component","elevation","square","variant"],he=function(e){return((e<1?5.11916*Math.pow(e,2):4.5*Math.log(e+1)+2)/100).toFixed(2)},ve=(0,I.ZP)("div",{name:"MuiPaper",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t[n.variant],!n.square&&t.rounded,"elevation"===n.variant&&t["elevation".concat(n.elevation)]]}})((function(e){var t,n=e.theme,a=e.ownerState;return(0,r.Z)({backgroundColor:(n.vars||n).palette.background.paper,color:(n.vars||n).palette.text.primary,transition:n.transitions.create("box-shadow")},!a.square&&{borderRadius:n.shape.borderRadius},"outlined"===a.variant&&{border:"1px solid ".concat((n.vars||n).palette.divider)},"elevation"===a.variant&&(0,r.Z)({boxShadow:(n.vars||n).shadows[a.elevation]},!n.vars&&"dark"===n.palette.mode&&{backgroundImage:"linear-gradient(".concat((0,fe.Fq)("#fff",he(a.elevation)),", ").concat((0,fe.Fq)("#fff",he(a.elevation)),")")},n.vars&&{backgroundImage:null==(t=n.vars.overlays)?void 0:t[a.elevation]}))})),be=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiPaper"}),o=n.className,i=n.component,s=void 0===i?"div":i,l=n.elevation,u=void 0===l?1:l,c=n.square,d=void 0!==c&&c,p=n.variant,m=void 0===p?"elevation":p,h=(0,w.Z)(n,me),v=(0,r.Z)({},n,{component:s,elevation:u,square:d,variant:m}),b=function(e){var t=e.square,n=e.elevation,r=e.variant,a=e.classes,o={root:["root",r,!t&&"rounded","elevation"===r&&"elevation".concat(n)]};return(0,T.Z)(o,pe,a)}(v);return(0,f.jsx)(ve,(0,r.Z)({as:s,ownerState:v,className:(0,S.Z)(b.root,o),ref:t},h))}));function ye(e){return(0,k.Z)("MuiCard",e)}(0,ee.Z)("MuiCard",["root"]);var ge=["className","raised"],_e=(0,I.ZP)(be,{name:"MuiCard",slot:"Root",overridesResolver:function(e,t){return t.root}})((function(){return{overflow:"hidden"}})),we=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiCard"}),o=n.className,i=n.raised,s=void 0!==i&&i,l=(0,w.Z)(n,ge),u=(0,r.Z)({},n,{raised:s}),c=function(e){var t=e.classes;return(0,T.Z)({root:["root"]},ye,t)}(u);return(0,f.jsx)(_e,(0,r.Z)({className:(0,S.Z)(c.root,o),elevation:s?8:void 0,ref:t,ownerState:u},l))}));function Se(e){return(0,k.Z)("MuiCardContent",e)}(0,ee.Z)("MuiCardContent",["root"]);var Ce=["className","component"],ke=(0,I.ZP)("div",{name:"MuiCardContent",slot:"Root",overridesResolver:function(e,t){return t.root}})((function(){return{padding:16,"&:last-child":{paddingBottom:24}}})),Te=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiCardContent"}),o=n.className,i=n.component,s=void 0===i?"div":i,l=(0,w.Z)(n,Ce),u=(0,r.Z)({},n,{component:s}),c=function(e){var t=e.classes;return(0,T.Z)({root:["root"]},Se,t)}(u);return(0,f.jsx)(ke,(0,r.Z)({as:s,className:(0,S.Z)(c.root,o),ownerState:u,ref:t},l))}));function xe(e){return(0,k.Z)("MuiTypography",e)}(0,ee.Z)("MuiTypography",["root","h1","h2","h3","h4","h5","h6","subtitle1","subtitle2","body1","body2","inherit","button","caption","overline","alignLeft","alignRight","alignCenter","alignJustify","noWrap","gutterBottom","paragraph"]);var Ee=["align","className","component","gutterBottom","noWrap","paragraph","variant","variantMapping"],Pe=(0,I.ZP)("span",{name:"MuiTypography",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,n.variant&&t[n.variant],"inherit"!==n.align&&t["align".concat((0,M.Z)(n.align))],n.noWrap&&t.noWrap,n.gutterBottom&&t.gutterBottom,n.paragraph&&t.paragraph]}})((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({margin:0},n.variant&&t.typography[n.variant],"inherit"!==n.align&&{textAlign:n.align},n.noWrap&&{overflow:"hidden",textOverflow:"ellipsis",whiteSpace:"nowrap"},n.gutterBottom&&{marginBottom:"0.35em"},n.paragraph&&{marginBottom:16})})),Ae={h1:"h1",h2:"h2",h3:"h3",h4:"h4",h5:"h5",h6:"h6",subtitle1:"h6",subtitle2:"h6",body1:"p",body2:"p",inherit:"p"},Re={primary:"primary.main",textPrimary:"text.primary",secondary:"secondary.main",textSecondary:"text.secondary",error:"error.main"},Fe=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiTypography"}),o=function(e){return Re[e]||e}(n.color),i=V((0,r.Z)({},n,{color:o})),s=i.align,l=void 0===s?"inherit":s,u=i.className,c=i.component,d=i.gutterBottom,p=void 0!==d&&d,m=i.noWrap,h=void 0!==m&&m,v=i.paragraph,b=void 0!==v&&v,y=i.variant,g=void 0===y?"body1":y,_=i.variantMapping,C=void 0===_?Ae:_,k=(0,w.Z)(i,Ee),x=(0,r.Z)({},i,{align:l,color:o,className:u,component:c,gutterBottom:p,noWrap:h,paragraph:b,variant:g,variantMapping:C}),E=c||(b?"p":C[g]||Ae[g])||"span",P=function(e){var t=e.align,n=e.gutterBottom,r=e.noWrap,a=e.paragraph,o=e.variant,i=e.classes,s={root:["root",o,"inherit"!==e.align&&"align".concat((0,M.Z)(t)),n&&"gutterBottom",r&&"noWrap",a&&"paragraph"]};return(0,T.Z)(s,xe,i)}(x);return(0,f.jsx)(Pe,(0,r.Z)({as:E,ref:t,ownerState:x,className:(0,S.Z)(P.root,u)},k))})),Oe=n(5682),Ne=["component","direction","spacing","divider","children"];function Me(t,n){var r=e.Children.toArray(t).filter(Boolean);return r.reduce((function(t,a,o){return t.push(a),o<r.length-1&&t.push(e.cloneElement(n,{key:"separator-".concat(o)})),t}),[])}var Ie=(0,I.ZP)("div",{name:"MuiStack",slot:"Root",overridesResolver:function(e,t){return[t.root]}})((function(e){var t=e.ownerState,n=e.theme,a=(0,r.Z)({display:"flex",flexDirection:"column"},(0,Y.k9)({theme:n},(0,Y.P$)({values:t.direction,breakpoints:n.breakpoints.values}),(function(e){return{flexDirection:e}})));if(t.spacing){var o=(0,Oe.hB)(n),i=Object.keys(n.breakpoints.values).reduce((function(e,n){return("object"===typeof t.spacing&&null!=t.spacing[n]||"object"===typeof t.direction&&null!=t.direction[n])&&(e[n]=!0),e}),{}),s=(0,Y.P$)({values:t.direction,base:i}),l=(0,Y.P$)({values:t.spacing,base:i});"object"===typeof s&&Object.keys(s).forEach((function(e,t,n){if(!s[e]){var r=t>0?s[n[t-1]]:"column";s[e]=r}}));a=(0,B.Z)(a,(0,Y.k9)({theme:n},l,(function(e,n){return{"& > :not(style) + :not(style)":(0,_.Z)({margin:0},"margin".concat((r=n?s[n]:t.direction,{row:"Left","row-reverse":"Right",column:"Top","column-reverse":"Bottom"}[r])),(0,Oe.NA)(o,e))};var r})))}return a=(0,Y.dt)(n.breakpoints,a)})),ze=e.forwardRef((function(e,t){var n=V((0,a.Z)({props:e,name:"MuiStack"})),o=n.component,i=void 0===o?"div":o,s=n.direction,l=void 0===s?"column":s,u=n.spacing,c=void 0===u?0:u,d=n.divider,p=n.children,m=(0,w.Z)(n,Ne),h={direction:l,spacing:c};return(0,f.jsx)(Ie,(0,r.Z)({as:i,ownerState:h,ref:t},m,{children:d?Me(p,d):p}))})),Le=ze,De=n(1774),je=n.n(De);var Ze=function(e){var t=e.datum,n=e.datumNumber,r=e.results,a=(e.setResults,t.pom_a),o=t.pom_b,i=t.version_a_date,s=t.version_b_date;console.log({datum:t});var l=function(e,t){return e.map((function(e){return(0,f.jsx)(we,{children:(0,f.jsx)(Te,{children:(0,f.jsxs)(Fe,{children:[(0,f.jsx)("b",{children:e.label})," ",e.content]})})},e.content)}))};return(0,f.jsxs)(de,{container:!0,spacing:2,children:[(0,f.jsx)(de,{item:!0,xs:12,children:(0,f.jsx)(we,{children:(0,f.jsx)(Te,{children:(0,f.jsxs)(de,{container:!0,children:[(0,f.jsxs)(de,{item:!0,xs:4,children:[(0,f.jsxs)(Fe,{variant:"h6",children:["Comparison Number ",n+1," of ",r.length]}),(0,f.jsxs)(Fe,{variant:"h4",children:["Trial ",t.nctid]})]}),(0,f.jsxs)(de,{item:!0,xs:4,children:[t.first_posted?(0,f.jsxs)(Fe,{children:["First Posted: ",t.first_posted]}):null,t.start_date?(0,f.jsxs)(Fe,{children:["Start Date: ",t.start_date]}):null]}),(0,f.jsxs)(de,{item:!0,xs:4,children:[t.primary_completion_date?(0,f.jsxs)(Fe,{children:["Primary Completion Date: ",t.primary_completion_date]}):null,t.last_update_posted?(0,f.jsxs)(Fe,{children:["Last Update Posted : ",t.last_update_posted]}):null]})]})})})}),(0,f.jsx)(de,{item:!0,xs:6,children:(0,f.jsx)(we,{children:(0,f.jsxs)(Te,{children:[(0,f.jsxs)(Fe,{variant:"h6",children:["Primary Outcomes for Version ",t.version_a,": ",i]}),(0,f.jsx)(Fe,{variant:"caption"}),(0,f.jsx)(Le,{spacing:1,children:l(t.pom_a)})]})})}),(0,f.jsx)(de,{item:!0,xs:6,children:(0,f.jsx)(we,{children:(0,f.jsxs)(Te,{children:[(0,f.jsxs)(Fe,{variant:"h6",children:["Primary Outcomes for Version ",t.version_b,": ",s]}),(0,f.jsx)(Le,{spacing:1,children:l(t.pom_b)})]})})}),(0,f.jsx)(de,{item:!0,xs:12,children:(0,f.jsx)(we,{children:(0,f.jsxs)(Te,{children:[(0,f.jsx)(Fe,{variant:"h6",children:"Compare the Raw Text"}),(0,f.jsx)(je(),{oldValue:JSON.stringify(a,void 0,4),newValue:JSON.stringify(o,void 0,4),splitView:!0,compareMethod:De.DiffMethod.WORDS,styles:{variables:{light:{codeFoldGutterBackground:"#6F767E",codeFoldBackground:"#E2E4E5"}}},leftTitle:"Version ".concat(t.version_a),rightTitle:"Version ".concat(t.version_b)})]})})})]})};function Be(e){return(0,k.Z)("MuiAppBar",e)}(0,ee.Z)("MuiAppBar",["root","positionFixed","positionAbsolute","positionSticky","positionStatic","positionRelative","colorDefault","colorPrimary","colorSecondary","colorInherit","colorTransparent"]);var We=["className","color","enableColorOnDark","position"],Ue=function(e,t){return"".concat(null==e?void 0:e.replace(")",""),", ").concat(t,")")},Ve=(0,I.ZP)(be,{name:"MuiAppBar",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t["position".concat((0,M.Z)(n.position))],t["color".concat((0,M.Z)(n.color))]]}})((function(e){var t=e.theme,n=e.ownerState,a="light"===t.palette.mode?t.palette.grey[100]:t.palette.grey[900];return(0,r.Z)({display:"flex",flexDirection:"column",width:"100%",boxSizing:"border-box",flexShrink:0},"fixed"===n.position&&{position:"fixed",zIndex:(t.vars||t).zIndex.appBar,top:0,left:"auto",right:0,"@media print":{position:"absolute"}},"absolute"===n.position&&{position:"absolute",zIndex:(t.vars||t).zIndex.appBar,top:0,left:"auto",right:0},"sticky"===n.position&&{position:"sticky",zIndex:(t.vars||t).zIndex.appBar,top:0,left:"auto",right:0},"static"===n.position&&{position:"static"},"relative"===n.position&&{position:"relative"},!t.vars&&(0,r.Z)({},"default"===n.color&&{backgroundColor:a,color:t.palette.getContrastText(a)},n.color&&"default"!==n.color&&"inherit"!==n.color&&"transparent"!==n.color&&{backgroundColor:t.palette[n.color].main,color:t.palette[n.color].contrastText},"inherit"===n.color&&{color:"inherit"},"dark"===t.palette.mode&&!n.enableColorOnDark&&{backgroundColor:null,color:null},"transparent"===n.color&&(0,r.Z)({backgroundColor:"transparent",color:"inherit"},"dark"===t.palette.mode&&{backgroundImage:"none"})),t.vars&&(0,r.Z)({},"default"===n.color&&{"--AppBar-background":n.enableColorOnDark?t.vars.palette.AppBar.defaultBg:Ue(t.vars.palette.AppBar.darkBg,t.vars.palette.AppBar.defaultBg),"--AppBar-color":n.enableColorOnDark?t.vars.palette.text.primary:Ue(t.vars.palette.AppBar.darkColor,t.vars.palette.text.primary)},n.color&&!n.color.match(/^(default|inherit|transparent)$/)&&{"--AppBar-background":n.enableColorOnDark?t.vars.palette[n.color].main:Ue(t.vars.palette.AppBar.darkBg,t.vars.palette[n.color].main),"--AppBar-color":n.enableColorOnDark?t.vars.palette[n.color].contrastText:Ue(t.vars.palette.AppBar.darkColor,t.vars.palette[n.color].contrastText)},{backgroundColor:"var(--AppBar-background)",color:"inherit"===n.color?"inherit":"var(--AppBar-color)"},"transparent"===n.color&&{backgroundImage:"none",backgroundColor:"transparent",color:"inherit"}))})),Ge=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiAppBar"}),o=n.className,i=n.color,s=void 0===i?"primary":i,l=n.enableColorOnDark,u=void 0!==l&&l,c=n.position,d=void 0===c?"fixed":c,p=(0,w.Z)(n,We),m=(0,r.Z)({},n,{color:s,position:d,enableColorOnDark:u}),h=function(e){var t=e.color,n=e.position,r=e.classes,a={root:["root","color".concat((0,M.Z)(t)),"position".concat((0,M.Z)(n))]};return(0,T.Z)(a,Be,r)}(m);return(0,f.jsx)(Ve,(0,r.Z)({square:!0,component:"header",ownerState:m,elevation:4,className:(0,S.Z)(h.root,o,"fixed"===d&&"mui-fixed"),ref:t},p))}));function He(e){return(0,k.Z)("MuiToolbar",e)}(0,ee.Z)("MuiToolbar",["root","gutters","regular","dense"]);var $e=["className","component","disableGutters","variant"],Je=(0,I.ZP)("div",{name:"MuiToolbar",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,!n.disableGutters&&t.gutters,t[n.variant]]}})((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({position:"relative",display:"flex",alignItems:"center"},!n.disableGutters&&(0,_.Z)({paddingLeft:t.spacing(2),paddingRight:t.spacing(2)},t.breakpoints.up("sm"),{paddingLeft:t.spacing(3),paddingRight:t.spacing(3)}),"dense"===n.variant&&{minHeight:48})}),(function(e){var t=e.theme;return"regular"===e.ownerState.variant&&t.mixins.toolbar})),qe=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiToolbar"}),o=n.className,i=n.component,s=void 0===i?"div":i,l=n.disableGutters,u=void 0!==l&&l,c=n.variant,d=void 0===c?"regular":c,p=(0,w.Z)(n,$e),m=(0,r.Z)({},n,{component:s,disableGutters:u,variant:d}),h=function(e){var t=e.classes,n={root:["root",!e.disableGutters&&"gutters",e.variant]};return(0,T.Z)(n,He,t)}(m);return(0,f.jsx)(Je,(0,r.Z)({as:s,className:(0,S.Z)(h.root,o),ref:t,ownerState:m},p))})),Ke=n(792),Qe=n(6702),Ye=n(2763);function Xe(e,t){return t||(t=e.slice(0)),Object.freeze(Object.defineProperties(e,{raw:{value:Object.freeze(t)}}))}function et(e,t){return et=Object.setPrototypeOf?Object.setPrototypeOf.bind():function(e,t){return e.__proto__=t,e},et(e,t)}var tt=e.createContext(null);function nt(t,n){var r=Object.create(null);return t&&e.Children.map(t,(function(e){return e})).forEach((function(t){r[t.key]=function(t){return n&&(0,e.isValidElement)(t)?n(t):t}(t)})),r}function rt(e,t,n){return null!=n[t]?n[t]:e.props[t]}function at(t,n,r){var a=nt(t.children),o=function(e,t){function n(n){return n in t?t[n]:e[n]}e=e||{},t=t||{};var r,a=Object.create(null),o=[];for(var i in e)i in t?o.length&&(a[i]=o,o=[]):o.push(i);var s={};for(var l in t){if(a[l])for(r=0;r<a[l].length;r++){var u=a[l][r];s[a[l][r]]=n(u)}s[l]=n(l)}for(r=0;r<o.length;r++)s[o[r]]=n(o[r]);return s}(n,a);return Object.keys(o).forEach((function(i){var s=o[i];if((0,e.isValidElement)(s)){var l=i in n,u=i in a,c=n[i],d=(0,e.isValidElement)(c)&&!c.props.in;!u||l&&!d?u||!l||d?u&&l&&(0,e.isValidElement)(c)&&(o[i]=(0,e.cloneElement)(s,{onExited:r.bind(null,s),in:c.props.in,exit:rt(s,"exit",t),enter:rt(s,"enter",t)})):o[i]=(0,e.cloneElement)(s,{in:!1}):o[i]=(0,e.cloneElement)(s,{onExited:r.bind(null,s),in:!0,exit:rt(s,"exit",t),enter:rt(s,"enter",t)})}})),o}var ot=Object.values||function(e){return Object.keys(e).map((function(t){return e[t]}))},it=function(t){var n,a;function o(e,n){var r,a=(r=t.call(this,e,n)||this).handleExited.bind(function(e){if(void 0===e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return e}(r));return r.state={contextValue:{isMounting:!0},handleExited:a,firstRender:!0},r}a=t,(n=o).prototype=Object.create(a.prototype),n.prototype.constructor=n,et(n,a);var i=o.prototype;return i.componentDidMount=function(){this.mounted=!0,this.setState({contextValue:{isMounting:!1}})},i.componentWillUnmount=function(){this.mounted=!1},o.getDerivedStateFromProps=function(t,n){var r,a,o=n.children,i=n.handleExited;return{children:n.firstRender?(r=t,a=i,nt(r.children,(function(t){return(0,e.cloneElement)(t,{onExited:a.bind(null,t),in:!0,appear:rt(t,"appear",r),enter:rt(t,"enter",r),exit:rt(t,"exit",r)})}))):at(t,o,i),firstRender:!1}},i.handleExited=function(e,t){var n=nt(this.props.children);e.key in n||(e.props.onExited&&e.props.onExited(t),this.mounted&&this.setState((function(t){var n=(0,r.Z)({},t.children);return delete n[e.key],{children:n}})))},i.render=function(){var t=this.props,n=t.component,r=t.childFactory,a=(0,w.Z)(t,["component","childFactory"]),o=this.state.contextValue,i=ot(this.state.children).map(r);return delete a.appear,delete a.enter,delete a.exit,null===n?e.createElement(tt.Provider,{value:o},i):e.createElement(tt.Provider,{value:o},e.createElement(n,a,i))},o}(e.Component);it.propTypes={},it.defaultProps={component:"div",childFactory:function(e){return e}};var st=it;var lt=function(t){var n=t.className,r=t.classes,a=t.pulsate,o=void 0!==a&&a,i=t.rippleX,s=t.rippleY,l=t.rippleSize,u=t.in,c=t.onExited,d=t.timeout,p=e.useState(!1),m=(0,g.Z)(p,2),h=m[0],v=m[1],b=(0,S.Z)(n,r.ripple,r.rippleVisible,o&&r.ripplePulsate),y={width:l,height:l,top:-l/2+s,left:-l/2+i},_=(0,S.Z)(r.child,h&&r.childLeaving,o&&r.childPulsate);return u||h||v(!0),e.useEffect((function(){if(!u&&null!=c){var e=setTimeout(c,d);return function(){clearTimeout(e)}}}),[c,u,d]),(0,f.jsx)("span",{className:b,style:y,children:(0,f.jsx)("span",{className:_})})};var ut,ct,dt,ft,pt,mt,ht,vt,bt=(0,ee.Z)("MuiTouchRipple",["root","ripple","rippleVisible","ripplePulsate","child","childLeaving","childPulsate"]),yt=["center","classes","className"],gt=d(pt||(pt=ut||(ut=Xe(["\n  0% {\n    transform: scale(0);\n    opacity: 0.1;\n  }\n\n  100% {\n    transform: scale(1);\n    opacity: 0.3;\n  }\n"])))),_t=d(mt||(mt=ct||(ct=Xe(["\n  0% {\n    opacity: 1;\n  }\n\n  100% {\n    opacity: 0;\n  }\n"])))),wt=d(ht||(ht=dt||(dt=Xe(["\n  0% {\n    transform: scale(1);\n  }\n\n  50% {\n    transform: scale(0.92);\n  }\n\n  100% {\n    transform: scale(1);\n  }\n"])))),St=(0,I.ZP)("span",{name:"MuiTouchRipple",slot:"Root"})({overflow:"hidden",pointerEvents:"none",position:"absolute",zIndex:0,top:0,right:0,bottom:0,left:0,borderRadius:"inherit"}),Ct=(0,I.ZP)(lt,{name:"MuiTouchRipple",slot:"Ripple"})(vt||(vt=ft||(ft=Xe(["\n  opacity: 0;\n  position: absolute;\n\n  &."," {\n    opacity: 0.3;\n    transform: scale(1);\n    animation-name: ",";\n    animation-duration: ","ms;\n    animation-timing-function: ",";\n  }\n\n  &."," {\n    animation-duration: ","ms;\n  }\n\n  & ."," {\n    opacity: 1;\n    display: block;\n    width: 100%;\n    height: 100%;\n    border-radius: 50%;\n    background-color: currentColor;\n  }\n\n  & ."," {\n    opacity: 0;\n    animation-name: ",";\n    animation-duration: ","ms;\n    animation-timing-function: ",";\n  }\n\n  & ."," {\n    position: absolute;\n    /* @noflip */\n    left: 0px;\n    top: 0;\n    animation-name: ",";\n    animation-duration: 2500ms;\n    animation-timing-function: ",";\n    animation-iteration-count: infinite;\n    animation-delay: 200ms;\n  }\n"]))),bt.rippleVisible,gt,550,(function(e){return e.theme.transitions.easing.easeInOut}),bt.ripplePulsate,(function(e){return e.theme.transitions.duration.shorter}),bt.child,bt.childLeaving,_t,550,(function(e){return e.theme.transitions.easing.easeInOut}),bt.childPulsate,wt,(function(e){return e.theme.transitions.easing.easeInOut})),kt=e.forwardRef((function(t,n){var o=(0,a.Z)({props:t,name:"MuiTouchRipple"}),i=o.center,s=void 0!==i&&i,l=o.classes,u=void 0===l?{}:l,c=o.className,d=(0,w.Z)(o,yt),p=e.useState([]),m=(0,g.Z)(p,2),h=m[0],v=m[1],b=e.useRef(0),y=e.useRef(null);e.useEffect((function(){y.current&&(y.current(),y.current=null)}),[h]);var _=e.useRef(!1),C=e.useRef(null),k=e.useRef(null),T=e.useRef(null);e.useEffect((function(){return function(){clearTimeout(C.current)}}),[]);var x=e.useCallback((function(e){var t=e.pulsate,n=e.rippleX,r=e.rippleY,a=e.rippleSize,o=e.cb;v((function(e){return[].concat((0,Z.Z)(e),[(0,f.jsx)(Ct,{classes:{ripple:(0,S.Z)(u.ripple,bt.ripple),rippleVisible:(0,S.Z)(u.rippleVisible,bt.rippleVisible),ripplePulsate:(0,S.Z)(u.ripplePulsate,bt.ripplePulsate),child:(0,S.Z)(u.child,bt.child),childLeaving:(0,S.Z)(u.childLeaving,bt.childLeaving),childPulsate:(0,S.Z)(u.childPulsate,bt.childPulsate)},timeout:550,pulsate:t,rippleX:n,rippleY:r,rippleSize:a},b.current)])})),b.current+=1,y.current=o}),[u]),E=e.useCallback((function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},n=arguments.length>2?arguments[2]:void 0,r=t.pulsate,a=void 0!==r&&r,o=t.center,i=void 0===o?s||t.pulsate:o,l=t.fakeElement,u=void 0!==l&&l;if("mousedown"===(null==e?void 0:e.type)&&_.current)_.current=!1;else{"touchstart"===(null==e?void 0:e.type)&&(_.current=!0);var c,d,f,p=u?null:T.current,m=p?p.getBoundingClientRect():{width:0,height:0,left:0,top:0};if(i||void 0===e||0===e.clientX&&0===e.clientY||!e.clientX&&!e.touches)c=Math.round(m.width/2),d=Math.round(m.height/2);else{var h=e.touches&&e.touches.length>0?e.touches[0]:e,v=h.clientX,b=h.clientY;c=Math.round(v-m.left),d=Math.round(b-m.top)}if(i)(f=Math.sqrt((2*Math.pow(m.width,2)+Math.pow(m.height,2))/3))%2===0&&(f+=1);else{var y=2*Math.max(Math.abs((p?p.clientWidth:0)-c),c)+2,g=2*Math.max(Math.abs((p?p.clientHeight:0)-d),d)+2;f=Math.sqrt(Math.pow(y,2)+Math.pow(g,2))}null!=e&&e.touches?null===k.current&&(k.current=function(){x({pulsate:a,rippleX:c,rippleY:d,rippleSize:f,cb:n})},C.current=setTimeout((function(){k.current&&(k.current(),k.current=null)}),80)):x({pulsate:a,rippleX:c,rippleY:d,rippleSize:f,cb:n})}}),[s,x]),P=e.useCallback((function(){E({},{pulsate:!0})}),[E]),A=e.useCallback((function(e,t){if(clearTimeout(C.current),"touchend"===(null==e?void 0:e.type)&&k.current)return k.current(),k.current=null,void(C.current=setTimeout((function(){A(e,t)})));k.current=null,v((function(e){return e.length>0?e.slice(1):e})),y.current=t}),[]);return e.useImperativeHandle(n,(function(){return{pulsate:P,start:E,stop:A}}),[P,E,A]),(0,f.jsx)(St,(0,r.Z)({className:(0,S.Z)(bt.root,u.root,c),ref:T},d,{children:(0,f.jsx)(st,{component:null,exit:!0,children:h})}))})),Tt=kt;function xt(e){return(0,k.Z)("MuiButtonBase",e)}var Et,Pt=(0,ee.Z)("MuiButtonBase",["root","disabled","focusVisible"]),At=["action","centerRipple","children","className","component","disabled","disableRipple","disableTouchRipple","focusRipple","focusVisibleClassName","LinkComponent","onBlur","onClick","onContextMenu","onDragLeave","onFocus","onFocusVisible","onKeyDown","onKeyUp","onMouseDown","onMouseLeave","onMouseUp","onTouchEnd","onTouchMove","onTouchStart","tabIndex","TouchRippleProps","touchRippleRef","type"],Rt=(0,I.ZP)("button",{name:"MuiButtonBase",slot:"Root",overridesResolver:function(e,t){return t.root}})((Et={display:"inline-flex",alignItems:"center",justifyContent:"center",position:"relative",boxSizing:"border-box",WebkitTapHighlightColor:"transparent",backgroundColor:"transparent",outline:0,border:0,margin:0,borderRadius:0,padding:0,cursor:"pointer",userSelect:"none",verticalAlign:"middle",MozAppearance:"none",WebkitAppearance:"none",textDecoration:"none",color:"inherit","&::-moz-focus-inner":{borderStyle:"none"}},(0,_.Z)(Et,"&.".concat(Pt.disabled),{pointerEvents:"none",cursor:"default"}),(0,_.Z)(Et,"@media print",{colorAdjust:"exact"}),Et)),Ft=e.forwardRef((function(t,n){var o=(0,a.Z)({props:t,name:"MuiButtonBase"}),i=o.action,s=o.centerRipple,l=void 0!==s&&s,u=o.children,c=o.className,d=o.component,p=void 0===d?"button":d,m=o.disabled,h=void 0!==m&&m,v=o.disableRipple,b=void 0!==v&&v,y=o.disableTouchRipple,_=void 0!==y&&y,C=o.focusRipple,k=void 0!==C&&C,x=o.LinkComponent,E=void 0===x?"a":x,P=o.onBlur,A=o.onClick,R=o.onContextMenu,F=o.onDragLeave,O=o.onFocus,N=o.onFocusVisible,M=o.onKeyDown,I=o.onKeyUp,z=o.onMouseDown,L=o.onMouseLeave,D=o.onMouseUp,j=o.onTouchEnd,Z=o.onTouchMove,B=o.onTouchStart,W=o.tabIndex,U=void 0===W?0:W,V=o.TouchRippleProps,G=o.touchRippleRef,H=o.type,$=(0,w.Z)(o,At),J=e.useRef(null),q=e.useRef(null),K=(0,Ke.Z)(q,G),Q=(0,Ye.Z)(),Y=Q.isFocusVisibleRef,X=Q.onFocus,ee=Q.onBlur,te=Q.ref,ne=e.useState(!1),re=(0,g.Z)(ne,2),ae=re[0],oe=re[1];h&&ae&&oe(!1),e.useImperativeHandle(i,(function(){return{focusVisible:function(){oe(!0),J.current.focus()}}}),[]);var ie=e.useState(!1),se=(0,g.Z)(ie,2),le=se[0],ue=se[1];e.useEffect((function(){ue(!0)}),[]);var ce=le&&!b&&!h;function de(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:_;return(0,Qe.Z)((function(r){return t&&t(r),!n&&q.current&&q.current[e](r),!0}))}e.useEffect((function(){ae&&k&&!b&&le&&q.current.pulsate()}),[b,k,ae,le]);var fe=de("start",z),pe=de("stop",R),me=de("stop",F),he=de("stop",D),ve=de("stop",(function(e){ae&&e.preventDefault(),L&&L(e)})),be=de("start",B),ye=de("stop",j),ge=de("stop",Z),_e=de("stop",(function(e){ee(e),!1===Y.current&&oe(!1),P&&P(e)}),!1),we=(0,Qe.Z)((function(e){J.current||(J.current=e.currentTarget),X(e),!0===Y.current&&(oe(!0),N&&N(e)),O&&O(e)})),Se=function(){var e=J.current;return p&&"button"!==p&&!("A"===e.tagName&&e.href)},Ce=e.useRef(!1),ke=(0,Qe.Z)((function(e){k&&!Ce.current&&ae&&q.current&&" "===e.key&&(Ce.current=!0,q.current.stop(e,(function(){q.current.start(e)}))),e.target===e.currentTarget&&Se()&&" "===e.key&&e.preventDefault(),M&&M(e),e.target===e.currentTarget&&Se()&&"Enter"===e.key&&!h&&(e.preventDefault(),A&&A(e))})),Te=(0,Qe.Z)((function(e){k&&" "===e.key&&q.current&&ae&&!e.defaultPrevented&&(Ce.current=!1,q.current.stop(e,(function(){q.current.pulsate(e)}))),I&&I(e),A&&e.target===e.currentTarget&&Se()&&" "===e.key&&!e.defaultPrevented&&A(e)})),xe=p;"button"===xe&&($.href||$.to)&&(xe=E);var Ee={};"button"===xe?(Ee.type=void 0===H?"button":H,Ee.disabled=h):($.href||$.to||(Ee.role="button"),h&&(Ee["aria-disabled"]=h));var Pe=(0,Ke.Z)(te,J),Ae=(0,Ke.Z)(n,Pe);var Re=(0,r.Z)({},o,{centerRipple:l,component:p,disabled:h,disableRipple:b,disableTouchRipple:_,focusRipple:k,tabIndex:U,focusVisible:ae}),Fe=function(e){var t=e.disabled,n=e.focusVisible,r=e.focusVisibleClassName,a=e.classes,o={root:["root",t&&"disabled",n&&"focusVisible"]},i=(0,T.Z)(o,xt,a);return n&&r&&(i.root+=" ".concat(r)),i}(Re);return(0,f.jsxs)(Rt,(0,r.Z)({as:xe,className:(0,S.Z)(Fe.root,c),ownerState:Re,onBlur:_e,onClick:A,onContextMenu:pe,onFocus:we,onKeyDown:ke,onKeyUp:Te,onMouseDown:fe,onMouseLeave:ve,onMouseUp:he,onDragLeave:me,onTouchEnd:ye,onTouchMove:ge,onTouchStart:be,ref:Ae,tabIndex:h?-1:U,type:H},Ee,$,{children:[u,ce?(0,f.jsx)(Tt,(0,r.Z)({ref:K,center:l},V)):null]}))})),Ot=Ft;function Nt(e){return(0,k.Z)("MuiIconButton",e)}var Mt=(0,ee.Z)("MuiIconButton",["root","disabled","colorInherit","colorPrimary","colorSecondary","edgeStart","edgeEnd","sizeSmall","sizeMedium","sizeLarge"]),It=["edge","children","className","color","disabled","disableFocusRipple","size"],zt=(0,I.ZP)(Ot,{name:"MuiIconButton",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,"default"!==n.color&&t["color".concat((0,M.Z)(n.color))],n.edge&&t["edge".concat((0,M.Z)(n.edge))],t["size".concat((0,M.Z)(n.size))]]}})((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({textAlign:"center",flex:"0 0 auto",fontSize:t.typography.pxToRem(24),padding:8,borderRadius:"50%",overflow:"visible",color:(t.vars||t).palette.action.active,transition:t.transitions.create("background-color",{duration:t.transitions.duration.shortest})},!n.disableRipple&&{"&:hover":{backgroundColor:t.vars?"rgba(".concat(t.vars.palette.action.activeChannel," / ").concat(t.vars.palette.action.hoverOpacity,")"):(0,fe.Fq)(t.palette.action.active,t.palette.action.hoverOpacity),"@media (hover: none)":{backgroundColor:"transparent"}}},"start"===n.edge&&{marginLeft:"small"===n.size?-3:-12},"end"===n.edge&&{marginRight:"small"===n.size?-3:-12})}),(function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({},"inherit"===n.color&&{color:"inherit"},"inherit"!==n.color&&"default"!==n.color&&(0,r.Z)({color:(t.vars||t).palette[n.color].main},!n.disableRipple&&{"&:hover":{backgroundColor:t.vars?"rgba(".concat(t.vars.palette[n.color].mainChannel," / ").concat(t.vars.palette.action.hoverOpacity,")"):(0,fe.Fq)(t.palette[n.color].main,t.palette.action.hoverOpacity),"@media (hover: none)":{backgroundColor:"transparent"}}}),"small"===n.size&&{padding:5,fontSize:t.typography.pxToRem(18)},"large"===n.size&&{padding:12,fontSize:t.typography.pxToRem(28)},(0,_.Z)({},"&.".concat(Mt.disabled),{backgroundColor:"transparent",color:(t.vars||t).palette.action.disabled}))})),Lt=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiIconButton"}),o=n.edge,i=void 0!==o&&o,s=n.children,l=n.className,u=n.color,c=void 0===u?"default":u,d=n.disabled,p=void 0!==d&&d,m=n.disableFocusRipple,h=void 0!==m&&m,v=n.size,b=void 0===v?"medium":v,y=(0,w.Z)(n,It),g=(0,r.Z)({},n,{edge:i,color:c,disabled:p,disableFocusRipple:h,size:b}),_=function(e){var t=e.classes,n=e.disabled,r=e.color,a=e.edge,o=e.size,i={root:["root",n&&"disabled","default"!==r&&"color".concat((0,M.Z)(r)),a&&"edge".concat((0,M.Z)(a)),"size".concat((0,M.Z)(o))]};return(0,T.Z)(i,Nt,t)}(g);return(0,f.jsx)(zt,(0,r.Z)({className:(0,S.Z)(_.root,l),centerRipple:!0,focusRipple:!h,disabled:p,ref:t,ownerState:g},y,{children:s}))})),Dt=n(2156),jt=n(5129);n(8472),(0,J.Z)({palette:{neutral:{main:"#fff",contrastText:"#000"}}});function Zt(e){var t=e.datumNumber,n=e.setDatumNumber,r=e.numComparisons,a=(e.outputData,e.batchNum),o=function(){n(t-1)},i=function(){n(t+1)};return(0,f.jsx)(K,{sx:{flexGrow:1},children:(0,f.jsx)(Ge,{position:"static",children:(0,f.jsxs)(qe,{children:[(0,f.jsxs)(Fe,{component:"div",variant:"h6",sx:{flexGrow:1},children:["Compare Trial Versions for Batch ",a]}),(0,f.jsxs)(Fe,{component:"div",children:[t>0?(0,f.jsx)(Lt,{color:"inherit",variant:"text",onClick:o,children:(0,f.jsx)(Dt.Z,{})}):null,t<r-1?(0,f.jsx)(Lt,{color:"inherit",variant:"text",onClick:i,children:(0,f.jsx)(jt.Z,{})}):null]})]})})})}for(var Bt=JSON.parse('{"1":"Add endpoint to composite endpoint","2":"Add endpoint","3":"Change endpoint","4":"Change endpoint, add endpoint","5":"Change in endpoint in a composite endpoint","6":"Change method of analysis","7":"Change number of events","8":"Change population","9":"Change readers","10":"Change timepoint","11":"Error","12":"From nothing to something","13":"Refine definition","14":"Remove endpoint","15":"Shuffle Endpoints","16":"Syntax","":""}'),Wt=[],Ut=Q.e,Vt=Q.C,Gt=Vt.length,Ht=0;Ht<Gt;Ht++)Wt.push("");var $t=function(){var t=(0,e.useState)(0),n=(0,g.Z)(t,2),r=n[0],a=n[1],o=(0,e.useState)(Vt[r]),i=(0,g.Z)(o,2),s=i[0],l=i[1],u=(0,e.useState)(Wt),c=(0,g.Z)(u,2),d=c[0],p=c[1],m=(0,e.useState)([]),h=(0,g.Z)(m,2),v=h[0],b=h[1];return(0,e.useEffect)((function(){l(Vt[r])}),[r]),(0,e.useEffect)((function(){for(var e=[],t=0;t<Gt;t++){var n={};n.nctid=Vt[t].nctid,n.version_a=Vt[t].version_a,n.version_b=Vt[t].version_b,n.classification_number=d[t],n.classification_meaning=Bt[d[t]],e.push(n)}b(e)}),[d]),(0,f.jsxs)(e.Fragment,{children:[(0,f.jsx)(Zt,{datumNumber:r,setDatumNumber:a,numComparisons:Gt,outputData:v,batchNum:Ut}),(0,f.jsx)(L,{children:(0,f.jsx)(K,{sx:{flexGrow:1,m:1},children:(0,f.jsx)(Ze,{datum:s,datumNumber:r,results:d,setResults:p})})})]})};t.createRoot(document.getElementById("root")).render((0,f.jsxs)(e.StrictMode,{children:[(0,f.jsx)(y,{}),(0,f.jsx)($t,{})]}))}()}();
//# sourceMappingURL=main.1cbe0146.js.map